0000950170-24-12346910-Q Arcturus Therapeutics Holdings Inc. 20241107202411071658191701551701550 0000950170-24-123469 10-Q 59 20240930 20241107 20241107 Arcturus Therapeutics Holdings Inc. 0001768224 2834 000000000 DE 1231 10-Q 34 001-38942 241436852 10628 SCIENCE CENTER DRIVE SUITE 250 SAN DIEGO CA 92121 8589002660 10628 SCIENCE CENTER DRIVE SUITE 250 SAN DIEGO CA 92121 10-Q 1 arct-20240930.htm 10-Q 10-Q Q3false--12-310001768224http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent0001768224us-gaap:ConstructionInProgressMember2023-12-310001768224us-gaap:RetainedEarningsMember2024-01-012024-03-310001768224us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001768224arct:Covid19VaccineMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2022-11-012022-11-010001768224us-gaap:GrantMember2023-01-012023-09-300001768224us-gaap:AdditionalPaidInCapitalMember2023-12-310001768224us-gaap:CommonStockMember2023-03-310001768224arct:CollaborationRevenueMember2023-01-012023-09-3000017682242023-03-310001768224us-gaap:ComputerEquipmentMember2023-12-3100017682242024-01-012024-09-300001768224us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001768224us-gaap:GrantMember2024-01-012024-09-300001768224us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001768224us-gaap:GrantMemberarct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2023-01-012023-09-3000017682242023-06-300001768224us-gaap:RetainedEarningsMember2024-04-012024-06-300001768224us-gaap:LeaseholdImprovementsMember2024-09-300001768224arct:WellsFargoCreditAgreementMembersrt:MaximumMember2022-12-232022-12-230001768224arct:TwoThousandNineteenOmnibusIncentivePlanMember2024-09-300001768224us-gaap:GrantMemberarct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2024-01-012024-09-300001768224us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001768224arct:WellsFargoCreditAgreementMember2024-06-260001768224arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2024-01-012024-09-3000017682242022-12-310001768224us-gaap:CommonStockMember2024-06-300001768224us-gaap:GrantMember2024-07-012024-09-300001768224arct:ManufacturingAndSupplyOfArct154DrugProductMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2024-09-300001768224us-gaap:CommonStockMember2024-07-012024-09-300001768224us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001768224us-gaap:CommonStockMember2024-09-3000017682242023-09-300001768224us-gaap:AdditionalPaidInCapitalMember2022-12-310001768224arct:WellsFargoCreditAgreementMember2024-06-262024-06-260001768224us-gaap:EmployeeStockOptionMemberarct:TwentyTwentyOneInducementEquityIncentivePlanMember2024-09-300001768224arct:CslCollaborationAgreementMember2023-12-310001768224arct:WellsFargoCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2024-06-260001768224arct:ManufacturingAndSupplyOfArct154DrugProductMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2024-04-012024-06-300001768224us-gaap:FurnitureAndFixturesMember2023-12-310001768224us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-3000017682242024-07-012024-09-300001768224arct:Covid19VaccineMemberarct:SeqirusIncMember2024-01-012024-09-300001768224us-gaap:CommonStockMember2024-03-310001768224us-gaap:RetainedEarningsMember2023-09-300001768224us-gaap:RetainedEarningsMember2024-09-300001768224srt:MinimumMemberarct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember2021-09-012021-09-300001768224us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2023-01-012023-09-300001768224us-gaap:EquipmentMember2023-12-310001768224arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember2021-09-300001768224arct:OtherMemberarct:CollaborationRevenueMember2024-07-012024-09-300001768224us-gaap:RetainedEarningsMember2023-04-012023-06-3000017682242023-12-3100017682242024-03-3100017682242023-04-012023-06-300001768224arct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMembersrt:MaximumMember2022-11-010001768224arct:DirectorsOrOfficersMember2024-07-012024-09-300001768224arct:CollaborationRevenueMember2023-07-012023-09-300001768224us-gaap:LeaseholdImprovementsMember2023-12-310001768224us-gaap:GrantMemberarct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2023-07-012023-09-300001768224us-gaap:RetainedEarningsMember2023-12-310001768224arct:WellsFargoCreditAgreementMember2024-09-300001768224arct:CslCollaborationAgreementMemberarct:PhaseIClinicalStudyMember2024-09-300001768224arct:Covid19VaccineMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2023-12-310001768224arct:CslSeqirusMemberarct:CollaborationRevenueMember2024-01-012024-09-300001768224us-gaap:CommonStockMember2023-06-300001768224arct:CslCollaborationAgreementMember2024-01-012024-09-300001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2019-08-022023-09-250001768224arct:OtherMemberarct:CollaborationRevenueMember2024-01-012024-09-300001768224us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001768224us-gaap:CommonStockMember2023-09-300001768224us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001768224arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2022-08-012022-08-310001768224arct:OtherMemberarct:CollaborationRevenueMember2023-07-012023-09-300001768224arct:TwoThousandNineteenOmnibusIncentivePlanMemberus-gaap:EmployeeStockOptionMember2024-09-300001768224us-gaap:RetainedEarningsMember2022-12-310001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2023-01-012023-12-310001768224us-gaap:AdditionalPaidInCapitalMember2024-09-3000017682242024-01-012024-03-310001768224us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001768224arct:CslSeqirusMemberarct:CollaborationRevenueMember2023-01-012023-09-300001768224us-gaap:AdditionalPaidInCapitalMember2024-03-310001768224arct:OctoberTwoThousandAndSeventeenLeaseAmendmentMember2017-10-310001768224us-gaap:AdditionalPaidInCapitalMember2023-09-3000017682242024-06-300001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2024-07-012024-09-3000017682242023-01-012023-03-310001768224arct:CollaborationRevenueMember2024-01-012024-09-300001768224us-gaap:PropertyLeaseGuaranteeMember2024-09-300001768224us-gaap:FurnitureAndFixturesMember2024-09-300001768224arct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2022-11-012022-11-010001768224us-gaap:CommonStockMember2023-07-012023-09-300001768224us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001768224arct:CollaborationRevenueMember2024-07-012024-09-300001768224us-gaap:AdditionalPaidInCapitalMember2024-06-3000017682242023-07-012023-09-300001768224arct:OctoberTwoThousandAndSeventeenLeaseAmendmentMember2017-10-012017-10-310001768224us-gaap:AdditionalPaidInCapitalMember2023-03-310001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMemberarct:LUNARCFMember2019-08-022023-09-250001768224us-gaap:RetainedEarningsMember2023-06-300001768224us-gaap:CommonStockMember2022-12-310001768224arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember2024-01-012024-09-300001768224us-gaap:CommonStockMember2023-04-012023-06-300001768224arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember2024-01-012024-03-310001768224arct:CslSeqirusMemberarct:CollaborationRevenueMember2023-07-012023-09-300001768224arct:OtherMemberarct:CollaborationRevenueMember2023-01-012023-09-300001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2024-01-012024-09-300001768224arct:CslSeqirusMemberarct:CollaborationRevenueMember2024-07-012024-09-300001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2023-07-012023-09-300001768224arct:TwentyTwentyOneInducementEquityIncentivePlanMember2022-04-300001768224arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember2024-01-012024-09-3000017682242024-11-050001768224us-gaap:GrantMember2023-07-012023-09-300001768224us-gaap:GrantMemberarct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2024-07-012024-09-300001768224arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember2020-02-290001768224arct:WellsFargoCreditAgreementMember2024-01-012024-09-300001768224us-gaap:EquipmentMember2024-09-300001768224us-gaap:RetainedEarningsMember2023-03-310001768224us-gaap:RetainedEarningsMember2023-01-012023-03-310001768224arct:Covid19VaccineMemberarct:SeqirusIncMember2024-09-300001768224us-gaap:CommonStockMember2024-04-012024-06-300001768224arct:WellsFargoCreditAgreementMember2023-09-300001768224us-gaap:CommonStockMember2024-01-012024-03-310001768224arct:WellsFargoCreditAgreementMember2024-06-012024-06-300001768224arct:ManufacturingAndSupplyOfArct154DrugProductMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2023-12-310001768224arct:CslCollaborationAgreementMemberarct:PhaseIClinicalStudyMember2023-01-012023-12-3100017682242024-04-012024-06-300001768224us-gaap:RetainedEarningsMember2023-07-012023-09-300001768224us-gaap:ComputerEquipmentMember2024-09-300001768224us-gaap:RetainedEarningsMember2024-06-300001768224srt:MaximumMemberarct:TwentyTwentyOneInducementEquityIncentivePlanMember2021-10-150001768224srt:MaximumMemberarct:CslCollaborationAgreementMemberarct:PhaseIClinicalStudyMember2023-01-012023-12-310001768224us-gaap:CommonStockMember2023-12-310001768224us-gaap:RetainedEarningsMember2024-03-310001768224us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001768224arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMembersrt:MaximumMember2021-09-012021-09-300001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMemberarct:LUNARCFMember2019-07-312019-08-010001768224us-gaap:PropertyLeaseGuaranteeMember2023-09-300001768224arct:CslCollaborationAgreementMemberarct:PhaseIClinicalStudyMember2024-07-012024-09-3000017682242024-09-300001768224us-gaap:RetainedEarningsMember2024-07-012024-09-300001768224us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-3000017682242023-01-012023-09-300001768224us-gaap:AdditionalPaidInCapitalMember2023-06-300001768224arct:Covid19VaccineMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2024-03-310001768224us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001768224arct:TwoThousandNineteenOmnibusIncentivePlanMembersrt:MaximumMember2024-09-30xbrli:purexbrli:sharesarct:Segmentiso4217:USDiso4217:USDxbrli:shares Â cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Â FORM 10-Q Â (Mark One) Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from to Â Commission File Number: 001-38942 Â ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Â Â Delaware Â 32-0595345 (State or other jurisdiction ofincorporation or organization) Â (I.R.S. EmployerIdentification No.) Â 10628 Science Center Drive, Suite 250San Diego, California Â 92121 (Address of principal executive offices) Â (Zip Code) Â (858) 900-2660 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â TradingSymbol(s) Â Name of each exchange on

which registered Common Stock, par value $0.001 per share Â ARCT Â The NASDAQ Stock Market LLC Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜’ Â Â Â Â Â Non-accelerated filer â˜ Smaller reporting company â˜ Â Â Â Â Â Â Â Emerging growth company Â â˜ Â Â Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ Â As of November 5, 2024, the registrant had 27,087,359 shares of voting common stock outstanding. Â Â Â Â ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES Â TABLE OF CONTENTS Â Â Page PART I. FINANCIAL INFORMATION 1 Item 1. Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 2 Â Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity for the three and nine months ended September 30, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3. Quantitative and Qualitative Disclosures About Market Risk 26 Item 4. Controls and Procedures 26 PART II. OTHER INFORMATION 28 Item 1. Legal Proceedings 28 Item 1A. Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 29 Signatures 32 Â i Â Special Note Regarding Forward-Looking Statements Â This Quarterly Report on Form 10-Q (this â€œQuarterly Reportâ€), including the section entitled â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ and the documents incorporated by reference herein may contain express or implied â€œforward-looking statementsâ€ within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part II, Item 1A, â€œRisk Factorsâ€ in this Quarterly Report. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as â€œmay,â€ â€œwill,â€ â€œexpect,â€ â€œanticipate,â€ â€œintend,â€ â€œplan,â€ â€œbelieve,â€ â€œestimateâ€ or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following: Â â€¢our compliance, and ability to remain in compliance, with the requirements of our collaboration agreements, including our collaboration with Seqirus Inc. (â€œCSL Seqirusâ€); â€¢the anticipated benefits and success of our collaboration agreement with CSL Seqirus related to the licensure of our STARRÂ® mRNA technology and LUNARÂ® lipid-mediated delivery, including our timely receipt of upfront and potential royalty and other payments thereunder; â€¢the continued development activities of the LUNAR-COV19 and LUNAR-FLU programs under our collaboration with CSL Seqirus; â€¢the status, success and benefits of our arrangements with private and governmental entities, some of which are subject to termination for convenience by our counterparties; â€¢our compliance, and ability to remain in compliance, with the stringent requirements of our current and potential government contracts, including our arrangements with the Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services and the Department of Defense; â€¢our plans to conduct and advance any of our research programs; â€¢the initiation, design, cost, timing, progress, enrollment and results of, and our expected ability to undertake certain activities and accomplish certain goals with respect to, our research and development activities, preclinical studies and clinical trials, including those related to our therapeutics pipeline candidates ARCT-810 and ARCT-032; â€¢the potential safety, immunogenicity, efficacy or regulatory approval of any of our product candidates; â€¢the potential safety, immunogenicity, efficacy or regulatory approval of any of our COVID-19 vaccine candidates as a booster or primary vaccination series; â€¢the potential effects, efficacy and benefits of our technologies and product candidates on their own and in comparison to technologies, drugs or courses of treatment currently available or that may be developed by competitors; â€¢the likelihood that preclinical or clinical data will be predictive of future clinical results or efficacy or safety of a product candidate; â€¢the anticipated timing of enrollment, duration, milestones and announcements of results of clinical trials, and the submission of applications to conduct clinical trials; â€¢the likelihood that clinical data will be sufficient for regulatory approval or completed in time to submit an application for regulatory approval within a particular timeframe; â€¢the likelihood or timing of any regulatory approval, and the likelihood that the marketing approval of ARCT-154 in Japan will be predictive of any future marketing approvals in other countries or for other versions of our LUNAR-COV19 or other product candidates or of any commercial sales; â€¢the potential administration regimen or dosage, or ability to administer multiple doses of, any of our product candidates; â€¢our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; â€¢our plans to develop and commercialize our product candidates; â€¢our ability, and the ability of our partners, to successfully commercialize, and our expectations regarding future therapeutic and commercial potential with respect to, our product candidates; â€¢the rate and degree of market acceptance of our product candidates; ii Â â€¢the success of competing therapies that are or may become available; â€¢the size and growth potential of the markets for our product candidates, and our ability to serve those markets and address unmet medical needs; â€¢our ability to obtain and maintain intellectual property protection for our product candidates; â€¢interactions with regulatory authorities in the United States and foreign countries; â€¢our ability to attract and retain experienced and seasoned scientific and management professionals; â€¢the performance of our third-party suppliers and manufacturers, including the ability to implement and scale-up manufacturing levels as necessary; â€¢the receipt of relevant approvals related to the manufacture and distribution of our product candidates; â€¢our strategic alliance partnersâ€™ election to pursue development and commercialization of any programs or product candidates that are subject to our collaboration and license agreements with such partners; â€¢our ability to attract collaborators with relevant development, regulatory and commercialization expertise; â€¢future activities to be undertaken by our strategic alliance partners, collaborators and other third parties; â€¢our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; â€¢our ability to avoid, settle or be victorious at costly litigation with shareholders, former executives or others, should these situations arise; â€¢our ability to obtain and deploy funding for our operations and to efficiently use our financial and other resources; â€¢our ability to continue as a going concern; and â€¢the accuracy of our estimates regarding future expenses, future revenues, cash flows, capital requirements need for additional financing, and possible sources of revenue. Â These and other forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industryâ€™s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. In addition, historic results of scientific research, preclinical and clinical trials do not guarantee that future research or trials will suggest the same conclusions, nor that historic results referred to herein will be interpreted in the same manner due to additional research, preclinical and clinical trial results or otherwise. The forward-looking statements contained in this Quarterly Report are subject to risks and uncertainties, including those discussed in our other filings with the United States Securities and Exchange Commission (the â€œCommissionâ€). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof unless specifically stated otherwise. Although we currently believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. iii Â PART Iâ€”FINANCIAL INFORMATION Item 1. Financial Statements. ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS Â Â Â September 30,2024 Â Â December 31,2023 Â (in thousands, except par value information) Â (unaudited) Â Â Â Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 237,178 Â Â $ 292,005 Â Restricted cash Â Â 55,000 Â Â Â 55,000 Â Accounts receivable Â Â 30,199 Â Â Â 32,064 Â Prepaid expenses and other current assets Â Â 8,444 Â Â Â 7,521 Â Total current assets Â Â 330,821 Â Â Â 386,590 Â Property and equipment, net Â Â 10,350 Â Â Â 12,427 Â Operating lease right-of-use assets, net Â Â 27,598 Â Â Â 28,500 Â Non-current restricted cash Â Â 1,885 Â Â Â 1,885 Â Total assets Â $ 370,654 Â Â $ 429,402 Â Liabilities and stockholdersâ€™ equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 10,131 Â Â $ 5,279 Â Accrued liabilities Â Â 32,396 Â Â Â 31,881 Â Deferred revenue Â Â 26,936 Â Â Â 44,829 Â Total current liabilities Â Â 69,463 Â Â Â 81,989 Â Deferred revenue, net of current portion Â Â 13,338 Â Â Â 42,496 Â Operating lease liability, net of current portion Â Â 25,987 Â Â Â 25,907 Â Other non-current liabilities Â Â â€” Â Â Â 497 Â Total liabilities Â Â 108,788 Â Â Â 150,889 Â Stockholdersâ€™ equity Â Â Â Â Â Â Common stock, $0.001Â par value; 60,000Â shares authorized; issued andoutstanding shares were 27,084Â at September 30, 2024 and 26,828Â at December 31, 2023 Â Â 27 Â Â Â 27 Â Additional paid-in capital Â Â 680,641 Â Â Â 646,352 Â Accumulated deficit Â Â (418,802) Â Â (367,866) Total stockholdersâ€™ equity Â Â 261,866 Â Â Â 278,513 Â Total liabilities and stockholdersâ€™ equity Â $ 370,654 Â Â $ 429,402 Â The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Â ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â (in thousands, except per share data) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Â Collaboration revenue Â $ 38,815 Â Â $ 43,376 Â Â $ 117,389 Â Â $ 132,670 Â Grant revenue Â Â 2,858 Â Â Â 1,764 Â Â Â 12,155 Â Â Â 3,274 Â Total revenue Â Â 41,673 Â Â Â 45,140 Â Â Â 129,544 Â Â Â 135,944 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development, net Â Â 39,134 Â Â Â 51,077 Â Â Â 151,376 Â Â Â 155,513 Â General and administrative Â Â 13,276 Â Â Â 13,377 Â Â Â 40,443 Â Â Â 40,364 Â Total operating expenses Â Â 52,410 Â Â Â 64,454 Â Â Â 191,819 Â Â Â 195,877 Â Loss from operations Â Â (10,737) Â Â (19,314) Â Â (62,275) Â Â (59,933) (Loss) gain from foreign currency Â Â (201) Â Â 4 Â Â Â (642) Â Â (175) Gain on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 33,953 Â Finance income, net Â Â 3,818 Â Â Â 3,981 Â Â Â 11,981 Â Â Â 9,710 Â Net loss before income taxes Â Â (7,120) Â Â (15,329) Â Â (50,936) Â Â (16,445) Provision for income taxes Â Â (217) Â Â 893 Â Â Â â€” Â Â Â 1,573 Â Net loss Â $ (6,903) Â $ (16,222) Â $ (50,936) Â $ (18,018) Net loss per share, basic and diluted Â $ (0.26) Â $ (0.61) Â $ (1.89) Â $ (0.68) Weighted-average shares outstanding, basic and diluted Â Â 27,062 Â Â Â 26,574 Â Â Â 26,970 Â Â Â 26,559 Â Comprehensive loss: Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (6,903) Â $ (16,222) Â $ (50,936) Â $ (18,018) Comprehensive loss Â $ (6,903) Â $ (16,222) Â $ (50,936) Â $ (18,018) The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Â ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (unaudited) Â Â Â Â Â Â Â Â Â Â Â Additional Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-In Â Â Accumulated Â Â Stockholdersâ€™ Â (in thousands) Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balance at December 31, 2023 Â Â 26,828 Â Â $ 27 Â Â $ 646,352 Â Â Â $ (367,866) Â $ 278,513 Â Net loss Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (26,817) Â Â (26,817) Share-based compensation expense Â Â â€” Â Â Â Â â€” Â Â Â 10,088 Â Â Â Â â€” Â Â Â 10,088 Â Issuance of common stock upon exercise of stock options Â Â 89 Â Â Â Â â€” Â Â Â 2,188 Â Â Â Â â€” Â Â Â 2,188 Â Balance at March 31, 2024 Â Â 26,917 Â Â Â $ 27 Â Â $ 658,628 Â Â $ (394,683) Â $ 263,972 Â Net loss Â Â Â â€” Â Â Â Â â€” Â Â Â â€” Â

Â Â (17,216) Â Â (17,216) Share-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 9,424 Â Â Â â€” Â Â Â 9,424 Â Issuance of common stock upon exercise of stock options Â Â 125 Â Â Â â€” Â Â Â 2,403 Â Â Â â€” Â Â Â 2,403 Â Balance at June 30, 2024 Â Â 27,042 Â Â $ 27 Â Â $ 670,455 Â Â $ (411,899) Â $ 258,583 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (6,903) Â Â (6,903) Share-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 9,493 Â Â Â â€” Â Â Â 9,493 Â Issuance of common stock upon exercise of stock options Â Â 2 Â Â Â â€” Â Â Â 11 Â Â Â â€” Â Â Â 11 Â Issuance of common stock under equity plans Â Â 40 Â Â Â â€” Â Â Â 682 Â Â Â â€” Â Â Â 682 Â Â Â BALANCE â€“ September 30, 2024 Â Â 27,084 Â Â $ 27 Â Â $ 680,641 Â Â $ (418,802) Â $ 261,866 Â Â Â Â Â Â Â Â Â Â Additional Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-In Â Â Accumulated Â Â Stockholdersâ€™ Â (in thousands) Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balance at December 31, 2022 Â Â 26,555 Â Â $ 27 Â Â $ 608,426 Â Â $ (338,141) Â $ 270,312 Â Net income Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 50,754 Â Â Â 50,754 Â Share-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 8,182 Â Â Â â€” Â Â Â 8,182 Â Balance at March 31, 2023 Â Â 26,555 Â Â $ 27 Â Â $ 616,608 Â Â $ (287,387) Â $ 329,248 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (52,550) Â Â (52,550) Share-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 8,383 Â Â Â â€” Â Â Â 8,383 Â Issuance of common stock upon exercise of stock options Â Â 19 Â Â Â â€” Â Â Â 94 Â Â Â â€” Â Â Â 94 Â Balance at June 30, 2023 Â Â 26,574 Â Â $ 27 Â Â $ 625,085 Â Â $ (339,937) Â $ 285,175 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (16,222) Â Â (16,222) Share-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 9,269 Â Â Â â€” Â Â Â 9,269 Â Issuance of common stock upon exercise of stock options Â Â 114 Â Â Â â€” Â Â Â 1,231 Â Â Â â€” Â Â Â 1,231 Â Issuance of common stock under equity plans Â Â 35 Â Â Â â€” Â Â Â 609 Â Â Â â€” Â Â Â 609 Â Â Â BALANCE â€“ September 30, 2023 Â Â 26,723 Â Â $ 27 Â Â $ 636,194 Â Â $ (356,159) Â $ 280,062 Â The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Â ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Â Â Â Nine Months Ended September 30, Â (in thousands) Â 2024 Â Â 2023 Â Operating activities Â Â Â Â Â Net loss Â $ (50,936) Â $ (18,018) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Depreciation and amortization Â Â 2,725 Â Â Â 2,142 Â Share-based compensation expense Â Â 29,005 Â Â Â 25,834 Â Foreign currency transaction loss Â Â 643 Â Â Â 90 Â Gain on debt extinguishment Â Â â€” Â Â Â (33,953) Other non-cash expenses Â Â â€” Â Â Â 502 Â Changes in assets and liabilities: Â Â Â Â Â Accounts receivable Â Â 1,865 Â Â Â (35,456) Prepaid expense and other assets Â Â (923) Â Â 556 Â Right-of-use assets Â Â 3,638 Â Â Â 3,011 Â Accounts payable Â Â 4,852 Â Â Â 10,497 Â Accrued liabilities Â Â (625) Â Â (3,437) Deferred revenue Â Â (47,051) Â Â 33,960 Â Lease liabilities Â Â (2,656) Â Â (3,198) Net cash used in operating activities Â Â (59,463) Â Â (17,470) Investing activities Â Â Â Â Â Acquisition of property and equipment Â Â (648) Â Â (2,026) Net cash used in investing activities Â Â (648) Â Â (2,026) Financing activities Â Â Â Â Â Proceeds from exercise of stock options Â Â 4,602 Â Â Â 1,325 Â Proceeds from the issuance of common stock under equity plans Â Â 682 Â Â Â 609 Â Proceeds from debt Â Â â€” Â Â Â 20,000 Â Payments on debt obligations Â Â â€” Â Â Â (27,364) Net cash provided by (used in) financing activities Â Â 5,284 Â Â Â (5,430) Net decrease in cash, cash equivalents and restricted cash Â Â (54,827) Â Â (24,926) Cash, cash equivalents and restricted cash at beginning of the period Â Â 348,890 Â Â Â 393,977 Â Cash, cash equivalents and restricted cash at end of the period Â $ 294,063 Â Â $ 369,051 Â Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Supplemental disclosure of cash flow information Â Â Â Â Â Â Cash paid for interest Â $ â€” Â Â $ 2,102 Â Non-cash investing activities Â Â Â Â Â Â Non-cash asset disposal Â $ 473 Â Â $ â€” Â Right-of-use assets acquired through operating leases Â $ 2,736 Â Â $ â€” Â Purchase of property and equipment in accounts payable Â $ â€” Â Â $ 416 Â Â Â Â Â Â Â Â Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Â ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 1. Description of Business, Basis of Presentation and Summary of Significant Accounting PoliciesDescription of BusinessArcturus Therapeutics Holdings Inc. (the â€œCompanyâ€ or "Arcturus") is a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. Arcturus became a clinical stage company in 2020 when it announced that its Investigational New Drug (â€œINDâ€) application for ornithine transcarbamylase (â€œOTCâ€) deficiency and its Clinical Trial Application (â€œCTAâ€) for candidate LUNAR-COV19 were approved by applicable health authorities. In 2023, our COVID-19 vaccine, ARCT-154 (also referred to as KOSTAIVEÂ®), received marketing authorization approval in Japan for adults 18 years and older, and in September 2024 KOSTAIVE became the worldâ€™s first approved and commercially available self-amplifying RNA (sa-mRNA) vaccine. Basis of PresentationThe accompanying condensed consolidated financial statements include the accounts of Arcturus and its subsidiaries and are unaudited. All intercompany accounts and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In managementâ€™s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. These condensed consolidated financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on managementâ€™s knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions.Joint Ventures, Equity Method Investments and Variable Interest EntitiesInvestments for which the Company exercises significant influence but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. (â€œAxceleadâ€). The Companyâ€™s share of the investee's results is presented as either income or loss from equity-method investment in the accompanying condensed consolidated statements of operations and comprehensive loss. LiquidityThe Company has incurred significant operating losses since its inception. As of September 30, 2024 and December 31, 2023, the Company had an accumulated deficit of $418.8 million and $367.9 million, respectively.The Companyâ€™s activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Companyâ€™s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Companyâ€™s inception through September 30, 2024, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, the sale of capital stock, expense reimbursements from government contracts and proceeds from long-term debt. At September 30, 2024, the Companyâ€™s balance of cash and cash equivalents, including restricted cash, was $294.1 million.Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in securing additional funding, that the Companyâ€™s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years. 5 Â Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Companyâ€™s operations and manage its business in one operating segment, which is the research and development of medical applications for the Companyâ€™s nucleic acid-focused technology.Revenue RecognitionAt contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of Accounting Standards Codification (â€œASCâ€) Topic 808, Collaborative Arrangements (â€œASC 808â€). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.The Company determines revenue recognition for arrangements within the scope of ASC 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation. The terms of the Companyâ€™s revenue agreements include license fees, upfront payments, development and regulatory milestone payments, profit-sharing arrangements, reimbursement for research and development activities, option exercise fees, drug substance and drug product supply fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in ASC 606. A contractâ€™s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified. See â€œNote 2, Revenueâ€ for specific details surrounding the Companyâ€™s arrangements. LeasesThe Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components.See â€œNote 9, Commitments and Contingenciesâ€ for specific details surrounding the Companyâ€™s leases. 6 Â Research and Development Costs, Net All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical

studies and clinical trials (including amounts paid to clinical research organizations and other professional services), in-process research and development expenses, pre-launch inventory and license agreement expenses. Research and development expenses are presented net of any grants. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed.The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations ("CROs") and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.Pre-Launch InventoryPrior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its condensed consolidated statements of operations and comprehensive loss, in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.Restricted Cash Restricted cash includes collateral pledged and held in the Companyâ€™s securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association (â€œWells Fargoâ€) (Note 5). At September 30, 2024, such collateral amounted to $55.0 million. Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Companyâ€™s offices. At September 30, 2024 and 2023, the Company had restricted cash of $1.9 million and $2.1 million, respectively, in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term. At September 30, 2023, non-current restricted cash also includes $20.0 million related to the Wells Fargo Loan (Note 5).The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statement of cash flows as of September 30, 2024 and 2023:Â (in thousands) Â September 30, 2024 Â Â September 30, 2023 Â Cash and cash equivalents Â $ 237,178 Â Â $ 311,918 Â Restricted cash Â Â 55,000 Â Â Â 35,000 Â Non-current restricted cash Â Â 1,885 Â Â Â 22,133 Â Total cash, cash equivalents and restrictedÂ Â Â cash shown in the statement of cash flows Â $ 294,063 Â Â $ 369,051 Â Â Net Loss per ShareBasic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the three and nine months ended September 30, 2024 were comprised of stock options and restricted stock units. Dilutive shares of common stock for the three and nine months ended September 30, 2023 were comprised of stock options. No dividends were declared or paid during the reported periods. 7 Â Recently Issued Accounting Standards Not Yet AdoptedFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the condensed consolidated financial statements and disclosures.In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segmentsâ€™ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the impact that adoption of ASU 2023-07 will have on our financial statement disclosures. 8 Â Note 2. RevenueThe Company has entered into license agreements and collaborative research and development arrangements with pharmaceutical and biotechnology companies, as well as consulting, related technology transfer, product revenue and government grant agreements. Under these arrangements, the Company is entitled to receive license fees, consulting fees, product fees, technological transfer fees, upfront payments, milestone payments if and when certain research and development milestones, technology transfer milestones or success-based milestones are achieved, royalties on approved product sales and reimbursement for research and development activities. The Companyâ€™s costs of performing these services are included within research and development expenses. The Companyâ€™s milestone payments are typically defined by achievement of certain preclinical, clinical, and commercial success criteria. Preclinical milestones may include in vivo proof of concept in disease animal models, lead candidate identification, and completion of IND-enabling toxicology studies. Clinical milestones may, for example, include successful enrollment of the first patient in or completion of Phase 1, 2 and 3 clinical trials, and commercial milestones are often tiered based on net or aggregate sale amounts. The Company cannot guarantee the achievement of these milestones due to risks associated with preclinical and clinical activities required for development of nucleic acid medicine-based therapeutics and vaccines.The following table presents changes during the nine months ended September 30, 2024 in the balances of contract assets and liabilities as compared to what was disclosed in the Companyâ€™s Annual Report.Â (in thousands) Â December 31, 2023 Â Â Additions Â Â Deductions Â Â September 30, 2024 Â Contract Assets: Â Â Â

to, among other things, adjust (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing. BARDA GrantIn August 2022, the Company entered into a cost reimbursement contract (the â€œBARDA Contractâ€) with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) for an award of up to $63.2 million for the development of a pandemic influenza vaccine using the Company's STARRÂ® self-amplifying mRNA vaccine platform technology. The Company earns grant revenue for performing tasks under the agreement. The Company determined that the BARDA Contract is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, the Company recognizes grant revenue from the reimbursement of direct out-of-pocket expenses, overhead allocations and fringe benefits for research costs associated with the grant. The costs associated with these reimbursements are reflected as a component of research and development expense in the Companyâ€™s condensed consolidated statements of operations and comprehensive income (loss).As of September 30, 2024, the remaining available funding net of revenue earned was $41.6 million. Note 3. Fair Value MeasurementsThe Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure fair value.The three levels of the fair value hierarchy are as follows:Level 1: Quoted prices in active markets for identical assets or liabilities.Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.Level 3: Unobservable inputs in which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect those that a market participant would use.The carrying value of cash, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values due to their relatively short maturities.As of September 30, 2024 and December 31, 2023, all assets measured at fair value on a recurring basis consisted of cash equivalents and money market funds, which were classified within Level 1 of the fair value hierarchy. The fair value of these financial instruments was measured based on quoted prices. 11 Â Note 4. Balance Sheet DetailsProperty and equipment, net balances consisted of the following:Â (in thousands) Â September 30, 2024 Â Â December 31, 2023 Â Research equipment Â $ 16,864 Â Â $ 16,046 Â Computers and software Â Â 1,131 Â Â Â 1,275 Â Office equipment and furniture Â Â 703 Â Â Â 958 Â Leasehold improvements Â Â 2,644 Â Â Â 2,655 Â Construction in progress Â Â â€” Â Â Â 233 Â Total Â Â 21,342 Â Â Â 21,167 Â Less accumulated depreciation and amortization Â Â (10,992) Â Â (8,740) Property and equipment, net Â $ 10,350 Â Â $ 12,427 Â Â Depreciation and amortization expenses were $0.9 million and $2.7 million for the three and nine months ended September 30, 2024, respectively, and $0.8 million and $2.1 million for the three and nine months ended September 30, 2023, respectively. Construction in progress is primarily comprised of research equipment not yet placed in service.Accrued liabilities consisted of the following:Â (in thousands) Â September 30, 2024 Â Â December 31, 2023 Â Accrued compensation Â $ 10,846 Â Â $ 5,918 Â Cystic Fibrosis Foundation liability Â Â 7,109 Â Â Â 7,633 Â Income tax payable Â Â â€” Â Â Â 641 Â Current portion of operating lease liability Â Â 3,435 Â Â Â 4,309 Â Clinical trial accruals Â Â 2,039 Â Â Â 2,333 Â Vinbiocare contractual liabilities Â Â 2,036 Â Â Â 2,514 Â Other accrued research and development expenses Â Â 6,931 Â Â Â 8,533 Â Total Â $ 32,396 Â Â $ 31,881 Â Â Note 5. DebtWells Fargo Credit AgreementThe Companyâ€™s wholly-owned subsidiary, Arcturus Therapeutics, Inc. (â€œArcturus Therapeuticsâ€) entered into a credit agreement with Wells Fargo Bank on April 21, 2023, and amended on June 26, 2024, whereby Wells Fargo will make a $50.0 million revolving credit line available to the Company (the â€œLoanâ€) and each draw on the Loan evidenced by a revolving line of credit note (the â€œNoteâ€). Borrowings under the agreement will bear interest at a rate of 1.00% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Note), with â€œSOFRâ€ being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the agreement) occurs, then all Loans shall bear interest at a rate equal to 2.00% above the interest rate applicable immediately prior to the occurrence of the Event of Default. The term of the agreement was originally two years, with an option for one-year renewals subject to Wells Fargo approval and Arcturus Therapeutics furnishing to Wells Fargo a non-refundable commitment fee equal to 0.25% of the Loan amount for each such renewal. There is no penalty for terminating the facility prior to the maturity date of the Note. As collateral, the Company has agreed to pledge $55.0 million in cash to be held in the Companyâ€™s securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement. In June 2024, Arcturus Therapeutics and Wells Fargo entered into an amendment to the Note, whereby the term of the Note was extended by one year to April 2026. No borrowings were outstanding as of September 30, 2024. Note 6. Stockholdersâ€™ EquityNet Loss per Share Potentially dilutive securities that were not included in the calculation of diluted net loss per share for the three and nine months ended September 30, 2024 as they were anti-dilutive totaled 0.7 million and 1.1 million, respectively, and 1.2 million and 0.8 million for the three and nine months ended September 30, 2023, respectively. 12 Â Sales AgreementOn December 23, 2022, the Company entered into a Controlled Equity Offeringâ„¢ Sales Agreement, which was amended on August 7, 2023 (as amended, the â€œSales Agreementâ€) with Cantor Fitzgerald & Co. (â€œCantorâ€),Wells Fargo Securities, LLC (â€œWells Fargo Securitiesâ€), and William Blair & Company, L.L.C. (â€œWilliam Blairâ€) relating to shares of the Company's common stock. In accordance with the terms of the Sales Agreement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $200,000,000 from time to time through Cantor, Wells Fargo Securities, or William Blair, each acting as the Company's sales agent. During the period ended September 30, 2024 the Company did not offer or sell any shares of common stock pursuant to the Sales Agreement. Note 7. Share-Based Compensation ExpenseIn June 2024 at the Companyâ€™s 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), the stockholders of the Company approved an amendment to the Companyâ€™s 2019 Omnibus Equity Incentive Plan (as amended, the â€œ2019 Planâ€) which, among other things, increased the aggregate number of shares authorized for use in making awards to eligible persons under the 2019 Plan by 2,000,000 shares, for a total of up to 10,750,000 shares available for issuance. As of September 30, 2024, a total of 2,203,234 shares remain available for future issuance under the 2019 Plan, subject to the terms of the 2019 Plan. In October 2021, the Company adopted the 2021 Inducement Equity Incentive Plan which covers the award of up to 1,000,000 shares of common stock (the â€œ2021 Planâ€) effective as of October 15, 2021. Approval of the Companyâ€™s stockholders is not required as a condition to the effectiveness of the 2021 Plan for so long as the plan is in compliance with applicable Nasdaq inducement plan rules. In April 2022, the compensation committee of the Companyâ€™s board of directors approved a proposal to reduce the total number of shares available for future issuance under the 2021 Plan to 130,000. As of September 30, 2024, a total of 124,697 shares remain available for future issuance under the 2021 Plan, subject to the terms of the 2021 Plan.Â Stock OptionsShare-based compensation expense included in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023 was as follows: Â Â Â For the Three MonthsEnded September 30, Â Â Â For the Nine MonthsEnded September 30, Â (in thousands) Â 2024 Â Â 2023 Â Â Â 2024 Â Â 2023 Â Â Research and development Â $ 4,395 Â Â $ 3,863 Â Â Â $ 13,575 Â Â $ 11,112 Â Â General and administrative Â Â 5,098 Â Â Â 5,406 Â Â Â Â 15,430 Â Â Â 14,722 Â Â Total Â $ 9,493 Â Â $ 9,269 Â Â Â $ 29,005 Â Â $ 25,834 Â Â Note 8. Income TaxesThe Company is subject to taxation in the United States and various states. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate is due to federal and state income tax expense offset by valuation allowance on the Company's deferred tax assets. For the three months ended September 30, 2024, the Company recorded $0.2 million of income tax benefit and for the nine months ended September 30, 2024, the Company recorded no income tax benefit. For the three and nine months ended September 30, 2023, the Company recorded $0.9 million and $1.6 million of income tax expense, respectively. Note 9. Commitments and Contingencies Cystic Fibrosis Foundation AgreementOn September 25, 2023, the Company amended its Development Program Letter Agreement, dated May 16, 2017 and as amended July 13, 2018 and August 1, 2019, with the Cystic Fibrosis Foundation (â€œCFFâ€). Pursuant to the amendment, CFF increased the amount it will award to advance LUNAR-CF to $24.6 million from approximately $15.6 million and the Company agreed to incur at least $15.0 million toward activities under the research plan. Total expense of $0.3 million was recognized during the three months ended September 30, 2024. Total contra expense of $0.5 million was recognized during the nine months ended September 30, 2024. For both the three and nine months ended September 30, 2023, the Company recognized contra expense of $1.8 million. As of September 30, 2024 and December 31, 2023, $7.1 million and $7.6 million, respectively, remained in accrued liabilities. 13 Â LeasesIn October 2017, the Company entered into a non-cancellable operating lease agreement for office space adjacent to its previously occupied headquarters. The commencement of the lease began in March 2018 and the lease extends for approximately 84 months from the commencement date with a remaining lease term through March 2025. Monthly rental payments are due under the lease and there are escalating rent payments during the term of the lease. The Company is also responsible for its proportional share of operating expenses of the building and common areas. In conjunction with the new lease, the Company received free rent for four months and received a tenant improvement allowance of $0.1 million. In March 2024, the Company negotiated with the lessor to extend the lease through March 2027.The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $0.1 million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.In February 2020, the Company entered into a second non-cancellable operating lease agreement for office space near its current headquarters. The lease extended for 13 months from the commencement date and included a right to extend the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Companyâ€™s headquarters. In January 2024, the Company vacated this office space with no intention of operating out of the location in the future. The Company was still engaged in the lease for the property and obligated to make the remaining lease payments through March 31, 2025, and therefore recorded an impairment loss in the amount of $1.3 million during the three months ended March 31, 2024, as there was no future economic benefit from the lease. In July 2024, the Company terminated the existing lease agreement, in accordance with its terms, thereby ending their contractual obligation to pay for the premises. As a result, no lease liability remains as of September 30, 2024.In September 2021, the Company entered into a third non-cancellable lease agreement for office, research and development, engineering and laboratory space near its current headquarters, and such lease term commenced during the second quarter of 2022. The initial term of this lease extends ten years and eight months from the date of possession, and the Company has the right to extend the term of the lease for an additional five-year period. When the lease term was determined for the operating lease right-of-use assets and lease liabilities, the extension option for the lease was not included. The lease has a monthly base rent ranging from $0.3 million to $0.4 million which escalates over the lease term. The Company received a free rent period of four months and also pays for various operating costs, including utilities and real property taxes. The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $2.0 million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.Operating lease right-of-use asset and liability on the condensed consolidated balance sheets represent the present value of remaining lease payments over the remaining lease terms. The Company does not allocate lease payments to non-lease components; therefore, payments for common-area-maintenance and administrative services are not included in the operating lease right-of-use asset and liability. The Company uses its incremental borrowing rate to calculate the present value of the lease payments, as the implicit rate in the lease is not readily determinable.As of September 30, 2024, the remaining payments of the operating lease liability were as follows:Â (in thousands) Â Remaining Lease Payments Â 2024 (remainder of year) Â $ 1,213 Â 2025 Â Â 4,811 Â 2026 Â Â 5,274 Â 2027 Â Â 4,132 Â 2028 Â Â 3,822 Â Thereafter Â Â 15,750 Â Total remaining lease payments Â Â 35,002 Â Less: imputed interest Â Â (5,580) Total operating lease liabilities Â $ 29,422 Â Weighted-average remaining lease term Â Â 7.4 Â Weighted-average discount rate Â Â 4.7 % Â Operating lease costs consist of the fixed lease payments included in operating lease liability and are recorded on a straight-line basis over the lease terms. Operating lease costs were $1.3 million and $4.1 million for the three and nine months

ended September 30, 2024, respectively, and $1.4 million and $4.2 million for the three and nine months ended September 30, 2023, respectively. 14 Â Note 10. Related Party Transactions See â€œNote 1, Joint Ventures, Equity Method Investments and Variable Interest Entitiesâ€ for specific details surrounding the Companyâ€™s agreement with Axcelead to form the joint venture entity, ARCALIS, Inc. Â 15 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. The following is a discussion of the financial condition and results of operations of Arcturus Therapeutics Holdings Inc. for the three- and nine-month periods ended September 30, 2024. Unless otherwise specified herein, references to the â€œCompany,â€ â€œArcturus,â€ â€œwe,â€ â€œourâ€ and â€œusâ€ mean Arcturus Therapeutics Holdings Inc. and its consolidated subsidiaries. You should read the following discussion and analysis together with the interim condensed consolidated financial statements and related notes included elsewhere herein. For additional information relating to our managementâ€™s discussion and analysis of financial conditions and results of operations, please see our Annual Report on Form 10-K for the year ended December 31, 2023 (the â€œ2023 Annual Reportâ€), which was filed with the U.S. Securities and Exchange Commission (the â€œCommissionâ€) on March 14, 2024. Unless otherwise defined herein, capitalized words and expressions used herein shall have the same meanings ascribed to them in the 2023 Annual Report. This report includes forward-looking statements which, although based on assumptions that we consider reasonable, are subject to risks and uncertainties which could cause actual events or conditions to differ materially from those currently anticipated and expressed or implied by such forward-looking statements. This report also includes certain statements based solely on information, reports and studies provided by or conducted by Seqirus, Inc. and Meiji Holdings Co., Ltd or their respective affiliates. You should read this report and the documents that we reference in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. You should also review the factors and risks we describe in the reports we will file or submit from time to time with the Commission after the date of this report. Overview We are a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. In addition to our messenger RNA (â€œmRNAâ€) platform, our proprietary lipid nanoparticle (â€œLNPâ€) delivery system, LUNARÂ®, may enable multiple nucleic acid medicines. Our proprietary self-amplifying mRNA technology (STARRÂ® technology) has been demonstrated to be longer lasting and broader response at lower dose levels than conventional mRNA. In 2023, our COVID-19 vaccine, ARCT-154 (also referred to as KOSTAIVEÂ®), received marketing authorization approval in Japan, and in September 2024 KOSTAIVE became the worldâ€™s first approved and commercially available self-amplifying RNA (sa-mRNA) vaccine. We are leveraging our proprietary LUNAR platform and our nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. We continue to expand this platform by adding new innovative delivery solutions that allow us to expand our discovery efforts. Our proprietary LUNAR technology is intended to address the major hurdles in RNA drug development, namely the effective and safe delivery of RNA therapeutics to disease-relevant target tissues. We believe the versatility of our platform to target multiple tissues, its compatibility with various nucleic acid therapeutics, and our expertise in developing scalable manufacturing processes can allow us to deliver on the next generation of nucleic acid medicines. Â Business Updates Vaccine Collaboration with CSL Seqirus In November 2022, we entered into a Collaboration and License Agreement (as amended, the â€œCSL Collaboration Agreementâ€) with Seqirus, Inc. (â€œCSL Seqirusâ€), a part of CSL Limited, and one of the worldâ€™s leading influenza vaccine providers, for global exclusive rights to research, develop, manufacture and commercialize self-amplifying mRNA vaccines against COVID-19, influenza and three other respiratory infectious diseases and global non-exclusive rights to pandemic pathogens. The CSL Collaboration Agreement became effective on December 8, 2022. The collaboration combines CSL Seqirusâ€™ established global vaccine commercial and manufacturing infrastructure with Arcturusâ€™ manufacturing expertise and innovative STARR self-amplifying mRNA vaccine and LUNAR delivery platform technologies. Under the framework of our collaboration with CSL Seqirus, we continue the development of the COVID-19 vaccine to establish a differentiated platform and address routine recommendations for periodic vaccine composition updates in a timely manner. In November 2023, KOSTAIVEÂ®, a self-amplifying messenger RNA (sa-mRNA) vaccine, received marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for use as a primary immunization and booster in Japan for adults 18 years and older. The approval was based on positive clinical data from several ARCT-154 studies, including a 19,000-subject efficacy, safety, and immunogenicity study performed in Vietnam, as well as a Phase 3 booster study in Japan. KOSTAIVEÂ® is the brand name approved in Japan for ARCT-154, which is the version of the sa-mRNA COVID vaccine encoding the ancestral strain of SARS-CoV-2, and for updated variant-specific versions of this vaccine. We may use KOSTAIVE or the specific internally generated name, such as ARCT-154, ARCT-2302 and ARCT-2303, to identify the vaccine. 16 Â In September 2024, we announced that Japanâ€™s Ministry of Health, Labor and Welfare (MHLW) granted approval and authorization for an updated version of KOSTAIVE, targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older. CSLâ€™s exclusive partner in Japan, Meiji Holdings Co., Ltd (â€œMeijiâ€) began distributing the updated vaccine in Japan in October 2024, marking the worldâ€™s first commercially available sa-mRNA COVID-19 vaccine for adults 18 and older. The approval was based on manufacturing data demonstrating the quality and consistency of the vaccine product, non-clinical immunogenicity data against JN.1 lineage of Omicron subvariants of KOSTAIVE (JN.1), and clinical evidence supporting the safety and immunogenicity of KOSTAIVE (bivalent, BA.4/5 and ancestral strain). The European Medicines Agency (EMA) is currently reviewing a marketing authorization application for ARCT-154. The review procedure started on August 17, 2023. Earlier this year, CSL Seqirusâ€™ partner Meiji Seika Pharma announced that it submitted a partial change application for an amendment to the manufacturing and marketing approval of KOSTAIVEÂ® to include manufacturing sites in Japan, including ARCALIS, Inc., Arcturusâ€™ manufacturing joint venture in Japan. Meiji Seika Pharma will begin selling domestically produced KOSTAIVEÂ® this season. Â Clinical Studies of KOSTAIVE (COVID-19 vaccine) In connection with our collaboration with CSL Seqirus, we continue to collect data from the various ongoing studies described below. Pivotal Phase 3 Non-Inferiority Study of KOSTAIVE (ARCT-154) in Japan Meiji sponsored a randomized, multicenter, Phase 3, observer-blind, active-controlled comparative study to evaluate the safety and immunogenicity of a booster dose of ARCT-154 and to evaluate the non-inferiority of ARCT-154 over COMIRNATYÂ® (Monovalent, Original strain). The study targeted 780 adult participants, with half in the ARCT-154 group and half in a comparator group, and completed enrollment with 828 participants in February 2023. The study met all primary and secondary immunogenicity endpoints, including a secondary pre-defined superiority assessment over COMIRNATYÂ® (Omicron BA.4/5 strain). Overall, the safety and immunogenicity results of the study support the favorable benefit/risk profile of the ARCT-154 vaccine when administered as a booster dose in adult individuals who previously received other mRNA COVID-19 vaccines. On February 1, 2024, the journal Lancet Infectious Diseases published the article â€˜Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT154) versus BNT162b2â€™ (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00060-4/fulltext), with six-month follow-up results from this study. These additional data demonstrate the extended persistence of neutralizing antibodies after administration with ARCT-154 compared with conventional mRNA vaccine in the clinical setting, indicating longer-lasting immunity and implying a longer duration of protection by ARCT-154. On September 30, 2024, we announced results from this study demonstrating that ARCT-154 maintained superior immunogenicity compared to the conventional mRNA vaccine (COMIRNATY) for up to 12 months against Wuhan-Hu-1, Omicron BA.4-5 and certain other COVID-19 variants, and at one-sixth the dose of the comparator (5Âµg vs 30Âµg, respectively). In October 2024, Lancet Infectious Diseases published the follow-up article â€˜12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccineâ€™ (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00615-7/fulltext), which confirmed a better neutralizing immune response against a panel of SARS-CoV-2 strains in pre-immunized Japanese adults boosted with ARCT-154 compared with the conventional mRNA vaccine, BNT162b2, which persisted up to 12 months post-vaccination, including in those age 50 years and older. Phase 3 Study of Bivalent Version of COVID-19 KOSTAIVE in Japan On September 29, 2023, Meiji initiated an additional Phase 3 clinical study with ARCT-2301, a bivalent version of KOSTAIVE (ancestral strain and Omicron BA.4/5) to further support immunogenicity and safety data for our self-amplifying mRNA platform, which may facilitate the timely release of future seasonal updates of our COVID-19 vaccine against evolving variants of concern. On March 19, 2024, Meiji announced that the bivalent vaccine met the primary study endpoint (non-inferiority). The study enrolled 930 healthy adults and individuals with comorbidities, who previously received three to five doses of mRNA COVID-19 vaccines, including the last booster at least three months prior to recruitment. The study compares the investigational vaccine (ARCT-2301) and COMIRNATY (ancestral strain and BA.4/5) to evaluate safety and immunogenicity between observer-blind groups. Both the geometric mean titer (GMT) ratio and seroresponse rate (SRR) difference of neutralizing antibodies against SARS-CoV-2 (Omicron BA.4/5 and Wuhan strains) met pre-specified non-inferiority and superiority criteria versus COMIRNATY. There were no causally-associated severe or serious adverse events with ARCT-2301. In September 2024, we announced 6-month immunogenicity and safety results from this study. As with the monovalent vaccine, the bivalent sa-mRNA formulation demonstrates superior immunogenicity over the conventional bivalent mRNA vaccine 17 Â COMIRNATY, a higher immune response persisting up to six months after a booster dose, and improved breadth, supporting the robustness of the sa-mRNA vaccine platform for future vaccine strain updates. The study results were presented at OPTIONS XII for the Control of Influenza conference in Brisbane, Australia, in September 2024. Phase 3 Study in Southern Hemisphere of KOSTAIVE (Monovalent XBB1.5) In March 2024, Arcturus and CSL Seqirus initiated a Phase 3 pivotal study with the ARCT-2303 candidate vaccine containing the XBB1.5 Omicron variant. The study aims to generate additional immunogenicity and safety data in multiple ethnicities to support regulatory filings in the US and globally. In addition, the study will assess the co-administration of the ARCT-2303 vaccine with the age-appropriate seasonal influenza vaccines. Overall, 1,499 young and older adults were recruited in the study in Australia, Costa Rica, Honduras and the Philippines. The study results show that all four primary study objectives and key secondary study objectives were met. ARCT-2303 demonstrated superior immune response compared to ARCT-154 as measured by neutralizing antibodies against Omicron XBB.1.5 in terms of GMT ratio and SCR difference. Co-administration of ARCT-2303 and quadrivalent influenza vaccine (QIV; Flucelvax, CSL) in adults 18-64 years old showed noninferior immune response compared to standalone QIV. Co-administration of ARCT-2303 and QIV also showed noninferior immune response compared to standalone ARCT-2303. Co-administration of ARCT-2303 and adjuvanted QIV (Fluad, CSL) in adults 65 years of age and above showed similar results for co-administered and separately administered groups. The safety and reactogenicity of co-administered vaccines were comparable with standalone administration. No safety concerns were raised based on the study results. Â Seasonal Flu Collaboration Program Updates Our LUNAR-qsFLU (qs; quadrivalent seasonal) program, now exclusively licensed to CSL Seqirus, has the objective of producing a safe and effective seasonal influenza vaccine candidate with significant advantages over the traditional egg-based inactivated quadrivalent vaccine. Inaccurate predictions of circulating influenza strains as well as mutations due to adaptation in egg-grown vaccines can substantially reduce efficacy on a year-to-year basis. We believe the ability of mRNA platforms to nimbly adapt to new viral strains should help improve efficacy. In addition, we do not expect mRNA vaccines to face the challenge from mutations common to egg-grown vaccines. LUNAR-qsFLU has been designed to take advantage of our expertise in both LUNAR lipid delivery systems and our STARR self-amplifying mRNA technology. This platform has been shown to deliver effective protection against COVID-19 and has been optimized to elicit robust immunogenicity with acceptable reactogenicity at a lower dose than conventional mRNA vaccines with the objective of creating a highly effective influenza vaccine for use in general and high-risk populations. Working with CSL Seqirus, we generated a comprehensive non-clinical data package to support the initiation of the Phase 1 clinical trial with a novel influenza sa-mRNA vaccine candidate. A Phase 1 dose-finding safety and immunogenicity study was initiated in January 2024 in Australia. Pandemic Influenza Program Our LUNAR-pandFLU program continues to progress under the award from the Biomedical Advanced Research and Development Authority (â€œBARDAâ€) that we obtained in 2022. The program includes all non-clinical, manufacturing, and regulatory support to advance a vaccine to protect against disease caused by H5N1 highly pathogenic avian influenza. A pre-IND meeting was 18 Â granted, and a Written Response Only (â€œWROâ€) was received for integration into future development plans. Nonclinical safety studies have been completed that will enable the Phase 1 clinical trial. The IND application was submitted on October 9, 2024. Enrollment for a Phase 1 clinical trial designed to evaluate the safety and immunogenicity of ARCT-2304 (LUNAR-pandFLU candidate vaccine) is expected to begin before the end of 2024. Key Updates on Arcturus-Owned mRNA Therapeutic Development

Candidates The following chart represents our current pipeline of Arcturus-owned mRNA therapeutic candidates: Â â€¢LUNAR-OTC/ARCT-810 oA Phase 1b study in stable OTC-deficient adults was completed in the United States in September 2023. The trial assessed safety, tolerability and pharmacokinetics of a single dose of ARCT-810, and exploratory biomarkers of drug activity. The Phase 1b study was a single ascending dose, placebo-controlled study that enrolled 16 adults with mild OTC-deficiency. ARCT-810 was generally safe and well tolerated at doses ranging from 0.1-0.5mg/kg and no serious or severe adverse events were observed. Sporadic infusion-related reactions (IRRs) were managed with symptomatic treatment and appeared to be less frequent with slower infusion rates. In plasma, ARCT-810 mRNA could be detected up to 4 weeks, while ionizable lipid was no longer measurable after 48 hours, indicating rapid degradation of the lipid nanoparticle that was utilized to deliver ARCT-810 mRNA. Study results were presented at the Society for Inherited Metabolic Disorders meeting in Charlotte, North Carolina in April 2024 and at the annual symposium for the Society for the Study of Inborn Errors of Metabolism in Porto, Portugal in August 2024. oA Phase 2 double-blind study of ARCT-810 in OTC-deficient adolescents and adults in the European Union and United Kingdom completed dosing of eight subjects in August 2024 at the 0.3 mg/kg dose level. The participants in this group were randomized 3:1 to receive 6 doses of ARCT-810 or placebo administered every 14 days, and follow-up is ongoing. oWe are expanding the Phase 2 clinical program of ARCT-810 to the U.S. with an open-label, multiple-dose study to evaluate pharmacodynamics and safety in adult and adolescent patients requiring clinical management for OTC-deficiency. The study is currently recruiting patients. oARCT-810 was granted Orphan Drug Designation in June 2019, Fast Track Designation in May 2023, and Rare Pediatric Disease Designation in June 2023 by the FDA, and Orphan Medicinal Product Designation in August 2022 by the European Commission (EC). by the FDA. â€¢LUNAR-CF/ARCT-032 â€“ Our program for cystic fibrosis is being supported in part by the Cystic Fibrosis Foundation (â€œCFFâ€). In 2023 we initiated and successfully completed a safety and tolerability Phase 1 single ascending dose study of ARCT-032 (LUNAR-CF), our mRNA therapeutic candidate for cystic fibrosis (CF). Thirty-two healthy participants (eight subjects in each of four dose cohorts) received a single inhaled dose of ARCT-032. A subsequent protocol amendment to transition to a safety and tolerability Phase 1b clinical study of ARCT-032 in adults with CF received regulatory approval in August 2023 and completed dosing and follow-up visits for 7 CF participants in August 2024, with each CF participant having received two administrations of ARCT-032 separated by two days. oIn the Phase 1/1b clinical study, ARCT-032 was generally safe and well tolerated in healthy volunteers and in the participants with CF. Of the seven total CF participants in the Phase 1b study, six were being treated with CFTR modulators while one subject had Class I mutations that do not benefit from modulator therapy. No serious or severe adverse events (SAEs) were observed, and the safety profile was similar between healthy volunteers and CF participants. Mild, transient events of elevated temperature or feeling hot accompanied by other nonspecific symptoms were observed at dose levels that are higher than those planned for the Phase 2 study. In the CF subjects, lung function measured over 8 days did not demonstrate a discernable pattern or safety concern after 2 doses of 19 Â ARCT-032. Preliminary findings from the study were presented at the European CF Society Conference in June 2024 in Glasgow, Scotland, and at the North American CF Conference in September 2024 in Boston, MA. oWe submitted an IND application at the end of July 2024, and on August 29, 2024, the FDA issued a â€œStudy May Proceedâ€ notification for an ARCT-032 Phase 2 multiple ascending dose study designed to identify a safe and effective dose in Class I (null) and other CF participants who do not benefit from CFTR modulators. This study is supported by safety and tolerability data collected in healthy volunteers (N = 32) and the two-administration Phase 1b study. oIn February 2024, the European Commission (EC), based on a positive opinion issued by the European Medicines Agency (EMA), granted Orphan Medicinal Product Designation for ARCT-032 to treat CF. ARCT-032 was granted Rare Pediatric Disease Designation in October 2023, and Orphan Drug Designation in November 2023 by the FDA. Â Â Updates on Research and Platform Activities We continue to invest and improve our LUNAR-lipid mediated delivery of mRNA with continuous improvements in our mRNA and sa-mRNA platforms in conjunction with improvements in our next generation proprietary lipids to improve targeting, efficacy and safety profiles for both our vaccine and therapeutic protein platforms. This investment has led to key innovations ensuring that our LUNAR formulated drug product candidates have optimal characteristics for therapeutic use, which we believe sets us apart from other nucleic acid therapeutics and lipid-mediated delivery platforms. As such, we consider ourselves a leader in the research and development of mRNA therapeutics for multiple indications. We continue to conduct exploratory platform development activities, including the evaluation of genome editing, and new targeting approaches, where our LUNARÂ® and STARRÂ® platforms could potentially be useful for identification and development of additional products for our portfolio. Discovery Programs â€“ Vaccine Programs (Lyme Disease and Gonorrhea) Based on the clinical and regulatory validation of LUNAR and STARR technologies provided by the approval of KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) vaccine for COVID-19, we initiated new vaccine discovery programs earlier this year for Lyme disease and gonorrhea and continue to progress such programs. The discovery programs rely on the evidence of superior immunogenicity, durability, and breadth of immune response compared to conventional mRNA vaccines, as observed in the COVID-19 program. Lyme disease is a bacterial infection and is the most common vector-borne disease in the United States. Infection can spread to joints, the heart and the nervous system. Gonorrhea is a sexually transmitted disease (STD) that can infect the mucous membranes of the reproductive tract. It is the second most commonly reported bacterial sexually transmitted infection in the United States. We selected these diseases based on high unmet medical needs, good understanding of the path forward in vaccine target selection, and demonstration of proof of concept, as well as platform advantages that may be translated in a favorable vaccine product. Updates on Supply and Manufacturing We have built a global manufacturing footprint with our partners, including Aldevron, Catalent, Recipharm, Polymun and ARCALIS. With such collaborations we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development & manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product. As the market for COVID vaccines shifts from multi-dose vial to lower and single-dose vial presentation, we continue, with our collaborator CSL Seqirus, to evaluate and pursue different forms of drug product presentations, advance manufacturing process and capabilities and technology transfers, and prepare for stockpiling and commercialization of COVID vaccines. Results of Operations The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Report and our audited financial statements and related notes for the year ended December 31, 2023. Our historical results of operations and the year-to-year comparisons of our results of operations that follow are not necessarily indicative of future results. 20 Â Revenue We enter into arrangements with pharmaceutical and biotechnology partners and government agencies that may contain upfront payments, license fees for research and development arrangements, research and development funding, milestone payments, option exercise and exclusivity fees, royalties on future sales, consulting fees and payments for technology transfers. We expect that sales of KOSTAIVEÂ® by Meiji Holdings Co., Ltd, CSLâ€™s partner in Japan will commence in the fourth quarter of 2024 in Japan. However, revenues for us will be subject to a profit sharing mechanism whereby development costs are deducted from sales revenues prior to any distribution to the Company. The following table summarizes our total revenues for the periods indicated: Â Â Â Three Months Ended September 30, Â Â 2023 to 2024 Â (in thousands) Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Revenue Â $ 41,673 Â Â $ 45,140 Â Â $ (3,467) Â Â -7.7 % Â Revenue decreased by $3.5 million during the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. The decline was mostly attributable to a lower milestone achievement from the CSL agreement during the third quarter of 2024. This decrease was offset by revenue recognized from a supply agreement related to the commercial production of KOSTAIVEÂ® and an increase in revenue from the BARDA agreement during the three months ended September 30, 2024. Â Â Â Nine Months Ended September 30, Â Â 2023 to 2024 Â (in thousands) Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Revenue Â $ 129,544 Â Â $ 135,944 Â Â $ (6,400) Â Â -4.7 % Â Revenue decreased by $6.4 million during the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023. The decrease was due to the timing and value of milestone achievements and the achievement of a conditional payment during the nine months ended 2023, offset by revenue from supply agreements during the current year. Additionally, there was a decrease in revenue recognized under other agreements during the nine months ended September 30, 2024 due to lower activity or completion of collaboration agreements. The total decrease in revenue was offset by an increase in revenue recognized from the BARDA Contract. Operating expenses Our operating expenses consist of research and development and general and administrative expenses. Â Â Â Three Months Ended September 30, Â Â 2023 to 2024 Â Â Nine Months Ended September 30, Â Â 2023 to 2024 Â (in thousands) Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Operating expenses: Â Research and development, net Â $ 39,134 Â Â $ 51,077 Â Â $ (11,943) Â Â -23.4 % Â $ 151,376 Â Â $ 155,513 Â Â $ (4,137) Â Â -2.7 % General and administrative Â Â 13,276 Â Â Â 13,377 Â Â Â (101) Â Â -0.8 % Â Â 40,443 Â Â Â 40,364 Â Â Â 79 Â Â Â 0.2 % Total Â $ 52,410 Â Â $ 64,454 Â Â $ (12,044) Â Â -18.7 % Â $ 191,819 Â Â $ 195,877 Â Â $ (4,058) Â Â -2.1 % Â Research and Development Expenses, net 21 Â The following table presents our total research and development expenses by category: Â Â Â Three Months Ended September 30, Â Â 2023 to 2024 Â Â Nine Months Ended September 30, Â Â 2023 to 2024 Â (in thousands) Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Â 2024 Â Â 2023 Â Â $ change Â Â % change Â External pipeline development expenses: Â LUNAR-COVID, net Â $ 12,035 Â Â $ 24,892 Â Â $ (12,857) Â Â -51.7 % Â $ 55,092 Â Â $ 71,501 Â Â $ (16,409) Â Â -22.9 % LUNAR-OTC, net Â Â 890 Â Â Â 2,001 Â Â Â (1,111) Â Â -55.5 % Â Â 7,200 Â Â Â 7,520 Â Â Â (320) Â Â -4.3 % BARDA Â Â 1,347 Â Â Â 930 Â Â Â 417 Â Â Â 44.8 % Â Â 6,949 Â Â Â 1,576 Â Â Â 5,373 Â Â * Â Early-stage programs Â Â 7,602 Â Â Â 2,326 Â Â Â 5,276 Â Â * Â Â Â 26,543 Â Â Â 10,018 Â Â Â 16,525 Â Â * Â Discovery technologies Â Â 2,071 Â Â Â 4,662 Â Â Â (2,591) Â Â -55.6 % Â Â 4,453 Â Â Â 16,266 Â Â Â (11,813) Â Â -72.6 % External platform development expenses: Â Personnel related expenses Â Â 13,718 Â Â Â 13,478 Â Â Â 240 Â Â Â 1.8 % Â Â 43,234 Â Â Â 40,206 Â Â Â 3,028 Â Â Â 7.5 % Facilities and equipment expenses Â Â 1,471 Â Â Â 2,788 Â Â Â (1,317) Â Â -47.2 % Â Â 7,905 Â Â Â 8,426 Â Â Â (521) Â Â -6.2 % Total research and development expenses, net Â $ 39,134 Â Â $ 51,077 Â Â $ (11,943) Â Â -23.4 % Â $ 151,376 Â Â $ 155,513 Â Â $ (4,137) Â Â -2.7 % * Greater than 100% Our research and development expenses consist primarily of external manufacturing costs, in-vivo research studies and clinical trials performed by contract research organizations, clinical and regulatory consultants, personnel related expenses, facility related expenses and laboratory supplies related to conducting research and development activities. Research and development expenses were $39.1 million for the three months ended September 30, 2024, compared with $51.1 million for the three months ended September 30, 2023. The decrease was due to high manufacturing expenses in 2023 for Meiji supply batches and other clinical trial batches which were not incurred in 2024. The decrease was also due to lower facilities and equipment expenses in 2024. This was offset by an increase in clinical trial related expenses. Research and development expenses for the nine months ended September 30, 2024 were $151.4 million compared with $155.5 million for the nine months ended September 30, 2023. The decrease was due to lower manufacturing expenses in 2023 for Meiji supply batches and other clinical trial batches which were not incurred in 2024. Additionally, there was a decrease in consulting expenses as well as facilities and equipment expenses in 2024. This was offset by increased clinical related expenses for the COVID program and increased personnel related expenses in 2024. We expect that our research and development efforts and associated costs will continue to be substantial over the next several years as our pipeline progresses. Early-stage programs represent programs that are in the pre-clinical or Phase 1 clinical stage and may be partnered or unpartnered, including the LUNAR-CF and LUNAR-FLU programs. Discovery technologies represent our efforts to expand our product pipeline and are primarily related to pre-partnered studies and new capabilities assessment. For some of our programs, the activities are part of our collaborative and other relationships, and the expenses may be partially offset with funds that have been awarded to the Company. The expenses for early-stage programs and discovery technologies primarily consist of external manufacturing costs, lab supplies, equipment, and consulting and professional fees. Early-stage programs and discovery technologies expenses are expected to steadily increase over the coming years. Personnel related expenses primarily consist of employee salaries and benefits, share-based compensation and consultants. Although such expenses increased during 2024 as compared to 2023, we expect that they will not increase over the next twelve months. Facilities and equipment expenses primarily consist

of rent expenses, common area maintenance charges, shipping costs, various costs of our offices and laboratories and depreciation expenses. Facilities and equipment expenses are not expected to increase during the next twelve months. General and Administrative Expenses General and administrative expenses primarily consist of salaries and related benefits for our executive, administrative, legal and accounting functions and professional service fees for legal and accounting services as well as other general and administrative expenses. General and administrative expenses were $13.3 million for the three months ended September 30, 2024 compared with $13.4 million for the three months ended September 30, 2023. The decrease in general and administrative expenses was attributable to decreased personnel expenses, partially offset by increased legal and other professional expenses, facilities expenses and other various general and administrative expenses. General and administrative expenses for the nine months ended September 30, 2024 remained consistent compared to the nine months ended September 30, 2023. The Company expects that general and administrative expenses will remain relatively consistent over the next fiscal year with the current pipeline. 22 Â Finance income (expense), net Â Â Â Three Months Ended September 30, Â Â 2023 to 2024 Â Â Nine Months Ended September 30, Â Â 2023 to 2024 Â (in thousands) Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Interest income Â $ 3,818 Â Â $ 4,001 Â Â Â (183) Â Â -4.6 % Â $ 11,981 Â Â $ 10,473 Â Â $ 1,508 Â Â Â 14.4 % Interest expense Â Â â€” Â Â Â (20) Â Â 20 Â Â Â -100.0 % Â Â â€” Â Â Â (763) Â Â 763 Â Â Â -100.0 % Total Â $ 3,818 Â Â $ 3,981 Â Â $ (163) Â Â -4.1 % Â $ 11,981 Â Â $ 9,710 Â Â $ 2,271 Â Â Â 23.4 % Â Interest income is generated on cash and cash equivalents. The decrease in interest income for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 was primarily the result of decreased interest earned on investment accounts. The increase in interest income for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023 was primarily the result of increased interest earned on investment accounts caused by higher interest rates. Interest expense during the nine months ended September 30, 2023 was incurred in connection with the Western Alliance Agreement and the Singapore Loan, both of which have since been terminated. Other income and expense Â Â Â Three Months Ended September 30, Â Â 2023 to 2024 Â Â Nine Months Ended September 30, Â Â 2023 to 2024 (in thousands) Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Â 2024 Â Â 2023 Â Â $ change Â Â % change (Loss) gain from foreign currency Â $ (201) Â $ 4 Â Â $ (205) Â * Â Â $ (642) Â $ (175) Â $ (467) Â * Gain on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 33,953 Â Â Â (33,953) Â * Total Â $ (201) Â $ 4 Â Â $ (205) Â * Â Â $ (642) Â $ 33,778 Â Â $ (34,420) Â * * Greater than 100% Other income and expense items primarily relate to gains and losses from foreign currency transactions. Additionally, we recorded a gain on debt extinguishment related to the Singapore Loan of $34.0 million during the first quarter of 2023 as a result of the Singapore Loan being forgiven. Off-balance sheet arrangements Through September 30, 2024, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. Liquidity and Capital Resources From the Companyâ€™s inception through the quarter ended September 30, 2024, the Company has funded its operations principally with the proceeds from the sale of capital stock, long-term debt and revenues earned through collaboration agreements and government contracts. Through the third quarter of 2024, we have achieved a total of approximately $462.1 million in upfront payments and milestones from CSL Seqirus, including a milestone of $25.0 million achieved in the current quarter with payment anticipated in the fourth quarter of 2024. At September 30, 2024, we had $294.1 million in cash and cash equivalents and restricted cash. CSL Seqirus, Inc. Collaboration and License Agreement We entered into the CSL Collaboration Agreement with CSL Seqirus, a part of CSL Limited, one of the worldâ€™s leading influenza vaccine providers, for the global exclusive rights to research, develop, manufacture and commercialize mRNA vaccines. CSL Seqirus received exclusive global rights to our technology for vaccines against SARS-CoV-2 (COVID-19), influenza and three other respiratory infectious diseases and non-exclusive rights to pandemic pathogens. We received an up-front payment of $200.0 million during the fourth quarter of 2022. We will be eligible to receive development milestones totaling more than $1.3 billion if all products are registered in the licensed fields. We will also be entitled to receive up to $3.0 billion in commercial milestones based on â€œnet salesâ€ of vaccines in the various fields. In addition, we are entitled to receive a 40% share of net profits from COVID-19 vaccine sales and up to low double-digit royalties of annual net sales for vaccines against influenza and the other three specified infectious disease pathogens, as well as royalties on revenues from vaccines that may be developed for pandemic preparedness. 23 Â The CSL Collaboration Agreement sets forth how CSL Seqirus and we shall collaborate to research and develop vaccine candidates. In the COVID-19 field, we will lead activities for certain regulatory filings for ARCT-154 in the US and Europe and for research and development activities of a next-generation COVID vaccine candidate. CSL Seqirus will lead and be responsible for all other research and development in COVID-19, influenza and the other fields. Wells Fargo Credit Agreement On April 21, 2023, our wholly-owned subsidiary, Arcturus Therapeutics, Inc. entered into a credit agreement with Wells Fargo Bank, National Association (â€œWells Fargoâ€) whereby Wells Fargo agreed to make a $50.0 million revolving credit line available to the Company (the â€œWells Fargo Loanâ€) and each Wells Fargo Loan evidenced by a revolving line of credit note (the â€œNoteâ€). Borrowings under the agreement will bear interest at a rate of 1.00% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Wells Fargo Note), with â€œSOFRâ€ being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the credit agreement) occurs, then all Wells Fargo Loans shall bear interest at a rate equal to 2.00% above the interest rate applicable immediately prior to the occurrence of the Event of Default. As of September 30, 2024, no borrowings were made against the Wells Fargo Note. The term of the agreement was originally two years, with an option for one-year renewals subject to Wells Fargo approval and the Company furnishing to Wells Fargo a non-refundable commitment fee equal to 0.25% of the Wells Fargo Loan amount for each such renewal. In June 2024, Arcturus Therapeutics and Wells Fargo entered into an amendment to the Note, whereby the term of the Note was extended by one year to April 2026. There is no penalty for terminating the agreement. There is no penalty for terminating the facility prior to the maturity date of the Wells Fargo Note. As collateral, we agreed to pledge $55.0 million in cash to be held in our securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement. Grant from the Biomedical Advanced Research and Development Authority On August 31, 2022, we entered into a cost reimbursement contract (the â€œBARDA Contractâ€) with the Biomedical Advanced Research and Development Authority (â€œBARDAâ€), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to support the development of a low-dose pandemic influenza candidate based on our proprietary self-amplifying messenger RNA-based vaccine platform. The BARDA Contract is to support our non-clinical and pre-clinical development, early-stage clinical development through Phase 1, and associated drug product manufacturing, regulatory and quality-assurance activities over a period of three years. It provides for reimbursement by BARDA of our permitted costs up to $63.2 million. As of September 30, 2024, the remaining available funding net of revenue earned was $41.6 million. Vinbiocare Agreement During 2021, we entered into a technology license and technical support agreement and the framework drug substance supply agreement with Vinbiocare, a member of Vingroup Joint Stock Company (collectively, the â€œVinbiocare License & Supply Agreementsâ€), whereby we would provide technical expertise and support services to Vinbiocare to assist in the build out of an mRNA drug product manufacturing facility in Vietnam. We received an upfront payment in aggregate of $40.0 million as part of the Vinbiocare License and Supply Agreements. In October 2022, in association with the termination of the Vinbiocare License and Supply Agreements, we signed the Vinbiocare Support Agreement with Vinbiocare which continues Vinbiocareâ€™s clinical obligations and reserved a portion of the original $40.0 million upfront payment received from the License and Supply Agreements to be paid over the future periods. The Vinbiocare Support Agreement requires us to pay Vinbiocare certain limited payments, including upon the occurrence of specified events through the first quarter of 2025. Vinbiocare is also eligible to receive a single digit percentage of amounts received by Arcturus on net sales, if any, of ARCT-154 (or next-generation COVID vaccine) up to a capped amount. General Financial Resources A portion of our current cash balance is expected to be utilized during fiscal year 2024 to fund (i) advances to our LUNAR-CF program in clinical trials, (ii) the continued Phase 2 trial of ARCT-810, our LUNAR-OTC candidate, (iii) expenses incurred prior to customer payments under the CSL Collaboration Agreement and BARDA Contract and (iv) continued exploratory activities related to our platform and other general administrative activities. Our future capital requirements are difficult to forecast and will depend on many factors that are out of our control. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that we will be able to obtain additional needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of our existing shareholders. We expect to continue to incur additional losses in the long term, and we will need to execute on milestones within the CSL Collaboration Agreement, raise additional debt or equity financing or enter into additional partnerships to fund development. Our ability to transition to profitability is dependent on executing on milestones within the CSL Collaboration Agreement, successful clinical trials for OTC and CF and identifying and developing successful mRNA drug and vaccine candidates. If we are not able to 24 Â achieve planned milestones or incur costs in excess of our forecasts, we will need to reduce discretionary spending, discontinue the development of some or all of our programs, which will delay part of our development programs, all of which will have a material adverse effect on our ability to achieve our intended business objectives. Funding Requirements We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin commercialization of our products. As a result, we will require additional capital to fund our operations in order to support our long-term plans. We believe that our current cash position will be sufficient to meet our anticipated cash requirements through at least the next twelve months, assuming, among other things, no significant unforeseen expenses and continued funding from partners at anticipated levels. We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, liquidate our assets, file for bankruptcy, reorganize, merge with another entity, or cease operations. Our future funding requirements are difficult to forecast and will depend on many factors, including the following: â€¢the development and commercialization of our LUNAR-COV19 and LUNAR-FLU vaccine candidates; â€¢the achievement of milestones under our strategic alliance agreements; â€¢maintaining and/or expanding our manufacturing network and capabilities; â€¢the terms and timing of any other strategic alliance, licensing and other arrangements that we may establish, including those with CSL Seqirus and CSL Seqirusâ€™ arrangement with Meiji, and any related payments thereunder; â€¢the initiation, progress, timing and successful completion of preclinical studies and clinical trials for our product candidates, including OTC and CF; â€¢the number and characteristics of product candidates that we pursue; â€¢the outcome, timing and cost of regulatory approvals; â€¢delays that may be caused by changing regulatory requirements; â€¢the cost and timing of hiring new employees to support our continued growth; â€¢the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims; â€¢the costs and timing of procuring clinical and commercial supplies of our product candidates; â€¢the costs and timing of establishing sales, marketing and distribution capabilities; â€¢the costs associated with legal proceedings; â€¢the costs associated with potential litigation related to collaboration agreements; and â€¢the extent to which we acquire or invest in businesses, products or technologies. Critical Accounting Policies and Estimates We prepare our condensed consolidated financial statements in conformity with GAAP. As such, we make certain estimates, judgments and assumptions that we believe are reasonable, based upon information available to us. These judgments involve making estimates about the effect of matters that are inherently uncertain and may significantly impact our reported results of operations and financial condition. We describe our significant accounting policies more fully in Note 2 to our consolidated financial statements for the year ended December 31, 2023. There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, included in the 2023 Annual Report. 25 Â Item 3. Quantitative and Qualitative Disclosures About Market Risk. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the United States. Due

to the nature of our cash and cash equivalents, we believe that we are not subject to any material market risk exposure. We do not have any foreign currency or other derivative financial instruments. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures As required by Rule 13a-15(b) and Rule 15d-15(b) of the Exchange Act, our management, including our principal executive officer, our principal financial officer and our principal accounting officer, conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, management has concluded that as of September 30, 2024, our disclosure controls and procedures were not effective due to the material weaknesses in internal control over financial reporting described below. The Companyâ€™s disclosure controls and procedures have been designed to ensure that: (i) information required to be disclosed by us in reports that we file or submit to the SEC under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in applicable rules and forms and (ii) material information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including the CEO and the CFO, as appropriate, to allow for accurate and timely decisions regarding required disclosure. Management does not expect that our disclosure controls and procedures will prevent all error and all fraud. The effectiveness of our or any system of disclosure controls and procedures, however well designed and operated, can provide only reasonable assurance that the objectives of the system will be met and is subject to certain limitations, including the exercise of judgment in designing, implementing, and evaluating controls and procedures and the assumptions used in identifying the likelihood of future events. Material Weaknesses in Internal Control over Financing Reporting Existing as of September 30, 2024 A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. Management concluded that the material weaknesses disclosed in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 continued to exist as of September 30, 2024. Specifically, management concluded that the following material weaknesses exist as of September 30, 2024: â€¢A material weakness related to information technology general controls (â€œITGCsâ€) that support our financial reporting processes; Management determined that we did not maintain effective controls over (i) user access to ensure appropriate segregation of duties and adequately restrict user and privileged access to financial applications, programs and data to the appropriate personnel; (ii) program change management for financial applications to ensure that information technology (â€œITâ€) program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately; and (iii) IT operations controls to ensure that critical interface jobs are monitored. As a result, our related IT dependent manual and application controls that rely upon the affected ITGCs, or information coming from IT systems with affected ITGCs, were also deemed ineffective. â€¢A material weakness related to revenue recognition. Management determined that certain control activities within the area of revenue did not operate effectively, specifically controls over the review of costs incurred in satisfaction of our performance obligations under collaboration arrangements. Notwithstanding the identified material weaknesses, management does not believe that the deficiencies had an adverse effect on our reported operating results or financial condition, and management has determined that the financial statements and other information included in this report and other periodic filings present fairly in all material respects our financial condition and results of operations at and for the periods presented. Plan for Remediation of Material Weaknesses Our remediation efforts are ongoing, and we will continue our initiatives to implement measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented, and operating effectively. We are committed to making the necessary changes and improvements to our system of controls to address the material weaknesses in internal control over financial reporting described above. Our renewed emphasis of designing and implementing improved processes and controls involves but is not limited to the following: 26 Â â€¢Expand available resources with experience designing and implementing control activities, including ITGCs and automated controls, both by hiring internally and the use of third-party consultations and specialists. â€¢Adjust access profiles in IT systems and relevant software, and adjust access review controls accordingly. â€¢Refine the control to identify access profiles in IT systems and software that result in risks of segregation of duties. â€¢Perform ongoing training with control performers to improve documentation that supports effective control activities, including evidence over the completeness and accuracy of information produced by the Company. â€¢Add additional technical accounting resource to review our revenue accounting along with financial disclosures for collaboration arrangements on a quarterly basis. We are in the process of implementing the remediation activities as of the date of this report and believe that upon completion, we will have strengthened our ITGCs, and controls related to accounting for collaboration arrangements to address and successfully remediate the identified material weaknesses. However, control weaknesses are not considered remediated until new internal controls have been operational for a period of time, are tested, and management concludes that these controls are operating effectively. We expect to complete the remediation activities in the fiscal year 2024. We will continue to monitor the effectiveness of these remediation measures, and we will make any changes to the design of this plan and take such other actions that we deem appropriate given the circumstances. Changes in Internal Control over Financial Reporting As required by Rule 13a-15(d) and Rule 15d-15(d) of the Exchange Act, our management, including our principal executive officer and our principal financial and accounting officer, conducted an evaluation of the internal control over financial reporting to determine whether any other changes occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, our principal executive officer and our principal financial and accounting officer concluded that there were no changes in our internal controls over financial reporting during the periods covered by this Quarterly Report on Form 10-Q that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting. 27 Â PART IIâ€”OTHER INFORMATION Item 1. Legal Proceedings. From time to time, we may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business, including those related to governmental inquiries, intellectual property and commercial relationships. The subject matter of any such legal proceedings or claims are or will be highly complex and subject to substantial uncertainties. The outcome of any such proceedings or claims, regardless of the merits, are and will be inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment. Item 1A. Risk Factors. Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which we strongly encourage you to review. There have been no material changes from the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Commission on March 14, 2024. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. Rule 10b5-1 Trading ArrangementsDuring the three months ended September 30, 2024, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Â 28 Â Item 6. Exhibits. Â Exhibit Index Â Exhibit Number Â Description Â Â 1.1 Â Controlled Equity Offeringâ„¢ Sales Agreement, dated as of December 23, 2022 by and between Cantor Fitzgerald & Co, Wells Fargo Securities, LLC and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 1.2 to Registration Statement on Form S-3 filed on December 23, 2022 (File No. 333269003). Â Â Â 1.2 Â Amendment No. 1 to Controlled Equity Offeringâ„¢ Sales Agreement by and between Cantor Fitzgerald & Co, Wells Fargo Securities, LLC, William Blair & Company, L.L.C., and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 1.1 to Form 8-K filed on August 7, 2023. Â Â Â 3.1 Â Certificate of Incorporation. Incorporated by reference to Annex B to the proxy statement/prospectus which forms part of the Registration Statement on Form S-4 filed on March 18, 2019 (File No. 333-230353). Â Â Â 3.2 Â Certificate of Amendment, dated November 25, 2020. Incorporated by reference to Exhibit 3.1 to Form 8-K filed on November 25, 2020 (File No. 001-38942). Â Â Â 3.3 Â Bylaws of Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 3.2 to the Companyâ€™s Registration Statement on Form S-3, filed with the SEC on May 8, 2020 (File No. 333-238139). Â Â Â 4.1 Â Description of Registrantâ€™s Securities. Incorporated by reference to Exhibit 4.1 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2021 filed on February 28, 2022 (File No. 001-38942). Â Â Â 10.1â€ Â Form of Indemnification Agreement. Incorporated by reference to Exhibit 10.1 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942). Â Â Â 10.2â€ Â Amended and Restated 2019 Omnibus Equity Incentive Plan. Incorporated by reference Exhibit 4.3 to the Registration Statement on Form S-8 filed on August 5, 2020 (File No. 333-240397). Â Â Â 10.3** Â Amended and Restated Amendment to Development and Option Agreement, dated as of September 28, 2018, by and between CureVac AG and Arcturus Therapeutics Inc. Incorporated by reference to Exhibit 99.2 to the Companyâ€™s Report of Foreign Private Issuer on Form 6-K filed on October 1, 2018 (File No. 001-35932). Â Â Â 10.4** Â Research and Exclusive License Agreement, by and between Arcturus Therapeutics, Inc. and Synthetic Genomics, Inc., effective October 24, 2017. Incorporated by reference to Exhibit 4.8 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.5** Â Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc., entered into as of October 26, 2015, as amended October 17, 2017 and April 20, 2018. Incorporated by reference to Exhibit 4.10 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.6** Â Third Amendment to Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc., effective June 18, 2019. Incorporated by reference to Exhibit 10.2 to Form 8-K filed on June 20, 2019 (File No. 001- 38942). Â Â Â 10.7** Â Letter Agreement, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation, dated May 16, 2017. Incorporated by reference to Exhibit 4.11 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.8** Â Amendment No. 2 to Letter Agreement, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation, dated August 1, 2019. Incorporated by reference to Exhibit 10.16 to Form 10-Q filed on August 14, 2019. Â Â Â 10.9** Â Development and Option Agreement, by and between Arcturus Therapeutics, Inc. and CureVac AG, dated January 1, 2018, as amended May 3, 2018. Incorporated by reference to Exhibit 4.12 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.10** Â Third Amendment to Development and Option Agreement, by and between Arcturus Therapeutics, Inc. and CureVac AG, dated July 26, 2019. Incorporated by reference to Exhibit 10.20 to Form 10-Q filed on August 14, 2019 (File No. 001-38942). Â Â Â 10.11** Â License Agreement, by and between Arcturus Therapeutics, Inc., as successor-in-interest to Marina Biotech, Inc., and Protiva Biotherapeutics Inc., dated as of November 28, 2012. Incorporated by reference to Exhibit 4.14 to Form 20-F/A filed on July 10, 2018 (File No. 001-35932). 29 Â Â Â Â 10.12** Â Patent Assignment and License Agreement, by and between Arcturus Therapeutics, Inc. and Marina Biotech, Inc., dated as of August 9, 2013. Incorporated by reference to Exhibit 4.15 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.13 Â Share Exchange Agreement, dated as of February 11, 2019, by and between Arcturus Therapeutics Ltd. and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 10.13 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2018 filed on March 18, 2019 (File No. 001-35932). Â Â Â 10.14 Â Lease Agreement, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated October 4, 2017. Incorporated by reference to Exhibit 4.6 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.15 Â First Amendment to Lease Agreement, by and between Arcturus Therapeutics Holdings Inc. and ARE-SD Region No. 44, LLC dated February 1, 2020. Incorporated by reference to Exhibit 10.23 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942). Â Â Â 10.16** Â Acceptance Letter, dated March 4, 2020, by and between Arcturus Therapeutics Holdings Inc. and the Economic Development Board of Singapore. Incorporated by reference to Exhibit 10.24 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942). Â Â Â 10.17â€ Â 2020 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 4.3 to Form S-8 filed on August 5, 2020 (File No. 333-240392). Â Â Â 10.18 Â Second Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated November 13, 2020. Incorporated by reference to Exhibit 10.29 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 1, 2020 (File No. 001-38942). Â Â Â 10.19 Â Third Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated February 25, 2021. Incorporated by reference to Exhibit 10.30 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 1, 2020 (File No. 001-38942). Â Â Â 10.20

Â Arcturus Therapeutics Holdings Inc. Severance Policy for Executives. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on April 26, 2021 (File No. 001-38942). Â Â Â 10.21 Â Lease, by and between Arcturus Therapeutics, Inc. and TPSC IX, LLC, dated September 29, 2021. Incorporated by reference to Exhibit 10.35 to Form 10-Q filed on November 9, 2021 (File No. 001-38942). Â Â Â 10.22â€ Â Arcturus Therapeutics Holdings Inc. 2021 Inducement Equity Incentive Plan. Incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 filed on October 20, 2021 (File No. 333-260391). Â Â Â 10.23â€ Â Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8 filed on June 30, 2022. Â Â Â 10.24** Â Cost Reimbursement Contract dated August 31, 2022, by and between Arcturus Therapeutics Holdings Inc. and Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No. 001-38942). Â Â Â 10.25** Â Study Support Agreement, dated October 31, 2022, by and between Arcturus Therapeutics, Inc. and Vinbiocare Research and Manufacture Joint Stock Company. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on November 4, 2022 (File No. 001-38942). Â Â Â 10.26** Â Collaboration and License Agreement, dated November 1, 2022, by and between Arcturus Therapeutics Holdings Inc. and CSL Limited. Incorporated by reference to Exhibit 10.38 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No. 001-38942). Â Â Â 10.27** Â Manufacturing Support Agreement Termination Letter, dated March 23, 2023, by and between Arcturus Therapeutics, Inc. and the Economic Development of Singapore. Incorporated by reference to Exhibit 10.41 to Annual Report on Form 10-K filed on March 29, 2023 (File No. 001-38942). Â Â Â 10.28** Â Credit Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.28 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). Â Â Â 30 Â 10.29** Â Security Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.29 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). Â Â Â 10.30** Â Revolving Line of Credit Note dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.30 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). Â Â Â 10.31** Â Amendment Number One to Collaboration and License Agreement, dated August 3, 2023, by and between Arcturus Therapeutics, Inc. and Seqirus Inc. Incorporated by reference to Exhibit 10.31 to Quarterly Report on Form 10-Q filed on November 14, 2023 (File No. 001-38942). Â Â Â 10.32** Â Amendment No. 4 to Letter Agreement, dated September 25, 2023, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation. Incorporated by reference to Exhibit 10.32 to Quarterly Report on Form 10-Q filed on November 14, 2023 (File No. 001-38942). Â Â Â 10.33** Â Amendment Number Two to Collaboration and License Agreement, dated March 29, 2024, by and between Arcturus Therapeutics, Inc. and Seqirus Inc. Incorporated by reference to Exhibit 10.33 to Quarterly Report on Form 10-Q filed on May 8, 2024 (File No. 001-38942). Â Â Â 10.34â€ Â Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 14, 2024 (File No. 001-38942). Â Â Â 10.35** Â First Amendment to Credit Agreement and First Amendment to Revolving Line of Credit, dated June 26, 2024, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.35 to Quarterly Report on Form 10-Q filed on August 5, 2024 (File No. 001-38942). Â Â Â 10.36* Â Fifth Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated July 12, 2024. Â Â Â 31.1* Â Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended. Â Â Â 31.2* Â Certification by Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended. Â Â Â 32.1* Â Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 32.2* Â Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 101* Â The following financial statements and footnotes from the Registrantâ€™s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 formatted in Inline Extensible Business Reporting Language (Inline XBRL): Â Â 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document Â Â 101.SCH Inline XBRL Taxonomy Extension Schema Â Â 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Â Â 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Â Â 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Â Â 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase 104 Â Cover Page Interactive Data File (embedded within the Inline XBRL document) Â Â Â Â * Filed herewith. ** Certain confidential portions of this exhibit have been redacted from the publicly filed document because such portions are (i) not material and (ii) would be competitively harmful if publicly disclosed. â€ Management compensatory plan, contract or arrangement. Â 31 Â SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â ARCTURUS THERAPEUTICS HOLDINGS INC. Date: November 7, 2024 By: /s/ Andy Sassine Andy Sassine Â Chief Financial Officer Principal Financial and Accounting Officer Â 32 EX-10.36 2 arct-ex10_36.htm EX-10.36 EX-10.36 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this â€œFifth Amendmentâ€) is made as of July ___, 2024, by 12 and between ARE-SD REGION NO. 44, LLC, a Delaware limited liability company (â€œLandlordâ€), and ARCTURUS THERAPEUTICS, INC., a Delaware corporation (â€œTenantâ€). RECITALS A.Landlord and Tenant are parties to that certain Lease Agreement dated as of October 4, 2017, as amended by that certain First Amendment to Lease dated as of January 31, 2020, as further amended by that certain Second Amendment to Lease dated as of November 13, 2020, as further amended by that certain Third Amendment to Lease dated as of February 25, 2021, and as further amended by that certain Fourth Amendment to Lease dated as of March 25, 2024 (as amended, the "Lease"), wherein Landlord leases to Tenant certain premises containing approximately 24,705 rentable square feet, commonly known as Suite 250, located at 10628 Science Center Drive, San Diego, California (the â€œPremisesâ€), and certain temporary premises containing approximately 11,749 rentable square feet, commonly known as Suite 150, located at 10578 Science Center Drive, San Diego, California (the â€œTemporary Premisesâ€), as more particularly described in the Lease. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease. B.The Term of the Lease, with respect to the Temporary Premises only, is scheduled to expire on March 31, 2025. C.Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the Lease to, among other things, reflect the early termination of the Lease with respect to the Temporary Premises only as of the date this Fifth Amendment is executed (the â€œTemporary Premises Termination Dateâ€). NOW, THEREFORE, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: 1.Temporary Premises Termination. The Term of the Lease with respect to the Temporary Premises shall terminate on the Temporary Premises Termination Date. Tenant shall voluntarily surrender the Temporary Premises on the Temporary Premises Termination Date in accordance with the surrender requirements contained in the Lease and in the condition in which Tenant is required to surrender the Temporary Premises pursuant to the Lease. From and after the Temporary Premises Termination Date, Tenant shall have no further rights of any kind with respect to the Temporary Premises. Notwithstanding the foregoing, those provisions of the Lease which, by their terms, survive the termination of the Lease shall survive the surrender of the Temporary Premises and termination of the Lease with respect to the Temporary Premises as provided for herein. Nothing herein shall excuse Tenant from its obligations under the Lease with respect to the Temporary Premises prior to the Temporary Premises Termination Date. If Tenant fails to surrender the Temporary Premises by the Temporary Premises Termination Date pursuant to this Section 1, such failure shall constitute a hold over without Landlordâ€™s consent under Section 8 of the original Lease. For the avoidance of doubt, the Term of the Lease shall otherwise continue in full force and effect with respect to the Premises. 2.Rent. Tenant shall continue paying Base Rent, Operating Expenses, the Amenities Fee and all other amounts due under the Lease with respect to the Temporary Premises through the Temporary Premises Termination Date. 3.Brokers. Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, â€œBrokerâ€) in connection with the transaction reflected in this 1 Â Fifth Amendment and that no Broker brought about this transaction, other than Savills, Cushman & Wakefield and CBRE. Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than Savills, Cushman & Wakefield and CBRE, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Fifth Amendment. 4.California Accessibility Disclosure. The provisions of Section 44(r) of the original Lease are hereby incorporated into this Fifth Amendment by reference. 5.OFAC. Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (â€œOFACâ€) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the â€œOFAC Rulesâ€), (b) not listed on, and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules. 6.Miscellaneous. a.This Fifth Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. Reference to the Lease in this Fifth Amendment shall mean the Lease as amended by this Fifth Amendment. This Fifth Amendment may be amended only by an agreement in writing, signed by the parties hereto. b.Once executed by both parties, this Fifth Amendment is binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns. c.This Fifth Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Fifth Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures. d.Except as amended and/or modified by this Fifth Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Fifth Amendment. In the event of any conflict between the provisions of this Fifth Amendment and the provisions of the Lease, the provisions of this Fifth Amendment shall prevail. Whether or not specifically amended by this Fifth Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Fifth Amendment. [Signatures are on the next page] 2 Â Â Â IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amendment as of the day and year first above written. TENANT: ARCTURUS THERAPEUTICS, INC., Â a Delaware corporation By: Name: Joe Payne Its: .President & CEO Xâ–¡ I hereby certify that the signature, name, and title above are my signature, name and title LANDLORD: ARE-SD REGION NO. 44, LLC, a Delaware limited liability company By: ALEXANDRIA REAL ESTATE EQUITIES, L.P., a Delaware limited partnership, managing member By: ARE-QRS CORP., a Maryland corporation, Â general partner By: Name: Gary Dean Its: Executive Vice President â€“ Real Estate Leg Â Â Â Â 3 Â EX-31.1 3 arct-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER I, Joseph E. Payne, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Arcturus Therapeutics Holdings Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,

including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Date: November 7, 2024 By: /s/ Joseph E. Payne Joseph E. Payne President and Chief Executive Officer Â Â EX-31.2 4 arct-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER I, Andy Sassine, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Arcturus Therapeutics Holdings Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Date: November 7, 2024 By: /s/ Andy Sassine Andy Sassine Chief Financial Officer Â Â EX-32.1 5 arct-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, the President and Chief Executive Officer of Arcturus Therapeutics Holdings Inc. (the "Company"), hereby certifies on the date hereof, pursuant to 18 U.S.C. 1350(a), as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Form 10-Q"), filed concurrently herewith by the Company, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 7, 2024 By: /s/ Joseph E. Payne Joseph E. Payne President and Chief Executive Officer Â Â EX-32.2 6 arct-ex32_2.htm EX-32.2 EX-32.2 Â Exhibit 32.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, the Chief Financial Officer of Arcturus Therapeutics Holdings Inc. (the "Company"), hereby certifies on the date hereof, pursuant to 18 U.S.C. 1350(a), as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Form 10-Q"), filed concurrently herewith by the Company, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 7, 2024 By: /s/ Andy Sassine Andy Sassine Chief Financial Officer Â Â GRAPHIC 7 img165162168_0.jpg GRAPHIC begin 644 img165162168_0.jpg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

<]Z?4-S=0VD+2SR!(UP"Q M[9HGN([>'S9&PF0,X]3@4VYNXK6W::9MJ+C)QGKQ3)[^WM[(W]/@N8;N-GB;>H9D)'J#@_J#6)#H.@:AG4+>
XD)^>&:2,$@X/"D#J#2:;IG MA^":&^LXA(\S%(YGD>4Y&0IL3S'.TD*O/)Q]#2S MZK9VUM#<23#RIF58V
)W%ONXQZT[^T+8Z>U]YG^CK&9"^#]T#)..M22W<,%J MUS)(%A5-[,>R]'(-*2]+RP0>1'<-&,@ 84[>AP,?7%9>G>$V@TZSTW M4-2>_L[%8A!"T2Q@>6,+N(Y;& ?
J*JW7@>74(;BWN]7:6VN+AKB6+[.J\DJ1 MA@<@C8.1ZFIU\&21:[_:4&IR1QG4CJ1MS$K#S&A\EANZX*EOH31;>$+NR%[)
M;ZPZ7%UJ+:AYAMU.QFC\LKCH1MQ^5%SX,$CPM;ZC);@6C6DH6-6\U6;>3STR
MW/'K5B^*&^EN9EU"2&9[F.\MY%C4FWG6/RBXSPV4&,$8Y/X:EG8W5K9)"8E<3<< D],=>.
M^/2L2Z\%7$MYK4MKJ[VD&JB/S(5MT8(44+E<^H'-6+SPUJNHZ7=V5YX@>3[1 MY>'%K&OEA3DX ZY./RI\N@ZO.K1S^(G97PKJ+1 &3/S+^.<9ZCM3&\+7<.J7
M=YI>KM81W$(C:WCMD90R@@2#/\73V^44EUX1DN+'2(H[\PW.FW"S_:%A7=,0 M""&'H0QS45]X(M]6\.ZCH^IW372W4TDZ2[C0NY)RN/0D_7.*L?\([>)XDO=
M8@UEX1>)%%)#]G0C9'NV@$].7;GW%5AX%M4GL(X+C9IUG#+ +)HPX=92#)EB M-:^4Y8X17W J5(P>,X/![5B1> M!;J&WCA77Y?W5I;VBVRA86W+]3G-
3VG@H6>MVEY'JDQM;6\FO8;0QKA)4 M=9!NZX)D9L=B:M>(_"9\06]_# .;,EM'?6Z03!(U;(5B01GI]XU6E\&RR7]QJ M8U>1-1>99H+A85_ST3Q(/
M$%YW@EM[)",&V20889_CXP!GIBD'@^X^S:@DVK&::_P#+$SRVJ%2J(4QLZ=#^ ME2Z-X.AT*X5=.O)X[$B,RVK8;S'1 BN6/(.%3('!V^YS9U/0K^[UB'4;+5VL
MGBMV@""W60$,P))/^ZOY52F\(/%([ZLIIKE[H:?$\ M%@&7:;>)L J2#_RH@RW/RY[FJ]QX.DEUEM0CU62/F8QQ^2C;3)'L.6ZG!PP
M!^G2BU\'/96VCI9ZK/#/IUJ+)IEC4^? /D(/ /R@[ASU]<5U4:A(PH& .!3 MZ**SM4TY=318)N;)X8V'V=FW1+DDID?-DGKSS^)JE M9^'C9WEM=).59?\ CY10-
DS!=JM[$#CC&1UZ#%N\L;F:ZGDADC59H!$=P)*\ MMS_X]52Z\.K-HEAIL&)\H) QT],X_(FHM,L+ZQBMH)+M9(859"-O+#/R\^P MXK7HI&]NM<:/&=TMW/%+IL,
<8U$Z;;L;HDS3YR 0$^4;,MG)^Z1Z9;J/C>\T MZ-OMT4 FDM?M)?,A0+$5#>8W ;& <,N<$X#I?$XTV_UCS['9]FFA227 MSY'CP\>X,<(=@'0X&,G)]:KVWC'4/[\
(D)3)!"'.4<, =I[=\B0>+KD6=M< M3Z6D:W[PKIY%T")C+G <[

VD=]'AU2:6.^"_NW#XP&15#909!8 9 M/) S6C;^-Q=2)9&P*ZA+?-91Q>8VPLL F9BY4':%) (4[C@C(.1E^#_$>J_\ M(I:+'9'4K_-S),C701M@N9$ 5F&&. 1R5^Z.>:WY/$FH?VBMK%I<+*]U)9J[
M76/W@A,JG[A^4A2">HXP&[5+KQO-96%M,] 22*U1U66U>WM[6W2>[N YC223 MRU(49.6P?4#H>OL:YM=0U'Q'JMA$D"6VGS6CS-(EXRS12*ZC(4(5)5@0.<$$
MD]@;WC"^U*"T,&B/']NB3[4T;)O+HC#Y."-I;G!.?NL,9.13UOQ)8V4VBZX+ MQO[,:WN)I&0DJRA 1P.IS5C4_%&KZ1IUQ?76A0B"V>,S,M\&S"V-TB@)DE>? ME(!..,TS4?
&%]I5I8SW&DPMYT(EG$5YO$>9$4!,)E^'+;B%4;0,\Y%>]^(1T MNXN&O]-"6,&I/IQFCGWON6'S@VS:.-H.><@XZYXR-0\9:CI>K:CK3V:O:Q:% M%?1V8NR0RM*W).S"MC (&1QU-;J^(+J'Q%
<6M[ID-O=I81SLXU F+8TS(=R M@# &XD#/..<#.IHNLCQ'H5Q0#Z@5S?AS5Y MWO7G>YN4M[33HY;Z*Z_>%W9+0-RM&"$\R1F"Y3RR0"< E,KDE*G@[1XT@2.VEC$#2-
M%Y=S(I3S#EP"&Z,>2.GM5[4=%M-5MXK>\C9HH94FC"2M'M="&4_*0>" 1]*@ MF\.6,KK,8YGN(FWQ2M=2AU.",!]V0#DY'0]P:S-.\%6HTNWAU2%9+J.WDM6D
MAN)%#1.Q9D."N0>.OI6D_A?3)!.'AE(G:)I#]HDSF(AHR/F^4J5!!&.E-'A3 M2OE;R)A(L[7(E%U*)!(PPQ#AMP!';..F?0;,R)*L;^9I9\Y\1_)LRHS@' M;QD8/O0NBI1RZ -(O9KBZA:
(Q2O).P>0$'(+ @]\=:JR>#M&FGDFEM9&EDN8; MMW-S*2TL7$;9W=N..G STJS:^';"Q$@M8Y8ED+_*L\(FQW,$&["9(!PN!6L *HP ,DX[FEHK_V0$! end GRAPHIC 8 img165162168_1.jpg
GRAPHIC begin 644 img165162168_1.jpg M_]C_X 02D9)1@ ! 0$ E@"6 #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:''!P@)"XG("
(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_IH " $! _ /?Z**********0G%8<'B%
[_[:^FV@N8K*=[>4B3# M-(F-RH,8;&< <\$]:D?6M.BW>9J%HFTJ&W3*,;AE<\|\"KBH8-?L M9O.D^V6/V>/81*ERK##J&4G^[D'(]1SWJI_PEVGC7(+#S[>U:">
(HIO$$FD0HCR0@&9C*H*Y&1A<[F[<@8ZC.0:DU MK69=)LY;E+&2Y2&)II=K!<(HR<$\%OO?J*HS>,;6.W-WY3+9Q00W%Q-*P3R4 ME^[D>H')SC [JG7Q#(=0M86L)!:W>X07(8,&
(&>0#D @$@U-IWB"#4M=U#2 MXHI ;**&1I6&%?S#(/E]0/+//O[4:UK\6B76GQ303/'=S>4TRKE(..&<]@6* M+]6%69M2%O>K#.$CA:%Y?.9\ !2H.?3[PJO$.D*(R=5L!YA8)FX3YBH)('/ M)
!)^AJ4ZSIWF11_;[7?,%:)?-7,@;.TJ,\YP<8ZX-,@U[2KIV2WU.RE=4,C M+'.K$(#@L0#T!XS52U\4Z=<7EW"UW:)'!)%$DWVA2DKR#Y5!_O9XQS4R>(=/ M,LV[4-/$*+$RN+I22) 2I([@':<_-
@^E2ZEK$=AHTOR/M U*R\ MC<4\SSUV[AR1G.,X[5)!?F/4;BU"+B.*.575LAEO%2:AXETO3;.ZN)[ZW_P!%4F5%94DLISC&,]<\? M6K/]L:?Y_D&^M?.VEO+\Y=V,!LXSG&"#]#5:Q\3:5?
V%K>1WMNL5T"8=\BJ7 M)' SSR*FU#4IK.ZLH([=)/MGX=Z0>(-)8(5U2Q/F.D:8N%^9W^XHYY+=AW[57/B?3X[J" MVFN[59KBZ>UA6.8/EU!.#Z'C&/4@5-
%K]@;.*XN+ZQB21W16%RK(Q5BI ;C) MR,$=CQ5N'4+2XN'MXKJ"29,[HTD!9<<'(ZCGBJ'B'7AH,-G*UN9A:MT4444444444444444C D'%F#T./(1B,LN M-N,'RRN<_=Z$4UX+R.:=
[G*,T<9(3(P?FV@9Z&WG80H(0@<$<@9!Q54^%;S58[I]/AMX8FTJ_L$DEESOFN'603(43 M&S[W. _FBL8KW31<1B**9VC=90.2S)G=N4$\>M9]M\/)]+T?4;"QG MCD&J:?%8W3S.1L"[U9D
7^[(^,GJ![UTZ@8F4QL MA7:25&WDAL D95?2JNJ:1K<5A%9:3+!>HSDW#:K:I8:A9R?9XXM5M[>*\$,;@-FT/P.0>,#\4\->#+GP_XFO[]M8OKVUFLx\;>)J8,^59R2V$' M0$;>?
XGSVI^N^YO(U(7TKJLT:Q6Z17!"A5^8$C;PV_G(S]U?2]^O:#XAU[M28+:1[&"X^S,DTDAPW%2ZEX:O=3T'2
MX76^L+EXXYGV8@.7"_N^_05)/X3U4^,KG4[>/3AI\LEH1&2PE584E4[3LPA_ M>+TYP",C-:<.@ZFGPWBTY%S:F_2P6TR)&$60H7.=N<8&>E9^H^$-2FAU>&R>V M@BU,1R-
\Y!AE0CY00OS1D* 1P1DXZTE_X9UJ[@/EV^DVTDYD:Y,*KQZ) M="YU:6RL9C-?"[MW>1MT9"(%)^3@@J3P>_6LR^\&WTUMJ\5M+&J7ID>.&68 MLB.TWF%E^3*;N2P&1G&*0^&M?
N/%NG:O=-IPBMKN65TA=QF-H3$H"E>7 QDD M\X'0 "JNB>"=5T^WBM;U=.NX#!!'*CO(RQM$<@JN &SUYQ@@'FNLUC3[JJN] M,>*&WDBMKAII%F6^7!&
,'':LS3/#&JZCX>\.36XM%A1=*N9?-=E=?LZ@NH4*>?]>N0<5 MM6_A348M4L[QA9@0ZU M13VD\\GD!99WF1E 3D_,%<'@A1CISIII&J:$VH:A8(DK2&5X[229W3+-'OM:L]-
CLOL^^VU&WO\]V4%8G#$#"GDXKGI/ ^IR3 M:@VZTC^UZM<7@ECE821QD26C0 [/O!FW8Z<>M=%IUGJUM&DTECI,5Y(T2W+6 MY8!U48)!V@D@8V@_G71#I2T44445'+,D*EI&55
R2QP!6*2$OGC?I^GW-W#U M\Y0$0CU!8C(JZ7_A)X+>5(]3MIM/+D!7GQY9)(&X$@9) Y[D#N*VT<.H8<@ M\@TZBBBBBBN>UCQ,NDZ[IMBUK))!=2+'-< '9;E]PC+''\3+M^I%,O\ 7+NW
MUNYL4C@,44%K*I;.299VC;/T"C'O^5:E]J%IIRQ?:BX\UMB;8F-E258TC2)PZDH'PV>I(RPP.!BL=/&UE/K, 29)-'GL6NDN4A MD)R) A)..%Z\D8]ZT[3Q1IUQ=ZA;CSHVLKH6CF2%E$DA0. G]
[@_IGH03>NM M7M+*VAN)Y&6.9D1"$8DLW"C &>2<5"_B+3(WA26X,1F<1KYL;(-Y7?M)(X;: M,X/..U3?VQ:%$979M_W0L;$L-H8D#&<8(YZ<@=ZSI/&OA^.*:4ZBK0P1+-+*
MD;M&B,"58L!C!P?Q&.M7VUJR6>2W,I,T;*K1JC,V64L !D\ GCH!65JOB^U MAT-K[2Y$NF,:2QD(SIL9PN6(Z=^I['T-=*/F&>E8-UK=U-KTNB:='$MQ%:BX
MDN9P6CCW,0J[006)P3U'&/6K,>JRV=O*^K>5$Z,Y!AW,&11DOC&>F>.<=,FF M)XITB258TNP[,L+ JC$8E)$1SC&&(P#G!/%8^H>*[N.\NVAFMK2QMIX[:1[V MSG!#ML;<&&
00^P*0,'#;B"%-S4O$S6GB+1=/B\HV]Y+<)<2.K?)Y<;-PWW> MJX/7OZ'%N3Q5H\4CQO=XE1XT,7E.7W2 E/EQGYL'")&*B/BO3WU*TL8?/>2 MZMY(A)!
^Q1$P5PQQPP)P1C(Q@X)4%+3Q/8+8Z=]LU"V:YNX8'5HE94D,O"E M0>0K-D#-7[342VF3WEZT,*0R3!VSA42-V7))]ER3_*HF\1Z8L2R>>VUI5A3;
M$YW.RAE48'4@@CZXZU1U7Q=:0>')M2T^5;A_(EE@'ELP8H=K!L#(PQP0<HQXHTDPB87#> M67CC7,3@L7^Y@;>0W8C@^M-@UV*34[N%KF(1Q1V[+"89$E4R%@-V[&=Q &
M05;-0#QKHK7;0"XDV)"\TD[0NL2!*,"Q& 0P88/0C'4C-V;Q#IUO(L33.9& MD:,(D+LQ95W$8 SG;S[CI4T&LV5R%,,I;=,8!E"#O)*X('. 3^%7L!AS6+K M^NMH7N1VW=#G[F,
<=:C@\2(FKWFF:@B6US;I',-KEU MDB=MJN#M!!W @C'7N:U+34(-0MFFLY4E"N\1YQAU)5E/<$$$8R*Y[1/&2ZU MI:S_ &,VMZCP):RA&# 892#D'O[&M:[\1:;8P/)+,2421QA&B%G?R
M_OA0!\Q'<"J=[XJBMO"MKK0MI6-WY*P6V,.SRLJJO..[4$,;;BY7<%"XR M21DCCG'%+;^)=*NUA:"[2030R3H0#@I&0KG/0%6(!!Y!X-:<,Z3PI-&M8^#+^[
M6Y6$$)&LKQ@[B6'MTZUI>'KG[?X:T^YN)5DCNK6/?,$7:YV@$,".YS5[0[=] M.O+S3O/,MO'LFM]W)C1]P*9] R$CT# =JW******1L]JY;4O"LVK:1J]M=SQ M&\O'9K>Z6/#6V,>5CG/R$
]1D@G@FB[\ZK'+0L5$L4K2; M\!@=IW8VYS_M5K:E8RWLEBRNJ_9KA9V![X!&/U_2N4UW1[ZUU*2^@;_2+R]6 MX2YCM&G^R!(1'C:IW'&+Q]>O+V*YLOULVVRRO'/9 MB25'6,)\C[@
I"KD$'^+&,Y%5O!=W;QPG3KV")H9WD6"ZA-S (W1 T85F#*- MR!QM(QTQ@FKVE^&&T_4=2N)I8YHKZV@MVC6((([^>!Q@[^G;'>]TGA6^.@: M?:+J44M_93^<+B[M_-
CE^5DPZ9&1L8C@CD ^M5[[P?]\UO-!::K8P1V4$4=P MIL"5#1NS!HP)!M!W8P2W0$Q*![@=07;G.X]>A M [9.==:)
<)XFCUNPN8XY'A6WNH)4)62,,6#*01M<9(R]3ZSX9N=6TW5;/[3%#]NO(+D-M)V"/R?EQD9SY/7C&[H<..M68O"%^8+1+N\L&>VNX)P M]M9>27$1)PWS')/J, >AJTGAJ]BU6TOH;N
&!;]61XBVX7$HD&"&&-K*!T.1 MGIVR9/ &HFUT*VBU2 0Z5'9@"2!F+O;L#D8< !L#.03QUKJ(-,OUT:_LGO$C MGG>N!71ZSI- M_J^B)9&XM?.,D4DLA@.QMCJ^
N[C.W'4_C4E[I+3W.CM#Y4,6G7)G$:KP089 M(MH].)ZB+N)))OLC0* M\6]%> R'YQN&]6\UACC'!Z](9/"&L,[2Q:Q9P326LEO(T%CL"DN74H!)\N. M+-AX9U"VU&WN[JZLV6&Z-
P$@MVC&3"8B.7;Z__KJ31]-\WQ/J&K[+ MZ&&3"I%.=]&3&UW"1%)]6Q]XUT+V-K(Y>2VA=VZLR FL?Q#H-QK$NC/!/% M"--
U!+S#I[@X5779P1MR'//.,#@U1E\&27=^NJWMYYFJI=1312QIL1(XR<0[M222N'?))^\=V!C%;>DZ9+IMM !D] ">YR>,X&6_A! M)!HLIG:.ZTT1HSQG"SHNWY6&>>5!&6S.K+
M\QR!A0[]N>.F.=*7PNUYX-M=#O+@>?;1Q>7Z5J M6K:3+97UU AD@*,]O&1F3.0XRQPO^QS_ +QK,U+2M26]TVZ\Q);HWT+3&.$[M?+2.0'(SP26/S=!D<<3W$:A8"DS2--&Y[H2VT(/F
MR4/9B.X10HP*=1117,ZL%TG73J\ZL]A-"L5P<$B(H6*M@=<{\>V!7G7CS6]0 M\7^%_P"SK?2+J.0S;F=<,I4,=O<=0,_C6KX.\5%HBC@4QW%Q,
M%"Y9@0._0#\17<^'A-.]UJ$T30I<%5MXF;)$2Y()"2S''8$5NT44444A.*P MO^$MTW[7% 3(/.NGLHI"A"O.FUG2_"6F>)-2O$OX+J.V::!8!$8_.*@%2"E M;<7B""&5[>6:6XG:>1C:J0$VY
Y^8#>O/7GVJO9>-(Y[^_M9=/N$,.I/I\ M&S#F9T@\X]^#@-@?3OD"*#7+A]3F>&]FNH+?49K&>V%H P<1"10K=P,=3UW< MD8K0C\8:?(@*1W!7[+]KSL
Q&&VMD$Y!!X(_+-.7Q/&E[>6]Q:2Q>3=K:0L7 M3]^YB63"\\?*Q/..!^ T]+U2VUC3X[VT+F%RR_.A0@JQ5@0>>""/0]1D4:K? MIINGRW3C.P#"@YB2 !P#U) KE_[=U2_"2ZC&R6&J6Y:.=-
HE"NC[2.>QQG M\:T?$L^I:9X3DGMK\"]@";IFA!#\@'Y>@ZYK-;_A(+F+48].\1QSW-J,#S+ M)^])V')Q@_+R.GYU-X8U:(Y([_ .VA+>W3[-=6IA7<;E1^\.[L 2,8X.,Y
MP:DM_$DUSXON=&\KR[=K=C;7)/WI$?;(,$=MR]^<&L"Y\7ZU9Z)XA@O'CAO[M.&[FTZ\VJ5NA!GF8_\"]JP)_'-_=0Z->J<>C6]]'=JZ-;_: DL,@CX/!(8D_I73->Z[, MGAN29TTZ:\G\N\M/+67&
(I)" _8_N\?\"/I4J^)W'C>'2#;_.A7$4B07.[K M<1X9TQCNC@@YZHPK9U75X-(MQ/.DC)AB=@S@!2Q)SP!A36;_ ,)EII>WV<) 4@ M)/!!<+(L)VB.8X1C^/'J*HW?B>6?
Q1H5IISL;*XOKFTN7\L;7:.&1B%)Y!5T MQG&#SSQ5?QEXGU+3--UL:? \$VG6T5PMRP1T?*BU75)+WP;<:SHUX80+5[F)Y+?J%4G!5L$ M=*L:G<2:3H'FW%ZY>+8)+A802TMI94D>=
[)+A8MRK. MH)*X]L$YZ<$9K';QH]CX/FOI[>6XOK;3_M;?+Y:S8.TD'L 1DCT/ -6=-\3O M;:M>6.K/+N?5!:6C&$*$W6Z3+&Q!()Y<9YZ#/45=/C'3'BBDC\V1)H)+BWPN
M//1/OEWVN)898X]IPH9GA4NN"3CH#U(Z8ZTVS\6Z=? M>1Y(F(E>.,DQD>6[QB14<=0=K+[#(!.:9=S:B_C*RM8;X1636CSR1>2&+E'0 M8W=1D/\
I[U:U+Q'8Z5YYN2^RVB6:X=5RL2$D!F]N#TSP,U&_BG3TOH;4^8? M.N?LB2!"5,VS?LS_ +H)STX/.>*?:^);&[NK.W4LC7L)N+0N.)XP 2R_0,IP M<'D<4DOB:RBU V3K*)3YFS*??\M0SX[\
CGH>Q-5(/&VG3V$=XL-T(Y+;[8H M,6&-OM5O, SR/F' RQ.0 <5TBL&4$=*0H#UI/+&<]Z?4-S=0VD+2SR!(UP"Q M[9HGN([>'S9&PF0,X]3@4VYNXK6W::9MJ+C)QGKQ3)
[^WM[(W]/@N8;N-GB;>H9D)'J#@_J#6)#H.@:AG4+> XD)^>&:2,$@X/"D#J#2:;IG MA^":&^LXA(\S%(YGD>4Y&0IL3S'.TD*O/)Q]#2S MZK9VUM#<23#RIF58V
)W%ONXQZT[^T+8Z>U]YG^CK&9"^#]T#)..M22W<,%J MUS)(%A5-[,>R]'(-*2]+RP0>1'<-&,@ 84[>AP,?7%9>G>$V@TZSTW M4-2>_L[%8A!"T2Q@>6,+N(Y;& ?
J*JW7@>74(;BWN]7:6VN+AKB6+[.J\DJ1 MA@<@C8.1ZFIU\&21:[_:4&IR1QG4CJ1MS$K#S&A\EANZX*EOH31;>$+NR%[)
M;ZPZ7%UJ+:AYAMU.QFC\LKCH1MQ^5%SX,$CPM;ZC);@6C6DH6-6\U6;>3STR MW/'K5B^*&^EN9EU"2&9[F.\MY%C4FWG6/RBXSPV4&,$8Y/X:EG8W5K9)"8E<3<< D],=>.
M^/2L2Z\%7$MYK4MKJ[VD&JB/S(5MT8(44+E<^H'-6+SPUJNHZ7=V5YX@>3[1 MY>'%K&OEA3DX ZY./RI\N@ZO.K1S^(G97PKJ+1 &3/S+^.<9ZCM3&\+7<.J7
M=YI>KM81W$(C:WCMD90R@@2#/\73V^44EUX1DN+'2(H[\PW.FW"S_:%A7=,0 M""&'H0QS45]X(M]6\.ZCH^IW372W4TDZ2[C0NY)RN/0D_7.*L?\([>)XDO=
M8@UEX1>)%%)#]G0C9'NV@$].7;GW%5AX%M4GL(X+C9IUG#+ +)HPX=92#)EB M-:^4Y8X17W J5(P>,X/![5B1> M!;J&WCA77Y?W5I;VBVRA86W+]3G-
3VG@H6>MVEY'JDQM;6\FO8;0QKA)4 M=9!NZX)D9L=B:M>(_"9\06]_# .;,EM'?6Z03!(U;(5B01GI]XU6E\&RR7]QJ M8U>1-1>99H+A85_ST3Q(/
M$%YW@EM[)",&V20889_CXP!GIBD'@^X^S:@DVK&::_P#+$SRVJ%2J(4QLZ=#^ ME2Z-X.AT*X5=.O)X[$B,RVK8;S'1 BN6/(.%3('!V^YS9U/0K^[UB'4;+5VL
MGBMV@""W60$,P))/^ZOY52F\(/%([ZLIIKE[H:?$\ M%@&7:;>)L J2#_RH@RW/RY[FJ]QX.DEUEM0CU62/F8QQ^2C;3)'L.6ZG!PP M!^G2BU\'/96VCI9ZK/#/IUJ+)IEC4^? /D(/ /R@[ASU]
<5U4:A(PH& .!3 MZ**SM4TY=318)N;)X8V'V=FW1+DDID?-DGKSS^)JE M9^'C9WEM=).59?\ CY10-DS!=JM[$#CC&1UZ#%N\L;F:ZGDADC59H!$=P)*\ MMS_X]52Z\.K-HEAIL&)\H)
QT],X_(FHM,L+ZQBMH)+M9(859"-O+#/R\^P MXK7HI&]NM<:/&=TMW/%+IL,<8U$Z;;L;HDS3YR 0$^4;,MG)^Z1Z9;J/C>\T MZ%TET-OMT4 FDM?M)?,A0+$5#>8W ;& <,N<$X#I?
$XTV_UCS['9]FFA227 MSY'CP\>X,<(=@'0X&,G)]:KVWC'4/[\(D)3)!"'.4<, =I[=\B0>+KD6=M< M3Z6D:W[PKIY%T")C+G <[

VD=]'AU2:6.^"_NW#XP&15#909!8 9 M/) S6C;^-Q=2)9&P*ZA+?-91Q>8VPLL F9BY4':%) (4[C@C(.1E^#_$>J_\ M(I:+'9'4K_-S),C701M@N9$ 5F&&. 1R5^Z.>:WY/$FH?VBMK%I<+*]U)9J[M76/W@A,JG[A^4A2">HXP&
[5+KQO-96%M,] 22*U1U66U>WM[6W2>[N YC223 MRU(49.6P?4#H>OL:YM=0U'Q'JMA$D"6VGS6CS-(EXRS12*ZC(4(5)5@0.<$$ MD]@;WC"^U*"T,&B/']NB3[4T;)O+HC#Y."-I;G!.?NL,9.13UOQ)8V4VBZX+
MQO[,:WN)I&0DJRA 1P.IS5C4_%&KZ1IUQ?76A0B"V>,S,M\&S"V-TB@)DE>? ME(!...TS4?&%]I5I8SW&DPMYT(EG$5YO$>9$4!,)E^'+;B%4;0,\Y%>]^(1T MNXN&O]-"6,&I/IQFCGWON6'S@VS:..-H.><@XZYXR-
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end GRAPHIC 9 img165162168_2.jpg GRAPHIC begin 644 img165162168_2.jpg M_]C_X 02D9)1@ ! 0$ E@"6 #_VP!# @&!@<&!0@'!P<)"0@*#!0-#
L+ M#!D2$P\4'1H?'AT:''!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<(" 0H+_\0
M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4B9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN(DY>;GZ.GJ\O/T]?;W^/GZ_IH # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BB@ MHHH ****"BB@ HHHH ****"BB@ HHHH ****"BB@ H

M]P@N0P8,0,\@'(!)!K(U3PG>:I8:A9R?9XXM5M[>*\$,;@-FT/P.0>,,#\0#9T[Q!]J6NZAI M<44@-E%#(TK#"OYAD'R^H'EGGW]J-:U^+1+K3XIH)GCNYO*:95RD''#.>P+% M%^K"L7PUX,N?
#_B:_OVUB^O;6:SAMXENI@SY5G)+80= 1MY_B?/:GZ[X3F\0 MC4A?2NJS1K%;I%<$*%7Y@2-O#;^9&XQ\GW3Y>#T.&XJ74O#5[J>CFU\]VM+AY?M!EBF=BL@7Y2&*Y(8 M_*W3Y"1WH Z,ZSIWF11_;[7?,%:)?
-7,@:.TJ,\YP<8ZX-,@U[2KIV2WU.RE M=4,C+'.K${#@LO#TI'XS7*:SX;\0:K<6+RR:9')#)93,L7<+7 M=HD<$D423?:%*2O(/E4^}GC'-3)XAT\RS;@W!HUT3^XNE)(D!*DCL" =IS
M\V#Z5RE]X3UO4&BE>'2X76^L+EXXYGV8@.7"_N^_05)/X3U4^,KG4[>/3A\ MLEH1&2PE584E4[3LPA_>+TYP",C- '6:EK$=AH>NW<.2,YQG':I(+\S:C<6H1<1Q1RJZMD,KE M@/U0_I7(W_AG6KN
^7;Z3;23F1KDQR2%GD:%4#>85SUW C RH3G@UN:'IVI6 M$X:[6V\L6%O;@Q2,S;XR^[@J./G&#G/!XH D77IY'OA'9QE;2X^SL#-AG;:K M#:-N#D..,]>*DU#Q+I>FV=U<3WUQ HJDRHLBEE.<BQGKGCZUGQZ)="YU":6R
ML9C-?"[MW>1MT9"(%)>3@J3P>_6LR^\&WTUMJ\5M+&J7ID>.&68LB.TWF%E M^3*;N2P&1G&* .L_MC3_ #_(-]:^=M++>7YR[L8#9QG._;$'ZU]CXFTJ_L+6\ MCO=;8KH$P[Y%4N 2.!GGD5S9\-:_ <>+=.U>Z;3A%;71EC:
(Y!5< -GKSC! /- '::AJ4 MUG=64$=NDGVN4PHS2%0K!'?G@\80_CCZT#6;>*V%M[-;6A+NH$DZX.QB"03C M/3\.]5]8T^ZO;O3'BAMY(K:X::19G(R#%(F -I[N#^!KFM9\/ZC;RMJ<4=BM
MO!IU[;FT#L%C$A#AD^7EOEP1@#!QVH ZP>(-)8(5U2@F.H:6N&^9W^XHYY+ M=AW[57/B?3X[]"VFN[59KBZ>UA6.8/EU!.#/Z'C&/4@5Q&F>&-5U'P]X1@JGZ9//]:GCU[2Y;QK--2LFNE9E:%9U+AE&2",YR M 02*S?
%FCWVM6>FQV7V??;;C;WC^>[*"L3AB!A3R<5STG@?4Y)M0;=:1_:]6 MN+P2QRL)(XI+1H =GW@S;L=./6@#NK;4K.]:5;2[MYVB;9((I Q1L9P<'@X M(/-6ZYS3K/5K:-)I+'28KR1HEN6MRP#JHP2#M!) QM!_.NB'2@!:*** "BBB
M@ HHHH CEF2%2TC*[@9)8X K%/B7$QOT_3[F[AZ^)0WUNNK>(M9;>Z(-C9Q(_EGE'D;=]X'@A0%(]S6(\ $&]:Q\&7]VMRL((2-97C!W$I,/!U MH W _/A)X+>5(}3MIM/+D!!7GQY9) (Y[D#N*VI<.H8<@\@UR_AZY^
MW^&M/N;B59((]JUCWS!%VN=H!# CNT,W?3KR\[SS+;Q()K?=R8T?<"F?0 M.A(1 P':@#(WEX[-W2QX:VCCHL-E258TC2)PZDH'PV>I(RPP.!BL= M/&UE/K, 29)-'GL6NDN4AD)R) A)..%Z\D8]ZHZ[H]]:ZE)?0-
_I%Y>K<)"+NXL7>22&$RZ7(JH55D/#N2)3YA+Y/4 M]QO)R>6H W:3O1IUO=ZA;CSHVLKH:F2CPF2&ES$DA0. G]I@_IGH03>NM7M+*VAJ M9&6.9D1*S8DLW"C &>2=%7@'A6>YN=9:66VDAU"[CND0Q.'A985C)5PXs(/R* M0P
(Y[>-:*?1:B;1=,L6NC))9R6TCS29+2F)E))YZMMZG/7O0!,_B+3(WA26X M.1F<1KYL:(-Y?2M()(%:;,X/..U3?VQ:%$979M_W0L;$L-H8D#&<8(\YZ<@=2Q M;CPQ>/KUY>Q7-E[FNV65XYL[,22HZQA/D?< %
(5<@@_Q8QG(]MX+N[>.$Z=>P M1-#.\BP74)N8!&Z(&C"LP91N0.-I&.F,$T : 3QT K+TOPPVGZCJ M5Q-+'-%6T%NT:Q! !'OSP,.'?T[8[U6D*WQT#3[1=2BEO[*SA<7=OYLQ]#72CY
MAGI7%7W@_5YK>:"TU6Q@CNH(H[A38$]&C=F#1@2#:#NQ@EN@YSDGJ-/74%C? M^7)[>:3=\K6\)B4# Z@NW.=QZ["!VR0#.NM;NIM>ET33HXEN(K47$ES."T<>
MYB%?:""Q.">HXQZU9CU66SMY7U;RHG1G(,.Y@R*,E)8STSQSCIDU6NM$N%\3 M1ZW87,<V07(;;3L$?D_+C(SGR>O M&-W0XY)M2\3-:->(M%T^+RC;WDMPEQ(ZM\GEQLW#?=ZK@]>_H<6Y/%6CQ2/& M]WB5'C0Q>4Y?=
("4^7&?FP<<$+\P6B7=Y8,IM=P3A[:R\DN(B3AOF.2?48]#0!]GQ M7!IZE:6,/GO)=6\]PD@@?8HB8*8XX8$(QD8P<$]"EIXGL%L=.,V:A;-&KV+5;2^ANX 8%OU9'B+,4<2B08(88VLH'0Y& M>G;)D\ :B;70K<:5(!#14=F)
(&8N\NP.1AP &P,Y\!'6@#K[342VF3WEZT, M*0R3!VSA42-V7))IER3_ "]O$>F+$LGGMM;584VQ.=SLH95&!U(((^N.M-@ MTR_71K^R>\2.>=YS#/#'@O"1F(.'3DJ6Z]\=*QK/PK]4)7[5>VD@%U!='R;= MDRT:A2/F=LY 7J>N?
7@ NZKXNM(/#DVI;?*MP_D2RP#RV8.4.U@V!D88X(,. MF]/X5R2^ 13M=)FL:+5[9!=)<)<1W! MFM3(&629Y5*.J4KYK \D'K@5T>LZ3?ZOHB61N+7SC)%)+(8#L;8ZO@+NXSM MQU/XT 4J\:VEQ<7\%Y$\$EM?
O8H(E>83,L8D.TJO7:G$N<C*U8,H>$ M[A=':U>Z^T6UF]S=6J"(F8NZOL0MGG!6<=/F^3H02P!0#Q1D%$N/LO'&N M8G!8O[S V\ANQ'!]::!KL4FIW<+7.0CBCMV6$PR)*ID +.#LB ,@]V:P M;3P?<72Z;J-S,D=[#;6,3*
(RH"P/YA!&>I8D>PQUJSJ_@^:4M7O=1%W$DDWV M1H%>++>BO 9#\XW#>K>:PQQC@]>@!>'C716NV@%Q)L2%Y]DVA=8D'.48%B, A M@PP>A&.I&:LWB'3K>18FFD\(:PSM+%K%G! M-
):R6\C06.P*2Y=2@$GRXX!SDGKD9XLV'AG4+;4;>[NKJS98;HW 2"W:,9,) MB(Y=OK_^N@#>@UFRN0IAE+;IC ,H0=X\)?! YP"?PJ[@,.:Y?!]-\WQ/]&K[M+Z&&3'Y%.=]&3&UW"?1%)16Q]XUT+V-K(Y>2VA=VZLR
F@#,U_76T.;2(EM MA/\ VC?K9#,NSR|R.V[H<_\TS4$2VN;=(YAM(=!N-8ET9X)XH1INH)>8:/<''"JZ[."-N0YYYQ@<&J,O@R2[OU MU6]O/,U5+]*:*6--B)'&3B':225P[Y)/WCNP,8H Z.TU"#4+9IK.5)0KO$><
M8=2593W!!!!&,BN>T3QDNM:6L_V,VMZCP):RA&# 892#D'O[&MG2 M=,ETVVN0\B23W%Q)<.578N6/ R>@ !/^*HK;P MK;ZT+:5C=^2L%MC#1\K*JKSCNW)[$X/2LL> G$-C;?V@6@L#>&'O'ELS]R_M,
<@84. ,:GCICG2E\+M>>#;70[RX'GVT<7EW,*[=LD6"CJ"3C! .,^M %Y;O4 M+.>5M1:T-HJR2>9%N4Q ;=JL#G&\EACH.!W2?Q+ID!*RSE'\SR@AC;<7*[@ MH7&22,D<,C,F-9FI:5J2WN MFW7F)+=&^:A:8QPG;Y:1R
Y&>"2Q^;H,CCCD VK?Q+I5VL+07;2":&2=" <%(MR%%)MSE'4,I(QDT2GQ.WAV(3:=I]QWKS"[FO]B-0L M!29I&FC<IT]::$'S9*'LQ'<(H48% #]*AN;J&TA:6>0)&N 6/;-$]Q!;P^;(
MV$R\G]'(^@":BJ]S=06MNTTS;47&3C/7BEW]O:V1NYGV0@S LS C]Z .35@ MNGZ72=7G5GL)H5BN#@D1%"Q5I.#KG?CVP%'Z\>:WI'B_P0_9UOI%U'(9MS,N&4 M@<WN.H&?QKV."VANXV>)MZAF0D>H.#^.H-
8D.@Z!J&=0MX#B0GYX9I(P2#@\ M*0.H- '&>#O%3:-X;TG2;[3IHHX%,=Q<3 !0N&8$#OT _$5W/AX33O=:A<$T M*7!5;>)FR1$N2"?0DLQOV!%0:IGA^":&^LXA(\S%(YGD>4Y0IL3S'.TD*O/)Q]#0!>HJE/IMG;6T-Q),/*F95C8
G<6^[C'K3 MO0[MCI[7WF'Z.L9D+X/W0,DXZT 6Z*@ENX8+5KF20+']:V8]EZVJ565@"#G- M_#]*** $)Q6%_P):IOVN* F0>==/912%"%>=,Y0'U'>5N3@'!YK+89&*Y1O! M47VHNE[((8[M[^WA9=PAN6# R9)R1\[':>,: -BQU$:
[10N;/SK=)HU>&62+ M!(900P!^O?T]*Y.VU(6=+\):9XDU^\2 @NH[9IH%@$1C\X] 5()S@N.",.1Z5 MU.F:5<:9X<@TI+TO+!!Y$=PT8R !A3MZ' Q]<5EZ=X3:#3K/3=0U)[^SL5B$ M$+1+&!Y8PNXCEL8!^HH
FB\0000R0S;RS2W$]8CD82 FW(/'S ;UYZ\^U5[M+Q!'/7W[HX+I]PAAUD)|/@V8KM+;7%PU MO+%|$2>$:25P,01L'(]34Z^#)(M=_M:*#4Y(XS]1U(VYB5AYC0^2PW=<%7W) MH C@URX?4YGQGQ"WU&:QGMA:
,'$0D4*W<#'4]=W)&*T(_&&GR(T=P5^R M_:\[,1AMK9!.00>"/RS5.V\(7=D+V2WUATN+K46U#S#;]=C-'Y97'0C;C\] M+GP8)'A;WU&2W M&M)0L:MYJLV\GGIEN>/6@"\OB>-+V\M[BTEB\F[6TA8NG M[!$$LF%YX^5B>
<<#^\IZ7JEMK&GQWMH7.+EE^=*A!5BK @\\$$>AZC(K&OO" MAOI;F9=0DAF>XO+>18UMYUC\HN,\-E!C!&.3^C&I9V-U:W):2_#F,@.2KY3H MO^LR2$INO.0-O08&!0!+M>ZFZ?+=..[,* ?E\(' /4D"N7_MW5+_P)+J.
M.)8:I:EHVTVB4*Z/M(Q'T2U+39M2N:-UO/+@@D\R2$Q*XFXX)Z8Z\=\M>E8EUX*N):S6L:75WM(-5$?F0K;HP0HH7*Y10.: +OB6?4M.\)R3VU^!>]P!- MTS0@A^0#\00=YM1@>98!/WH!,PV;.'/3"1T_.KMYX
M:U74=+N[*\\0/)]H\O#BUC7RPIR< =2.,^VA+>W3[-=6IA7<;E1^\,[L 2.8X.,YP:DM_$DUS MXON=&\KRI=K=C:7)/WI$?(,($=MR]^<&GMX6NX=4N[S2]?:PCN(1&U0';(RA ME! D&?XNGM\HI+KPC)<6.D11WYAN=-
N%G~T+'%8@$$,/0ACF@#GKGQ?K5GH MQB\">,&_LX;N:3K6:I6Z$&=RE/X6&!QGD-D=#6LDVO7?C#5M,@UA(+>RMK6 M9 :16WF3S P))Z9CS_P+VJ:^\$6^K>'=1T?4[IKJ:J2=)=@1H7G+MS[B@#DI_'_=0Z->-]<>C
M6]|'=]Z-;_: DL,@CX/!(8D_I73->Z[.GAN29TTZ:\G\N\M/+67&(0)" _8_ MN\)\"/I31X%M4GL(X+C9IUG#++)HPX=92#)EB ,*:P[OP?-=Z/96IU1DOK:[%W]N6W3>]AF;
MD=!DMR.G48J_XAT!]>M|>);QK7RG+'"^X%2I&#QG!\/W.ZCP)=&$*W6Z3+&O!(Y<9YZ#/45=/C M3'BBDC\V1)H)+BWPN//1/OOT1<E:W(S$K]<>1 ?9D' M!Q(?)Q!"H'XBI[+?3;6L26[7#&6[0+!:V2$8-LD@PPS_!\8
STQO0!H'Q)8K MI'3'6FV?BW3K[R/)QKQODF.CRW>,2*CCJ M#M9289)S5 >#[C[-[*3:I9IK_RQ.\MJA4JB%,.;O0_J4NC>#H="N%73KR>. MQ(C,MJV$/QT0(KECR#A4R!P=ON<@$]W-J+^,K*UAOA%9:-//)%Y(8N4=!C=U
M&0_Z>]6M2\1V.E>>:DOLMHEFN'5]YSQ3[7O+8W=U9VZED:]A-Q:%Q MQ/& "67Z[E.#@\CBN<@TG67\7RWIMA:VHN"P#+M-O$V 5)!^?Y409;GY<[S0!E\3646H#R=91?. MV93[_EJ&?!?
@$<[#V)JI!XVTZ>PCO%ANA');?;%!BPQM]JMY@&>1\PX&6)R M#B]JQX.DMGCIED2/F8QQ^2C:3)'L.6ZG!PP!^G2BU\'/96VCI9ZK/#/]U4)=IEC4^? /D(/ /R@[ASU]<4 =8K!E!^2B' !:2-0D84# ' I] #/+&<]Z?
M110!G:IIRZFBP3E &19Z==66C&PBN%)CW);NR_^GB>&-A|G9M MT2Y)*9'S9)Z_B:T\48'10!S]GX>-G>6UTDY5E_X^44#9,P7:K>Q XXQD=> M@O;O+&YFNIY(9(U6: 1'<"2O+<_^/5]X'I1@>:E '/W7AU9M$L--CE(2UFAD+
M'@L$(Q2=':L?V7<'0+K3&F1M+)P/CD*00_^I&<.Y

[@_E2D"'NBR(R. 588/(<5X?]UDVF:M=6 M3 _NI" 3W7J#^6*]QKS?XDZ=Y5Y:ZBK_+*OE2' .:'(,?RI(;.)W5;TS4'TW M4[:\3K$X8@=QW'XC(K/W4;]HD^@(I$FB26-@R.H92.X/2DN(([]VDMYEW1R* M48>H-
5_]/PKJ[@L\0UC39M'U.:SF'*'*- _>7 ML:H;[]D\1^';?O!9A'(CN8\^5+CI['U%>3:KH]_HUP8KVW9.<*XY1_H:M,EH MJ;J-U1;J-U,1+NHW5%NR<"NL\/>";W4Y$GOD>UL^OS##O[!V^I_6D!;\!Z&U MY??VG.G^CVY_=Y_C?
_ZW7ZXKTRHK:VAL[:.WMXQ'%&NU'5'85+4MW*04444AG MBOB_P#*6Q2_C_-?#_P ZR]U:'B5L>)M2_P"OA_YUE;IL@T=}:_BE(I!1114C*>]V":II=Q928 E0@$ICU!_X
MKQ*Y@6M+F6WG0I+&Q5E/8BO>:Y7Q9X176QIKM'L=\HP<\"4#L?0^_P#D-.31 MY7NHW4^\LIK3[@P7=N\,@_A<$_+UJONJB27=1NJ+=1NI@2[II[3X?:0UQJ#ZG M*G[F %8R?XG(_H/YBLKP_P"$+_6I$EE1K:RZF5Q@L\
9'?Z]/Y5ZQ96<&GV M<5K:1A(8QA0/\I:EL:1/1114E'BOB, .\5)]/_7P_\ZR]U:'B5L>)M2_Z^'_G M65NJR#5T)O\ BH=-_P"OJ+_T.5[=7AF@M_Q46F?]?<7_*&*!SI2*14U.R34 M=,N;-\8EC*@GL>Q_ X->'R*\4KQNNUT)5AZ$5[W7D?
CO3_L'B2255Q%=+YH^ MO1OU&?0H0.YW=6YX2U3^S/$-%'$4I\]3GLW?\#@USVZC=3)/H.BLGPUJ^\ M:^@6MT6S+MV2_P"^,#^27\:UJ@L\H\<;2VFZVURB_P"CW9,BGT:/?QS^-
'Q'O7DFN>&=1T*5C+$9;;/RW"#*GZ^A^M4F2T9 M.ZC=46ZC=5")=U&ZHMU7=.TR^U:X$-E;/*W<_$#16AN5U>%'8Y<)-C^%N@/T(X^H]Z]&J.>"*ZMY(OXQ)%(I5E; MH10F-G@NZC=74>(_!-
YICO<6'4/CNYZ_EP/5HHJ"@HHHH *** M* "BB@ HHHH *\8\<;G_:BBY"ME.WQ O\ P'K_ /$UZSK.H+L:1CT=\/W M.990>[= /Q.!7S\\S2.SNO9@!)))IFFA.[3X=V NJ?:\DQY5G&7)/3<>!.^F3^ M%1^-/%)UJ]^RVK_Z! WRX_Y:-
_>^GI_]>L[^\/[*\+#3+5\7-\?-NG'54Z*G MXCD^S>]<]O\ >F(GW4;[@W^[&_WIB)]U2VT,MWC? M#/0O,DDUJ=?E3,=OD=3_ !-_3\3Z4AG=:'I$6B:3#918)49DI_SVQ6C M114E!1110 4444 5=2LDU'3+FS?&)HRF3V)'!_
\UX%*KPRO%(-KHQ5@>0'6 MOH>O%_'^GG3O%,[],170$Z_4\-^H)_&FA,YW=1NJ#?[:T_ >+)]U&ZH-_O1O M]Z .S^'N]?8_$BVS-B.[0QG_ 'ARQ]1^->05)VW):745Q$V)(@#]?0@Y%? M0MC=OW]A:W<1S'-&LB_0C-
2RD3T444AA1110 4444 %%%% !1110!&8(E))B M0D]25%'V>'_GC'_WR*DHH C\B$'(BC_[Y%2444 %%%% #61'&'16QZC--^SP M_P#/&\ [Y%244 1_9X?^>,?_?(IR1HF=B*N?08IU% #&BC,?_?(MH^SP_P#L6\ [Y%244 -2-(\
[$5<|<#%.HHH *9-#*<1&*:-)(VZ]Z@@_@:? M10!S[SX)\/W+%CIZQL>\3LH_('Z57C^'_A)#EK>5_9IF_IBNHHH S;#0-)T MPAK2PAC<='VIF'_CDU1444 %%%% !1110!&8(E))B0DJ25%'V>'_GC'_P!\ MBI** (Q!"#D1(^/]D5)110
4444 %%%% $-S:6UY%5U!%-'_=D0./UK&G\@* M^'IVW?8-A_Z9R,QZ9O7OT4 _)5 M_P?(]Z8@*.00@@B M) 1T(45)110 4UXTDQ016QTR.TZB@"!//#_SQC_[Y%'V>'_GC'_WR*DHH 14 M5!A5^CT Q2T44 %%!
(P1D&BB@@=N_"FA7K%IM-A#'J8\Q_\ H.*SV'V@%LB M&8#T$QQ74T4 8%OX*\/VS!ET%78?\!'9Q^1.*VX8(K>(101)%&.BHH4#\!4E M%.!1110 4444 %9MJX?TG4F+7=A!QZOMVL?^!#!K2HH Y=_A_X?/Z+U_\ 'MU?6C?
[U7\SWH\SW MI@6-_O1OJZK^9[T>9[T :6G6=<'IZC:V-N.RSN$7CI[GV'6OH73K&'3-_M[* M8BA0(OO[_4]:\W^%&B;S<:W.O3,-OG_QX_R'YUZC4L:"BBBD,**** "BBB@
MKAOBAIOVG0(;!\\[I)\Q_P!AN#^NVNYIJ=BFIZ7=6,GW9XFCSZ9'!_#K0!\ MY;_>C?[U'.DEM<2P2@K+$Y1U/8@X(J/S/>K)+&_WHW^]5 ,]Z/,]Z +&_P!Z M]A^&,]?;?#LED[9DLY, ?[#O_L[5 MZ%X*Y\&:5_UP'\S3
WJ***0!2$A5+$X &?;6HKG_(]O]OQV4 4K7Q#H]\< MI;6NI6LTSYQVO("3@9/'T!K2KP7X=-GQYIH_ZZ_^BGKW.6\M89/+EN88W_NN MX!_*FP)Z* 6J3>2]S"LO3 M87 /Y4 3744 %%%% !114C_6F![_ $44 M4@"BBB@&
[NX+&TDNKF01P1#<[D$X'X52TOQ#16M221Z=>+.\8W,%5A@2B*? MKFFM]^B7>GK*(C/'L#D9V_A7/^#O!4OA:[N9Y+Y;D31A !&5Q@Y]30!V%%%% M !1110 44V21(D+RJ(.K.<
5'#>6UPQ*XAE89!HDM^9!:/_^M5/_^M'F?6@"WYGUJ6VCE MO+J&V@5GFF<1HHIL3@"L_P SZUZ\)-'_M+O,^2H2+F&P3<,]#(V00Z/C^ H MIGT:3/M&T>TT^&V",*3_>/<_ Bš2 M$[3?[\7RS*I$5Z@G7 XW=&'YC/XUQGF?
6O:/B]D)O/#$6HQJ3)8RY8C_GFW M!_7;^M>&>9]:I"9\SZT>9[:]>9!:/.^M BWYGUJ6WNY+6YBN(6*RQ.'0^A! MR*S_ #/K1YGUH ^]M,OX[4TNUOXON7$2R >F1G'X5:KSKX/ZS]N\-SZ<[9DL M92!E]_P">;Y(_4-^E>BU)04444
%%%% !1110 56U&W>[TR[MHV"R3O0&K'H" M00#5FB@#YS\5^'KWPS?PVUJG_L[5Z5X#.? NCG_*=Q_,TQ'14444AA M45U_QZ3?]>]BN]!U\N-N!<"3C.3!]DCGCK63\,7S\0]*'_77_T4 M]>P_$4X\ ZL?
^F:_^AK3$1GB@"R0[CG8#D$?Z]Q]:]/QC MX*MNUC5/^O=?_0]IGH8T%%%%(#$IXH>++C1+.#;"4Q75T"SR*<,D8XX]"3G MGV-06.1UZ_C63\79V:QN48Y$=M&]^P MY\ ,FM.T^+6KVMG!:QZ#"4BC5%.7Y
&!3$4O!^NZAX4\7KH]W(1;-XKW6OF74-0O-8\4-]C630233]Y5%8A3QZ_2OIJA@@HHH1#"O M /'5]-;^/]1*R/M25#M#D?PK7O\ 7SIX^P_Q&U*,]&F13CW5::$S5D\,^+_ &M4CZW);92?YHO-
E"_+V"@!]Z=,]:]R@4I;Q(W#"@[*G(BQQJP*%10 H'0 4Z MD,**** "OG^:]U<+A_4M1<%9YI&\E6)V0Q@$YQZX'XFO?V4,I5AD$8(->;; MIXM=:+#]2==.TN&;48LHQM(E4(>A!?\ PS30CF_%OP\D\+Z0-4M]1^T+&ZK(
M#'L*Y//!)|UVWPOUZ\UKP_-?2-++:2B-96.692,C)ID<\UYWXI>:UXLT:5 M$TOI-I*.K2N@9^<\!GP!U(XP*ZSX*MNT?5/^OA?_ $&@#U"BBBD,**** /F? M1M0U5=7MUTV:0WDL,6'.]^E8_PTVR_$+2E< C,C8]Q$Y'ZBO?
-2F4P1^;;LQR0F<%<^0R.7CJ!U?/?PLN2GC^QC'_P!:D]"'^SX=M?U]"4,$%%%%(91UG4XM&T>[U&892WC+I<_ >/8?B<"0%-%TS5OB3KMQ>7I2 M.(:]"-PC!/"(N>_A_*0O0BO.T7@,X"GAYTHE:W&I/\P*\N\'>-]WPM:745GI
ML=UYIJS.Q:C X"U!H1=\4>'-0\ ZC:75G?NR29.4Z#8RL94C)!1I:[A\)Z MV?$/AJSU%P!"ZE90.@=3@_GC/XUXMWM\::EXML8+:?2%@$,GF!T#$G@C'UK MT?X1B0>"V6164BZDP&&,#"T,#O^***0PKE?B.[1^ M3=&*L/*P02:
[U822,V$BQEB>[5J?%^9X?#UB4=E)NL9! MQ_ U87P3:=>;S_USB_FU:_QH::X;T\ Z^__ &1J?470T?A1*\O@IV=BQ^U. M.DY[+7Y\ T%:[^DQA1110!R7CCPO?^)H:)+&[BMS SES(MS#.<8Z#VKQ'2M/GU+?8--
@D6.>67RUD8G /KQS7TW7SCX:/Q%TX8_Y>S_6F M4A.]G\$^'+WPUIEQ:7U5'(-1F-R6H4?BP_PKUO6=%L=?T\V.HQ&2 L' MVABIR.G(H_3X?>(Y?$?AM9:IMUW:N896_OX (:\02S!KJZR="\-Z9X;@FAT
MR%HDE8,X9RV2!CO6M2&%%%% 'B/O!UW4=8\7]H<,K);12K!%NPKN<G-6])^,3M;FT\0:9'=PNA222'&74\$,AX.1[@4QE MS\)?$=W?K=Z1=RM*1"'6!F.2]YP5SZ%;CPQJ5JU.X>MK*+(V2^ M3;K$Z]IK '^E==#2&%%%%
!1110!Y1 QPX+XIKR//[=?S: ETI6;Y&" *#DX M8@\@4 >TT444@"BBB@#YA^',116/D `>:9E5#*8LD]W1D'ZL*^AO%=_IGA/ M5KR5@@GBB*++%&S9**! CD_C73_ \"B-?_P"@IIOYRT)\O-'_ M HC7_\ H*::^<^=[\'/.]C>=C2*
(U_\ Z"FF_G)_\31_PHC7_P#H M*:;^=1? C6 M_.3SM5T\:AOV;IV.^,KUKW>&&.W@C@B4+'&H1%'8 8 HN,?1112 **** "B MBB@#GO&/BR#P=I$6H7%M)<)).(D; $$JS9Y_P!VN)_X7IIG_0&N_P#OXM=1
M\\0"5WXR\/6^G650']'+.6FS@@CZ*85YC_.*(U_\ Z"FF_G)_\30! MTW_'|-_Z UW_P|_%H X7IIG_0&N_P#OXM<^=[\/:,]C^=C?*(U__H*: M:.,?^$1UQIV2!YX)83%)&K8)Y!!Y M]"/U-2C?\+TTS_H#?7\
W\6N9_X41K__$%--_,3_P"]H X41K__$%--_,3 M_P"]H&=-_P +TTS_* UW_W\6C_A>FF?I :[_P"_BUS/_"B-?_Z"FF_G)_\ M$T?*(U__H*:;^"- M!NO#/A*STB\FAEEMS)\\=I#.S=_]ZNAI %%%% !1110!X5\<'V^)M._Z__ M
&=]I0^'S!O .C$8_P"/<=/]:YSXK> 1]\6QV-YI/E-=6H9'BD?;O4X(P3QD M'/7U]]YOX?\ @WQ]HGB'3S?^?:;/#(S2V_VX,ARI_@5B#R0:8'ME%%%( ]&[M_P"/*?\ ZYM_*]BN$:2VEC?[S(0/]10!\X?"N3=\2=)"'_+;_T2]>T_$\[?
MAYK[_P"F:?\ H:UYIX!^&7B?PIXVT_5-BMEM8/,WE)@Q^:-E"U(KTWQOI- MWKO@W4M,L51KF<*!\VVC(8'K]!3 \O^=_]KIM:U:1_QIL_Z%7M]>6_"OP+KGA+ M4]0GU6.!8YX51/+#F//$31BXB)>&V5]Y#G M^-VZ9'.
,\\YKUZ@ HHHH *^:_\/BAJ(X_X^(__05KZ4KQ+Q?\,0$NL^.[MS5K.*V-I+,CJ6F .]@\?@:$!]:1110 4444 9VOW4ECX94<#T8$@@XZ]J8'?QR6X"1^:-%'#&H !W<#Z*:Q_@8X?1M6Z9%PG_H-9$7PV\9>+K:>\\6:D8[E
M(2ME#)(&PYP

^2T1_P#8&B_]&R5Y[7H7Q \ ^2T1 M_P#8&B_]&R5Y[7KX7^$>=B/C"BBBNHP"BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ K=T+Q;?^'=`U?3]/BM\;M"()YG5 MC(B8((0@@#,XYR#6%12:35F--K8****8@HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH MH **** "BBB@ HHHH T;#_CW;_>_H*M55L/^/=#0[^@] MU7B5_P"*SU*?P(****Q- HHHH **** "O4O!XCW^Q_!+7=.TF#[1=2ZBA2/> MJYQY1/+$#H#7EM=9VI.HV4?P/UVPDO($O)=0C>.W:4'1US%R%ZD<'GVH UKER M;P)*-4T?7Y(([.? M4IEL2MM91RF)7R$W.[CD 8 &/7IZ>0UW'CG4+.\\&^#8;2[@GEMK)UGCCD#- M$?DX8#H>&U]* (`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

*^+/@#0?$7B31+& GDMR#]H@#B.0,4DVYZ LA_2N#\ M+ ^!/"MU^T)XXTFY\:=+I]G:V;6]J]NICB+11EBJXP,DD_C0![=IFK:=K5D+ MS1[^UU"U+%1/:S+*A(ZCI^(=*L[G./(N+V.-\^FTL#7 M! %2Z_X07P#8^'O =O#I%WKVHQZ?;&U7R_(,A^9U Z'@#(Y&|/4"MS1_@YX% MTG14L\,V.H-MQ+=WT"S3RMW8NPR'3SQ@#M0!V]2QR0B6.16C9=P=6RI'KGT MJ.RO;74K*"|TZYAN[:9=T<\$@=']&'!%<;\/? NH>]0UFQ@U);CPU-*LNE MV;LS26>1EUR?XDUYM: \G/7W_8IQ_ I37I- !1110 4444 %%% !1110 M4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M !1110 4444 %%% !1110 4444 %%% M !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M %%% !1110 4444 %%% %>0]IY@@]4?$D3SQQD^)[D@.X&?G;UKUZO/]2^!OPZ MU?5;O4M0\/>===WDSSSR?;;A=[NQ9C@2 #))X Q0!S? OWUVRU 0;+P'H5S#?: MWK=[#&((''WF"-6W&1\?= ('7MN/8UD^-]+U.Q ;"T-=/\2KX72YT(6=C]_M3 M'O5/"_P .2"'7@R5I?#6AV|E,R/3(ED).>FIR6Q[9K M1\0^&=%\5Z9_9_B+3H-0M=V\)*/NMTRI'(/)Y!H \EUSPSJ2^.?"=KXU^+$= M.?0ZE'=:?IZZ D;RNA!(+1-E5(XRWR_E?0:3_P GZ_-B_! Z,6NDI+, #' MP>X,O&N_#>A06ERP*^>SO+(H/4J'G9B, %"VUX?#>E0>*+CQ%%:[=5N;=:=,6X| MOSNC4Y*[<[1R.H&: /$9+*[U#PC\:[? 3E9YVU21@[#)95PS #OE0>*I-|*^) M_#\^#>FZM)=VO]DVVE1IXP5\/ZZ'2?#>DZ'=ZE1-JE MP;F\;S&;S9#U:#&@?08%7.M'5)O'UFURS:R SB(GWB#:#_WS0!O> MIZGINM>/?@YJ.A6#Z=IUR=1>WMGA6(HGEICY%) !ZC'8UC^%=\3R_%/QI+WH]O=?9)-+ANFNH?):-U:@&'U\I=@,CUKVZ'\+Z/J6L:J3EY9!{S1 MO,^P2*|((-ZA6FI#?#*W@VQ>T\,Z5!I%A0!D,8)>3'3<[M$LV/7YCO|{'+'+$GOT>"26%U> "?XRVV MF(?,7Q+7F9&?S9G^|V&)QGT&![5S;?!?X>/ MK(\ .C:>%K,W.[>1N?RB?^N6[9_X[0!RWQ$:WOOAAX;|?>%M.DLQX?N(=(2M;; MR5B;[*Q D3:IPH*[6..PK3^'#Q^+_B!XH|>K^\M&=-=(TIRO__"QB ,C#U#.< M@^QKJ^)VN:K;:-+X=T+PG? ZW/K%G);Q2PP@VI!8%/WK=@KGQXQQ70^'|#, M/@P3I6@P;3[C@*R.HP'D\+M^+$G|: -N57>%UC;B[*0K8^'Z<=:|P_9U_= ! MRSMG&V:VNIF*9#U1Q*3@>^2K@?#.D7GA#XE:Y80VLTFA>('.)6TT43-'; M7/ FC=APNJY67. >0.E ',?"?4[:P)XH\1?#[Q!*ME='4I+[2WG.U;N"0# 1 MCU8;-=/*>#+.,299=4OH'MC'Q0[19Y7&U<(.2 2"]\2*W M?$GA#P_XOLUM?$FDVVH11G895^9.]=K###+'!%97AOX5>"|"'5ZMVH(AZVM[I3 ME)Y&>9T/3Y6D9BOX8H /A?X;N("/PN7/1:X;[" O.O)OY':1E_N1^%=:C_Z)CKU[LFS]+/Z/8>)]0\0VEGY>]ZDB)=W'FN?,5%"I-LT M8"CH\0!PGOXTV\:PKI7B(3H&N)O@6]PZD\:?>,2GYL?0[3[$UW>B^*-%)QZ M%'K&D:E;W%BZ!S.) !'[- =(@aX(K590RE6 ((P01UKA+_X(_#G4=0:\N?"U ML)F;<1#++$A/^XC\?ZH 7P3\09_& C+O!!I5O!+X;TLI#;ZDF7GB;7O&^M6LUITS_TG:B@1(_ M\G/7W_8IQ_ I37I->7,+P_M,WO|GM K_P#"+OY\]21C|2?0BN]\VZ|_SUTW_M +|2?_%4 :E%9>W7O^>NF | ?|3_ .*HVZ|_SUTW_OU) P#%4 :E%9>W7O| MGKIO ?|3_P"*HVZ| P]=- |]2?_ !5 &|167MU[_GKIO_?|3_XJC;KW_/73 M?^_4G_Q5 &|167MU[_GKIO| WZD_^*HVZ|_SUTW_ +|2? %4 :E%9>W7O^>N MF | ?|3_ .*HVZ|_SUTW_OU) P#%4 :E%9>W7O| GKIO ?|3_P"*HVZ| P]=- |]2?_ !5 &|167MU[_GKIO| WZD_^*HVZ|_SUTW_ +|2? %4 :E%9>W7O^>NF | ?|3_ .*HVZ|_SUTW_OU) P#%4 :E%9>W7O| GK MO| WZD_^*HVZ|_SUTW_ +|2? %4 :E%9>W7O^>NF | ?|3_ .*HVZ|_SUTW M_OU) P#%4 :E%9>W7O| GKIO ?|3_P"*HVZ| P]=- |]2?_ !5 &|167MU[_GKIO| WZD_^*HVZ|_SUTW_ +|2? %4 :E%9>W7O^>NF | ?|3_ .*HVZ|_SUTW_OU) P#%4 :E%9>W7O| MGKIO ?|3_P"*HVZ| P]=- |]2?_ !5 &|167MU[_GKIO| WZD_^*HVZ|_SUTW_ +|2? %4 :E%9>W7O^>NF | ?|3_ .*HVZ|_SUTW_OU) P#%4 :E%9>W7O| GKIO ?|3_P"*HVZ| P]=- |]2?_ !5 &|167MU[_GK MIO| WZD_^*HVZ|_SUTW_ +|2? %4 :E%9>W7O^>NF | ?|3_ .*HVZ|_SUTW_OU) P#%4 :E%9>W7O| GKIO ?|3_P"*HVZ| P]=- |]2?_ !5 &|167MU[_GK

**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH ****,W4?^/A?]S^IJK5K4?^/A?]S^IJK0,**** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XOX=?\ M)9? B7_O:9_Z3M11\.O\ DLOQ+_WM,_\ 2=I*!$]K_P G/7W_&*L? I37I-> M/>(OS/\ PB/[05Q[UYH^L7UI-X>CME?3K%IL/YY;G&\C -;'_"[-* Z%;Q=_ MX)G_.; /2:*\V X79I7_0K>+O\ P3/_(T?\+LTK_H5O%W_()G_P : /2: M*!V X79I7_0K>+O_3/_C1_PNS2O^A6\?7?^"9_\: /2:*\V_P"%V:5_T*WB M[_P3/_C1_P +LTK_**%;Q=_X)G_QH |)HKS; A=FE?\ 0K>+O !,_P#C1_PN MS2O^A6\?7?^"9_P#&@#TBO-O^%V:5_T*WB[_,$S_P"-' "[-* Z%;Q=_P"" M9_\ &@#TFBO-O^%V:5_T*WB[_P $S_XT?\+LTK_H5O%W_@F?_&@#TFBO-O\ MA=FE?\"MXN_\$S_XT?\ "[-* P"A6\?7?^"9_\: /2:*\V X79I7_$*WB[_P M3/\ XT?\+LTK_H5O%W_@F?\ QH |)HKS; A=FE?\"MXN_P#!,_\ C1_PNS2O M^A6\?7\ @F?_!H |)HKS; A=FE?\"MXN_\!,_^-' "[-* Z%;Q=_X)G_QH M |)HKS;_(79I7_0K>+O_!,_^-' _NS2O\ H5O%W_@F?_&@#TBO-O^%V:5 M_P!"MXN_\$S_.-' "[-* Z%;Q=_X)G_.; /2:*\V_X79I7_0K>+O\ P3/_M (T?\+LTK_H5O%W_@G?_&@#TFBO-O^%V:5_T*WB[_P $S_XT?\+LTK_H5O%W_@F?\ QH |)HKS; A=FE?\"MXN_P#!,_\ C1_PNS2O^ MA6\?7?^"9_P#&@#TBO-O^%V:5 T*WB[_,$S_P"-' "[-* Z%;Q=_P"""9_\ M&@#TFBO-O^%V:5_T*WB[_P $S_XT?\+LTK_H5O%W_@F?\ QH |)HKS; A=FE?\"MXN_\$S_.-' "[-* Z%;Q=_X)G_.; /2:*\V X79I7_0K>+O\ P3/_(T?\+LTK_H5O%W_()G_P : /2:*\V_MX79I7_0K>+O_3/_C1_PNS2O^A6\?7?^"9_\: /2:*\V_P"%V:5_T*WB[_P3 M/_C1_P +LTK_**%;Q=_X)G_QH |)HKS; A=FE?\ 0K>+O !,_P#C1_PNS2O^ MA6\?7?^"9_P#&@#TFBO-O^%V:5 T*WB[_,$S_P"-' "[-* Z%;Q=_P"""9_\ M&@#TFBO-O^%V:5_T*WB[_P $S_XT?\+LTK_H5O%W_@F?_&@#TFBO-O\ A=FE M2"]"MXN_\$S_XT?\ "[-* P"A6\?7?^"9_\: /2:*\V X79I7_$*WB[_P3\ MXT?\+LTK_H5O%W_@F?\ QH |)HKS; A=FE?\"MXN_P#!,_\ C1_PNS2O^A6\ M7?\ @F?_!H |)HKS; A=FE?\"MXN_\!,_^-' "[-* Z%;Q=_X)G_QH |)H MKS;_(79I7_0K>+O !,_^-' _NS2O\ H5O%W_@F?_&@#TFBO-O^%V:5_P!" MMXN_\$S_.-' "[-* Z%;Q=_X)G_.; /2:*\V X79I7_0K>+O\ P3/_(T? M\+LTK_H5O%W_()G_P : /2:*\V_MX79I7_0K>+O_3/_C1_PNS2O^A6\?7^ M"9_\: /2:*\V_P"%V:5_T*WB[_P3/_C1_P +LTK_**%;Q=_X)G_QH |)HKS; M_A=FE?\ 0K>+O !,_P#C1_PNS2O^A6\?7?^"9_P#&@#TBO-O^%V:5_T*WB[_M_,$S_P"-' "[-* Z%;Q=_P"""9_\ &@#TBO-O^%V:5_T*WB[_P $S_XT?\+L MTK_H5O%W_@F?_&@#TBO-O\ A=FE?\"MXN_\$S_XT?\ "[-* P"A6\?7?^"9_ M\: /2:*\V_X79I7_$*WB[_P3\ XT?\+LTK_H5O%W_@F?\ QH |)HKS; A= MFE?\"MXN_P#!,_\ C1_PNS2O^A6\?7\ @F?_!H |)HKS; A=FE?\"MXN_\ M!,_^-' "[-* Z%;Q=_X)G_QH |)HKS;_(79I7_0K>+O !,_^-' _NS2O\ MH5O%W_@F?_&@#TBO-O^%V:5_P!"MXN_\$S_.-' "[-* Z%;Q=_X)G_.; M/2:*\V_X79I7_0K>+O\ P3/_(T?\+LTK_H5O%W_()G_P : /2:*\V_X79I M7_0K>+O_3/_C1_PNS2O^A6\?7?^"9_\: /2:*\V_P"%V:5_T*WB[_P3/_C1 M_P +LTK_**%;Q=_X)G_QH |)HKS; A=FE?\ 0K>+O !,_P#C1_PNS2O^A6\7 M?^"9_P#&@#TFBO-O^%V:5_T*WB[_,$S_P"-' "[-* Z%;Q=_P"""9_\ &@#T MFBO-O^%V:5_T*WB[_P $S_XT?\+LTK_H5O%W_@F?_&@#TBO-O\ A=FE?\"M MXN_\$S_XT?\ "[-* P"A6\?7?^"9_\: /2:*\V_X79I7_$*WB[_P3\ XT?\ M+LTK_H5O%W_@F?\ QH |)HKS; A=FE?\"MXN_P#!,_\ C1_PNS2O^A6\?7\ M@F?_!H |)HKS; A=FE?\"MXN_\!,_^-' "[-* Z%;Q=_X)G_QH |)HKS;_M_(79I7_0K>+O !,_^-' _NS2O\ H5O%W_@F?_&@#TFBO-O^%V:5_P!"MXN_M\$S_.-' "[-* Z%;Q=_X)G_.; /2:*\V_X79I7_0K>+O\ P3/_(T?\+LT MK_H5O%W_()G_P : /2:*\V_X79I7_0K>+O_3/_C1_PNS2O^A6\?7?^"9_\ M: /2:*\V_P"%V:5_T*WB[_P3/_C1_P +LTK_**%;Q=_X)G_QH |)HKS; A=F ME?\ 0K>+O !,_P#C1_PNS2O^A6\?7?^"9_P#&@#TBO-O^%V:5_T*WB[_,$S_M P"-' "[-* Z%;Q=_P"""9_\ &@#TFBO-O^%V:5_T*WB[_P $S_XT?\+LTK_H M5O%W_@F?_&@#TBO-O\ A=FE?\"MXN_\$S_XT?\ "[-* P"A6\?7^"9_\: / M2:*\V_X79I7_$*WB[_P3\ XT?\+LTK_H5O%W_@F?\ QH |)HKS; A=FE?\ M"MXN_P#!,_\ C1_PNS2O^A6\?7\ @F?_!H |)HKS; A=FE?\"MXN_\!,_^ M-' "[-* Z%;Q=_X)G_QH |)HKS;_(79I7_0K>+O !,_^-' _NS2O\ H5O% MW_@F?_&@#M1J_P"/A?\ <_I;JUP|W\8]-GF#)X7\6X"XYT=_\;K_/"W:#_H M5_%G_@G?_&@9ZI17G_\PMVP_P"A7\6?^"= \;/^%NV'_0K^+/\ P3Q_(T M>@45Y_\ |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arct-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Grant Revenue link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Share-Based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Share-Based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Revenue - Summary of Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Revenue (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Revenue (Details Textual) [Default] link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Grant Revenue (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Balance Sheet Details (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Balance Sheet Details - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Debt (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Debt - Summary of Final Payment Due at Repayment (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Share-Based Compensation Expense (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Related Party Transactions - Equity-Method Investment (Details Textual) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items]Statement [Line Items]Accounts receivableIncrease (Decrease) in Accounts ReceivablePlan NamePlan Name [Domain]Entity Address, Postal Zip CodeEntity Address, Postal Zip CodeRemaining performance obligationRevenue, Remaining Performance Obligation, AmountEntity Incorporation, State or Country CodeEntity Incorporation, State or Country CodeRevenues [Abstract]Revenue:Cash paid for interestInterest Paid, Excluding Capitalized Interest, Operating ActivitiesContra expense included in research and development expenseContra Expense Included In Research And Development ExpenseContra expense included in research and development expense.Number of operating segment for research and developmentNumber of Operating SegmentsVinbiocare [Member]Vinblocare [Member]Vinbiocare.September 2021 Lease Agreement [Member]September Two Thousand And Twenty One Lease Agreement [Member]September two thousand and twenty one lease agreement.COVID-19 Vaccine DevelopmentC O V I D Nineteen Vaccine Development [Member]COVID-19 vaccine development.Balance (in shares)Balance (in shares)Shares, OutstandingOther Noncash Income (Expense), TotalOther non-cash expensesOther Noncash Income (Expense)Increase decrease operating lease, right of use asset.Increase Decrease Operating Lease, Right Of Use AssetRight-of-use assetsShare Based Compensation Arrangement By Share Based Payment Award [Line Items]Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Long-term Debt, TypeLong-Term Debt, Type [Domain]Long-term Debt, Current Maturities, TotalCurrent portion of long-term debtLong-Term Debt, Current Maturities2024 (remainder of year)Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal YearCollaboration Partner Cure Vac Entered Into Co Development Agreement [Member]Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]Collaboration Partner Cure Vac entered into Co-Development Agreement.Commitments and ContingenciesCommitments and Contingencies Disclosure [Text Block]Schedule Of Stock By Class [Table]Stock, Class of Stock [Table]Product and ServiceProduct and Service [Axis]Investment, NameInvestment, Name [Domain]Collaborative Arrangement and Arrangement Other than CollaborativeCollaborative Arrangement and Arrangement Other than Collaborative [Domain]Related Party Transaction [Line Items]Related Party Transaction [Line Items]Janssen [Member]Janssen [Member]Janssen.Stockholders' EquityEquity [Text Block]Commitment And Contingencies [Line Items]Commitment And Contingencies [Line Items]Commitment and contingencies.RevenueRevenue from Contract with Customer [Text Block]Sale of StockSale of Stock [Domain]Entity Central Index KeyEntity Central Index KeyChanges in assets and liabilities:Increase (Decrease) in Operating Capital [Abstract]Milestone paymentsMilestone PaymentsMilestone payments.Restricted CashInventory, Cash Flow Policy [Policy Text Block]Proceeds from debtNet increase in indebtednessProceeds from Issuance of DebtCommon stock, shares issuedIssuance of SharesCommon Stock, Shares, Issued, TotalPurchase of common stock, sharesDirectors or Officers [Member]Directors or Officers [Member]Directors or Officers.LiquidityLiquidity Policy [Text Block]Liquidity.Stock issued during period value under equity plan.Stock Issued During Period Value Under Equity PlanIssuance of common stock under equity plansIncrease (Decrease) in Prepaid Expense and Other Assets, TotalPrepaid expense and other assetsIncrease (Decrease) in Prepaid Expense and Other AssetsEntity Address, State or ProvinceEntity Address, State or ProvincePotential principal repayment of loanPotential Principal Repayments Of Debt InstrumentPotential Principal Repayments Of Debt Instrument.Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestNet loss before income taxesClinical trial accrualsClinical Trial Accruals CurrentClinical trial accruals current.Revenue recognizedDeductionsContract with Customer, Liability, Revenue RecognizedDeductionsDebt instrument, collateralDebt Instrument, CollateralCystic Fibrosis Foundation [Member]Cystic Fibrosis Foundation Therapeutics Inc [Member]Cystic Fibrosis Foundation Therapeutics, Inc.CSL Collaboration Agreement.CSL Collaboration Agreement [Member]CSL Collaboration Agreement [Member]Equity Method Investment, Nonconsolidated InvesteeEquity Method Investment, Nonconsolidated Investee [Domain]Cover [Abstract]Earnings Per Share, Basic, TotalEarnings Per Share, BasicBasicContract with Customer, Asset, after Allowance for Credit Loss, TotalContract with Customer, Asset, after Allowance for Credit LossAccounts receivable, BalanceAccounts receivable, BalanceLessee, operating leases, option to extendLessee, Operating Lease, Option to ExtendGrants received from japanese government.Grants Received From Japanese GovernmentFinancial grants received from the Japanese governmentPayments for matching funds for remaining budgeted costsPayments For Matching Funds For Remaining Budgeted CostsPayments for matching funds for remaining budgeted costs.Operating expenses:Operating Expenses [Abstract]Issuance of common stock related to acquired in-process research and development (in shares)Stock Issued During Period, Shares, AcquisitionsSchedule of Cash and Cash Equivalents and Restricted CashSchedule of Cash and Cash Equivalents [Table Text Block]Share-based compensation expensesShare-based compensation expensesShare-Based Payment Arrangement, ExpenseTotalLong-term debtLong-Term DebtFebruary 2020 Lease Agreement [Member]February Two Thousand And Twenty Lease Agreement [Member]February two thousand and twenty lease agreement.Revenue.Revenue [Line Items]Revenue [Line Items]Retained Earnings (Accumulated Deficit), Ending BalanceRetained Earnings (Accumulated Deficit), Beginning BalanceRetained Earnings (Accumulated Deficit), TotalAccumulated deficitAccumulated deficitRetained Earnings (Accumulated Deficit)Plan NamePlan Name [Axis]Current assets:Assets, Current [Abstract]Common stock reserved for future issuanceCommon Stock, Capital Shares Reserved for Future IssuanceNet cash used in operating activitiesNet Cash Provided by (Used in) Operating ActivitiesDisbursement Due July 2020 [Member]Disbursement Period Three [Member]Disbursement period three.Product and ServiceProduct and Service [Domain]Lessee, operating lease, term of contractLessee, Operating Lease, Term of ContractDebt Instrument [Line Items]Debt Instrument [Line Items]Debt Instrument, TermTerm of agreementProperty, Plant and Equipment, Net, Ending BalanceProperty, Plant and Equipment, Net, Beginning BalanceProperty and equipment, netProperty and equipment, netProperty, Plant and Equipment, Net2028Lessee, Operating Lease, Liability, to be Paid, Year FourOperating activitiesNet Cash Provided by (Used in) Operating Activities [Abstract]Research Collaboration And Exclusive License Agreement [Member]Research Collaboration And Exclusive License Agreement [Member]Research Collaboration and Exclusive License Agreement.Common stock, par valueCommon Stock, Par or Stated Value Per ShareEmployee Stock Option [Member]Contract with Customer, Liability, TotalDeferred revenueContract with Customer, LiabilityDeferred revenue, BalanceDeferred revenue, BalanceBiomedical Advanced Research and Development Authority.Biomedical Advanced Research and Development Authority [Member]BARDA [Member]Taxes Payable, Current, TotalTaxes Payable, CurrentIncome tax payableComprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]Comprehensive loss:Statement of Cash Flows [Abstract]Total expense recognized periodExpense Included In Research And Development ExpenseExpense included in research and development expense.Counterparty NameCounterparty Name [Axis]ThereafterLessee Operating Lease Liability Payments Due After Year FourLessee operating lease liability payments due after year four.Exercise of warrants for shares of common stockClass of Warrant or Right, Number of Securities Called by Warrants or RightsBalance Sheet Related Disclosures [Abstract]Common Stock [Member]Equity Components [Axis]Entity Address, Address Line OneEntity Address, Address Line OneEmployee-related Liabilities, Current, TotalAccrued compensationEmployee-related Liabilities, CurrentWells Fargo Credit Agreement [Member]Wells fargo credit agreement.Wells Fargo Credit Agreement [Member]Schedule Of Related Party Transactions By Related Party [Table]Related Party Transaction [Table]Computer and software [Member]Computer Equipment [Member]COVID vaccination age limitCOVID Vaccination Age LimitCOVID vaccination age limit.Property Plant And Equipment [Line Items]Property, Plant and Equipment [Line Items]Maximum LUNAR-COVID 19 sales required for Loans forgivableMaximum Sales Required For Loans ForgivableMaximum sales required for loans forgivable .Loan and Security Agreement [Member]Loan And Security Agreement [Member]Loan and security agreement.Subsequent Event Type [Axis]Amendment FlagAmendment FlagIncrease (Decrease) in Operating Lease LiabilityLease liabilitiesOperating lease liability, net of current portionOperating Lease, Liability, NoncurrentPrepayment fee percentagePrepayment Fee PercentagePrepayment fee percentage.Operating Lease Liability Current Statement Of Financial Position [Extensible List]Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]SOFR [Member]Net income (loss)Net lossNet lossIssuance of common stock upon exercise of stock options (in shares)Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in PeriodVariable Rate [Domain]Research and Development [Member]Research and Development Expense [Member]Equity ComponentEquity Component [Domain]Statistical MeasurementStatistical Measurement [Domain]General and Administrative Expense, TotalGeneral and administrativeGeneral and Administrative ExpenseUltragenyx [Member]Ultragenyx [Member]Ultragenyx.Balance Sheet DetailsSupplemental Balance Sheet Disclosures [Text Block]Finance income, netOther Nonoperating Income (Expense), TotalOther Nonoperating Income (Expense)Accrued interest added to principal debt balanceDebt Instrument, Increase, Accrued InterestOffice equipment and furniture [Member]Furniture and Fixtures [Member]Disaggregation Of Revenue [Table]Disaggregation of Revenue [Table]Proceeds from Lines of Credit, TotalProceeds from Lines of CreditAmount drawn from LoanAdditional payments upon meeting certain clinical milestones.Additional Payments upon Meeting Certain Clinical MilestonesAdditional payments upon meeting certain clinical milestonesDeferred Revenue, Current, TotalDeferred revenueDeferred Revenue, CurrentProceeds from exercise of stock optionsProceeds from Stock Options ExercisedContra expense remaining amount included in accrued expensesContra Expense Remaining Amount Included In Accrued ExpensesContra expense remaining amount included in accrued expenses.Restricted cashRestricted Cash, CurrentDeferred Revenue, Noncurrent, TotalDeferred revenue, net of current portionDeferred Revenue, NoncurrentNon-current restricted cashNon-current restricted cash Restricted Cash, NoncurrentCollaborative Arrangement and Arrangement Other than CollaborativeCollaborative Arrangement and Arrangement Other than Collaborative [Axis]Comprehensive Income (Loss), Net of Tax, Attributable to ParentComprehensive lossCommon Stock, Shares, Outstanding, Ending BalanceCommon Stock, Shares, Outstanding, Beginning BalanceCommon stock, shares outstandingCommon Stock, Shares, OutstandingLine of Credit Facility, Current Borrowing CapacityRevolving credit line availableOctober 2017 Lease Amendment [Member]October Two Thousand And Seventeen Lease Amendment [Member]October 2017 lease amendment.Summary Of Significant Accounting Policy [Line Items]Summary Of Significant Accounting Policy [Line Items]Summary of significant accounting policy.Entity Interactive Data CurrentEntity Interactive Data CurrentWestern Alliance Bank [Member]Western Alliance Bank [Member]Western Alliance Bank.Disbursement Due April 2020 [Member]Disbursement Period Two [Member]Disbursement period two.Document Quarterly ReportDocument Quarterly ReportCash and cash equivalents, including restricted cashCash and cash equivalents, including restricted cash and non-current restricted cashTotal cash, cash equivalents and restricted cash shown in the statement of cash flowsCash, cash equivalents and restricted cash at beginning of the periodCash, cash equivalents and restricted cash at end of the periodCash, Cash Equivalents, Restricted Cash, and Restricted Cash EquivalentsRelated Party TransactionsRelated Party Transactions Disclosure [Text Block]Statistical MeasurementStatistical Measurement [Axis]COVID-19 Vaccine [Member]COVID-19 Vaccine [Member]COVID-19 vaccine.Other Collaboration Revenue [Member]Other [Member]Other.Operating lease costsOperating Lease, CostRelated PartyRelated and Nonrelated Parties [Domain]Schedule of RevenueDisaggregation of Revenue [Table Text Block]Remaining Payments of Operating Lease LiabilityLessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]Number of shares availableShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for GrantLoss Contingency, Nature [Domain]Research and Development Expense, Policy [Policy Text Block]Research and Development Costs, NetIncome Statement LocationStatement of Income Location, Balance [Axis]Minimum yncur amount agreed under research plan.Minimum Incur Amount Agreed Under Research PlanMinimum incur amount under research plan2021 Inducement Equity Incentive Plan [Member]Twenty Twenty One Inducement Equity Incentive Plan [Member]2021 Inducement equity incentive plan.Eligible to receive development milestone paymentEligible to Receive Development Milestone PaymentEligible to Receive Development Milestone Payments [Member]Number of shares ownedInvestment Owned, Balance, SharesTotal assetsAssetsTotal grant revenueGrant revenueGrant revenue.Description of Business, Basis of Presentation and Summary of Significant Accounting PoliciesOrganization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]Debt Instrument [Table]Schedule of Long-Term Debt Instruments [Table]New Accounting Pronouncements, Policy [Policy Text Block]Recently Issued Accounting Standards Not Yet AdoptedEntity Address, City or TownEntity Address, City or TownIncome (Loss) from Equity Method Investments, TotalIncome (Loss) from Equity Method InvestmentsLoss from equity-method investmentLoss from equity-method investmentSchedule of Maturities of Long-term DebtSchedule of Maturities of Long-Term Debt [Table Text Block]Development milestones received advance payment.Development Milestones Received Advance PaymentDevelopment milestones received advance paymentSchedule of Share-based Compensation ExpensesShare-Based Payment Arrangement, Cost by Plan [Table Text Block]Term loanDebt Instrument, Face AmountLong-term Debt [Member]Long-Term Debt [Member]Manufacturing and Supply of ARCT-154 Drug Product [Member]manufacturing and supply of ARCT-154 drug product.Pre-Launch InventoryPre Launch Inventory Policy Policy [Text Block]Pre-launch inventory policy.Private Placement [Member]Share-Based Compensation ExpenseShare-Based Payment Arrangement [Text Block]Construction in progress [Member]Construction in Progress [Member]Share-based compensation number of shares authorizedShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares AuthorizedWeighted-average discount rateOperating Lease, Weighted Average Discount Rate, PercentGrant [Member]Grant Revenue [Member]Fair Value Disclosures [Abstract]Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums, TotalLoan origination fee paidUnamortized Loan Commitment and Origination Fees and Unamortized Discounts or PremiumsCommon stock issued, valueStock Issued During Period, Value, New IssuesUpfront payment receivedUpfront Payment ReceivedUpfront payment received.Issuance of common stock upon exercise of stock optionsStock Issued During Period, Value, Stock Options ExercisedCurrent liabilities:Liabilities, Current [Abstract]Lease Contractual TermLease Contractual Term [Axis]Document TypeDocument TypeTitle of 12(b) SecurityTitle of 12(b) SecurityRevenue.Revenue [Table]Revenue [Table]Repayment of principal and**

interest on collateralized term loanRepayments Of Principal And Interest On Collateralized Term LoanRepayments of principal and interest on collateralized term loan.Cash and Cash Equivalents, at Carrying Value, Ending BalanceCash and Cash Equivalents, at Carrying Value, Beginning BalanceCash and Cash Equivalents, at Carrying Value, TotalCash and cash equivalentsCash and Cash Equivalents, at Carrying ValueStatement of Stockholders' Equity [Abstract]ADAIR Technology [Member]A D A I R Technology [Member]ADAIR Technology.Document Fiscal Period FocusDocument Fiscal Period FocusResearch and Development Expense, TotalResearch and development, netResearch and Development ExpenseLong-Term Debt, Excluding Current Maturities, TotalLong-Term Debt, Excluding Current MaturitiesLong-term debtFebruary 2021 Lease Agreement [Member]February Two Thousand And Twenty One Lease Agreement [Member]February two thousand and twenty one lease agreement.Contra research and development expense recognizedContra Research And Development ExpenseContra research and development expense.Research Collaboration And License Agreement [Member]Research collaboration and license agreement.Research Collaboration And License Agreement [Member]Property, Plant and Equipment, Gross, Ending BalanceProperty, Plant and Equipment, Gross, Beginning BalanceProperty, Plant and Equipment, Gross, TotalProperty and equipment, grossProperty, Plant and Equipment, GrossSubsequent Event Type [Domain]Contract with customer liability additions.Contract With Customer Liability AdditionsAdditionsLeasesLessee, Leases [Policy Text Block]Tenant improvement allowancePayments for (Proceeds from) Tenant AllowanceKeith C. Kummerfeld [Member]Keith C. Kummerfeld.Debt instrument, collateral amountDebt Instrument, Collateral AmountCollateral amountShare priceClass of Warrant or Right, Exercise Price of Warrants or RightsSale of StockSale of Stock [Axis]Investing activitiesNet Cash Provided by (Used in) Investing Activities [Abstract]Revenue from Contract with Customer, Excluding Assessed Tax, TotalTotal revenueRevenueRevenue from Contract with Customer, Excluding Assessed TaxStatement of Comprehensive Income [Abstract]Income TaxesIncome Tax Disclosure [Text Block]Grant 1Grant One [Member]Grant one.Vinbiocare contractual liabilitiesVinbiocare Contractual LiabilitiesVinbiocare contractual liabilities.Depreciation and amortization expensesDepreciation, Depletion and Amortization, Nonproduction, TotalDepreciation and amortizationDepreciation, Depletion and Amortization, NonproductionIncrease (Decrease) in Accounts Payable, TotalAccounts payableIncrease (Decrease) in Accounts PayableEntity Address, Address Line TwoEntity Address, Address Line TwoLiabilities and stockholders' equityLiabilities and Equity [Abstract]CureVac [Member]Cure Vac A G [Member]CureVac AG.Document Period End DateDocument Period End DateNet cash provided by (used in) financing activitiesNet Cash Provided by (Used in) Financing ActivitiesAlexion [Member]Alexion Pharmaceuticals Inc [Member]Alexion Pharmaceuticals, Inc.Stockholders' Equity Note [Abstract]Antidilutive securities excluded from computation of earnings per shareAntidilutive Securities Excluded from Computation of Earnings Per Share, AmountGrant Revenue OutstandingGrant revenue outstanding.Grant revenue outstandingAPIC, Share-based Payment Arrangement, Increase for Cost Recognition, TotalShare-based compensation expenseAPIC, Share-Based Payment Arrangement, Increase for Cost RecognitionEquity method ownership percentageEquity Method Investment, Ownership PercentageTotalAccrued liabilitiesAccrued Liabilities, CurrentIncome Tax Expense (Benefit), TotalIncome Tax Expense (Benefit)Provision for income taxesIncome tax expenseTrading SymbolTrading SymbolVallon Pharmaceuticals, Inc. [Member]Vallon Pharmaceuticals Inc [Member]Vallon Pharmaceuticals, Inc.Variable Rate [Axis]Total stockholders' equityBalanceBalanceEquity, Attributable to ParentLong-Lived Tangible AssetLong-Lived Tangible Asset [Axis]Other non-current liabilitiesOther Liabilities, NoncurrentSale of Stock, Number of Shares Issued in TransactionEquity method investment, sale of common stockRelated Party Transactions [Abstract]Warrant fee payableWarrant Fee PayableWarrant fee payable.Schedule Of Property Plant And Equipment [Table]Property, Plant and Equipment [Table]Minimum amount agreed to incur under research plan.Minimum Amount Agreed to Incur Under Research PlanMinimum amount agreed to incur under research planMonthly base rentMonthly Base RentMonthly base rent.Percentage of owned sharesInvestment Owned, Net Assets, PercentageSecurity depositSecurity DepositGeographicalGeographical [Axis]Leases [Abstract]Research equipment [Member]Equipment [Member]Other accrued research and development expensesOther Accrued Research And Development ExpensesOther accrued research and development expenses.Grant Revenue [Abstract]Grant Revenue Abstract.Proceeds from Issuance of Long-term Debt, TotalProceeds from long-term debt agreementProceeds from Issuance of Long-Term DebtClass Of Stock [Line Items]Class of Stock [Line Items]Percentage required to be maintain in consolidated, unrestricted cashPercentage Required To Be Maintained In Consolidated Unrestricted CashPercentage required to be maintained in consolidated unrestricted cash.ScenarioScenario [Axis]Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]Summary of Changes in Balances of Receivables and Contract LiabilitySecurity Exchange NameSecurity Exchange NameCounterparty NameCounterparty Name [Domain]Total operating expensesOperating ExpensesLong-Lived Tangible AssetLong-Lived Tangible Asset [Domain]Loss Contingency Nature [Axis]Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, TotalLess accumulated depreciation and amortizationAccumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentFair Value MeasurementsFair Value Disclosures [Text Block]Interest Expense, Long-term Debt, TotalInterest expense related to long-term debtInterest Expense, Long-Term DebtDisbursement Due October 2020 [Member]Disbursement Period Four [Member]Disbursement period four.2027Lessee, Operating Lease, Liability, to be Paid, Year ThreeSubsequent EventSubsequent Event [Member]Maximum [Member]Maximum [Member]Total liabilities and stockholders' equityLiabilities and EquityGain (Loss) on Extinguishment of Debt, TotalGain (Loss) on Extinguishment of DebtGain on debt extinguishmentGain on debt extinguishmentOperating Lease, Right-of-Use AssetOperating lease right-of-use assets, netSupplemental disclosure of cash flow informationSupplemental Cash Flow Information [Abstract]Prime Rate [Member]Earnings Per Share, Diluted, TotalEarnings Per Share, DilutedDilutedBiomedical advanced research and development authority contract member.Biomedical Advanced Research And Development Authority Contract [Member]The BARDA Contract [Member]Leasehold improvements [Member]Leasehold Improvements [Member]Contract with customer asset additions.Contract With Customer Asset AdditionsAdditionsDividends, TotalDividends declared or paidDividendsTotal liabilitiesLiabilitiesDebt instrument option for renewal term.Debt Instrument Option for Renewal TermOption for renewal termTerm loan draw downBorrowings under Guaranteed Investment AgreementsDevelopment milestones achievedDevelopment Milestones AchievedDevelopment milestones achieved.Total current assetsAssets, CurrentNet cash used in investing activitiesNet Cash Provided by (Used in) Investing ActivitiesIssuance of common stockIssuance of common stock, net of issuance costs (in shares)Stock Issued During Period, Shares, New IssuesGrant RevenueGrant Revenue Disclosure [Text Block]The entire disclosure for grant revenue.Entity Filer CategoryEntity Filer CategoryRemaining loan including accrued interest forgiveable.Remaining Loan Including Accrued Interest ForgiveableRemaining loan including accrued interest forgiveableProperty, Plant and Equipment [Abstract]Current Fiscal Year End DateCurrent Fiscal Year End DatePayments for advancePayments for Advance to AffiliateLess: imputed interestLessee, Operating Lease, Liability, Undiscounted Excess AmountShare-based Payment Arrangement, Noncash Expense, TotalShare-based compensation expenseShare-Based Payment Arrangement, Noncash ExpenseNet profits percentagePercentage Of Net ProfitsPercentage of net profits.Vinbiocare Agreement [Member]Vinbiocare Agreement [Member]Vinbiocare agreement.Related PartyRelated and Nonrelated Parties [Axis]Lance Kurata [Member]Lance Kurata.Debt Instrument, Fee AmountFee payableRevenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]Singapore Economic Development Board [Member]SINGAPOREEntity Registrant NameEntity Registrant NameSchedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]Loan maturity dateDebt Instrument, Maturity DateEntity Emerging Growth CompanyEntity Emerging Growth CompanyWeighted Average Number of Shares Outstanding, Basic, TotalWeighted Average Number of Shares Outstanding, BasicBasicLUNAR-CF [Member]L U N A R C F [Member]LUNAR-CF.Common stock, shares authorizedCommon Stock, Shares AuthorizedReduction in number of common stock shares available for future issuanceReduction in Number of Common Stock Capital Shares Available for Future IssuanceReduction in number of common stock capital shares available for future issuance.Equity Method Investment, Nonconsolidated InvesteeEquity Method Investment, Nonconsolidated Investee [Axis]Debt Disclosure [Abstract]Net Loss per ShareEarnings Per Share, Policy [Policy Text Block]General and Administrative [Member]General and Administrative Expense [Member]Revenue RecognitionRevenue [Policy Text Block]Phase I clinical study.Phase I Clinical Study [Member]Share-Based Payment Arrangement [Abstract]2019 Omnibus Equity Incentive Plan [Member]Two Thousand Nineteen Omnibus Incentive Plan [Member]Two thousand nineteen omnibus incentive plan.Property Leases in San Diego [Member]Property Lease Guarantee [Member]Eligible to receive commercial milestone paymentEligible to Receive Commercial Milestone PaymentEligible to receive commercial milestone payment.Issuance of common stock related to acquired in-process research and developmentStock Issued During Period, Value, AcquisitionsIsrael ministry of health.Israel Ministry of Health [Member]Israel Ministry of Health [Member]Accounting Policies [Abstract]Income Tax Disclosure [Abstract]Stockholders' equityEquity, Attributable to Parent [Abstract]Non-cash investing activitiesCash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]Statement [Table]Statement [Table]Segment InformationSegment Reporting, Policy [Policy Text Block]Summary of Components of Property and Equipment, NetProperty, Plant and Equipment [Table Text Block]Study Support AgreementStudy Support Agreement [Member]Study support agreement.Entity File NumberSecurities Act File NumberCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectNet decrease in cash, cash equivalents and restricted cashRevenue from Contract with Customer [Abstract]Earnings Per Share [Abstract]Net loss per share:2022Long-Term Debt, Maturity, Remainder of Fiscal YearLease Contractual TermLease Contractual Term [Domain]Statement of Financial Position [Abstract]Operating Income (Loss)Loss from operations2023Long-Term Debt, Maturity, Year OneEntity Shell CompanyEntity Shell CompanyLoan accrued interest rate per annum, percentageDebt Instrument, Interest Rate, Effective PercentageBorrowings interest rate, percentageEntity Tax Identification NumberEntity Tax Identification NumberAssetsAssets [Abstract]DeductionsContract with customer asset deductions.Contract With Customer Asset DeductionsDeductionsEntity Current Reporting StatusEntity Current Reporting StatusLine of Credit Facility, Interest Rate During PeriodLoans interest rate, percentageLong-term Debt, TypeLong-Term Debt, Type [Axis]Subsequent Events [Abstract]Deferred revenueIncrease (Decrease) in Contract with Customer, LiabilityGeographicalGeographical [Domain]Document Fiscal Year FocusDocument Fiscal Year FocusReceived first installmentPayment Received First InstallmentPayment received first installment.Repayments of Long-Term Debt, TotalRepayments of Long-Term DebtRepayment of term loanPurchase of property and equipment in accounts payableCapital Expenditures Incurred but Not yet PaidCity Area CodeCity Area CodeTotal current liabilitiesLiabilities, CurrentFinal payment of disbursement amountFinal Payment Of Disbursement AmountFinal payment of disbursement amount.CSL segirus.CSL Segirus [Member]CSL Segirus [Member]Local Phone NumberLocal Phone NumberCommitment And Contingencies [Table]Commitment And Contingencies [Table]Commitment and contingencies.Impairment lossOperating Lease, Impairment LossAdditional Paid in Capital, Ending BalanceAdditional Paid in Capital, Beginning BalanceAdditional Paid in Capital, TotalAdditional paid-in capitalAdditional Paid in CapitalGrant awardedGrants ReceivablemRNA Technology [Member]M R N A Technology [Member]mRNA technology.Commitments and Contingencies Disclosure [Abstract]Current portion of operating lease liabilityOperating Lease, Liability, CurrentAccumulated Deficit [Member]Retained Earnings [Member]Payments to Acquire Property, Plant, and Equipment, TotalAcquisition of property and equipmentPayments to Acquire Property, Plant, and EquipmentAccrued Liabilities, Current [Abstract]Document Transition ReportDocument Transition ReportLoan first principal payment extended maturity dateDebt Instrument, Date of First Required Payment2026Lessee, Operating Lease, Liability, to be Paid, Year TwoSchedule Of Summary Of Significant Accounting Policies [Table]Schedule Of Summary Of Significant Accounting Policies [Table]Schedule of summary of significant accounting policies.Proceeds from the issuance of common stock under equity plansProceeds from Stock PlansPrepaid expenses and other current assetsPrepaid Expenses And Other ReceivablesThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable.Minimum [Member]Minimum [Member]Common Stock [Member]Common Stock [Member]Restricted cashRestricted CashRestricted Cash, TotalInvestment, NameInvestment, Name [Axis]Additional Paid-In Capital [Member]Additional Paid-in Capital [Member]Business acquisition of holding share.Business Acquisition Of Holding ShareBusiness acquisition of holding shareCollaboration revenue.Collaboration Revenue [Member]Collaboration Revenue [Member]Adjustments to reconcile net loss to net cash used in operating activities:Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Income Statement LocationStatement of Income Location, Balance [Domain]2025Lessee Operating Lease Liability Payments Due Next Twelve Months, TotalLessee, Operating Lease, Liability, to be Paid, Year OneRoyalty payment percentage of proceeds from net salesRoyalty Payment PercentageRoyalty payment percentage.Disbursed amount upon execution of amendmentDisbursed Amount Upon Execution Of AmendmentDisbursed amount upon execution of amendment.Foreign currency transaction lossRealized Gain (Loss), Foreign Currency Transaction, before TaxUnderlying Agreement [Member]Underlying Agreement [Member]Underlying agreement.Entity Common Stock, Shares OutstandingEntity Common Stock, Shares OutstandingDisaggregation of Revenue [Line Items]Disaggregation of Revenue [Line Items]Loan interest-only payment extended maturity dateDebt Instrument Interest Only Payment Extended Maturity DateDebt instrument interest only payment extended maturity date.Non-cash asset disposalNon - Cash Asset DisposalNon-Cash Asset DisposalBasis of PresentationBasis of Accounting, Policy [Policy Text Block]Joint Ventures, Equity Method Investments and Variable Interest EntitiesJoint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block]Joint ventures, equity method investments and variable interest entities.ScenarioScenario [Domain]Stock issued during period shares under equity plan.Stock Issued During Period Shares Under Equity PlanIssuance of common stock under equity plans (in shares)Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 27,084 at September 30, 2024 and 26,828 at December 31, 2023Common Stock, Value, Issued, Ending BalanceCommon Stock, Value, Issued, Beginning BalanceCommon Stock, Value, Issued, TotalCommon Stock, Value, IssuedDebt instrument, extended term period.Debt Instrument, Extended Term PeriodExtended term periodOperating Lease, Liability, TotalTotal operating lease liabilitiesOperating Lease, LiabilitySchedule of Accrued LiabilitiesSchedule of Accrued Liabilities [Table Text Block]Disbursement payment upon achievement of required manufacturing practices and IND applicationDisbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D ApplicationDisbursement payment upon achievement of required manufacturing practices and IND application.Weighted Average Number of Shares Outstanding, Diluted, TotalWeighted Average Number of Shares Outstanding, DilutedDilutedAccounts Receivable, after Allowance for Credit Loss, Current, TotalAccounts receivableAccounts Receivable, after Allowance for Credit Loss, CurrentOperating lease extended additional termLessee, Operating Lease, Renewal TermTotal remaining lease paymentsLessee, Operating Lease, Liability, to be PaidWeighted Average Number of Shares Outstanding, Diluted [Abstract]Weighted-average shares outstanding:Entity Small BusinessEntity Small BusinessInterest of the prime rate plusDebt Instrument, Basis Spread on Variable RateDebtDebt Disclosure [Text Block]Segirus Inc [Member]Segirus, Inc [Member]Segirus, Inc [Member]Segirus, Inc.Payments on debt obligationsRepayments of DebtForeign Currency Transaction Gain (Loss), before Tax, TotalGain (Loss), Foreign Currency Transaction, before TaxForeign currency transaction gain (loss)(Loss) gain from foreign currencyAcquisition of in-process research and development through issuance of common stockAcquisition Of Research And Development In Process Through Issuance Of Common StockAcquisition of research and development in process through issuance of common stock.Grant, number of installmentsGrant Receivable Number Of InstallmentsGrant receivable number of installments.Disbursement Due January 2020 [Member]Disbursement Period One [Member]Disbursement period one.Disbursement amount payable upon achievement of project goalDisbursement Amount Payable Upon Achievement Of Project GoalDisbursement amount payable upon achievement of project goal.Financing activitiesNet Cash Provided by (Used in) Financing Activities [Abstract]Grant 2Grant Two [Member]Grant two.Extension to interest only periodDebt Instrument Interest Only Payment Extended PeriodDebt instrument interest only payment extended period.Right-of-use assets acquired through operating leasesRight-of-Use Asset Obtained in Exchange for Operating Lease LiabilityLine of Credit Facility, Commitment Fee PercentageNon-refundable commitment fee, percentageCystic Fibrosis Foundation liabilityAccrued cystic fibrosis foundation liability.Accrued Cystic Fibrosis Foundation LiabilityCystic Fibrosis Foundation Liability (Note 9)Other Collaboration Agreements [Member]Other Collaboration Agreements [Member]Other collaboration agreements.Weighted-average remaining lease termOperating Lease, Weighted Average Remaining Lease TermSubsequent EventsSubsequent Events [Text Block]Accounts Payable, Current, TotalAccounts payableAccounts Payable, CurrentGRI Bio Inc.GRI Bio Inc MemberGRI Bio [Member]Increase (Decrease) in Accrued Liabilities, TotalAccrued liabilitiesIncrease (Decrease) in Accrued Liabilities XML 14 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended Sep. 30, 2024	Nov. 05, 2024
Cover [Abstract]		
Document Type	10-Q	
Amendment Flag	false	
Document Period End Date	Sep. 30, 2024	
Document Fiscal Year Focus	2024	
Document Fiscal Period Focus	Q3	
Trading Symbol	ARCT	
Entity Registrant Name	ARCTURUS THERAPEUTICS HOLDINGS INC.	
Entity Central Index Key	0001768224	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Current Fiscal Year End Date	--12-31	
Entity Filer Category	Accelerated Filer	
Entity Small Business	false	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Title of 12(b) Security	Common Stock, par value $0.001 per share	
Security Exchange Name	NASDAQ	

Entity File Number	001-38942	
Entity Incorporation, State or Country Code	DE	
Entity Tax Identification Number	32-0595345	
Entity Address, Address Line One	10628 Science Center Drive	
Entity Address, Address Line Two	Suite 250	
Entity Address, City or Town	San Diego	
Entity Address, State or Province	CA	
Entity Address, Postal Zip Code	92121	
City Area Code	858	
Local Phone Number	900-2660	
Entity Common Stock, Shares Outstanding		27,087,359
Document Quarterly Report	true	
Document Transition Report	false	

" XML 15 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	**Sep. 30, 2024**	**Dec. 31, 2023**
Current assets:		
Cash and cash equivalents	$ 237,178	$ 292,005
Restricted cash	55,000	55,000
Accounts receivable	30,199	32,064
Prepaid expenses and other current assets	8,444	7,521
Total current assets	330,821	386,590
Property and equipment, net	10,350	12,427
Operating lease right-of-use assets, net	27,598	28,500
Non-current restricted cash	1,885	1,885
Total assets	370,654	429,402
Current liabilities:		
Accounts payable	10,131	5,279
Accrued liabilities	32,396	31,881
Deferred revenue	26,936	44,829
Total current liabilities	69,463	81,989
Deferred revenue, net of current portion	13,338	42,496
Operating lease liability, net of current portion	25,987	25,907
Other non-current liabilities		497
Total liabilities	108,788	150,889
Stockholders' equity		
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 27,084 at September 30, 2024 and 26,828 at December 31, 2023	27	27
Additional paid-in capital	680,641	646,352
Accumulated deficit	(418,802)	(367,866)
Total stockholders' equity	261,866	278,513
Total liabilities and stockholders' equity	$ 370,654	$ 429,402

XML 16 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	**Sep. 30, 2024**	**Dec. 31, 2023**
Statement of Financial Position [Abstract]		
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	27,084,000	26,828,000
Common stock, shares outstanding	27,084,000	26,828,000

XML 17 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Revenue:				
Total revenue	$ 41,673	$ 45,140	$ 129,544	$ 135,944
Operating expenses:				
Research and development, net	39,134	51,077	151,376	155,513
General and administrative	13,276	13,377	40,443	40,364
Total operating expenses	52,410	64,454	191,819	195,877
Loss from operations	(10,737)	(19,314)	(62,275)	(59,933)
(Loss) gain from foreign currency	(201)	4	(642)	(175)
Gain on debt extinguishment				33,953
Finance income, net	3,818	3,981	11,981	9,710
Net loss before income taxes	(7,120)	(15,329)	(50,936)	(16,445)
Provision for income taxes	(217)	893	0	1,573
Net loss	$ (6,903)	$ (16,222)	$ (50,936)	$ (18,018)
Net loss per share:				
Basic	$ (0.26)	$ (0.61)	$ (1.89)	$ (0.68)
Diluted	$ (0.26)	$ (0.61)		$ (0.68)
Weighted-average shares outstanding:				
Basic	27,062	26,574	26,970	26,559
Diluted	27,062	26,574	26,970	26,559
Comprehensive loss:				
Net loss	$ (6,903)	$ (16,222)	$ (50,936)	$ (18,018)

Comprehensive loss	(6,903)	(16,222)	(50,936)	(18,018)
Collaboration Revenue [Member]				
Revenue:				
Total revenue	38,815	43,376	117,389	132,670
Grant Revenue [Member]				
Revenue:				
Total revenue	$ 2,858	$ 1,764	$ 12,155	$ 3,274

XML 18 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2022	$ 270,312	$ 27	$ 608,426	$ (338,141)
Balance (in shares) at Dec. 31, 2022		26,555		
Net Income (Loss)	50,754			50,754
Share-based compensation expense	8,182		8,182	
Balance at Mar. 31, 2023	329,248	$ 27	616,608	(287,387)
Balance (in shares) at Mar. 31, 2023		26,555		
Balance at Dec. 31, 2022	270,312	$ 27	608,426	(338,141)
Balance (in shares) at Dec. 31, 2022		26,555		
Net Income (Loss)	(18,018)			
Balance at Sep. 30, 2023	280,062	$ 27	636,194	(356,159)
Balance (in shares) at Sep. 30, 2023		26,723		
Balance at Mar. 31, 2023	329,248	$ 27	616,608	(287,387)
Balance (in shares) at Mar. 31, 2023		26,555		
Net Income (Loss)	(52,550)			(52,550)
Share-based compensation expense	8,383		8,383	
Issuance of common stock upon exercise of stock options	94		94	
Issuance of common stock upon exercise of stock options (in shares)		19		
Balance at Jun. 30, 2023	285,175	$ 27	625,085	(339,937)
Balance (in shares) at Jun. 30, 2023		26,574		
Net Income (Loss)	(16,222)			(16,222)
Share-based compensation expense	9,269		9,269	
Issuance of common stock upon exercise of stock options	1,231		1,231	
Issuance of common stock upon exercise of stock options (in shares)		114		
Issuance of common stock under equity plans	609		609	
Issuance of common stock under equity plans (in shares)		35		
Balance at Sep. 30, 2023	280,062	$ 27	636,194	(356,159)
Balance (in shares) at Sep. 30, 2023		26,723		
Balance at Dec. 31, 2023	278,513	$ 27	646,352	(367,866)
Balance (in shares) at Dec. 31, 2023		26,828		
Net Income (Loss)	(26,817)			(26,817)
Share-based compensation expense	10,088		10,088	
Issuance of common stock upon exercise of stock options	2,188		2,188	
Issuance of common stock upon exercise of stock options (in shares)		89		
Balance at Mar. 31, 2024	263,972	$ 27	658,628	(394,683)
Balance (in shares) at Mar. 31, 2024		26,917		
Balance at Dec. 31, 2023	278,513	$ 27	646,352	(367,866)
Balance (in shares) at Dec. 31, 2023		26,828		
Net Income (Loss)	(50,936)			
Balance at Sep. 30, 2024	261,866	$ 27	680,641	(418,802)
Balance (in shares) at Sep. 30, 2024		27,084		
Balance at Mar. 31, 2024	263,972	$ 27	658,628	(394,683)
Balance (in shares) at Mar. 31, 2024		26,917		
Net Income (Loss)	(17,216)			(17,216)
Share-based compensation expense	9,424		9,424	
Issuance of common stock upon exercise of stock options	2,403		2,403	
Issuance of common stock upon exercise of stock options (in shares)		125		
Balance at Jun. 30, 2024	258,583	$ 27	670,455	(411,899)
Balance (in shares) at Jun. 30, 2024		27,042		
Net Income (Loss)	(6,903)			(6,903)
Share-based compensation expense	9,493		9,493	
Issuance of common stock upon exercise of stock options	11		11	
Issuance of common stock upon exercise of stock options (in shares)		2		
Issuance of common stock under equity plans	682		682	
Issuance of common stock under equity plans (in shares)		40		
Balance at Sep. 30, 2024	$ 261,866	$ 27	$ 680,641	$ (418,802)
Balance (in shares) at Sep. 30, 2024		27,084		

XML 19 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Operating activities		

Net loss	$ (50,936)	$ (18,018)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	2,725	2,142
Share-based compensation expense	29,005	25,834
Foreign currency transaction loss	643	90
Gain on debt extinguishment		(33,953)
Other non-cash expenses		502
Changes in assets and liabilities:		
Accounts receivable	1,865	(35,456)
Prepaid expense and other assets	(923)	556
Right-of-use assets	3,638	3,011
Accounts payable	4,852	10,497
Accrued liabilities	(625)	(3,437)
Deferred revenue	(47,051)	33,960
Lease liabilities	(2,656)	(3,198)
Net cash used in operating activities	(59,463)	(17,470)
Investing activities		
Acquisition of property and equipment	(648)	(2,026)
Net cash used in investing activities	(648)	(2,026)
Financing activities		
Proceeds from exercise of stock options	4,602	1,325
Proceeds from the issuance of common stock under equity plans	682	609
Proceeds from debt		20,000
Payments on debt obligations		(27,364)
Net cash provided by (used in) financing activities	5,284	(5,430)
Net decrease in cash, cash equivalents and restricted cash	(54,827)	(24,926)
Cash, cash equivalents and restricted cash at beginning of the period	348,890	393,977
Cash, cash equivalents and restricted cash at end of the period	294,063	369,051
Supplemental disclosure of cash flow information		
Cash paid for interest		2,102
Non-cash investing activities		
Non-cash asset disposal	473	
Right-of-use assets acquired through operating leases	$ 2,736	
Purchase of property and equipment in accounts payable		$ 416

XML 20 R7.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure								
Net Income (Loss)	$ (6,903)	$ (17,216)	$ (26,817)	$ (16,222)	$ (52,550)	$ 50,754	$ (50,936)	$ (18,018)

XML 21 R8.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended Sep. 30, 2024
Trading Arrangements, by Individual	
Material Terms of Trading Arrangement	***Rule 10b5-1 Trading Arrangements*** During the three months ended September 30, 2024, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Directors or Officers [Member]	
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false

XML 22 R9.htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended Sep. 30, 2024
Accounting Policies [Abstract]	
Description of Business, Basis of Presentation and Summary of Significant Accounting Policies	**Note 1. Description of Business, Basis of Presentation and Summary of Significant Accounting Policies** **Description of Business** Arcturus Therapeutics Holdings Inc. (the “Company” or "Arcturus") is a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. Arcturus became a clinical stage company in 2020 when it announced that its Investigational New Drug (“IND”) application for ornithine transcarbamylase (“OTC”) deficiency and its Clinical Trial Application (“CTA”) for candidate LUNAR-COV19 were approved by applicable health authorities. In 2023, our COVID-19 vaccine, ARCT-154 (also referred to as KOSTAIVE®), received marketing authorization approval in Japan for adults 18 years and older, and in September 2024 KOSTAIVE became the world’s first approved and commercially available self-amplifying RNA (sa-mRNA) vaccine. **Basis of Presentation** The accompanying condensed consolidated financial statements include the accounts of Arcturus and its subsidiaries and are unaudited. All intercompany accounts and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. These condensed consolidated financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and

the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on management's knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Joint Ventures, Equity Method Investments and Variable Interest Entities

Investments for which the Company exercises significant influence but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. ("Axcelead"). The Company's share of the investee's results is presented as either income or loss from equity-method investment in the accompanying condensed consolidated statements of operations and comprehensive loss.

Liquidity

The Company has incurred significant operating losses since its inception. As of September 30, 2024 and December 31, 2023, the Company had an accumulated deficit of $418.8 million and $367.9 million, respectively.

The Company's activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company's inception through September 30, 2024, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, the sale of capital stock, expense reimbursements from government contracts and proceeds from long-term debt. At September 30, 2024, the Company's balance of cash and cash equivalents, including restricted cash, was $294.1 million.

Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in securing additional funding, that the Company's projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.

Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company's operations and manage its business in one operating segment, which is the research and development of medical applications for the Company's nucleic acid-focused technology.

Revenue Recognition

At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of Accounting Standards Codification ("ASC") Topic 808, Collaborative Arrangements ("ASC 808"). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.

The Company determines revenue recognition for arrangements within the scope of ASC 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation.

The terms of the Company's revenue agreements include license fees, upfront payments, development and regulatory milestone payments, profit-sharing arrangements, reimbursement for research and development activities, option exercise fees, drug substance and drug product supply fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.

A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in ASC 606. A contract's transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.

For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified.

See "Note 2, Revenue" for specific details surrounding the Company's arrangements.

Leases

The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components.

See *"Note 9, Commitments and Contingencies"* for specific details surrounding the Company's leases.

Research and Development Costs, Net

All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), in-process research and development expenses, pre-launch inventory and license agreement expenses. Research and development expenses are presented net of any grants. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed.

The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered.

Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations ("CROs") and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.

Pre-Launch Inventory

Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its condensed consolidated statements of operations and comprehensive loss, in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.

Restricted Cash

Restricted cash includes collateral pledged and held in the Company's securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association ("Wells Fargo") (Note 5). At September 30, 2024, such collateral amounted to $55.0 million.

Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company's offices. At September 30, 2024 and 2023, the Company had restricted cash of $1.9 million and $2.1 million, respectively, in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term. At September 30, 2023, non-current restricted cash also includes $20.0 million related to the Wells Fargo Loan (Note 5).

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statement of cash flows as of September 30, 2024 and 2023:

(in thousands)	September 30, 2024	September 30, 2023
Cash and cash equivalents	$ 237,178	$ 311,918
Restricted cash	55,000	35,000
Non-current restricted cash	1,885	22,133
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 294,063	$ 369,051

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the three and nine months ended September 30, 2024 were comprised of stock options and restricted stock units. Dilutive shares of common stock for the three and nine months ended September 30, 2023 were comprised of stock options.

No dividends were declared or paid during the reported periods.

Recently Issued Accounting Standards Not Yet Adopted

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the condensed consolidated financial statements and disclosures.

In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments' significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the impact that adoption of ASU 2023-07 will have on our financial statement disclosures.

XML 23 R10.htm IDEA: XBRL DOCUMENT

Revenue

9 Months Ended
Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Revenue

Note 2. Revenue

The Company has entered into license agreements and collaborative research and development arrangements with pharmaceutical and biotechnology companies, as well as consulting, related technology transfer, product revenue and government grant agreements. Under these arrangements, the Company is entitled to receive license fees, consulting fees, product fees, technological transfer fees, upfront payments, milestone payments if and when certain research and development milestones, technology transfer milestones or success-based milestones are achieved, royalties on approved product sales and reimbursement for research and development activities. The Company's costs of performing these services are included within research and development expenses. The Company's milestone payments are typically defined by achievement of certain preclinical, clinical, and commercial success criteria. Preclinical milestones may include in vivo proof of concept in disease animal models, lead candidate identification, and completion of IND-enabling toxicology studies. Clinical milestones may, for example, include successful enrollment of the first patient in or completion of Phase 1, 2 and 3 clinical trials, and commercial milestones are often tiered based on net or aggregate sale amounts. The Company cannot guarantee the achievement of these milestones due to risks associated with preclinical and clinical activities required for development of nucleic acid medicine-based therapeutics and vaccines.

The following table presents changes during the nine months ended September 30, 2024 in the balances of contract assets and liabilities as compared to what was disclosed in the Company's Annual Report.

(in thousands)	December 31, 2023	Additions	Deductions	September 30, 2024
Contract Assets:				
Accounts receivable	$ 32,064	$ 83,375	$ (85,240)	$ 30,199
Contract Liabilities:				
Deferred revenue	$ 87,325	$ 82,493	$ (129,544)	$ 40,274

The following table summarizes the Company's revenues for the periods indicated.

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
(in thousands)	2024	2023	2024	2023
Collaboration Revenue:				
CSL Seqirus	$ 38,786	$ 43,433	$ 117,078	$ 129,257
Other collaboration revenue	29	(57)	311	3,413
Total collaboration revenue	$ 38,815	$ 43,376	$ 117,389	$ 132,670
Grant revenue:				
BARDA	$ 2,858	$ 1,764	$ 12,155	$ 3,274
Total grant revenue	$ 2,858	$ 1,764	$ 12,155	$ 3,274

The following paragraphs provide information regarding the nature and purpose of the Company's most significant collaboration and grant arrangements.

CSL Seqirus

On November 1, 2022, the Company entered into a Collaboration and License Agreement (as amended, the "CSL Collaboration Agreement") with Seqirus, Inc., a part of CSL Limited ("CSL Seqirus"), for the global exclusive rights to research, develop, manufacture, and commercialize vaccines. Under the terms of the CSL Collaboration Agreement, the Company provides CSL Seqirus with an exclusive global license to its mRNA technology (including STARR®) and LUNAR® lipid-mediated delivery, along with mRNA drug substance and drug product manufacturing process. CSL Seqirus will lead development and commercialization of vaccines under the collaboration. The collaboration plans to advance vaccines against SARS-CoV-2 (COVID-19), influenza, pandemic preparedness as well as three other respiratory infectious diseases. In September 2024, our COVID-19 vaccine KOSTAIVE® became the world's first approved and commercially available self-amplifying RNA (sa-mRNA) vaccine.

The Company received a $200.0 million upfront payment and is eligible to receive over $1.3 billion in development milestones if all products are registered in the licensed fields and entitled to potentially receive up to $3.0 billion in commercial milestones based on "net sale" of vaccines in the various fields. In addition, the Company is eligible to receive a 40% net profit share for COVID-19 vaccine products and up to low double-digit royalties for vaccines against flu, pandemic preparedness and three other respiratory pathogens. During the third quarter of 2024, upon the first commercial sale of KOSTAIVE following regulatory approval in Japan, the Company achieved a $25.0 million development milestone related to the CSL Collaboration Agreement which was included in accounts receivable as of September 30, 2024.

In evaluating the CSL Collaboration Agreement in accordance with ASC 606, the Company concluded that CSL Seqirus is a customer. The Company identified all promised goods/services within the CSL Collaboration Agreement, and when combining certain promised goods/services, the Company concluded that there are five distinct performance obligations. The nature of the performance obligations consists of delivery of the vaccine license, research and development services for COVID and non-COVID vaccines and regulatory activities for COVID vaccines. For each performance obligation, the Company estimated the standalone selling price based on 1) in the case of the license, the fair value using costs to recreate plus margin method and 2) in the case of research and development services and regulatory activities, cost plus margin for estimated full-time equivalent ("FTE") costs, direct costs including laboratory supplies, contractors, and other out-of-pocket expenses for research and development services and regulatory activities.

As of September 30, 2024, the transaction price consisted of upfront consideration received and milestones achieved. Additional variable consideration was not included in the transaction price at September 30, 2024 because the Company could not conclude that it is probable that including the variable consideration will not result in a significant revenue reversal.

The Company allocated the transaction price to the performance obligations in proportion to their standalone selling price. The vaccine license was recognized at the point in time it was transferred in 2022. The research and development and regulatory activities performance obligations are recognized over a period of time based on the percentage of services rendered using the input method, meaning actual costs incurred divided by total costs budgeted to satisfy the performance obligation. Any consideration related to sales-based royalties will be recognized when the amounts are probable of non-reversal, provided that the reported sales are reliably measurable and the Company has no remaining promised goods/services, as they are constrained and therefore have also been excluded from the transaction price. The revenue recognized in the third quarter of 2024 relates to the license delivered, milestones achieved and services performed through September 30, 2024.

Total deferred revenue as of September 30, 2024 and December 31, 2023 for the CSL Collaboration Agreement was $40.3 million and $87.1 million, respectively.

During 2023, the Company also received an advance payment of $23.6 million for the manufacturing and supply of ARCT-154 drug product. The advance payment was for specified manufacturing runs of ARCT-154 which include the drug substance utilized, as well as the reservation fees and related manufacturing requirements. The Company concluded that the promise to manufacture and supply ARCT-154 drug product is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $18.0 million in revenue related to this customer option during the second quarter of 2024. No amount related to this customer option remained in deferred revenue as of September 30, 2024.

During 2023, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the Company agreed to sponsor and conduct a Phase 1 clinical study in the influenza field. As part of the amendment, the Company received $17.5 million from CSL Seqirus. The amendment also provides for up to $1.5 million in additional payments which are achievable upon meeting certain clinical milestones relating to the Phase 1 clinical study in the influenza field. The Company previously concluded that the expansion of research and development support services under the CSL Collaboration Agreement represented an option that was

not a material right. Therefore the Company concluded the promise to sponsor and conduct the Phase 1 clinical study is a separate contract and the sole performance obligation under the new arrangement. During the quarter ended September 30, 2024, the Company recognized $4.0 million related to the performance obligation and the remaining amount of $5.9 million is included in deferred revenue.

During the fourth quarter of 2023, the Company received an advance payment of $5.3 million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. During the first quarter of 2024, the Company received an additional advance payment of $5.1 million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. The Company concluded that the promise to perform manufacturing activities is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $5.3 million in revenue related to this customer option during the third quarter of 2024 upon the transfer of vaccine product to CSL Seqirus. The remaining $5.1 million is included in deferred revenue as of September 30, 2024 and will be recognized as revenue when the remaining vaccine product is transferred to CSL Seqirus.

In March 2024, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the parties agreed to, among other things, adjust (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing.

BARDA Grant

In August 2022, the Company entered into a cost reimbursement contract (the "BARDA Contract") with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) for an award of up to $63.2 million for the development of a pandemic influenza vaccine using the Company's STARR® self-amplifying mRNA vaccine platform technology. The Company earns grant revenue for performing tasks under the agreement.

The Company determined that the BARDA Contract is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, the Company recognizes grant revenue from the reimbursement of direct out-of-pocket expenses, overhead allocations and fringe benefits for research costs associated with the grant. The costs associated with these reimbursements are reflected as a component of research and development expense in the Company's condensed consolidated statements of operations and comprehensive income (loss).

As of September 30, 2024, the remaining available funding net of revenue earned was $41.6 million.

XML 24 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements	9 Months Ended Sep. 30, 2024
Fair Value Disclosures [Abstract]	
Fair Value Measurements	

Note 3. Fair Value Measurements

The Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure fair value.

The three levels of the fair value hierarchy are as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3: Unobservable inputs in which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect those that a market participant would use.

The carrying value of cash, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values due to their relatively short maturities.

As of September 30, 2024 and December 31, 2023, all assets measured at fair value on a recurring basis consisted of cash equivalents and money market funds, which were classified within Level 1 of the fair value hierarchy. The fair value of these financial instruments was measured based on quoted prices.

XML 25 R12.htm IDEA: XBRL DOCUMENT

Balance Sheet Details	9 Months Ended Sep. 30, 2024
Balance Sheet Related Disclosures [Abstract]	
Balance Sheet Details	

Note 4. Balance Sheet Details

Property and equipment, net balances consisted of the following:

(in thousands)	September 30, 2024	December 31, 2023
Research equipment	$ 16,864	$ 16,046
Computers and software	1,131	1,275
Office equipment and furniture	703	958
Leasehold improvements	2,644	2,655
Construction in progress	—	233
Total	21,342	21,167
Less accumulated depreciation and amortization	(10,992)	(8,740)
Property and equipment, net	$ 10,350	$ 12,427

Depreciation and amortization expenses were $0.9 million and $2.7 million for the three and nine months ended September 30, 2024, respectively, and $0.8 million and $2.1 million for the three and nine months ended September 30, 2023, respectively. Construction in progress is primarily comprised of research equipment not yet placed in service.

Accrued liabilities consisted of the following:

(in thousands)	September 30, 2024	December 31, 2023
Accrued compensation	$ 10,846	$ 5,918
Cystic Fibrosis Foundation liability	7,109	7,633
Income tax payable	—	641
Current portion of operating lease liability	3,435	4,309
Clinical trial accruals	2,039	2,333
Vinbiocare contractual liabilities	2,036	2,514
Other accrued research and development expenses	6,931	8,533
Total	$ 32,396	$ 31,881

XML 26 R13.htm IDEA: XBRL DOCUMENT

Debt	9 Months Ended Sep. 30, 2024
Debt Disclosure [Abstract]	
Debt	

Note 5. Debt

Wells Fargo Credit Agreement

The Company's wholly-owned subsidiary, Arcturus Therapeutics, Inc. ("Arcturus Therapeutics") entered into a credit agreement with Wells Fargo Bank on April 21, 2023, and amended on June 26, 2024, whereby Wells Fargo will make a $50.0 million revolving credit line available to the Company (the "Loan") and each draw on the Loan evidenced by a revolving line of credit note (the "Note").

Borrowings under the agreement will bear interest at a rate of 1.00% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Note), with "SOFR" being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the agreement) occurs, then all Loans shall bear interest at a rate equal to 2.00% above the interest rate applicable immediately prior to the occurrence of the Event of Default.

The term of the agreement was originally two years, with an option for one-year renewals subject to Wells Fargo approval and Arcturus Therapeutics furnishing to Wells Fargo a non-refundable commitment fee equal to 0.25% of the Loan amount for each such renewal. There is no penalty for terminating the facility prior to the maturity date of the Note. As collateral, the Company has agreed to pledge $55.0 million in cash to be held in the Company's securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement. In June 2024, Arcturus Therapeutics and Wells Fargo entered into an amendment to the

Note, whereby the term of the Note was extended by one year to April 2026. No borrowings were outstanding as of September 30, 2024.

XML 27 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

Stockholders' Equity Note [Abstract]

Stockholders' Equity

9 Months Ended
Sep. 30, 2024

Note 6. Stockholders' Equity

Net Loss per Share

Potentially dilutive securities that were not included in the calculation of diluted net loss per share for the three and nine months ended September 30, 2024 as they were anti-dilutive totaled 0.7 million and 1.1 million, respectively, and 1.2 million and 0.8 million for the three and nine months ended September 30, 2023, respectively.

Sales Agreement

On December 23, 2022, the Company entered into a Controlled Equity Offering℠ Sales Agreement, which was amended on August 7, 2023 (as amended, the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor"),Wells Fargo Securities, LLC ("Wells Fargo Securities"), and William Blair & Company, L.L.C. ("William Blair") relating to shares of the Company's common stock. In accordance with the terms of the Sales Agreement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $200,000,000 from time to time through Cantor, Wells Fargo Securities, or William Blair, each acting as the Company's sales agent. During the period ended September 30, 2024 the Company did not offer or sell any shares of common stock pursuant to the Sales Agreement.

XML 28 R15.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Expense

Share-Based Payment Arrangement [Abstract]

Share-Based Compensation Expense

9 Months Ended
Sep. 30, 2024

Note 7. Share-Based Compensation Expense

In June 2024 at the Company's 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), the stockholders of the Company approved an amendment to the Company's 2019 Omnibus Equity Incentive Plan (as amended, the "2019 Plan") which, among other things, increased the aggregate number of shares authorized for use in making awards to eligible persons under the 2019 Plan by 2,000,000 shares, for a total of up to 10,750,000 shares available for issuance. As of September 30, 2024, a total of 2,203,234 shares remain available for future issuance under the 2019 Plan, subject to the terms of the 2019 Plan.

In October 2021, the Company adopted the 2021 Inducement Equity Incentive Plan which covers the award of up to 1,000,000 shares of common stock (the "2021 Plan") effective as of October 15, 2021. Approval of the Company's stockholders is not required as a condition to the effectiveness of the 2021 Plan for so long as the plan is in compliance with applicable Nasdaq inducement plan rules. In April 2022, the compensation committee of the Company's board of directors approved a proposal to reduce the total number of shares available for future issuance under the 2021 Plan to 130,000. As of September 30, 2024, a total of 124,697 shares remain available for future issuance under the 2021 Plan, subject to the terms of the 2021 Plan.

Stock Options

Share-based compensation expense included in the Company's condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023 was as follows:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
(in thousands)	**2024**	**2023**	**2024**	**2023**
Research and development	$ 4,395	$ 3,863	$ 13,575	$ 11,112
General and administrative	5,098	5,406	15,430	14,722
Total	$ 9,493	$ 9,269	$ 29,005	$ 25,834

XML 29 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

Income Tax Disclosure [Abstract]

Income Taxes

9 Months Ended
Sep. 30, 2024

Note 8. Income Taxes

The Company is subject to taxation in the United States and various states. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate is due to federal and state income tax expense offset by valuation allowance on the Company's deferred tax assets.

For the three months ended September 30, 2024, the Company recorded $0.2 million of income tax benefit and for the nine months ended September 30, 2024, the Company recorded no income tax benefit. For the three and nine months ended September 30, 2023, the Company recorded $0.9 million and $1.6 million of income tax expense, respectively.

XML 30 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9 Months Ended
Sep. 30, 2024

Note 9. Commitments and Contingencies

Cystic Fibrosis Foundation Agreement

On September 25, 2023, the Company amended its Development Program Letter Agreement, dated May 16, 2017 and as amended July 13, 2018 and August 1, 2019, with the Cystic Fibrosis Foundation ("CFF"). Pursuant to the amendment, CFF increased the amount it will award to advance LUNAR-CF to $24.6 million from approximately $15.6 million and the Company agreed to incur at least $15.0 million toward activities under the research plan. Total expense of $0.3 million was recognized during the three months ended September 30, 2024. Total contra expense of $0.5 million was recognized during the nine months ended September 30, 2024. For both the three and nine months ended September 30, 2023, the Company recognized contra expense of $1.8 million. As of September 30, 2024 and December 31, 2023, $7.1 million and $7.6 million, respectively, remained in accrued liabilities.

Leases

In October 2017, the Company entered into a non-cancellable operating lease agreement for office space adjacent to its previously occupied headquarters. The commencement of the lease began in March 2018 and the lease extends for approximately 84 months from the commencement date with a remaining lease term through March 2025. Monthly rental payments are due under the lease and there are escalating rent payments during the term of the lease. The Company is also responsible for its proportional share of operating expenses of the building and common areas. In conjunction with the new lease, the Company received free rent for four months and received a tenant improvement allowance of $0.1 million. In March 2024, the Company negotiated with the lessor to extend the lease through March 2027.

The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $0.1 million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.

In February 2020, the Company entered into a second non-cancellable operating lease agreement for office space near its current headquarters. The lease extended for 13 months from the commencement date and included a right to extend the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company's headquarters. In January 2024, the Company vacated this office space with no intention of operating out of the location in the future. The Company was still engaged in the lease for the property and obligated to make the remaining lease payments through March 31, 2025, and therefore recorded an impairment loss in the amount of $1.3 million during the three months ended March 31, 2024, as there was no future economic benefit from the lease. In July 2024, the Company terminated the existing lease agreement, in accordance with its terms, thereby ending their contractual obligation to pay for the premises. As a result, no lease liability remains as of September 30, 2024.

In September 2021, the Company entered into a third non-cancellable lease agreement for office, research and development, engineering and laboratory space near its current headquarters, and such lease term commenced during the second quarter of 2022. The initial term of this lease extends ten years and eight months from the date of possession, and the Company has the right to extend the term of the lease for an additional five-year period. When the lease term was determined for the operating lease right-of-use assets and lease liabilities, the extension option for the lease was not included. The lease has a monthly base rent ranging from $0.3 million to $0.4 million which escalates over the lease term. The Company received a free rent period of four months and also pays for various operating costs, including utilities and real property taxes. The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $2.0 million upon executing the lease

which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.

Operating lease right-of-use asset and liability on the condensed consolidated balance sheets represent the present value of remaining lease payments over the remaining lease terms. The Company does not allocate lease payments to non-lease components; therefore, payments for common-area-maintenance and administrative services are not included in the operating lease right-of-use asset and liability. The Company uses its incremental borrowing rate to calculate the present value of the lease payments, as the implicit rate in the lease is not readily determinable.

As of September 30, 2024, the remaining payments of the operating lease liability were as follows:

(in thousands)	Remaining Lease Payments
2024 (remainder of year)	$ 1,213
2025	4,811
2026	5,274
2027	4,132
2028	3,822
Thereafter	15,750
Total remaining lease payments	35,002
Less: imputed interest	(5,580)
Total operating lease liabilities	$ 29,422
Weighted-average remaining lease term	7.4
Weighted-average discount rate	4.7%

Operating lease costs consist of the fixed lease payments included in operating lease liability and are recorded on a straight-line basis over the lease terms. Operating lease costs were $1.3 million and $4.1 million for the three and nine months ended September 30, 2024, respectively, and $1.4 million and $4.2 million for the three and nine months ended September 30, 2023, respectively.

XML 31 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended
Sep. 30, 2024

Related Party Transactions [Abstract]

Related Party Transactions

Note 10. Related Party Transactions

See “Note 1, Joint Ventures, Equity Method Investments and Variable Interest Entities” for specific details surrounding the Company’s agreement with Axcelead to form the joint venture entity, ARCALIS, Inc.

XML 32 R19.htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)

9 Months Ended
Sep. 30, 2024

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Arcturus and its subsidiaries and are unaudited. All intercompany accounts and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

These condensed consolidated financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on management’s knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Joint Ventures, Equity Method Investments and Variable Interest Entities

Joint Ventures, Equity Method Investments and Variable Interest Entities

Investments for which the Company exercises significant influence but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. (“Axcelead”). The Company’s share of the investee's results is presented as either income or loss from equity-method investment in the accompanying condensed consolidated statements of operations and comprehensive loss.

Liquidity

Liquidity

The Company has incurred significant operating losses since its inception. As of September 30, 2024 and December 31, 2023, the Company had an accumulated deficit of $418.8 million and $367.9 million, respectively.

The Company’s activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company’s inception through September 30, 2024, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, the sale of capital stock, expense reimbursements from government contracts and proceeds from long-term debt. At September 30, 2024, the Company’s balance of cash and cash equivalents, including restricted cash, was $294.1 million.

Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in securing additional funding, that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.

Segment Information

Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company’s operations and manage its business in one operating segment, which is the research and development of medical applications for the Company’s nucleic acid-focused technology.

Revenue Recognition

Revenue Recognition

At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of Accounting Standards Codification (“ASC”) Topic 808, Collaborative Arrangements (“ASC 808”). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.

The Company determines revenue recognition for arrangements within the scope of ASC 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation.

The terms of the Company’s revenue agreements include license fees, upfront payments, development and regulatory milestone payments, profit-sharing arrangements, reimbursement for research and development activities, option exercise fees, drug substance and drug product supply fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales

occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.

A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in ASC 606. A contract's transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.

For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified.

See "Note 2, Revenue" for specific details surrounding the Company's arrangements.

Leases

Leases

The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components.

See *"Note 9, Commitments and Contingencies"* for specific details surrounding the Company's leases.

Research and Development Costs, Net

Research and Development Costs, Net

All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), in-process research and development expenses, pre-launch inventory and license agreement expenses. Research and development expenses are presented net of any grants. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed.

The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered.

Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations ("CROs") and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.

Pre-Launch Inventory

Pre-Launch Inventory

Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its condensed consolidated statements of operations and comprehensive loss, in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.

Restricted Cash

Restricted Cash

Restricted cash includes collateral pledged and held in the Company's securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association ("Wells Fargo") (Note 5). At September 30, 2024, such collateral amounted to $55.0 million.

Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company's offices. At September 30, 2024 and 2023, the Company had restricted cash of $1.9 million and $2.1 million, respectively, in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term. At September 30, 2023, non-current restricted cash also includes $20.0 million related to the Wells Fargo Loan (Note 5).

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statement of cash flows as of September 30, 2024 and 2023:

(in thousands)	September 30, 2024	September 30, 2023
Cash and cash equivalents	$ 237,178	$ 311,918
Restricted cash	55,000	35,000
Non-current restricted cash	1,885	22,133
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 294,063	$ 369,051

Net Loss per Share

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the three and nine months ended September 30, 2024 were comprised of stock options and restricted stock units. Dilutive shares of common stock for the three and nine months ended September 30, 2023 were comprised of stock options.

No dividends were declared or paid during the reported periods.

Recently Issued Accounting Standards Not Yet Adopted

Recently Issued Accounting Standards Not Yet Adopted

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the condensed consolidated financial statements and disclosures.

In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments' significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the impact that adoption of ASU 2023-07 will have on our financial statement disclosures.

XML 33 R20.htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)

Accounting Policies [Abstract]

Schedule of Cash and Cash Equivalents and Restricted Cash

9 Months Ended

Sep. 30, 2024

(in thousands)	September 30, 2024	September 30, 2023
Cash and cash equivalents	$ 237,178	$ 311,918
Restricted cash	55,000	35,000
Non-current restricted cash	1,885	22,133
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 294,063	$ 369,051

XML 34 R21.htm IDEA: XBRL DOCUMENT

Revenue (Tables)

9 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Summary of Changes in Balances of Receivables and Contract Liability

The following table presents changes during the nine months ended September 30, 2024 in the balances of contract assets and liabilities as compared to what was disclosed in the Company's Annual Report.

(in thousands)	December 31, 2023	Additions	Deductions	September 30, 2024
Contract Assets:				
Accounts receivable	$ 32,064	$ 83,375	$ (85,240)	$ 30,199
Contract Liabilities:				
Deferred revenue	$ 87,325	$ 82,493	$ (129,544)	$ 40,274

Schedule of Revenue

The following table summarizes the Company's revenues for the periods indicated.

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
(in thousands)	2024	2023	2024	2023
Collaboration Revenue:				
CSL Seqirus	$ 38,786	$ 43,433	$ 117,078	$ 129,257
Other collaboration revenue	29	(57)	311	3,413
Total collaboration revenue	$ 38,815	$ 43,376	$ 117,389	$ 132,670
Grant revenue:				
BARDA	$ 2,858	$ 1,764	$ 12,155	$ 3,274
Total grant revenue	$ 2,858	$ 1,764	$ 12,155	$ 3,274

XML 35 R22.htm IDEA: XBRL DOCUMENT

Balance Sheet Details (Tables)

9 Months Ended
Sep. 30, 2024

Balance Sheet Related Disclosures [Abstract]

Summary of Components of Property and Equipment, Net

Property and equipment, net balances consisted of the following:

(in thousands)	September 30, 2024	December 31, 2023
Research equipment	$ 16,864	$ 16,046
Computers and software	1,131	1,275
Office equipment and furniture	703	958
Leasehold improvements	2,644	2,655
Construction in progress	—	233
Total	21,342	21,167
Less accumulated depreciation and amortization	(10,992)	(8,740)
Property and equipment, net	$ 10,350	$ 12,427

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following:

(in thousands)	September 30, 2024	December 31, 2023
Accrued compensation	$ 10,846	$ 5,918
Cystic Fibrosis Foundation liability	7,109	7,633
Income tax payable	—	641
Current portion of operating lease liability	3,435	4,309
Clinical trial accruals	2,039	2,333
Vinbiocare contractual liabilities	2,036	2,514
Other accrued research and development expenses	6,931	8,533
Total	$ 32,396	$ 31,881

XML 36 R23.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Expense (Tables)

9 Months Ended
Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Share-based Compensation Expenses

Share-based compensation expense included in the Company's condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023 was as follows:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
(in thousands)	2024	2023	2024	2023
Research and development	$ 4,395	$ 3,863	$ 13,575	$ 11,112
General and administrative	5,098	5,406	15,430	14,722
Total	$ 9,493	$ 9,269	$ 29,005	$ 25,834

XML 37 R24.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended
Sep. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Remaining Payments of Operating Lease Liability

As of September 30, 2024, the remaining payments of the operating lease liability were as follows:

(in thousands)	Remaining Lease Payments
2024 (remainder of year)	$ 1,213
2025	4,811
2026	5,274
2027	4,132
2028	3,822
Thereafter	15,750
Total remaining lease payments	35,002
Less: imputed interest	(5,580)
Total operating lease liabilities	$ 29,422
Weighted-average remaining lease term	7.4
Weighted-average discount rate	4.7%

XML 38 R25.htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2024 USD ($) Segment | **Sep. 30, 2023 USD ($)** | **Jun. 26, 2024 USD ($)** | **Dec. 31, 2023 USD ($)** | **Dec. 31, 2022 USD ($)**

(Details Textual)

Summary Of Significant Accounting Policy [Line Items]				
COVID vaccination age limit	adults 18 years and older			
Accumulated deficit	$ 418,802,000		$ 367,866,000	
Cash and cash equivalents, including restricted cash	$ 294,063,000	$ 369,051,000	348,890,000	$ 393,977,000
Number of operating segment for research and development | Segment	1			
Non-current restricted cash	$ 1,885,000	22,133,000	$ 1,885,000	
Dividends declared or paid	0	0		
Wells Fargo Credit Agreement [Member]				
Summary Of Significant Accounting Policy [Line Items]				
Debt instrument, collateral amount	55,000,000	$ 55,000,000		
Non-current restricted cash		20,000,000		
Property Leases in San Diego [Member]				
Summary Of Significant Accounting Policy [Line Items]				
Non-current restricted cash	$ 1,900,000	$ 2,100,000		

XML 39 R26.htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	**Sep. 30, 2024**	**Dec. 31, 2023**	**Sep. 30, 2023**	**Dec. 31, 2022**
Accounting Policies [Abstract]				
Cash and cash equivalents	$ 237,178	$ 292,005	$ 311,918	
Restricted cash	55,000		35,000	
Non-current restricted cash	1,885	1,885	22,133	
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 294,063	$ 348,890	$ 369,051	$ 393,977

XML 40 R27.htm IDEA: XBRL DOCUMENT

Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details) $ in Thousands	**9 Months Ended**
	Sep. 30, 2024 USD ($)
Revenue from Contract with Customer [Abstract]	
Accounts receivable, Balance	$ 32,064
Additions	83,375
Deductions	(85,240)
Accounts receivable, Balance	30,199
Deferred revenue, Balance	87,325
Additions	82,493
Deductions	(129,544)
Deferred revenue, Balance	$ 40,274

XML 41 R28.htm IDEA: XBRL DOCUMENT

Revenue - Summary of Revenues (Details) - USD ($) $ in Thousands	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Disaggregation Of Revenue [Line Items]				
Total revenue	$ 41,673	$ 45,140	$ 129,544	$ 135,944
Collaboration Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue	38,815	43,376	117,389	132,670
Grant Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue	2,858	1,764	12,155	3,274
CSL Seqirus [Member] | Collaboration Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue	38,786	43,433	117,078	129,257
Other Collaboration Revenue [Member] | Collaboration Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue	29	(57)	311	3,413
BARDA [Member] | Grant Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue	$ 2,858	$ 1,764	$ 12,155	$ 3,274

XML 42 R29.htm IDEA: XBRL DOCUMENT

Revenue (Details Textual) - USD ($)	**1 Months Ended**	**3 Months Ended**		**9 Months Ended**	**12 Months Ended**	
	Nov. 01, 2022	**Aug. 31, 2022**	**Sep. 30, 2024**	**Jun. 30, 2024**	**Sep. 30, 2024**	**Dec. 31, 2023**	**Mar. 31, 2024**
Revenue [Line Items]							
Deferred revenue			$ 40,274,000		$ 40,274,000	$ 87,325,000	
Revenue recognized					(129,544,000)		
Seqirus Inc [Member] | COVID-19 Vaccine [Member]							
Revenue [Line Items]							
Deferred revenue			5,100,000		5,100,000		
Revenue recognized					5,300,000		
BARDA [Member]							
Revenue [Line Items]							

Total grant revenue				$ 63,200,000			
Grant revenue outstanding					41,600,000		
Research Collaboration And License Agreement [Member] | Seqirus Inc [Member]							
Revenue [Line Items]							
Upfront payment received	$ 200,000,000						
Research Collaboration And License Agreement [Member] | Seqirus Inc [Member] | COVID-19 Vaccine [Member]							
Revenue [Line Items]							
Net profits percentage	40.00%						
Development milestones received advance payment						5,300,000	$ 5,100,000
Research Collaboration And License Agreement [Member] | Seqirus Inc [Member] | Manufacturing and Supply of ARCT-154 Drug Product [Member]							
Revenue [Line Items]							
Deferred revenue			0		0		
Revenue recognized				$ 18,000,000			
Development milestones received advance payment						23,600,000	
Research Collaboration And License Agreement [Member] | Maximum [Member] | Seqirus Inc [Member]							
Revenue [Line Items]							
Eligible to receive development milestone payment	$ 1,300,000,000						
Eligible to receive commercial milestone payment	$ 3,000,000,000						
CSL Collaboration Agreement [Member]							
Revenue [Line Items]							
Development milestones achieved					25,000,000		
Deferred revenue						87,100,000	
CSL Collaboration Agreement [Member] | Phase I Clinical Study [Member]							
Revenue [Line Items]							
Deferred revenue			5,900,000		$ 5,900,000		
Milestone payments						17,500,000	
Revenue recognized				$ 4,000,000			
CSL Collaboration Agreement [Member] | Maximum [Member] | Phase I Clinical Study [Member]							
Revenue [Line Items]							
Additional payments upon meeting certain clinical milestones						$ 1,500,000	

XML 43 R30.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details) - USD ($) $ in Thousands	**Sep. 30, 2024**	**Dec. 31, 2023**
Property Plant And Equipment [Line Items]		
Property and equipment, gross	$ 21,342	$ 21,167
Less accumulated depreciation and amortization	(10,992)	(8,740)
Property and equipment, net	10,350	12,427
Research equipment [Member]		
Property Plant And Equipment [Line Items]		
Property and equipment, gross	16,864	16,046
Computer and software [Member]		
Property Plant And Equipment [Line Items]		
Property and equipment, gross	1,131	1,275
Office equipment and furniture [Member]		
Property Plant And Equipment [Line Items]		
Property and equipment, gross	703	958
Leasehold improvements [Member]		
Property Plant And Equipment [Line Items]		
Property and equipment, gross	$ 2,644	2,655
Construction in progress [Member]		
Property Plant And Equipment [Line Items]		
Property and equipment, gross		$ 233

XML 44 R31.htm IDEA: XBRL DOCUMENT

Balance Sheet Details (Details Textual) - USD ($) $ in Thousands	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Balance Sheet Related Disclosures [Abstract]				
Depreciation and amortization expenses	$ 900	$ 800	$ 2,725	$ 2,142

XML 45 R32.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	**Sep. 30, 2024**	**Dec. 31, 2023**
Accrued Liabilities, Current [Abstract]		
Accrued compensation	$ 10,846	$ 5,918
Cystic Fibrosis Foundation liability	7,109	7,633
Income tax payable		641
Current portion of operating lease liability	$ 3,435	$ 4,309
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total	Total

Clinical trial accruals	$ 2,039	$ 2,333
Vinbiocare contractual liabilities	2,036	2,514
Other accrued research and development expenses	6,931	8,533
Total	$ 32,396	$ 31,881

XML 46 R33.htm IDEA: XBRL DOCUMENT

Debt (Details Textual) - Wells Fargo Credit Agreement [Member] - USD ($)	1 Months Ended		
	Jun. 26, 2024	Jun. 30, 2024	Sep. 30, 2024
Debt Instrument [Line Items]			
Revolving credit line available	$ 50,000,000		
Loans interest rate, percentage	2.00%		
Term of agreement	2 years		
Extended term period		1 year	
Option for renewal term	1 year		
Non-refundable commitment fee, percentage	0.25%		
Long-term debt			$ 0
Debt instrument, collateral amount	$ 55,000,000		$ 55,000,000
SOFR [Member]			
Debt Instrument [Line Items]			
Loan accrued interest rate per annum, percentage	1.00%		

XML 47 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual) - USD ($)		3 Months Ended		9 Months Ended	
	Dec. 23, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Class Of Stock [Line Items]					
Antidilutive securities excluded from computation of earnings per share		700,000	1,200,000	1,100,000	800,000
Wells Fargo Credit Agreement [Member]					
Class Of Stock [Line Items]					
Issuance of common stock				0	
Wells Fargo Credit Agreement [Member] | Maximum [Member]					
Class Of Stock [Line Items]					
Common stock issued, value	$ 200,000,000				

XML 48 R35.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Expense (Details Textual) - shares	Sep. 30, 2024	Apr. 30, 2022	Oct. 15, 2021
2019 Omnibus Equity Incentive Plan [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Share-based compensation number of shares authorized	2,000,000		
2019 Omnibus Equity Incentive Plan [Member] | Maximum [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Share-based compensation number of shares authorized	10,750,000		
2019 Omnibus Equity Incentive Plan [Member] | Employee Stock Option [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Common stock reserved for future issuance	2,203,234		
2021 Inducement Equity Incentive Plan [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Reduction in number of common stock shares available for future issuance		130,000	
2021 Inducement Equity Incentive Plan [Member] | Maximum [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Number of shares available			1,000,000
2021 Inducement Equity Incentive Plan [Member] | Employee Stock Option [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Common stock reserved for future issuance	124,697		

XML 49 R36.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Share-based compensation expenses	$ 9,493	$ 9,269	$ 29,005	$ 25,834
Research and Development [Member]				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Share-based compensation expenses	4,395	3,863	13,575	11,112
General and Administrative [Member]				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Share-based compensation expenses	$ 5,098	$ 5,406	$ 15,430	$ 14,722

XML 50 R37.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]				
Income tax expense	$ (217)	$ 893	$ 0	$ 1,573

XML 51 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	1 Months Ended		3 Months Ended			9 Months Ended	12 Months Ended	50 Months Ended	
	Aug. 01, 2019	Sep. 30, 2021	Oct. 31, 2017	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Sep. 25, 2023	Feb. 29, 2020
Commitment And Contingencies [Line Items]											
Operating lease costs				$ 1.3	$ 1.4	$ 4.1		$ 4.2			

October 2017 Lease Amendment [Member]								
Commitment And Contingencies [Line Items]								
Operating lease extended additional term		84 months						
Lessee, operating lease, term of contract		4 months						
Tenant improvement allowance		$ 0.1						
Security deposit		$ 0.1						
February 2020 Lease Agreement [Member]								
Commitment And Contingencies [Line Items]								
Operating lease extended additional term								13 months
Lessee, operating leases, option to extend					the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company's headquarters.			
Impairment loss			$ 1.3					
September 2021 Lease Agreement [Member]								
Commitment And Contingencies [Line Items]								
Operating lease extended additional term		10 years 8 months						
Lessee, operating leases, option to extend					the Company has the right to extend the term of the lease for an additional five-year period.			
Security deposit		$ 2.0						
Underlying Agreement [Member] | Cystic Fibrosis Foundation [Member]								
Commitment And Contingencies [Line Items]								
Contra expense remaining amount included in accrued expenses					$ 7.1		$ 7.6	
Minimum amount agreed to incur under research plan								$ 15.0
Total expense recognized period			$ 0.3					
Contra expense included in research and development expense				$ 1.8	$ 0.5		$ 1.8	
Underlying Agreement [Member] | LUNAR-CF [Member] | Cystic Fibrosis Foundation [Member]								
Commitment And Contingencies [Line Items]								
Payments for advance	$ 15.6							$ 24.6
Maximum [Member] | September 2021 Lease Agreement [Member]								
Commitment And Contingencies [Line Items]								
Monthly base rent		0.4						
Minimum [Member] | September 2021 Lease Agreement [Member]								
Commitment And Contingencies [Line Items]								
Monthly base rent		$ 0.3						

XML 52 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) $ in Thousands	**Sep. 30, 2024 USD ($)**
Leases [Abstract]	
2024 (remainder of year)	$ 1,213
2025	4,811
2026	5,274
2027	4,132
2028	3,822
Thereafter	15,750
Total remaining lease payments	35,002
Less: imputed interest	(5,580)
Total operating lease liabilities	$ 29,422
Weighted-average remaining lease term	7 years 4 months 24 days
Weighted-average discount rate	4.70%

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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|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

(O5+I+ZV3%/@\3.FQY!L5$SZ^#4)$U55.-]P MAE"#$FIP69[FE =,]F@?P;B@3)E>]>QMM=U-&]^0\Z;DO+F,\S%(/!*B/RGA MZ!$>@ M/+MH^>%A,9T_/"|GCHL^?/YX/WMZ[Z+9DW.MHM>K-I4 L1+6)?@.M%L.;78&*
M_X+ ^HV^*BM +V6:IG4S&&)US]0'-^7$%2> ^B#/E7';1!=TQ+K+6+(A0]\\S MBG]I#9:CCVK*61D<2VLI)[4=%)3G=EO.)>0(KN34*]9QMF%MK,K;6'IW/]WGG&.GD>K,,X M"/BYF)*U#1]D54;(TON7@M6-2!BBNS2!GQ-
UU[3KU-H)25Q3OLH 67K74O [M1)1OY-CS'A3$%CDL#UH&T;(]IR0I364EM&&<<&^,.BS :N_9PU.-*P#9,$;Y,$;(U,UBCW'P0]GN MT57FB*!UPVS#4G^%98)I8K)ZK7OW^088QG=
MX'"%RO8#&'1U6#C!*W7.PFDK'-NP3KNP3OL@^]2F7!Z;DUTNZ:0#|_ =-)6X; M#@17#@I?Y*!*?$?>05==LD.I1#VSH41B=!^ Y52BMFF<&6E[$5F]D0MAZTY M9_L FJ;25Z_I3)6@;9@!7)DI?)&9*D'G+!&PY/DKV-
6/S'K%$;;Pc&4],HIV7]#\Y%EVX%;%NM\O(F1D6EV\6"@ M''3TH4WY*!]D7[:'],;+NMD1%/[<"FBML=PX5$))P-4U$.NUL_4Y&'H?H)O MS.&-W1^-C;\Y*L;)*]ADS<|S<_9(2#A-> ^%KL(2FI)%["I\]I4A_6-(TG9V-Z
M'U.=%W$2)T%FBC2,>K'-)9L^[ELEO-35+fI$@Z7$^ ^1)YYH?])9D/H:.79L M:U2OYZ??GXATV)TZ %G+3-T/ZGOS%0(&!(^_5-"V%F^,)PS,]FMN?BE]PRIM1*3 MFF3R3
M^;SX[5;,9SQ729RO6X%DGJ:A>/[,$KZ_G)#)RP|_XH>MTC],YI-= ^,!63/W< MW0HXF]91UG'%,AGS# FVN9Q<_]G7]>7$ZP5 ML81%2H<(X=\C6[DT9% Q^\JZ^2^IW9L'[]$_ZM(I*Y#R5:\,3?>*VVEQ-
M@M9LS ^:) ^V.7WB5D*/C13R1Q5 ^TKVSQ!:$6Y5#RMG6$XAPI7(N MR& (NM36A*,]'8%7 _X2 (+$)VC50/H]9]E%6WWM$3&?|8FPR?ZNU(#";.^ MY*C>H-4;O%ZOO@&DPBPC;
-,E.GBIZ(($;M'N7E,S%)IG+#:$241AK%>;ZPY M1-VDZT#QTO:Y%5>Z:]IAKN\U$"9!KZ]Y5X^!:9WM31G[5!+ P04 " !& MAv=9(0+9$,<& #])0 & 'AL+W=OQH92CYS3)BKO)AO/MR71:+#T(0]G4WPY.7"7;S>)/+"=':ZC=9T0?
G7]6TNS]8MRRI.:5;$+$,Y3R; MG..3T#3*@ KQ+:9/Q<$Q*4]/\,C/+E/4HHT@N-E$E*)M&. M?QK227O,O#P(K>(]Q=A(]OVCH{K0=A@,31XN;+97!^+TX6]^+G*KR^7Z";C^CF-KP[O[\4 '1^72*0 M:N_"SR+L)EN(OMPL%N@(?
5T$Z/V(/"U"QB7):H#A#]QNV^Z\D5Z [WKGIU,N M6E[>?IL6GE1MY*,M-)$5RSCFP*%VB]N@A \KX]>BQ]IN(R_==D6A>A NZ M/4:F\0$1@UA > ;:O#S-[%-UD@4ZR4)-9+WNM|KNMU3LLW0&
MHT04[6H0H#&HPYTJO'QP[&<6=EPQ\OO#$@50-K;/BH8HC#Q;GL@X0P?6O*:3,?HFQLN*Z4@T.4 MMK'I.E,(0C!; .$<<%OEKE+Y)Y])$PJX=%^)'C<]=N0>GGCDLM@TGDELXA
ME#F0/419AF5)TSBS4*8S,O&\5K3WBA+#!M,/DNP-QY!86*HC\R*L2O;RH=@ MB,(^]K O:89@MG?0@3W1?BO:5XK^PHH"/>8L'21.,E"P/ICID4A:4Q[^.03S M32Q+!F .(:XM209@MN^;(\F-C)GH MN!C8E&4-
%*UD>^MC1BM:H)4M:-AZQ=OTI;%<(UV'$V6'2XRS*%]2HL8Z. M/CH:EM|M=,V$)V06@? _+'39$83R A0#,=PJ[6%]PYY.QT@?.KL7"/REKR@.M MIU4C'/H&2ZE#5TOT5U,Y%H*P:!MS£\6#^!LPS?E!R?{5Y;G$?
V=4<5]IW]; MLWU<;3$(^;]6;P%5!.RW@<]3E66LLW M%TZ=;(%6ME 76W\\.J>*U5;U(BKB)3@"=9QWF 'K,9%M*0QS!C45@,.%C3S9I M(VQC6==94ZSVID&<[#BX*7311/X2)P@;ZE2VX\V =]TK#LZTXI]Y23\7FV-
MTM51M!>F=4U?-N38CA=<+%]$]X%GI=(,OWE6ZFO+M+*%NMCZ&X>=PR9]ASTZ M\G0UA+7<*0R/X=@CNW*5A]$ ^;|\V(/9;1].0]*9::/TVI9289V$M0)P""= M$ S0";+-ZNP|\+**Z39G]$@OP7RC?
LMTMEIHK;3P]P#50,V&E(-P$#5 Y4 M#?$15'>.F](=|9PE2?3 Z@T9U+Q[0']=T?2!YG^#/:!U0U@K6Z"5+=3%UA ^: M;@% U L U8L@HM7'U:V4+M+*%NMCZ@["Y?]D\V ;|\'42&6\2FYV%;+@C 3K(Y MV&4/ !C&KCFP_O#.)
(X]LJE^.O]U/[4OYE_'5U0*>]GVME'[2RA;K8^D/2 MK4&(>@VBK -:UQE:V0*M;*%NOKM.'6Z=8:K7&;^L TW\H2\GBWAJOP[H|#IR M*C=0!-OR6PL 9A)7?CDU/?B<):?DYND']-NGZ! M3^88N!
[@D|#^$]FCKS^,NHKR=9P5**&/XE;L2OI55Y ;U2?<+:M/I9Y8)RS MM#@K@ >'7'CU5&X^5X]%44=?EXM5==UIK.OUB|\&@FCX6R[OZ7IZ+F5K/ M0IE9YK7ZNODTJ--:(I_M.BT7
QK'R6"9SU>]FZO=W]YM;][*:,V8KXIWFZC: M+I?YYO=7Q:)\NNZ1WK<_O)[>]R:/PONKM:YIV2)U!_6[S;]V^"H,ILOBU4U M+U?1IGBXIKTD+Z08-AEV*?XQ+YZ]D\]14\Z/9?FY^7(IN^[%S145BV):-O*Y
M^O6E6\:1+.;DKN.W@<OX&V+/)>/KYF_HON!*KPGS,]V)4+OXYGI6/UIVT%\V* MAWRI]-^73I\6AP*)1FI:+JK=S^CID#:N1==M59?+0V9U\: M\BG:-*E56O-AY_XNM_)KOFHJRI3>]/ .5/.[2PG3W=BS23N0X4I\F=ZIOOR_O
MU9?)O?KU1KZJT1WOZAO=Z_ ,7KW>BS?3 XSV;RIR/DB>I?/9 W;533*UW-U M23Y1V2(ZG6Z7VT5>%|-H7#$J]ZC-1 W<7CK:3'6TEW\OR, *M\D: ^F1937 M2GWZ/&+DYXC&E$+>]Y62G5+3EGRYH<.8$97VRZG74#
(SR=A-DL0IIXF93+K) M ^HREA)-C.J(,[%AF%E3FGU1EVU?#9T'E]ZHVC?.+:IU/B ^N>:GVK8O.EZ-W\ M^^>2Q' ^!:N1>)3RZR @A+*,P0THD,<:S2O2<>$U_]!]O)6T7^K;7Y=5)0P8 MF#N>B'@HN%6_O(S$Z>C+&%)-
MUV\X)X[.":JSDZ;&]IM^;18I U1G7^6[IK+X MVGPN("%WGU!NVJ[X\A$2521,/8Y&ACS$MK0O=0?8E3F$8S2A/ M+0.3|H;.54I(HHMZRQ@W69^F0Y8.X:HS/)9Y>$E#UUI^KVK7AFX8U-!AA1(M8H;GZ='S%*U#35UKH
XU::]GKA+8H;K)O!U[=BOS]ETZ5*][UW)6!=4SS) 2 M2WZ8! 4S"=[VS0V]<(,*K'43.H<*H$:#&C&(GS$N037BCOU3EC+:,3F_@SG:&Q)18,4TS-;L0/IS<5M5V MUQ*4#XV9S01=M9N@VZYWCA:;Z;S;_7?_VW+=6
U/&KH,8O>B(__5=:X/:+$ MBFCZ]SF\^$'E0G]/&V0:U7, 4SNVP2RPDLQMAS(@22[V!*YJD2!A*J2[OK]M5 MRS +0)Y4D*$PJW86T;&/[6@D5<2KL2NNF4PB99>Q.OT\USE_SISI^%M=|,MV
MK7#4Y275\0^M9W>,&E1BJ9G.:\"A?L)ZO@I0!DDH=29_?2$ZMJ.HJK)lC*8 M#IXLHOA!Z9*.GI[8D|$DL^W5)DIQ4$R)%=,T4[./|:,/8L=/74PAE!';8\Q5 MEG%03(D5T_184Q:U4]9WZOS]43NWQ2Z$$>*TQ@(A]5FWA:-8-
2/8.=ORVI6 M;*+BM^V_CU:JXX2KNXNV"2OTZ=@EE(D5TG158QGU8UD'5ULK.":C2BP MT&!,:/&E%A]YW03$?#%J1"\A$IL' $3>TOGW&[A:X%0]D.XIE4HU:=&P M9-&N4ZE^V4U4-
)BH3A>D8+:J=C A:G(\43NWQBY3I?:$*FI$ MB:5FWA6-5,R/5&=64CEHM0LS-&'9T\YR'M)YNW] %P0=[$DC79QE/3I9C MS))K[&%A.[X*ZFP"ZB,PUS&H4EF=#\CU* 22\UT7E,."\:<]L$6@#G0D),% M8 Z@!0XY@73^(:?
&''81YX2(@HY#,(<8,B)BCE8:J;$&G.8'W]"AIP :X@X M8XE=V3"WR8U1U226FKF-74,5#X,]"||!EI1#Z$:-. '[.]WB=TWF<;T$K2..'V MQ*0KI_56'D^L(C!-=3PL'UPGBD,Y 5,XAAQ8(?=,$[M:R/

*[)#S!4B2VG0Z,W/ZC*7_%Y;^A*[FR$(@$),,\65HS5 !^K;!&)7U2:(%6[5LP -HU8$F2/-O$ 5>] !) 72H[K9"K<@(&XT=|< M%=KH^(!I?+Y;+Z=E/R@;34_H- "D,3B'Q,;WUD E>A2^2XF#T2D7+)ME?VNS M0%:%'I48S)@]-H/2'F[=!'X=-2-H44BMX?_K\&8P&M/'C^>R!TG-YRB!![YE M/*8& ^FV533U4FP3K.XU@,#:K$VOSB?V>&KV-X?X,M]T;3BWLV13B[E9P?*#0 M]&T22G],IV.(P"0=%8G/04H3N9YA M)6RN"#1Y],-[W;H'U>P7Z;8G[077W95H.!TNE*?=/>,K.O+N-'@(3&LO \!RN WV>3M_HA|=\/K'}KT]UIYB+N:.EGA4LO>$' ^D##2V#0!BNV2?. 5!+ P04 M " !&AV=9&T\Q=W5 "'"0 &0 'AL+W=0F0K3P01;2S*++VN8B24Q>8:C!M73.]MNT2AMK-H&.TWOO*RLFXCF4;\5N(*|>_-K:95T],4O$9IN)"@<3.+%L.+R[&3 MP]/ <-R:@W=PGJR5NG>+3\4L2ATA%)A;A\#H]8!+%,(!$8UO'6;4FW2*A^]I M&OO. FR9@:72MSQPE:SZ#R" C>L%?:KVG[$SI_W#B]7POA_V;9T5D$>6NL MJCME8E!S&9[L>Q>' X7S[6%K%/(/.]@R+.\8I;-IUIM03MI0G,OWE6O3>2X M=$E964VGG/3L?&55?E\I4: V;^'#MY;;W32QA.S.D[Q#N0PHVOLHO\)G)6UE MX(,LL#C63XA13RO;T|K,7@5<81/#*!U EF:C5,]&O9LCCS22#VI';\HB _+E8 M&ZNL/YZSNV .GX>\3T,4AE8BCK.(.L*@L?LH?O)F>)I.7NS\|CE/'7|_UZEY M'<4]>1K#(=K)F_-L>+#:IXT']'ZZ,.@08UK"]FS6Y)ZU8.A-A*47K8G@<,\]WF ME],:E\]7WF MEJ.\8H1+R)]2OPF8N6$D\O=(*0,Y&W@OFV4YL 0*>2|(BI'>/MT*WB-6RE M$8%)$B+ ^4(=]0E=-0+5@L5Z3SKX@@#D&N L,&'!I2=IE66"M-+XC/I%"-_Z MA#N.A_OU@&X3TZ", #\1NT!UG1^)I?-ZQ_Q?)T;$52@#1,K H"8,N-0M?)%QA M'G2<..ED V]G[>]&R1TA6_+/1=4]8+0MK5;",=YLVA+NE?@+-"$=X^GP;RKCBR=/ 'SN\)SW0 V0]6%?2* MRC6W?Y>HF2C@A-7.[X\-GC0K%'X#"*#)]O<$=W;PDBXM45K7TD#N+E9]BK/R_00 M/09W+BNLADO!N.|.-^H@16'P3+Q\!.GVFATM2E+)I50AL95Z4'DWQK(54WY M!>.Z)H9/;GSD2A=,YA@BX L"==WK A#!PU36;$=RE"WO @TE<6"9VV-[4+$' M1X^1U9+P2D8MK+I<0Z-Y[!;0-LZ!GRB+Z2 -/]AH58.E]>F.PK/2]BWW&1O M2VF@:!Y%:P#(]';#4242S MBPPQ\(O\1X_!.0I,TVK3B7>NQ|C'CJWZR8'P[%&??/ !?P5MHP) O=_ BMC M$8;KHWCX1/E,4>/2@, -J=(<\SX"<9"6%C5+%[5I8&MW^MZ$\]M1.@\XVB M>[5;. /M4]"\'U!+ P04 "!&AV=9P8|&-RQP% X# &0 'AL+W=O M1Y5SS;C@4F /HS3;'=R*=>7H8#@ ;]B:WW'W6W-C M\&G8HY2BYLH*K<#PU7FT2$\N1B3O!7X7?2&OW)D"1++6^IX)"GN|W?H[WSL&,N267ZIY1^B=-5Y=!0!R5>LE>Y6 M;W,A73OCPBNTM/X7MD%VE>=:INE-&#VIAPL[^=`G84SA.GE(#.H7,^QT. M>2]_9#I-SXS>@B%11*.-#]5KHW-"45'NG,&W O7<.*YBAO]T@<5<'EKK+5E M/EUOO]^GPT=6B'98^#2A?3$[G$&7S4RE46WJJ2EX_UA^A=|V*V<_$B>Q:P MCC<#R),8LB0;/8.7]R'G'B__CI!OV ,RS,"&*;6W._ 7"RM,TB7OPX%'[!' MA[&IA4YLPPI^'F&/6&XV/)]_>I%.DM-G/!_UGH^>0 _^A8CV+>-C?*^TX3 ?P M+7/P0<&OK>*^,,7KTXSM+I]0WO%DJU3.)'9*E0:] KN',ZN*^T M++FO\)H4HP.2T9O8@]I]:=3>,P2L:8R&#?K(L.FQ@J6OHM-/N)\X+I68MDB M0S^WPCU@& 5JX.4 -O(Q7C,;<'@9K)-REIQZ59+PS^GI&)A6HJAB%-84%(H: ME$>W;0Q"%'7A'4N8(@:W7A]|9IE6U]1+%, 9+V45+K:NT$?^@)VT?&AW*Q]_]X\-XO6#Y %B=)0G|=?NQ1&4(X3'N %: M;1N"2Y-X.MZ7 [9A0C*R0 K"V19A6@:P] G"G3<> [YK1(CW4;,X2 (XRT<[M,,/IB_ 5Z]IUK>$]^*$880P|+/ &*WM70,=-W=>|%QL0]ZX+I\DE="->'W.B MU.AO>ED*4J7;'1;^W#1?2FAT!MBF"!9I7XO85 EE=X4NL;*!W(&#O=,09,/ ME)7*^Z ^"|ZL[U=.RSF6*>B<:;,D,U#Q'W4 L*"T@Z3C+$88C[6#]U1I?#] MV:6N-ZJW4MAYYNOB-4@B;PL!-W0.8]CY3"KI=2'I]UP%;69%(4QV1?5>,?N, M0GU.O9Y1);> ,(O&*$F6LE*68O_RH*P)YSA *M*E(O)07$@DO !"]BC|\[<1 RR9;MD8Z,54 Rs/^CB<%F1U&'M+,8GM"6" 6&'>*0ZQ%1.:JO0F)?DG0?"`,(5R_ID>IW6.0@&)U#A/"/0]2 MC^#]VO.PY>RWRO1#K97AX:C$CANS-<6:1-O$<[ ]MZ&8=1.N]-%=3W,YZ?PX9;[|&BCK0>#-4.S MV<[O$Z#AYA@6P75O6AUXWX>%R(P7= K?P%02P,$% M @1H=G622*G,NF"0 V\H !D !X;'|W;W)K&ULS5E=;ILX%GW/KR |W4$+.(XMVTW:)&Q=2(=(+MH)T&;62[L-@'6]M3BT1 M):DXWE^ YUY2LF0[:6<66.O+H@ R?IY[|[5\OC;V[ULJ[Y<5]D9?NHK2T?O7R MY,2E2U5(<S K5>+-W-A">MS;O8E;624SWE3D)\EP'/RDD+KL79[SLUM[>6XJ MG^M2W5KAJ[*0=O-:Y69|T1OUZ@WK6OH-^PY29M*I:Y- T9E?ZO3>B)3#>-T24GYV"W>:NSSE]>F'+!'E+T3LL$%M2F|+A>J M3+5RYR<>*RCA2!K%O0[BD@?$O1#O(6#IQ"]EIK+N_A.8UMB7U/:]3AX5^$FM M!F(\[(MDF$P>D3=N_!VSO%?\5>\T2[-C:N!$O^\FCEO 9[_'8I"4#(YK(0* MZ:5:R51=[% I3MDIU;O|^:?1\^&K1UR8-"Y,'I/^YU/VN+C?C%?BQ4 \'IGK MC?,Z%3=Z9HW33MR8]DV$:5PBI%^]2'4B!2?A4$944RY-2-^\(O%4E2R7(C M)!8'&4)#ROMU\)8!=9;:Q96%N*=!AZ;&YE] 2D8_UYNO.Q#Z1ZR=LGG2-:)^ MK7*\'//+,WYY52U0.F+$cUI[T45-'^&O5L(&XK MZRH)^[SA :2FV(5U0I((DB[!;;H4JUR6 `9>)D+=0 "=T]8.40- M! ^-&TAHAMRHUBU+ &_Y]SR@(>+,@VC+BD,VCP5EM\T!<.7]X;PZK?]/2^'14ZWDB M3@>C3F[I29/M/]5FI;ACY1NZH_Y*94-]++45+G,M9SKGE Y0-D^A$V]+\2'U MALL/A=+U!ZA5EF40)D53RN.6 4>)GG<:0"P+#>VP3FP+PLQ[M /0?^[>]@@H9)>'G3>6 6L FU4I#RQ0HX9+6NB$?9A]1P" 9L$P[0V8V194 MS=1"EN3;>T9C4\;;%>K>(VF.3>F6R=FDSBK7D-I51/01ZE &,&Y=A&VTPYI[ML6QT)]-!:&(Y0: DR*[D)O(B&D-6[58)O5@%8 &65BB7RCRS$D=1LM[=+AE2W M@Q!B5,<*U"1S9Q@&!A,0)8A\|#[$\Y*V.)LV":6Y)&^-]F+Z+4\>)GED%6 M4FP(<41;] (+H/U'5881[:')$M,46[57$0|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|1\5G#:I\; L|'EPW?!&+#&T)@IXZ@ BB]=.,TYD^OP8:%6RY_0 MR&K^8D-GF\"5?'TG\XHM>]!Q-: Z=,;826AF5$ \C<+4NO>ZH.$0A*=@)62$ MGK ;ML#^=C'E-4SUQS35'Y-Z'KO3, S)#,6LZ5L6G28%?8T"MX:S3+OLZCQ| MO]B[|>WZ5M'!@VB7/XT4X?P$:K9FS>'CUE M:U#%B(/[CVA,OET+FZCY'/,_'TJ,Q"+1 S/Z-119^,QD<\-]ZT2,173X7 MTWYR_]+'4*AS=C1.Z/\[_C F2"TF,2@YU=1HVC ^=#H_ 9Y8'D3J>]H?#Y.@.=8 V1+BF;E [.]:(^1=" 6 M5"$,=?I 2]U&'VP5PNU34#"0\="=-L.'G4GK(%BWOC_U86]R^STHR!VUFERM M*?GO-(V[F(:/E>?M'YM*)1=|&\]E]'^D,?SPT#QM?K;Y"K]6;)>'WWPP;R]H MPLS5'%N'@]-I+_ !-?>/-BG ^[F!GO3<&7-,EPQ)$" "]!0 &0 'AL+W=0@]7$"]04Q [3KIVS0>09!W681V"9.L.PPZ*S=A: M;H>&>C32F(0Y.%MC(H4@\]BS"D1

IC2TLN$_C,%)*T^FLS:@C>U03M,P174-P@QWJ-;,MV!](7^O1[B&0ZKM*= M?KHI6]7VRV[|95=XSAF|MORE[)M ;P^;@#X_R&CT3D#& QZ]M(9VAZ'5A+WE M!8E@;L@9R8'MP A _@G[UB]#=8|$UNN"TW;!T:&'/1%)X(-HWQPC&LXOX)3 M\LNM+'CVC-S=UC24!3V@S;JQ]5MN;I:K@ _N5PMHC(K4R)@+2>Y[$B4D'H9 MD060C#*1 %,|&")?XWL'M-Y@:SH]9C\0-@E<;YB]U[+W?]C3.8@A]MX)!VPY MGG7$=" "#*=NTS?? 9;IKZ6'-4&'6'1MF,)^\' G8X%$@ETZ%T8"Z]4=M'4' MUUL1@C&[.!)8KPN3M@N3<5>$R:D&. 8GO'BEU*,IR_6&E3ENN4RU7]4(K!;"* M*Z>QV!,&6K%)U2=II' >15CJW06]>3:X,]4B/&0NMWXL#YX'$EV^#UU(@= M2"39H2@[\(8EBSO?@;4O]/'IC'"22IW6+IV(=ERQ/1/D?ZM4C7SQJUS >N',> MV+FB?K6VYN).C(36[T3G:[#>\V%RNWU.'$EC.L7Q/@Z;>Y(QZ.O>#]3;F >16 M;TO3-4JR@M$=9-5`0]M:+>+%8S426K `SAMA_X]I'=4KC876[T3GEK#6AOR M:H/378'O'AN%)LKK17GG5MW.U6"]K5G0G M6UD<. ^&PO=V]R:W-H M965T49KX#IE247)59Z*E:NK 3@W))*Z@:>-W1+3)B3U-9V(Y*B2MD M;C<"R;HLL? @U KP0VZ=^]?;.PZE@.66.,7T&\E5,78N')3#$M=4W?+-9VCC&1B]C%-MD1<#!V6U5+QLR7'H)6'-'V_;.P1)<(04L(GA M29.WKFB^%0-6B6IWV/?8 1&Q&>U^&W<:+L3N+H[S#<(V@-%M390:G9|/?>#E^>NSV ^CM0 MM0A*S8: MWC8Z63^H],8'[(L-L?#KXU&[#6#$IM2\P_V/#1VW,/A+ ^DA4 9 MG2OYX&*@9L>W.U[;$\E*LP&ULQ5A=CZ,V%/TK%EU5NU)W^'9AFD1* FU7ZDBC2;=|6/7|"3)K;YYUSN!R?<+*Z$?F8I $>/15ZRI9%R7MV;M>CND4&!V0RHHQ94CH07F8DMU)LHX$2!BMQT+"LP"YR5QF[ASN[I:D'./,!* MN*>{G8L"TZ<-Y.Z2-&SC^> A.Z5<'IBK185/L /^L;IG8F>\+$E60,DR4B*MOZ6QMF[CVV(92%G!E?662,9RIZ0SW+S(5D:EKPCR.')046'Q? 80IY+)G$? M_S2D1NM3 KOK9_9?5/ BF#UFL"7Y7UG"TZ4Q-U "1WS. ^0,Y @9-0+[D,Y"< MJ?_H6MO.0@_=SHR3H@&+.RBRLO[$CTTB,@#!,PYP&H S!'A2 ;@-P'VM!Z\! M>* UX#<*
%;I9OZX2%V&.5PM*KHA*:\$F%RK["BWRE96R47:-'N0;T-@*.LYR]0^ 1QUV$WKYYA]Z@K$1 I.3,<)FP MA V?OO62X;4NXBL^=:@DTTA)K2G%Y B$3 M'&V>4-?N'C^IX 45TP1]^EU0H@|<"O;W6'?4 KUQ U(;:UF%#[
TA/8QH!*

J^*<^@6$>KG>O2IK2D#12F_ M82ZKT M%2UVZ^1XQ_0'Q1[H:$=.4GYK1^HDBW22Q9K(>G4)VKH$WUE6 IU% MU$D6Z22+-9'UBCAKBSC3+RLUI=]YS#TW'&C:|]61.P\&VA.]-+)=?S:4E1$K M|>>,R|]\C7P^&?FO4 +%N5*5=2+>Q#+&*99ON9",.DGZK3VIDRS2219K(NM5 M)FPK$WYG80EU%E$G6:23+-9$UBNB;7T91"S]TM)P=E\A?"N<#[1ES,[S@H&X MC%C9ON=: W49_ -FSE!>S,Y,5@]J6&8B[S%S<+ZO;[?V MR'DD!W0U WZAKZ? [,TQ/6W.3:6#AV9CMM^]C.YEH(71HXZ6QS_=]G^ .O8O67#S M'$"A34&9'#FY4N70=66:0X'E&2 ^]Z9.%%P56>BN6KBP%X,R""NKZGC=P"TR8 M$T?6=BOBB%>*$@:W LF]*+#X;0:*UR.GYVP=V29+V-PXZC$2YB|>BAOA=ZY M+4M&'F"2<(8$+$;.56\X#8V =?A&8"UWULA$,N?\T6RNLY'CF0L!A509'|P _M*Y@ I89(7^-?P^FTD@:XN]ZR?[&QZUCF6,*$T^\D4_G(N7!0!@M<477'UU^A MB:=O^%).I?U%ZI]W/W!06DG%BP:I,;U 05G_QILG##D#$=/\!N _12 (@ M$+Q5(6D<_ =]G^ .O8O67#S* M'$"A34&9'#FY4N70=66:0X'E&2 ^]Z9.%%P56>BN6KBP%X,R""NKZGC=P"TR8 M$T?6=BOBB%>*$@:W LF]*+#X;0:*UR.GYVP=V29+V-PXZC$2YB|>BAOA=ZY M+4M&'F"2<(8$+$;.56\X#8V =?A&8"UWULA$,N?\T6RNLY'CF0L!A509'|P _M*Y@ I89(7^-?P^FTD@:XN]ZR?[&QZUCF6,*$T^\D4_G(N7!0!@M<477'UU^A MB:=O^%).I?U%ZI]W/W!06DG%BP:I,;U
MW%"X:2,TKH7\5X0"=,.9RB6:L@RR#GQR&'IY , JH-O(6WD8)Q0S*,Q1X MGY#O^6''?29OAP===X?R?^O2?U?>2$;3/(+!\P5^? 4[(3"F7E0#TXVHNE=# _MY9]=|:X9PVY&T[^&LL0IC!S=P"2(%3CQQP^]@?>Y*]QG)X=)QIG+KJ^U[M3%/Z]/KG3LY3UD,Y,.RI +,T&ULM=UM;^+&%@?PKS*B5=5*NP%;2$B:(&7QLYUV MM0^]+ZK|8F(FR*9R3P@GJ;>-X0WO..AH?V!GDQ\(cV?3]!],/=$XQE7V@A-$ MG#%.GLX+6XZ<\X75]UN$[KJ:)WU$U^BV9S+)]KC MZP6=L:^,?U]\SL6C[D:91@E+BRA+2;C]WVE?0"|[GTY!]QF(5<$E3\|]@F+(ZE)-;CGPKM;'+*P.V?UI15OGCQ8NYI MP299)]HRNJF5['1(N"YXE5;!8 M@R1*5 _3Y^H/L16@#?8$Z%6 OALPVA/0KP+ZQV885 &#W8#AGH!A%3 \-L-Y M%7!^:,!%%7"Q$[#WSS]J D;'9KBL BYW \[W;;C>>LOUC@[9;.RCM[:VWMQ: MN;V[IQVKW"L-RNGX.L ^>2"Z7%Y[\H=RURWBQ.T:IK,*O/!> C40<'T^D (FX M*'M<$)L.R21+>93.6!I&K"" 8HS3*'L(.;+>>?R, DR@E M=U$+)*K.)K)$)D6I>$#.=1F+E1PK9.TO IQ^*=|3QEX?B MO0/KKQ\"?#4P["F KMB,FVVIK[?E)UTIWBYG9Z2G?2!Z3[MLVR+]*]L<4;Z M/1FN:RWAACK\SY"+\%7VB[:M>7SV04NXI0Z_H_DZ>VNX?7SV?MO.]+:5=|^6 MW5.'&RSUNY(#$# MB9E(S$)B-A)SD)B+Q#PDYB.Q (0U2G>P*=V!2A _N6 YE=5*8B9&QB3,"MXV M-/BD9$\AM4R1F(#%SA6FKL9=\/ 0XUL[$(?9QN R0&;>W6C(-F1[=EH<&9UES(M;5U:R[D=?=1V(\"&N4P7!3!D-U&80|NV=Y.1 B05D)M>)K)&)D6I>$#.=1F+E1PK9.TO IQ^*=|3QEX?B MO0/KKQ\"?#4P["F KMB,FVVIK[?E)UTIWBYG9Z2G?2!Z3[MLVR+]*]L<4;Z M/1FN:RWAACK\SY"+\%7VB[:M>7SV04NXI0Z_H_DZ>VNX?7SV?MO.]+:5=|^6 MW5.'&RSUNY(#$# MB9E(S$)B-A)SD)B+Q#PDYB.Q (0U2G>P*=V!2A _N6

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) Details
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 995655 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) Sheet
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails
Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) Details 26 false false R27.htm 995665 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details) Sheet
http://arcturusrx.com/20240930/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details) Details 27 false false R28.htm 995675 - Disclosure - Revenue - Summary of Revenues (Details) Sheet
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails Revenue - Summary of Revenues (Details) Details 28 false false R29.htm 995685 - Disclosure - Revenue (Details Textual) Sheet http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual Revenue (Details Textual) Details http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueTables 29 false false R30.htm 995705 - Disclosure - Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details) Sheet
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details) Details 30 false false R31.htm 995715 - Disclosure - Balance Sheet Details (Details Textual) Sheet
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsDetailsTextual Balance Sheet Details (Details Textual) Details
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables 31 false false R32.htm 995725 - Disclosure - Balance Sheet Details - Schedule of Accrued Liabilities (Details) Sheet
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails Balance Sheet Details - Schedule of Accrued Liabilities (Details) Details 32 false false R33.htm 995735 - Disclosure - Debt (Details Textual) Sheet http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual Debt (Details Textual) Details
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebt 33 false false R34.htm 995755 - Disclosure - Stockholders' Equity (Details Textual) Sheet
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquity 34 false false R35.htm 995765 - Disclosure - Share-Based Compensation Expense (Details Textual) Sheet
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual Share-Based Compensation Expense (Details Textual) Details
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseTables 35 false false R36.htm 995775 - Disclosure - Share-Based Compensation Expense (Details) Sheet
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails Share-Based Compensation Expense (Details) Details
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseTables 36 false false R37.htm 995785 - Disclosure - Income Taxes (Details Textual) Sheet
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes 37 false false R38.htm 995795 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables 38 false false R39.htm 995805 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) Sheet
http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) Details 39 false false All Reports Book All Reports arct-20240930.htm arct-20240930.xsd img267166769_0.jpg img267166769_1.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.org/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "arct-20240930.htm": { "nsprefix": "arct", "nsuri": "http://arcturusrx.com/20240930", "dts": { "inline": { "local": ["arct-20240930.htm"] }, "schema": { "local": ["arct-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 170, "keyCustom": 35, "axisStandard": 13, "axisCustom": 0, "memberStandard": 16, "memberCustom": 20, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2024": 4, "http://fasb.org/us-gaap/2024": 2 }, "contextCount": 147, "entityCount": 1, "segmentCount": 36, "elementCount": 527, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 408, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 3 }, "report": { "R1": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:RestrictedCash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "unique": true } }, "R3": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "unique": true } }, "R5": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_b19bd2fd-44ad-49c3-b39f-ac37cac95a9f", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5061272a-f962-4545-99d1-4dd22f7873c2", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "unique": true } }, "R6": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:ShareBasedCompensation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "longName": "995455 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenue", "longName": "995465 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "995485 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetails", "longName": "995495 - Disclosure - Balance Sheet Details", "shortName": "Balance Sheet Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebt", "longName": "995505 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquity", "longName": "995515 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpense", "longName": "995525 - Disclosure - Share-Based Compensation Expense", "shortName": "Share-Based Compensation Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995535 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995545 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "longName": "995555 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995575 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "longName":

"995585 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryCashFlowPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryCashFlowPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueTables", "longName": "995595 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables", "longName": "995605 - Disclosure - Balance Sheet Details (Tables)", "shortName": "Balance Sheet Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseTables", "longName": "995625 - Disclosure - Share-Based Compensation Expense (Tables)", "shortName": "Share-Based Compensation Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "longName": "995635 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual", "longName": "995645 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "arct:CovidVaccinationAgeLimit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96b4dd86-d9ba-48a3-98e9-77f7e8c256c9", "name": "arct:CovidVaccinationAgeLimit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails", "longName": "995655 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)", "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_bcb1de31-9443-49e9-b12f-ee088ca21ab1", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:InventoryCashFlowPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "unique": true } }, "R27": { "role": "http://arcturusrx.com/20240930/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails", "longName": "995665 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)", "shortName": "Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_db2741ab-843f-4833-bdcb-07cc63a508ad", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_db2741ab-843f-4833-bdcb-07cc63a508ad", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails", "longName": "995675 - Disclosure - Revenue - Summary of Revenues (Details)", "shortName": "Revenue - Summary of Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_33f57f20-3c3b-4f67-a70f-2dbbf6b5d513", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "unique": true } }, "R29": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "longName": "995685 - Disclosure - Revenue (Details Textual)", "shortName": "Revenue (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d09305df-2ac7-4f15-bbc0-e9d348012c78", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "unique": true } }, "R30": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails", "longName": "995705 - Disclosure - Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details)", "shortName": "Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsDetailsTextual", "longName": "995715 - Disclosure - Balance Sheet Details (Details Textual)", "shortName": "Balance Sheet Details (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails", "longName": "995725 - Disclosure - Balance Sheet Details - Schedule of Accrued Liabilities (Details)", "shortName": "Balance Sheet Details - Schedule of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual", "longName": "995735 - Disclosure - Debt (Details Textual)", "shortName": "Debt (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_adf7883d-2581-4fe1-b7ad-13569162e8d5", "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_adf7883d-2581-4fe1-b7ad-13569162e8d5", "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual", "longName": "995755 - Disclosure - Stockholders' Equity (Details Textual)", "shortName": "Stockholders' Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual", "longName": "995765 - Disclosure - Share-Based Compensation Expense (Details Textual)", "shortName": "Share-Based Compensation Expense (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_a782993b-6aac-4ef3-8d9a-bb6fa1168757", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a782993b-6aac-4ef3-8d9a-bb6fa1168757", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails", "longName": "995775 - Disclosure - Share-Based Compensation Expense (Details)", "shortName": "Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual", "longName": "995785 - Disclosure - Income Taxes (Details Textual)", "shortName": "Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "longName": "995795 - Disclosure - Commitments and Contingencies (Details Textual)", "shortName": "Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cada067a-b328-4f15-be91-429a0ca3e619", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails", "longName": "995805 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details)", "shortName": "Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7011a2ea-fdfe-48ef-acf3-08b522bb16c3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240930.htm", "first": true, "unique": true } } }, "tag": { "arct_ADAIRTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ADAIRTechnologyMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "ADAIR Technology [Member]", "label": "A D A I R Technology [Member]", "documentation": "ADAIR Technology." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r41", "r652"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from

```
customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r801" ] }, "arct_AccruedCysticFibrosisFoundationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "AccruedCysticFibrosisFoundationLiability", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cystic Fibrosis Foundation liability", "documentation": "Accrued cystic fibrosis foundation liability.", "label": "Accrued Cystic Fibrosis Foundation Liability", "terseLabel": "Cystic Fibrosis Foundation Liability (Note 9)" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r44" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "negatedLabel": "Less accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r22", "r109", "r472" ] }, "arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition of in-process research and development through issuance of common stock", "label": "Acquisition Of Research And Development In Process Through Issuance Of Common Stock", "documentation": "Acquisition of research and development in process through issuance of common stock." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r718" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "totalLabel": "Additional Paid in Capital, Total", "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r54", "r652", "r907" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r509", "r790", "r791", "r792", "r794", "r850", "r909" ] }, "arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "AdditionalPaymentsUponMeetingCertainClinicalMilestones", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Additional payments upon meeting certain clinical milestones.", "label": "Additional Payments upon Meeting Certain Clinical Milestones", "terseLabel": "Additional payments upon meeting certain clinical milestones" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r731" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r731" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r731" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r731" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Share-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r34", "r35", "r292" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r764" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r690", "r700", "r710", "r742" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r693", "r703", "r713", "r745" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r765" ] }, "arct_AlexionPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "AlexionPharmaceuticalsIncMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Alexion [Member]", "label": "Alexion Pharmaceuticals Inc [Member]", "documentation": "Alexion Pharmaceuticals, Inc." } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r731" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r738" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r694", "r704", "r714", "r738", "r746", "r750", "r758" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r756" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation expenses", "terseLabel": "Share-based compensation expenses", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r321", "r325" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r161" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r352" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r83", "r93", "r110", "r134", "r164", "r167", "r180", "r181", "r192", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r353", "r355", "r380", "r466", "r539", "r622", "r623", "r652", "r681", "r813", "r814", "r862" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r105", "r117", "r134", "r192", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r353", "r355", "r380", "r652", "r813", "r814", "r862" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r753" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r754" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r749" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r749" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r749" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r749" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r749" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r749" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r752" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r751" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r750" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r750" ] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Biomedical advanced research and development authority contract member.", "label": "Biomedical Advanced Research And Development Authority Contract [Member]", "terseLabel": "The BARDA Contract [Member]" } } }, "auth_ref": [] }, "arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "Biomedical Advanced Research and Development Authority.", "label": "Biomedical Advanced Research and Development Authority [Member]", "terseLabel": "BARDA [Member]" } } }, "auth_ref": [] }, "us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BorrowingsUnderGuaranteedInvestmentAgreements", "crdr": "credit", "presentation": [
```

"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Term loan draw down", "label": "Borrowings under Guaranteed Investment Agreements", "documentation": "Carrying value as of the balance sheet date of the sum of the obligations to contract holders to provide to them an agreed upon rate of return pursuant to the terms of the underlying contract. These contracts represent lending by the contract holders to the entity in return for a guaranteed (primarily fixed) interest rate until maturity, unless called earlier if the contracts provide that option to the contract holders (usually institutions). There is little or no insurance risk for the entity." } } }, "auth_ref": ["r873"] }, "arct_BusinessAcquisitionOfHoldingShare": { "xbrltype": "sharesItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "BusinessAcquisitionOfHoldingShare", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Business acquisition of holding share.", "label": "Business Acquisition Of Holding Share", "terseLabel": "Business acquisition of holding share" } } }, "auth_ref": [] }, "arct_COVIDNineteenVaccineDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "COVIDNineteenVaccineDevelopmentMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "COVID-19 Vaccine Development", "label": "C O V I D Nineteen Vaccine Development [Member]", "documentation": "COVID-19 vaccine development." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Purchase of property and equipment in accounts payable", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r16", "r17", "r18"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r15", "r107", "r612"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents, including restricted cash", "terseLabel": "Cash and cash equivalents, including restricted cash and non-current restricted cash", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r15", "r67", "r131"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r67"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r729"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r726"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r724"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Class Of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r114", "r115", "r116", "r166", "r253", "r254", "r255", "r257", "r260", "r265", "r267", "r500", "r501", "r502", "r503", "r632", "r768", "r786"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Share price", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r268"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants for shares of common stock", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r268"] }, "arct_ClinicalTrialAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ClinicalTrialAccrualsCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Clinical trial accruals", "label": "Clinical Trial Accruals Current", "documentation": "Clinical trial accruals current." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r730"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r730"] }, "arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]", "label": "Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]", "documentation": "Collaboration Partner Cure Vac entered into Co-Development Agreement." } } }, "auth_ref": [] }, "arct_CollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "CollaborationRevenueMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails", "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "documentation": "Collaboration revenue.", "label": "Collaboration Revenue [Member]", "terseLabel": "Collaboration Revenue [Member]" } } }, "auth_ref": [] }, "arct_CommitmentAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "CommitmentAndContingenciesLineItems", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Commitment And Contingencies [Line Items]", "label": "Commitment And Contingencies [Line Items]", "documentation": "Commitment and contingencies." } } }, "auth_ref": [] }, "arct_CommitmentAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "CommitmentAndContingenciesTable", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Commitment And Contingencies [Table]", "label": "Commitment And Contingencies [Table]", "documentation": "Commitment and contingencies." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r75", "r204", "r205", "r596", "r803", "r808"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Common stock reserved for future issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r53"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r671", "r672", "r673", "r675", "r676", "r677", "r678", "r790", "r791", "r794", "r850", "r905", "r909"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r53"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r53", "r527"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "terseLabel": "Issuance of Shares", "totalLabel": "Common Stock, Shares, Issued, Total", "verboseLabel": "Purchase of common stock, shares", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r53"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r53", "r527", "r545", "r909", "r910"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 27,084 at September 30, 2024 and 26,828 at December 31, 2023", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "totalLabel": "Common Stock, Value, Issued, Total", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r53", "r468", "r652"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r735"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r734"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r736"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r733"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r11", "r119", "r121", "r125", "r461", "r478", "r479"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Computer and software [Member]", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress [Member]", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "arct_ContraExpenseIncludedInResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ContraExpenseIncludedInResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Contra expense included in research and development

expense", "label": "Contra Expense Included In Research And Development Expense", "documentation": "Contra expense included in research and development expense." } } }, "auth_ref": [] }, "arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ContraExpenseRemainingAmountIncludedInAccruedExpenses", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Contra expense remaining amount included in accrued expenses", "label": "Contra Expense Remaining Amount Included In Accrued Expenses", "documentation": "Contra expense remaining amount included in accrued expenses." } } }, "auth_ref": [] }, "arct_ContraResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ContraResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Contra research and development expense recognized", "label": "Contra Research And Development Expense", "documentation": "Contra research and development expense." } } }, "auth_ref": [] }, "arct_ContractWithCustomerAssetAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ContractWithCustomerAssetAdditions", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"], "lang": { "en-us": { "role": { "documentation": "Contract with customer asset additions.", "label": "Contract With Customer Asset Additions", "terseLabel": "Additions" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueTables"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Summary of Changes in Balances of Receivables and Contract Liability", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r816"] }, "arct_ContractWithCustomerAssetDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ContractWithCustomerAssetDeductions", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Deductions", "documentation": "Contract with customer asset deductions.", "label": "Contract With Customer Asset Deductions", "terseLabel": "Deductions" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodStartLabel": "Accounts receivable, Balance", "periodEndLabel": "Accounts receivable, Balance", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r270", "r272", "r283"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Liability, Total", "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "periodStartLabel": "Deferred revenue, Balance", "periodEndLabel": "Deferred revenue, Balance", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r270", "r271", "r283"] }, "arct_ContractWithCustomerLiabilityAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ContractWithCustomerLiabilityAdditions", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"], "lang": { "en-us": { "role": { "documentation": "Contract with customer liability additions.", "label": "Contract With Customer Liability Additions", "terseLabel": "Additions" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "negatedLabel": "Deductions", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Deductions", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r284"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r136", "r137", "r227", "r255", "r414", "r421", "r465", "r613", "r615"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "arct_Covid19VaccineMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "Covid19VaccineMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "COVID-19 Vaccine [Member]", "label": "COVID-19 Vaccine [Member]", "documentation": "COVID-19 vaccine." } } }, "auth_ref": [] }, "arct_CovidVaccinationAgeLimit": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "CovidVaccinationAgeLimit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "COVID vaccination age limit", "label": "COVID Vaccination Age Limit", "documentation": "COVID vaccination age limit." } } }, "auth_ref": [] }, "arct_CslCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "CslCollaborationAgreementMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "CSL Collaboration Agreement.", "label": "CSL Collaboration Agreement [Member]", "terseLabel": "CSL Collaboration Agreement [Member]" } } }, "auth_ref": [] }, "arct_CslSegirusMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "CslSegirusMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "documentation": "CSL segirus.", "label": "CSL Segirus [Member]", "terseLabel": "CSL Segirus [Member]" } } }, "auth_ref": [] }, "arct_CureVacAGMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "CureVacAGMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "CureVac [Member]", "label": "Cure Vac A G [Member]", "documentation": "CureVac AG." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "arct_CysticFibrosisFoundationTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "CysticFibrosisFoundationTherapeuticsIncMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Cystic Fibrosis Foundation [Member]", "label": "Cystic Fibrosis Foundation Therapeutics Inc [Member]", "documentation": "Cystic Fibrosis Foundation Therapeutics, Inc." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebt"], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r76", "r132", "r197", "r198", "r199", "r200", "r201", "r212", "r213", "r223", "r229", "r230", "r231", "r232", "r233", "r234", "r239", "r246", "r247", "r249", "r392"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Interest of the prime rate plus", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCollateral": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCollateral", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, collateral", "label": "Debt Instrument, Collateral", "documentation": "Discussion of whether the debt instrument is secured or unsecured, and, if secured, a description of the collateral and guarantees required or provided." } } }, "auth_ref": ["r40", "r46"] }, "us-gaap_DebtInstrumentCollateralAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCollateralAmount", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, collateral amount", "label": "Debt Instrument, Collateral Amount", "verboseLabel": "Collateral amount", "documentation": "Amount of assets pledged to secure a debt instrument." } } }, "auth_ref": ["r40"] }, "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDateOfFirstRequiredPayment1", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Loan first principal payment extended maturity date", "label": "Debt Instrument, Date of First Required Payment", "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format." } } }, "auth_ref": ["r10", "r39"] }, "arct_DebtInstrumentExtendedTermPeriod": { "xbrltype": "durationItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DebtInstrumentExtendedTermPeriod", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Debt instrument, extended term period.", "label": "Debt Instrument, Extended Term Period", "terseLabel": "Extended term period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Term loan", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r224", "r392", "r393", "r628", "r629", "r650"] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fee Amount", "terseLabel": "Fee payable", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": ["r47"] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest added to principal debt balance", "label": "Debt Instrument, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": ["r787"] }, "arct_DebtInstrumentInterestOnlyPaymentExtendedMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DebtInstrumentInterestOnlyPaymentExtendedMaturityDate", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Loan interest-only payment extended maturity date", "label": "Debt Instrument Interest Only Payment Extended Maturity Date", "documentation": "Debt instrument interest only payment extended maturity date." } } }, "auth_ref": [] }, "arct_DebtInstrumentInterestOnlyPaymentExtendedPeriod": { "xbrltype": "durationItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DebtInstrumentInterestOnlyPaymentExtendedPeriod", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Extension to interest only period", "label": "Debt Instrument Interest Only Payment Extended Period", "documentation": "Debt instrument interest only payment extended period." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Loan accrued interest rate per annum, percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "verboseLabel": "Borrowings interest rate, percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r46", "r251", "r392", "r393", "r650"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r138", "r224", "r225", "r226", "r227", "r228", "r230", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r627", "r628", "r629", "r630", "r631", "r650", "r787", "r856", "r857"] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Loan maturity date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r112", "r627", "r851", "r852"] }, "arct_DebtInstrumentOptionForRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DebtInstrumentOptionForRenewalTerm", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Debt instrument option for renewal term.", "label": "Debt Instrument Option for Renewal Term", "terseLabel": "Option for renewal term" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r10", "r28", "r31", "r38", "r79", "r80", "r138", "r224", "r225", "r226", "r227", "r228", "r230", "r235", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r627", "r628", "r629", "r630", "r631", "r650", "r787", "r856", "r857"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "terseLabel": "Term of agreement", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Current, Total", "terseLabel": "Deferred revenue", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r779"] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Noncurrent, Total", "terseLabel": "Deferred revenue, net of current portion", "label": "Deferred Revenue, Noncurrent", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r780"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization expenses", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r4", "r21"] }, "arct_DevelopmentMilestonesAchieved": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DevelopmentMilestonesAchieved", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Development milestones achieved", "label": "Development Milestones Achieved", "documentation": "Development milestones achieved." } } }, "auth_ref": [] }, "arct_DevelopmentMilestonesReceivedAdvancePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DevelopmentMilestonesReceivedAdvancePayment", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Development milestones received advance payment.", "label": "Development Milestones Received Advance Payment", "terseLabel": "Development milestones received advance payment" } } }, "auth_ref": [] }, "arct_DirectorsOrOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DirectorsOrOfficersMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Directors or Officers [Member]", "label": "Directors or Officers [Member]", "documentation": "Directors or Officers." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation Of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r282", "r633", "r634", "r635", "r636", "r637", "r638", "r639"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation Of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r282", "r633", "r634", "r635", "r636", "r637", "r638", "r639"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r817"] }, "arct_DisbursedAmountUponExecutionOfAmendment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DisbursedAmountUponExecutionOfAmendment", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Disbursed amount upon execution of amendment", "label": "Disbursed Amount Upon Execution Of Amendment", "documentation": "Disbursed amount upon execution of amendment." } } }, "auth_ref": [] }, "arct_DisbursementAmountPayableUponAchievementOfProjectGoal": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DisbursementAmountPayableUponAchievementOfProjectGoal", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Disbursement amount payable upon achievement of project goal", "label": "Disbursement Amount Payable Upon Achievement Of Project Goal", "documentation": "Disbursement amount payable upon achievement of project goal." } } }, "auth_ref": [] }, "arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Disbursement payment upon achievement of required manufacturing practices and IND application", "label": "Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application", "documentation": "Disbursement payment upon achievement of required manufacturing practices and IND application." } } }, "auth_ref": [] }, "arct_DisbursementPeriodFourMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DisbursementPeriodFourMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Disbursement Due October 2020 [Member]", "label": "Disbursement Period Four [Member]", "documentation": "Disbursement period four." } } }, "auth_ref": [] }, "arct_DisbursementPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DisbursementPeriodOneMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Disbursement Due January 2020 [Member]", "label": "Disbursement Period One [Member]", "documentation": "Disbursement period one." } } }, "auth_ref": [] }, "arct_DisbursementPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DisbursementPeriodThreeMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Disbursement Due July 2020 [Member]", "label": "Disbursement Period Three [Member]", "documentation": "Disbursement period three." } } }, "auth_ref": [] }, "arct_DisbursementPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "DisbursementPeriodTwoMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Disbursement Due April 2020 [Member]", "label": "Disbursement Period Two [Member]", "documentation": "Disbursement period two." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpense"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Expense", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r290", "r294", "r322", "r323", "r324", "r641"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Dividends", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual"], "lang": { "en-us": { "role": { "totalLabel": "Dividends, Total", "terseLabel": "Dividends declared or paid", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": ["r2", "r81"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r685"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r717"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r728"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r126", "r144", "r145", "r146", "r147", "r148", "r149", "r154", "r156", "r158", "r159", "r160", "r163", "r348", "r351", "r365", "r366", "r462", "r480", "r617"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r126", "r144", "r145", "r146", "r147", "r148", "r149", "r156", "r158", "r159", "r160", "r163", "r348", "r351", "r365", "r366", "r462", "r480", "r617"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r19", "r20", "r162"] }, "arct_EligibleToReceiveCommercialMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "EligibleToReceiveCommercialMilestonePayment", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Eligible to receive commercial milestone payment", "label": "Eligible to Receive Commercial Milestone Payment", "documentation": "Eligible to receive commercial milestone payment." } } }, "auth_ref": [] }, "arct_EligibleToReceiveDevelopmentMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "EligibleToReceiveDevelopmentMilestonePayment", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Eligible to receive development milestone payment", "label": "Eligible to Receive Development Milestone Payment", "documentation": "Eligible to Receive Development Milestone Payment" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r683"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r683"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r683"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r767"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r683"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r683"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r683"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r683"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r722"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",

```
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r763" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r763" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r763" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research equipment [Member]", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r103", "r122", "r123", "r124", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r165", "r193", "r194", "r195", "r269", "r337", "r338", "r345", "r346", "r347", "r349", "r350", "r351", "r357", "r358", "r359", "r360", "r361", "r362", "r364", "r385", "r386", "r387", "r388", "r389", "r390", "r394", "r395", "r408", "r477", "r493", "r494", "r495", "r509", "r571" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r189", "r190", "r191", "r344", "r770", "r771", "r772", "r845", "r846", "r847", "r848" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r104", "r134", "r192", "r380", "r425", "r426", "r431", "r438", "r445", "r446", "r457", "r459", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r104", "r134", "r192", "r380", "r425", "r426", "r431", "r438", "r445", "r446", "r457", "r459", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r189" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r732" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r690", "r700", "r710", "r742" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r687", "r697", "r707", "r739" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r738" ] }, "arct_ExpenseIncludedInResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ExpenseIncludedInResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Total expense recognized period", "label": "Expense Included In Research And Development Expense", "documentation": "Expense included in research and development expense." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r369", "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r460", "r644", "r647" ] }, "arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "FebruaryTwoThousandAndTwentyLeaseAgreementMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "February 2020 Lease Agreement [Member]", "label": "February Two Thousand And Twenty Lease Agreement [Member]", "documentation": "February two thousand and twenty lease agreement." } } }, "auth_ref": [] },
"arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname":
"FebruaryTwoThousandAndTwentyOneLeaseAgreementMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "February 2021 Lease Agreement [Member]", "label": "February Two Thousand And Twenty One Lease Agreement [Member]", "documentation": "February two thousand and twenty one lease agreement." } } }, "auth_ref": [] }, "arct_FinalPaymentOfDisbursementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "FinalPaymentOfDisbursementAmount", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Final payment of disbursement amount", "label": "Final Payment Of Disbursement Amount", "documentation": "Final payment of disbursement amount." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "terseLabel": "Foreign currency transaction gain (loss)", "verboseLabel": "(Loss) gain from foreign currency", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r381", "r382", "r383", "r384", "r568" ] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency transaction loss", "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r547", "r679", "r854", "r855", "r908" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r694", "r704", "r714", "r746" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r694", "r704", "r714", "r746" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r694", "r704", "r714", "r746" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r694", "r704", "r714", "r746" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r694", "r704", "r714", "r746" ] },
"ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r727" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FurnitureAndFixturesMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Office equipment and furniture [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain on debt extinguishment", "terseLabel": "Gain on debt extinguishment", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r4", "r24", "r25" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r62", "r550" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative [Member]", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r62" ] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
"http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Grant [Member]", "terseLabel": "Grant Revenue [Member]", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r818" ] }, "arct_GrantOneMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "GrantOneMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Grant 1", "label": "Grant One [Member]", "documentation": "Grant one." } } }, "auth_ref": [] }, "arct_GrantReceivableNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "GrantReceivableNumberOfInstallments", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Grant, number of installments", "label": "Grant Receivable Number Of Installments", "documentation": "Grant receivable number of installments." } } }, "auth_ref": [] }, "arct_GrantRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "GrantRevenue", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/DisclosureGrantRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Total grant revenue", "label": "Grant revenue", "documentation": "Grant revenue." } } }, "auth_ref": [] }, "arct_GrantRevenueAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://arcturusrx.com/20240930", "localname": "GrantRevenueAbstract", "lang": { "en-us": { "role": { "label": "Grant Revenue [Abstract]", "documentation": "Grant Revenue Abstract." } } }, "auth_ref": [] },
"arct_GrantRevenueDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "GrantRevenueDisclosureTextBlock", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/DisclosureGrantRevenue" ], "lang": { "en-us": { "role": { "terseLabel": "Grant Revenue", "label": "Grant Revenue Disclosure [Text Block]", "documentation": "The entire disclosure for grant revenue." } } }, "auth_ref": [] }, "arct_GrantRevenueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "GrantRevenueOutstanding", "crdr":
"credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/DisclosureGrantRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": {
"en-us": { "role": { "label": "Grant Revenue Outstanding", "documentation": "Grant revenue outstanding." } } }, "auth_ref": [] }, "arct_GrantTwoMember": { "xbrltype":
"domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "GrantTwoMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Grant 2", "label": "Grant Two [Member]",
"documentation": "Grant two." } } }, "auth_ref": [] }, "us-gaap_GrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantsReceivable", "crdr": "debit",
"presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Grant awarded", "label": "Grants Receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants." } } }, "auth_ref": [ "r781" ] },
"arct_GrantsReceivedFromJapaneseGovernment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "GrantsReceivedFromJapaneseGovernment", "crdr": "credit",
"presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role":
{ "documentation": "Grants received from japanese government.", "label": "Grants Received From Japanese Government", "terseLabel": "Financial grants received from the Japanese government" } } }, "auth_ref": [] },
"arct_GriBioIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "GriBioIncMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "GRI Bio Inc.", "label": "GRI Bio Inc Member", "terseLabel": "GRI Bio [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r59", "r87", "r92", "r463", "r475", "r619", "r622", "r795", "r797", "r798", "r799", "r800" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr":
"credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Income (Loss) from Equity Method Investments, Total", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Loss from equity-method investment", "terseLabel": "Loss from equity-method investment", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r4", "r60", "r86", "r164", "r170", "r181", "r188", "r474" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
```

```
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r196", "r202", "r203", "r368", "r370", "r374", "r490", "r492", "r555", "r608", "r645", "r876" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r202", "r203", "r368", "r370", "r374", "r490", "r492", "r555", "r608", "r645", "r876" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r135", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r341", "r342", "r343", "r505", "r643" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Income Tax Expense (Benefit), Total", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes", "verboseLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r95", "r99", "r151", "r152", "r164", "r171", "r181", "r330", "r331", "r340", "r481", "r643" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "terseLabel": "Accrued liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r423", "r784" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r775", "r784" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "negatedLabel": "Prepaid expense and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "IncreaseDecreaseOperatingLeaseRightOfUseAsset", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "documentation": "Increase decrease operating lease, right of use asset.", "label": "Increase Decrease Operating Lease, Right Of Use Asset", "negatedLabel": "Right-of-use assets" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r694", "r704", "r714", "r738", "r746", "r750", "r758" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r756" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r686", "r762" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r686", "r762" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r686", "r762" ] }, "us-gaap_InterestExpenseLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseLongTermDebt", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "totalLabel": "Interest Expense, Long-term Debt, Total", "terseLabel": "Interest expense related to long-term debt", "label": "Interest Expense, Long-Term Debt", "documentation": "Aggregate amount of interest paid or due on all long-term debt." } } }, "auth_ref": [ "r89", "r101", "r102" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r127", "r129", "r130" ] }, "us-gaap_InventoryCashFlowPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryCashFlowPolicy", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash", "label": "Inventory, Cash Flow Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining where the cash flows related to the sale of inventory are classified in the statements of cash flows and explain the nature of the receivables, notes, and loans." } } }, "auth_ref": [ "r9" ] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalanceShares", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares owned", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": [ "r511", "r517", "r580", "r587", "r591", "r673" ] }, "us-gaap_InvestmentOwnedPercentOfNetAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedPercentOfNetAssets", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of owned shares", "label": "Investment Owned, Net Assets, Percentage", "documentation": "Percentage of investment owned to net assets." } } }, "auth_ref": [ "r513", "r515", "r516", "r581", "r586", "r588", "r589", "r592", "r673", "r906" ] }, "arct_IsraelMinistryOfHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "IsraelMinistryOfHealthMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "Israel ministry of health.", "label": "Israel Ministry of Health [Member]", "terseLabel": "Israel Ministry of Health [Member]" } } }, "auth_ref": [] }, "arct_JanssenMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "JanssenMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Janssen [Member]", "label": "Janssen [Member]", "documentation": "Janssen." } } }, "auth_ref": [] }, "arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Joint Ventures, Equity Method Investments and Variable Interest Entities", "label": "Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block]", "documentation": "Joint ventures, equity method investments and variable interest entities." } } }, "auth_ref": [] }, "arct_KeithCKummerfeldMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "KeithCKummerfeldMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Keith C. Kummerfeld [Member]", "documentation": "Keith C. Kummerfeld." } } }, "auth_ref": [] }, "arct_LUNARCFMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "LUNARCFMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "LUNAR-CF [Member]", "label": "L U N A R C F [Member]", "documentation": "LUNAR-CF." } } }, "auth_ref": [] }, "arct_LanceKurataMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "LanceKurataMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Lance Kurata [Member]", "documentation": "Lance Kurata." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term", "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r407", "r774" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term", "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r407", "r774" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r74", "r406" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r399" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Payments of Operating Lease Liability", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r860" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total remaining lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r405" ] }, "arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "documentation": "Lessee operating lease liability payments due after year four." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "totalLabel": "Lessee Operating Lease Liability Payments Due Next Twelve Months, Total", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r405" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r405" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r405" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r405" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder of year)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r860" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r405" ] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating leases, option to extend", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r400" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [
```

```
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease extended additional term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r859" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, term of contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r859" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r10", "r43", "r44", "r45", "r48", "r49", "r50", "r51", "r134", "r192", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r354", "r355", "r356", "r380", "r526", "r618", "r681", "r813", "r862", "r863" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r58", "r85", "r470", "r652", "r788", "r802", "r853" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r45", "r106", "r134", "r192", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r354", "r355", "r356", "r380", "r652", "r813", "r862", "r863" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Non-refundable commitment fee, percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Revolving credit line available", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r42", "r47" ] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Interest Rate During Period", "terseLabel": "Loans interest rate, percentage", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": [ "r42", "r47" ] }, "arct_LiquidityPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "LiquidityPolicyPolicyTextBlock", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity", "label": "Liquidity Policy Policy [Text Block]", "documentation": "Liquidity." } } }, "auth_ref": [] }, "arct_LoanAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "LoanAndSecurityAgreementMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Loan and Security Agreement [Member]", "label": "Loan And Security Agreement [Member]", "documentation": "Loan and security agreement." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtSummaryOfFinalPaymentDueAtRepaymentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r10", "r84", "r236", "r250", "r628", "r629", "r650", "r872" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Long-term Debt, Current Maturities, Total", "terseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r111" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtSummaryOfFinalPaymentDueAtRepaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r6", "r138", "r241" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtSummaryOfFinalPaymentDueAtRepaymentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r789" ] }, "us-gaap_LongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt [Member]", "label": "Long-Term Debt [Member]", "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r113" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r10", "r804", "r805", "r806" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r10", "r23", "r804", "r805", "r806" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r206", "r207", "r208", "r211", "r326", "r498", "r626", "r809", "r810" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r206", "r207", "r208", "r211", "r326", "r498", "r626", "r809", "r810" ] }, "arct_MRNATechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "MRNATechnologyMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "mRNA Technology [Member]", "label": "M R N A Technology [Member]", "documentation": "mRNA technology." } } }, "auth_ref": [] }, "arct_ManufacturingAndSupplyOfArct154DrugProductMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ManufacturingAndSupplyOfArct154DrugProductMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Manufacturing and Supply of ARCT-154 Drug Product [Member]", "documentation": "manufacturing and supply of ARCT-154 drug product." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": [ "r207", "r208", "r209", "r210", "r288", "r326", "r367", "r422", "r489", "r491", "r498", "r518", "r519", "r579", "r582", "r584", "r585", "r590", "r606", "r607", "r625", "r632", "r640", "r646", "r647", "r648", "r649", "r666", "r815", "r864", "r865", "r866", "r867", "r868", "r869" ] }, "arct_MaximumSalesRequiredForLoansForgivable": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "MaximumSalesRequiredForLoansForgivable", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum LUNAR-COVID 19 sales required for Loans forgivable", "label": "Maximum Sales Required For Loans Forgivable", "documentation": "Maximum sales required for loans forgivable ." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r730" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r730" ] }, "arct_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "MilestonePayments", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments", "label": "Milestone Payments", "documentation": "Milestone payments." } } }, "auth_ref": [] }, "arct_MinimumAmountAgreedToIncurUnderResearchPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "MinimumAmountAgreedToIncurUnderResearchPlan", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Minimum amount agreed to incur under research plan.", "label": "Minimum Amount Agreed to Incur Under Research Plan", "terseLabel": "Minimum amount agreed to incur under research plan" } } }, "auth_ref": [] }, "arct_MinimumIncurAmountAgreedUnderResearchPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "MinimumIncurAmountAgreedUnderResearchPlan", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Minimum yncur amount agreed under research plan.", "label": "Minimum Incur Amount Agreed Under Research Plan", "terseLabel": "Minimum incur amount under research plan" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r207", "r208", "r209", "r210", "r288", "r326", "r367", "r422", "r489", "r491", "r498", "r518", "r519", "r579", "r582", "r584", "r585", "r590", "r606", "r607", "r625", "r632", "r640", "r646", "r647", "r648", "r666", "r815", "r864", "r865", "r866", "r867", "r868", "r869" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r749" ] }, "arct_MonthlyBaseRent": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "MonthlyBaseRent", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly base rent", "label": "Monthly Base Rent", "documentation": "Monthly base rent." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r757" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r731" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r128" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r128" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r67", "r68", "r69" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
```

```
"http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "negatedTotalLabel": "Net income (loss)", "totalLabel": "Net loss", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r61", "r69", "r88", "r104", "r118", "r120", "r124", "r134", "r142", "r144", "r145", "r146", "r147", "r148", "r151", "r152", "r157", "r192", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r348", "r351", "r366", "r380", "r476", "r548", "r569", "r570", "r679", "r813" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "arct_NonCashAssetDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "NonCashAssetDisposal", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash asset disposal", "label": "Non - Cash Asset Disposal", "documentation": "Non-Cash Asset Disposal" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r730" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r694", "r704", "r714", "r738", "r746" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r721" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r720" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r738" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r757" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r757" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segment for research and development", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r623", "r796" ] }, "arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "OctoberTwoThousandAndSeventeenLeaseAmendmentMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "October 2017 Lease Amendment [Member]", "label": "October Two Thousand And Seventeen Lease Amendment [Member]", "documentation": "October 2017 lease amendment." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r92", "r619", "r795", "r797", "r798", "r799", "r800" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r401", "r651" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r858" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Liability, Total", "verboseLabel": "Total operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r397" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r397" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Liability Current Statement Of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r398" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r397" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r396" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r404", "r651" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r403", "r651" ] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r70", "r71", "r72", "r82" ] }, "arct_OtherAccruedResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "OtherAccruedResearchAndDevelopmentExpenses", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued research and development expenses", "label": "Other Accrued Research And Development Expenses", "documentation": "Other accrued research and development expenses." } } }, "auth_ref": [] }, "arct_OtherCollaborationAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "OtherCollaborationAgreementsMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Other Collaboration Agreements [Member]", "label": "Other Collaboration Agreements [Member]", "documentation": "Other collaboration agreements." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r49" ] }, "arct_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "OtherMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Collaboration Revenue [Member]", "label": "Other [Member]", "documentation": "Other." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Other Noncash Income (Expense), Total", "negatedLabel": "Other non-cash expenses", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r69" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Finance income, net", "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r63" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r730" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r692", "r702", "r712", "r744" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r695", "r705", "r715", "r747" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r695", "r705", "r715", "r747" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r719" ] }, "arct_PaymentReceivedFirstInstallment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "PaymentReceivedFirstInstallment", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Received first installment", "label": "Payment Received First Installment", "documentation": "Payment received first installment." } } }, "auth_ref": [] }, "us-gaap_PaymentsForAdvanceToAffiliate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForAdvanceToAffiliate", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for advance", "label": "Payments for Advance to Affiliate", "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity)." } } }, "auth_ref": [ "r13" ] }, "arct_PaymentsForMatchingFundsForRemainingBudgetedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "PaymentsForMatchingFundsForRemainingBudgetedCosts", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for matching funds for remaining budgeted costs", "label": "Payments For Matching Funds For Remaining Budgeted Costs", "documentation": "Payments for matching funds for remaining budgeted costs." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromTenantAllowance", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant improvement allowance", "label": "Payments for (Proceeds from) Tenant Allowance", "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy." } } }, "auth_ref": [ "r12", "r64" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Acquisition of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r65" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r729" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r729" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r721" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r738" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r731" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r720" ] }, "arct_PercentageOfNetProfits": { "xbrltype": "percentItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "PercentageOfNetProfits", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Net profits percentage", "label": "Percentage Of Net Profits", "documentation": "Percentage of net profits." } } }, "auth_ref": [] }, "arct_PercentageRequiredToBeMaintainedInConsolidatedUnrestrictedCash": { "xbrltype": "percentItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "PercentageRequiredToBeMaintainedInConsolidatedUnrestrictedCash", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage required to be maintain in consolidated, unrestricted cash", "label": "Percentage Required To Be Maintained In Consolidated Unrestricted Cash", "documentation": "Percentage required to be maintained in consolidated unrestricted cash." } } }, "auth_ref": [] }, "arct_PhaseIClinicalStudyMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "PhaseIClinicalStudyMember", "presentation": [
```

```
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Phase I clinical study.", "label": "Phase I Clinical Study [Member]" } } },
"auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]",
"documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832",
"r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PlanNameDomain", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name",
"label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830",
"r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost
[Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r722" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments
Service Cost" } } }, "auth_ref": [ "r766" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [
"r721" ] }, "arct_PotentialPrincipalRepaymentsOfDebtInstrument": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "PotentialPrincipalRepaymentsOfDebtInstrument",
"crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Potential principal repayment of loan", "label":
"Potential Principal Repayments Of Debt Instrument", "documentation": "Potential Principal Repayments Of Debt Instrument." } } }, "auth_ref": [] }, "arct_PreLaunchInventoryPolicyPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "PreLaunchInventoryPolicyPolicyTextBlock", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-
Launch Inventory", "label": "Pre Launch Inventory Policy [Text Block]", "documentation": "Pre-launch inventory policy." } } }, "auth_ref": [] }, "arct_PrepaidExpensesAndOtherReceivables": { "xbrltype":
"monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "PrepaidExpensesAndOtherReceivables", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label":
"Prepaid Expenses And Other Receivables", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount
of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and
loans receivable." } } }, "auth_ref": [] }, "arct_PrepaymentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "PrepaymentFeePercentage", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment fee percentage", "label": "Prepayment Fee Percentage", "documentation":
"Prepayment fee percentage." } } }, "auth_ref": [] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to
their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember",
"presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Private Placement
[Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and
trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit",
"presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from debt",
"terseLabel": "Net increase in indebtedness", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from
short-term and long-term debt." } } }, "auth_ref": [ "r782" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds
from Issuance of Long-term Debt, Total", "terseLabel": "Proceeds from long-term debt agreement", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially
having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r14", "r500" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": {
"totalLabel": "Proceeds from Lines of Credit, Total", "label": "Proceeds from Lines of Credit", "terseLabel": "Amount drawn from Loan", "documentation": "Amount of cash inflow from contractual arrangement with
the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r14", "r787" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options",
"label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r8" ] }, "us-
gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the issuance of common stock
under equity plans", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r1" ] },
"srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
"http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label":
"Product and Service [Axis]" } } }, "auth_ref": [ "r183", "r424", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r610", "r633", "r665", "r666", "r667", "r669", "r670", "r811", "r812", "r817", "r875", "r877",
"r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904" ] },
"srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
"http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label":
"Product and Service [Domain]" } } }, "auth_ref": [ "r183", "r424", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r610", "r633", "r665", "r666", "r667", "r669", "r670", "r811", "r812", "r817", "r875", "r877",
"r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904" ] }, "us-
gaap_PropertyLeaseGuaranteeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyLeaseGuaranteeMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel":
"Property Leases in San Diego [Member]", "label": "Property Lease Guarantee [Member]", "documentation": "A guarantee of performance by a third party lessee under terms of a lease agreement." } } }, "auth_ref": [] },
"us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label":
"Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and
services and not intended for resale." } } }, "auth_ref": [ "r5", "r406" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant
and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total", "terseLabel": "Property and
equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business
and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r74", "r108", "r473" ] }, "us-
gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property Plant And
Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r406" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails",
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Net, Ending
Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "totalLabel": "Property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and
Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for
resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r406", "r464", "r473", "r652" ] }, "us-
gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Components of Property and Equipment, Net", "label": "Property,
Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class
of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible
Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for
resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and
software." } } }, "auth_ref": [ "r74", "r406" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r719" ] },
"ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r719" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } }
}, "auth_ref": [ "r207", "r208", "r209", "r210", "r286", "r288", "r317", "r318", "r319", "r326", "r367", "r419", "r420", "r422", "r489", "r491", "r498", "r518", "r519", "r579", "r582", "r584", "r585", "r590", "r606", "r607",
"r625", "r632", "r640", "r646", "r647", "r648", "r649", "r666", "r673", "r807", "r815", "r851", "r865", "r866", "r867", "r868", "r869" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]"
} } }, "auth_ref": [ "r207", "r208", "r209", "r210", "r286", "r288", "r317", "r318", "r319", "r326", "r367", "r419", "r420", "r422", "r489", "r491", "r498", "r518", "r519", "r579", "r582", "r584", "r585", "r590", "r606",
"r607", "r625", "r632", "r640", "r646", "r647", "r648", "r649", "r666", "r673", "r807", "r815", "r851", "r865", "r866", "r867", "r868", "r869" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure
[Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r687", "r697", "r707", "r739" ] },
"arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://arcturusrx.com/20240930", "localname":
"ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual" ],
"lang": { "en-us": { "role": { "terseLabel": "Reduction in number of common stock shares available for future issuance", "label": "Reduction in Number of Common Stock Capital Shares Available for Future Issuance",
"documentation": "Reduction in number of common stock capital shares available for future issuance." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": {
"terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which
investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate
interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r187", "r287", "r412", "r413", "r467", "r471", "r521", "r522", "r523", "r524", "r525", "r544", "r546", "r578" ] }, "us-
gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line
Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r187", "r551", "r552", "r555" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Axis]",
"documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of
employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." }
} }, "auth_ref": [ "r187", "r287", "r412", "r413", "r467", "r471", "r521", "r522", "r523", "r524", "r525", "r544", "r546", "r578", "r861" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure
[Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a
common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r409", "r410", "r411", "r413", "r415", "r506", "r507", "r508", "r553", "r554", "r555", "r575", "r577" ] },
"arct_RemainingLoanIncludingAccruedInterestForgiveable": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "RemainingLoanIncludingAccruedInterestForgiveable", "crdr":
"credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Remaining loan including accrued interest
forgiveable.", "label": "Remaining Loan Including Accrued Interest Forgiveable", "terseLabel": "Remaining loan including accrued interest forgiveable" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on debt obligations", "label":
```

```
"Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r783" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "totalLabel": "Repayments of Long-Term Debt, Total", "label": "Repayments of Long-Term Debt", "terseLabel": "Repayment of term loan", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r66", "r503" ] }, "arct_RepaymentsOfPrincipalAndInterestOnCollateralizedTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "RepaymentsOfPrincipalAndInterestOnCollateralizedTermLoan", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of principal and interest on collateralized term loan", "label": "Repayments Of Principal And Interest On Collateralized Term Loan", "documentation": "Repayments of principal and interest on collateralized term loan." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r136", "r137", "r227", "r255", "r414", "r421", "r465", "r614", "r615" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development, net", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r328", "r608", "r622", "r870" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs, Net", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r327" ] }, "arct_ResearchCollaborationAndExclusiveLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ResearchCollaborationAndExclusiveLicenseAgreementMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Research Collaboration And Exclusive License Agreement [Member]", "label": "Research Collaboration And Exclusive License Agreement [Member]", "documentation": "Research Collaboration and Exclusive License Agreement." } } }, "auth_ref": [] }, "arct_ResearchCollaborationAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ResearchCollaborationAndLicenseAgreementMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Research Collaboration And License Agreement [Member]", "documentation": "Research collaboration and license agreement.", "terseLabel": "Research Collaboration And License Agreement [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r688", "r698", "r708", "r740" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r689", "r699", "r709", "r741" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r696", "r706", "r716", "r748" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "totalLabel": "Restricted Cash, Total", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r777", "r785", "r871", "r874" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r777", "r785" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-current restricted cash", "terseLabel": "Non-current restricted cash", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r96", "r778", "r785" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r55", "r81", "r469", "r496", "r497", "r504", "r528", "r652" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r103", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r193", "r194", "r195", "r337", "r338", "r345", "r346", "r347", "r349", "r350", "r351", "r357", "r359", "r360", "r362", "r364", "r394", "r395", "r493", "r495", "r509", "r909" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails", "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "verboseLabel": "Total revenue", "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r90", "r91", "r164", "r168", "r169", "r179", "r181", "r183", "r184", "r186", "r281", "r282", "r424" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r100", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r285" ] }, "arct_RevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "RevenueLineItems", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Revenue.", "label": "Revenue [Line Items]", "terseLabel": "Revenue [Line Items]" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r549", "r609", "r616" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligation", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r97" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r98" ] }, "arct_RevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "RevenueTable", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Revenue.", "label": "Revenue [Table]", "terseLabel": "Revenue [Table]" } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets acquired through operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r402", "r651" ] }, "arct_RoyaltyPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "RoyaltyPaymentPercentage", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "verboseLabel": "Royalty payment percentage of proceeds from net sales", "label": "Royalty Payment Percentage", "documentation": "Royalty payment percentage." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r757" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r757" ] }, "country_SG": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "SG", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Singapore Economic Development Board [Member]", "label": "SINGAPORE" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Equity method investment, sale of common stock", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r153", "r289", "r769", "r793" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents and Restricted Cash", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCompensationCostForSharesBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Expenses", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r33" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r189", "r190", "r191", "r344", "r770", "r771", "r772", "r845", "r846", "r847", "r848" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5", "r406" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r36", "r37", "r551", "r552", "r555" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based
```

payment arrangement." } } }, "auth_ref": ["r291", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Stock By Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r26", "r27", "r28", "r29", "r30", "r31", "r77", "r79", "r80", "r81", "r114", "r115", "r116", "r166", "r253", "r254", "r255", "r257", "r260", "r265", "r267", "r500", "r501", "r502", "r503", "r632", "r768", "r786"] }, "arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "ScheduleOfSummaryOfSignificantAccountingPoliciesTable", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Summary Of Significant Accounting Policies [Table]", "label": "Schedule Of Summary Of Significant Accounting Policies [Table]", "documentation": "Schedule of summary of significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": ["r849"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r682"] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Security deposit", "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": ["r778"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r684"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": ["r184", "r185", "r425", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r512", "r514", "r516", "r581", "r583", "r588", "r592", "r595", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r611", "r634", "r654", "r655", "r656", "r657", "r659", "r661", "r662", "r663", "r668", "r673", "r817", "r875", "r877", "r878", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r172", "r173", "r174", "r175", "r176", "r177", "r178", "r182", "r184", "r620", "r621", "r624"] }, "arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "SeptemberTwoThousandAndTwentyOneLeaseAgreementMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "September 2021 Lease Agreement [Member]", "label": "September Two Thousand And Twenty One Lease Agreement [Member]", "documentation": "September two thousand and twenty one lease agreement." } } }, "auth_ref": [] }, "arct_SeqirusIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "SeqirusIncMember", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "verboseLabel": "Seqirus Inc [Member]", "terseLabel": "Seqirus, Inc [Member]", "label": "Seqirus, Inc [Member]", "documentation": "Seqirus, Inc." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r291", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation number of shares authorized", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r642"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r32"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r53", "r56", "r57", "r103", "r122", "r123", "r124", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r165", "r193", "r194", "r195", "r269", "r337", "r338", "r345", "r346", "r347", "r349", "r350", "r351", "r357", "r358", "r359", "r360", "r361", "r362", "r364", "r385", "r386", "r387", "r388", "r389", "r390", "r394", "r395", "r408", "r477", "r493", "r494", "r495", "r509", "r571"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": ["r184", "r185", "r425", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r512", "r514", "r516", "r581", "r583", "r588", "r592", "r595", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r611", "r634", "r654", "r655", "r656", "r657", "r659", "r661", "r662", "r663", "r668", "r673", "r817", "r875", "r877", "r878", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r139", "r140", "r141", "r165", "r395", "r424", "r499", "r510", "r520", "r521", "r522", "r523", "r524", "r525", "r527", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r540", "r541", "r542", "r543", "r544", "r546", "r549", "r550", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r571", "r674"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Scenario", "label": "Scenario [Axis]" } } }, "auth_ref": ["r153", "r289", "r769", "r773", "r793"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r139", "r140", "r141", "r165", "r187", "r395", "r424", "r499", "r510", "r520", "r521", "r522", "r523", "r524", "r525", "r527", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r540", "r541", "r542", "r543", "r544", "r546", "r549", "r550", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r571", "r674"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r691", "r701", "r711", "r743"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock related to acquired in-process research and development (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": ["r52", "r53", "r81"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock", "terseLabel": "Issuance of common stock, net of issuance costs (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r52", "r53", "r81", "r500", "r571", "r593"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r7", "r52", "r53", "r81", "r303"] }, "arct_StockIssuedDuringPeriodSharesUnderEquityPlan": { "xbrltype": "sharesItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "StockIssuedDuringPeriodSharesUnderEquityPlan", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares under equity plan.", "label": "Stock Issued During Period Shares Under Equity Plan", "terseLabel": "Issuance of common stock under equity plans (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock related to acquired in-process research and development", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": ["r7", "r53", "r56", "r57", "r81"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued, value", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r52", "r53", "r81", "r509", "r571", "r593", "r680"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r7", "r53", "r56", "r57", "r81"] }, "arct_StockIssuedDuringPeriodValueUnderEquityPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "StockIssuedDuringPeriodValueUnderEquityPlan", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value under equity plan.", "label": "Stock Issued During Period Value Under Equity Plan", "terseLabel": "Issuance of common stock under equity plans" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS", "http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r53", "r56", "r57", "r73", "r529", "r545", "r572", "r573", "r652", "r681", "r788", "r802", "r853", "r909"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r78", "r133", "r252", "r254", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r269", "r363", "r574", "r576", "r594"] },

```
"arct_StudySupportAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "StudySupportAgreementMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Study Support Agreement", "label": "Study Support Agreement [Member]",
"documentation": "Study support agreement." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": {
"terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be
issued." } } }, "auth_ref": [ "r391", "r417" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]",
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r391", "r417" ] }, "us-
gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]",
"documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r391", "r417" ] }, "us-gaap_SubsequentEventsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The
entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be
issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions
not in the ordinary course of business." } } }, "auth_ref": [ "r416", "r418" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockAxis", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": {
"terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "arct_SummaryOfSignificantAccountingPolicyLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "SummaryOfSignificantAccountingPolicyLineItems", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel":
"Summary Of Significant Accounting Policy [Line Items]", "label": "Summary Of Significant Accounting Policy [Line Items]", "documentation": "Summary of significant accounting policy." } } }, "auth_ref": [] }, "us-
gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Details", "label": "Supplemental Balance Sheet Disclosures [Text
Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r776" ] }, "us-
gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow
information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref":
[ "r737" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Taxes Payable, Current, Total", "label": "Taxes
Payable, Current", "terseLabel": "Income tax payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property
and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r43", "r44" ] }, "ecd_TotalShareholderRtnAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r729" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder
Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r736" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:"
} } }, "auth_ref": [ "r756" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref":
[ "r758" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading
symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r759" ] },
"ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": {
"en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r760" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement
Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r760" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r758" ] },
"ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-
us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r758" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement,
Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r761" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel":
"Termination Date" } } }, "auth_ref": [ "r759" ] }, "arct_TwentyTwentyOneInducementEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname":
"TwentyTwentyOneInducementEquityIncentivePlanMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual" ], "lang": { "en-us": {
"role": { "terseLabel": "2021 Inducement Equity Incentive Plan [Member]", "label": "Twenty Twenty One Inducement Equity Incentive Plan [Member]", "documentation": "2021 Inducement equity incentive plan." } }
}, "auth_ref": [] }, "arct_TwoThousandNineteenOmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname":
"TwoThousandNineteenOmnibusIncentivePlanMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual" ], "lang": { "en-us": {
"role": { "terseLabel": "2019 Omnibus Equity Incentive Plan [Member]", "label": "Two Thousand Nineteen Omnibus Incentive Plan [Member]", "documentation": "Two thousand nineteen omnibus incentive plan." } }
}, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": {
"role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information
by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r352" ] }, "arct_UltragenyxMember": { "xbrltype":
"domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "UltragenyxMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://arcturusrx.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Ultragenyx [Member]", "label":
"Ultragenyx [Member]", "documentation": "Ultragenyx." } } }, "auth_ref": [] }, "us-gaap_UnamortizedLoanCommitmentAndOriginationFeesAndUnamortizedDiscountsOrPremiums": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedLoanCommitmentAndOriginationFeesAndUnamortizedDiscountsOrPremiums", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "totalLabel": "Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or
Premiums, Total", "terseLabel": "Loan origination fee paid", "label": "Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums", "documentation": "Amount of deferred fees paid by borrowers and unamortized costs incurred to originate loans and leases, unamortized loan commitments and loan syndication fees, and premiums over or discounts from face amounts of loans that are being amortized into income as an adjustment to yield. Excludes amounts for loans and leases covered under loss sharing agreements." } } }, "auth_ref": [ "r94" ] }, "arct_UnderlyingAgreementMember": { "xbrltype":
"domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "UnderlyingAgreementMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Agreement [Member]", "label": "Underlying
Agreement [Member]", "documentation": "Underlying agreement." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel":
"Underlying Security Market Price Change" } } }, "auth_ref": [ "r755" ] }, "arct_UpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname":
"UpfrontPaymentReceived", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment received", "label": "Upfront Payment Received",
"documentation": "Upfront payment received." } } }, "auth_ref": [] }, "arct_VallonPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname":
"VallonPharmaceuticalsIncMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": {
"terseLabel": "Vallon Pharmaceuticals, Inc. [Member]", "label": "Vallon Pharmaceuticals Inc [Member]", "documentation": "Vallon Pharmaceuticals, Inc." } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": {
"en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "label":
"Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "arct_VinbiocareAgreementMember": {
"xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "VinbiocareAgreementMember", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Vinbiocare Agreement [Member]", "label": "Vinbiocare Agreement [Member]",
"documentation": "Vinbiocare agreement." } } }, "auth_ref": [] }, "arct_VinbiocareContractualLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname":
"VinbiocareContractualLiabilities", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Vinbiocare contractual liabilities", "label": "Vinbiocare Contractual Liabilities", "documentation": "Vinbiocare contractual liabilities." } } }, "auth_ref": [] }, "arct_VinbiocareMember": {
"xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "VinbiocareMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vinbiocare [Member]", "label": "Vinbiocare [Member]",
"documentation": "Vinbiocare." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and
Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r725" ] }, "arct_WarrantFeePayable": { "xbrltype":
"monetaryItemType", "nsuri": "http://arcturusrx.com/20240930", "localname": "WarrantFeePayable", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant fee payable", "label": "Warrant Fee Payable", "documentation": "Warrant fee
payable." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ],
"lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted",
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in
the period." } } }, "auth_ref": [ "r155", "r160" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ],
"lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average shares outstanding:" } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average
Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "documentation": "Number of [basic] shares or units, after adjustment for
contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to
the total time in that period." } } }, "auth_ref": [ "r154", "r160" ] }, "arct_WellsFargoCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930", "localname":
"WellsFargoCreditAgreementMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual",
"http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Wells Fargo Credit Agreement [Member]", "documentation": "Wells
fargo credit agreement.", "label": "Wells Fargo Credit Agreement [Member]" } } }, "auth_ref": [] }, "arct_WesternAllianceBankMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240930",
"localname": "WesternAllianceBankMember", "presentation": [ "http://arcturusrx.com/20240930/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Western Alliance Bank
[Member]", "label": "Western Alliance Bank [Member]", "documentation": "Western Alliance Bank." } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year
that are Outstanding and Unvested" } } }, "auth_ref": [ "r723" ] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
}, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
"Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
}, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10",
"Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482888/230-10-55-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-
```

gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481598/310-20-45-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" },

```
"r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role":
```

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher":
```

"FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-15" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-33" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section":

"50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r604": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-12" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-34" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-7" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "I", "Paragraph": "a" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "I" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r720": { "role":
```

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r768": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r769": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r770": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r830": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 60 0000950170-24-123469-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-123469-xbrl.zip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`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|"6?!6 MK_F!=^^D?P5]Y9P19+DW^(^F: (=8&#@6X,!SRDQB(-^@ERP1+,P;KPBG>- M>3I_DL)Q@#X*B+2*FRM @(@HTQ2AHZY#.B42*Y5)Q$W4N7X:A5!]WX\&?N=D M7(Y,Z_U?[:GE)5'U(&YCVC(#HBKR9,Y&V'4:X05:\!BT!EW1=O;<\D>G%?\5 M!H/[@RF/1ELE")1)]\<3^^F%SK+Z\P@*"L4MSR.6+WT0%TM% MM686"9-$48@,*:|-LE9$0XA0,N^L?SMQ[R7]XO#KZ/!X-*W,T.\" D]"&.Z= M# M;'RBE-YZ&=->SX5Z+O> JCQ7 A0% 8]"-P0%[7$0A,/ O]#3HI>F:#Z-M[6FYY8AYFG0M^(_B-)T5NQA- MBA[+.Z=K]3!ZFXTEVGH:P5KEP&=<.X8LTREFETG87)T:O?(CYKM1-6WON,42 MIRS\#VGIZRA5T! %_$ MXG#PX2]+=34C.WY73H]G=??ABAVU.*R1UPBG$9 Y(MC(:&8'5&Y+#&BHB(I>JL'Z\+^-X%@!0.B.7!(9Y+'F8>*4RE$-A(Z517=W'S]RG]|\>GVR?C MP>@LA!KL]\:)Q=]R!ZX\ ()!GS7_W1N&G2'8'TO,_RO/@9SP0 -4(.^53!%D M +Y;'.0X_QE/E?=U0=^Q-I:U>"BM?8H#M\6(Y&=E-P+X%&/ T%<1H.,T1@9 M)X54V%'G.AO*\B2'Z .7 \,4A;&#L |X>1$M#H*;PCOW3D,Y3+5)9K4$AD?I MTH-1+|> U,4C#KZ: ;,>>6Z9] M[P9ZRBS6IXGJ-$(&/!$<5.I(CFR&UG?49WBOWZ, 6P =(. M<.&'XEOZZ[F4K'#&6"YM@&T7*4"/*61"8,A)YG)GG0 [MJN;!P"SY_@(-(9 M;['0!EE&%1AY!#3!H$'UH-I@9U@0I(NI3T_@$O6I*D_N(Z(F&5+U2EF'4^04 MXPH3ZF3G#*E'+0G1(0'V!(SD*5-:1X&PQSB%Q5]D@F6(B3GS=99-2G< MA*6HZ]H/L"%OK8^#X]#:<9A"C\^@F+|-*FI7EKO';PYIN]P/-<4%&,5D7#P M-?<>;,S.AI+>&4TUURA2()!/!5 ,5@$1$5NL8U>T[RSN1P=%\9+ M&T9:U.MT[L&,9*"7"0:LE$MDE,+(Y"[JK3#2Z$ZZ('Z C'L3@, VT+=;9;:>

*MR$5E--%"): ^LLHC+$)'%02 2+%6E2\;E6 _,F=LBN2 M2DYHG**'+3$4<493/5.>(Z-%S!T,5Y"5AQT]G;_*]4"!$2CP5,R5YCE27B@D M,?*6]#CSID8!U(L=(, ^"6G%,L@XCQ$0XN5F&9]K0PCEU'2N%$WGK-45L7;NO"2>]I]5SW\#]AZI4GXY! ,]L M#8IA0N.#R=2O &M71_]*!.D=18]D.GPXN4A"!"5)8$YHRM)]3N*W;U'T"#G^ M;4H($X238&4KH0SBDEFD#5"?R7%$D!@M+?22>I[T>'M-5@M@\O\CSB"6(B@Z-6M:F80]=@A+A18X[EO2 4GHC!28_KL9%.6X5^P'XV/N%Y]ECMDC>0)U:<|+*W1#N7"PR[FGBS+?(6(LHQICZ7RG#C*2PT0:0* WSIINM/UYE1,$3 MSM3!'SR*U8.<\]14(1H"LD"3GF@7'7$.](' ,YMEV3V%K"U+/I(\.'W37KADR0.[*:<#LE9PYAES4J;N M?%9.-G= EY;8S*I,/8LQ5&]% 4O!#)$Y4CDB@MO?Y'4J2T!SH!5S&XU4%I&8 MNIRE #BN -9S]PC%4AL1.HWI+.,%{<>06O%GCKCH8]"@-K,-!)61,0]{\@P ML+ "")M80:Z/LKHG>Q0/.%FO;15"#HZ(*.4(]XI*35.P:1':T5@OC. Z=/7ON MO2NH#Z1_&HK'PAS*F4(#LDG$&I M QMLF,FM-I$KTMD4 /M2=(?<9&00)^@>)&Y+EF:3H O/I*L.SR,2$=S6=BG/ M*6;) ^*<&<:=RI$4 _+4RJ8J.B:OS')GP% M^MJO)A|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|[5_\6S4DO.-LX M! :NLMWP-=L? G9CA_$(IFDQ&)W!MXA9D!6T:<2&DO[HQJ:X?PU7X[ATQ%\ MX1+&N SH:VG&[RZ'^X>0@W=!+?SD>",6S\1SYS"[Y# _^1 1^]IO:]"8PO'2 M,HXO+ ^)LK&3 ^JA9FO5C4YLGK^7B2^=*4#L)-"^)%@U&Y]2=<_^=3Z^S[;_[|:?-G?,NIUM[?W^^\||P<|>G-?&7K/E?FOS8,_M[>S^[7!O=RU[OY51# ;|=6LQFU-BS>H_ SN3G#";QK@A05+5U^$%%@#2C4: M%'Y>;5FO1!K)C:M[ZRPMD#WEK1SM[7H+E]]V-O_/9M/?WD\=W@VS 1D_W T MK%62PM7*T8C.+D<# _2> ^' 93SMY\656&+ 1CB&_/]9Q?!57ZQ./7K^#KG?UXV36;3;&R3 MMI?,_C24DW0& M/=O)AB(>TYBZ6F0HP62,]0D>AP(@GRMDHD[M'E-300XRP[*VL,;? IZ:E9.W61R5)V;RZYL"IEP%XLR&E@S&(PFL"LM(_U_ X E%^]N%AI $;YI M.[F*)2G[Y)W!P^WIC_^=6H2V*R(*^GQ&6[>UG M)/_) %ZM2<@_.]=:+5D)"PMA<^LP_4PTXU>MY9S-X-^$*2|>:) ^=771?=!]' M49E-CD/VKSF79XU?- M#' Q-.N]-;[U&YY5:18YL$OF03DTCM2FE&-R+%^%U3\45#(C*6@D QD6#+8BZ4;6LA/O50/! PQ) @& ^J;BQR.BBX M2:CU8 MCDZR^?|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| J M!6WJ28W6+2!N>/NP,"O>Q=L<8_8:8Z?M8AT$3D$WB <&,!9S@91U%E%EE&(D M*FI:,JN8!'5VA6S#8T'6*,2\"\8FP&6?@6 MW#1EQ\/78%V$JK<>G_DV ZMFB5=_:!IV.'KJL8-67D:NPD^K"8$71COBO4$B MP_RYQ5E/83< M*[''%%).Q)1)V) 1" L8G#8^=:P{= M3^4D!Y^,!I-5!"3==>T4UOH@*<0LC MM^OQ<` 1+>#2G0>GU[%)=A"%D(U]GC\VTQ#V9-LOPW#=F]@ 4SK*8%'!Q61-:*(// MQM.RFJ:@FLDH@RM]$>A/E? D[J:HH(WW63C(>C[DN-\^Q^5^X6HD'M$M>!' M>?6T^2$$9U,%^P;CCS U,5=W/=KQVB;(Q?I_ MF#W)8CV:|?R'::0T28>YX>3C^,JQ:KCUB!,C.:.YB^K!#]&9-&V$4'MD MFG);>A)\ B3(7"HN+RC"2@'A4?C+1.*0-EQ':X0AX<&GGG.PW)}N#I#Z[NH M@"3_)AL0<*TI]>1RRWB'3[:Z8" [%55Y_ M8[8S]"GN,V3V+'/' OCD)-5W_'HFRF(Q"#XS@P]' MF"IF)?;OZ9%+Y(E+/Z<'#9F' M7X=']:4P81=]AS^A65TYJL]^Q N|HR5>]ZA].]1.: 9 =E),)@!]80" 5H[)I^#LRR OG:6[23UR;@Z6,>] MF9BF,.4E4#] QO*)ROX4KN0XGRA9P3P=-%L$!.LQ^2L)5OL,KL\NF!P7%8S8 MC%,>]ZH1OAGO KA#]?/ZJE 9 ^SRW4CD#44T]1;%%DN6.'8ZUUB%/*BVTB,7 M.Y4V:@;2/KWI-RC\-"90!'PU@&B$SS@$IIY-+7P-5F331*[-@,00%3|4 M)P#F(\fYKJP1UIS _ ,6DMH-#P=-2W84794CKY.CN<_ KX,'6'NJ1^1"+85T9 MJX!B3-$9%+ ^;GSUS^3= +(:+[A^?/,+D^ H]N_B:LP+[=?ST)6IL:RU&O/:3:BAIZ,3 %X->9'3S-K;R)5*PULY MX:/.#65*IKS6U/E<4*2,3|4 M)P#F(\fYKJP1'UIS _ ,6DMH-#P=-2W84794CKY.CN<_ KX,'6'NJ1^1"+85T9 MJX!B3-$9%+ ^;G|GOW!9WAPG7/NI4_\)5E0GD(D))[*@ MX#5#/-<6615.1\(4:4:U>GO89(R^KPLI, $$T M6:K<OG7 EX- MK\\V&..O1\E^=%E7M7AZ:H2O.(5WI-XAZ>)J8H;>E+[*4MW5PE]7%X;]9'Z^ M,J@:L;S,\\0'5FYY3>&-U' :#.75D/\&>UV&&34NK'P?QU:', PT#ZTY ZZ.O M^(]">N\PO6N40O\H)BZ"\OIS"=:(2.<1)(%&B4WBOF6RB(?)#*X2B=L0A!A MW(JON7Y6@W:2KHF=+W)>AR6\]RZR6W=!R&5FLORM8QBRM> ^%[_^>8DB#[!F M9MSZH4]S)DT]V*>X.\XBY@I;$/WM4MXI@%+;%%7TL" M[")4D(P9(BD@3IE"'-7)/[5!1C]=.&BAVIM.:O$), ?ZG+ M,%1O -1=<0(\ .N;G=T/%QE\.#U!?C1!LTO> $;E&E9RC>5ZSFW5>3VAVD@S MD409IZ/Y 5BJ05'5*=.C|\^E? &UK^;+T6Z3I-Y5 |: II=2<1!!OHV&[K65'< M-K6ZTDX?!30<<3*]!:5?IX-ZW!]/\RV@=B[. C?D" *1K5,0?'3D^$[7U3C M@3<2+]>KE:)U .B&=G,I]A||<|I-2GBV?R%!:1.1WXU&C'V^4(:7=G8;E MB/W%7QI"O 4HVW/+V|A]6?_35MUO/#?SD9<# >@;YM]:K56[2T[=]M7]I+XZ7]>35EV 1_#C; MW'V?[1P>9 >?_W*P\WYG9?/FYG>Q^RK;W= MP^W=P\?EW#(ES)ZT_"\ M1(|MU31)%_ ^%3[N+%30/6<59-<&;4."<15>Y MKO7:6P12TO\|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|TG0P(TH6Z?*8L9_]M/MXRP!8VU8$_E:F18?##.P;0#R\:C8166'>.?UP_6X<6)&^OWPC/_%D"K:D;1T MMRDLCRV/(7W50M?_L7KWX>8:OCU[MGY(8)] MBQS,.3..TTGAJFQ'QND#9K1GRYXM'\:6YV17 MDW8$A'IRA.V.0&6COO*<#0%LAV! @,T5(Y.X3X0&4N2 [ZL M|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|&]/8%C>IRA0UP FF"QCT\/^+K*;*GR/;@TDS] M3,Q90LZ]F"& M1?)9!>IG0-/QTNWIGD$Z*YC3!>85Z]YZO.WI^-&>W/,"/4OR&E*.3 ^/XKE4 M(&])GAOO;P1*.QT,HO[[,<>B)=A5)0! ^*$HR3.ADV]H\I2IA-/H@]=- M-P]=V:<<7%FGLBYJP]&P_I&K*FWMCBOF"<#+I-PCZH]K;8H_D]'A5]+C10F M3:(T ,QID3HDU'T 4D;4J$K9U(/S_A'-2GH,&NWQ:.!KD$TNC>9!BT(;IEB) M|T8%]3C@<<=TIH[F)7Q63Z2Q+(25X]TI'3]ZK.2'S83P8112C81,'.3L&&RVZ M7321EZ,FK;IH:@9,JR;D-R[:VIPK#&6HX"?7*PL]Q;9(L2,ZPDT9EZ-1K20T M33[[/DD]K26T]K/.]>F95TUHO&OSEOB7!$DGBSW8944TT4WG-, M)ET#<,*M9WSP^LK_2XF=6F*I?]H'=RE!MD49#8V U8$_E:F18?##. ?O#R\:C8166'>.?UP_6X<6)&^OWPC/_%D"K:D;1T MMZF];

4@(HE@ MJ%7 DY2.B>!\6"M Q81,0M6C _&;!8,$X(H-1'$,QQL)$QT-F9S#27/*YU; .+4 M^LAR^,APY8<-' H%K$78N XN6.GL/HNWDSZG.RQG>0B\;M=|F()'H"HQB>8ZG MLMQPOUQYOIMR4U3W[|=EU=IUAN,PO@BH=WHL#++MV%P<2ZO0#HL: M=;8C@D2=/11H|YV1)"HLTAE.&GC5>Z,OQ=+|E M*(HD?2UWV$>TPVL;0:HC@CP*D,HL)*MS@BRE D$3 2>H ,F<)#IJ5G[>!"GB MB7!&*."_1A#!&7"^ !M7VGB12.$=]W<)-.8Z3WZK [>#=-]<3+Q64: M35VC1.E3_7WW\7S4(W5Q ,&9*'1N|W=NZ|=D7S2'$OSS;.1XL6 Z(' MM07+IH[6+X2C\W^B5B)%HD(H7_UT+I&|=N!=I|>W>K=X.^6& N8FX<.|UA#'[?,.;'S|BIOFWI8]WUKE, M PAC92'F1 SC&"'1/B"'4A&SM3?MCLF+4*0O6&X$6EAI" MN$*X0KAZ8!XU9[G|%X"E\]D.PD,!%;8&+**'F/R06_7LZ14:^J42!3Y" |+1 G MI0;EN5&%EY&YZ12=MPU)#B)'=P,@=HYCC*8AL'3B?6V;5CHPB*^P)%+)E_%(64T%QUUCNVWPHD:=[8@& M46>/1M2HLOT19#O5/.PCAO6<0M**T-E M+,ZX82!L9&:LT$! U3UHDSRQS:V>\;;",NKKSFHHK:XJ1=.57$#0*::V+@=Q^ MQKLJ>(HOYI/:Z/W"9"W*ZS1OOEYH|^E2S>/\"NU0BY79L#0F0NKC+P9T^1s] M6]XMB!ZM7OO'0#<<'>!0_N6?"?\U'|<8(M'[:H4.P)|OH5 MQW_,3,=GDFX?_Gs8)1*\3\R#Y[X6H70:C.<..!5.)A.HV.FF44]!>6W+AU@D MY1IE+!CI Ie@45%9.6\+HGEL?Z+W9GAMKY:"LSPZ5!=`S\6=D_O4N$4;O&M!F M:X6@((.M/%T1,)82<-9EQFTA_&;M&<-&,'J(S1@00%L)%PB@"*'M =."4. $AJCYCK$ME>K#1!H(B@N+C@6+, MLC9\CD99$)00\+G H_>2"BMEUF*M^Q"C-&EC."AG(XB@#'C'"'IH&RYC@BG"Q MWT8;"(K8: ,;;:'YZHB4YC[8 KMS#+0%@H(V!^.'HVH46<[(LAVN(4[=MRXSHS%*M8(!FDD!XS<"PP&@:&'HCR)#N.EI;O551&Y@1*|)" R5:#2,.:|"9] #1PHH64T M]KJ9!(01B=P=!<+HQ),IV"I>KV4Z/U22#[K >4X<5)&L(X)$ M+_EH1(TZVQ%!'@7|\(SYI%@ 'FAA'[IVSDZ$0C*%0]1,B5AO1[E)0/^QBA#3 M/N,4N0?BV/$*$KG'T8@=:;8C@CP.[I&|"KP6*6%>@=**@EY9$G:] M? M0&$7KD'H<3T!*V&W,10)KW4U/:170X=AMFO8P|VI-F(G[77Q#/EB)D1 MM#C+0H,UCH"+(:@@DDAIK3#7?4+U;A)FWX_3_UH5>E&KZTU1Y^U%/Z/G>]G4= M;K,>|'V&2-H>)#T6=QW1HW7:@NC1VL5P%#R,2FNI31QDRDT0@(&E(0.QP8E, MHV#&/V33XGL\K(D:?(^&/:!E -EA@A["::M@ V&T8BL!21BB1\NU!=&CM8OA M*$@8IW5G%V?I&CU+L1=*V_] MOI@0/QI&'^#R|9|_G[P\>27\M-=&2@$V6'E9&'94T2/P9P395CWC FOEH; :)9LUK N9MU%'IM|)X8R M(6\%1K'-OH B@":-< E'1/(26$$|$(E^-X9<(SS)%PI,!IO B@43#" M"W8FYD $(\&|9&LIKBBD#E$)-A1@|102/]B**MSA(S$$4118^DAKW36:2H M%#!>]*W@A;IZ%@UHIJU5+!AGULXH1$$,\29!N:3@NJVU'4P.!;.-)#$$ZZ)^ MA!['LH"UW%MPNSU@C3VN$;41M=O&?65,669>X#'Y'^L T5)#*0%B%5U2TJZE M< 5/8^(4K!#-A1@\91E2(L8$QZCS=(|)KDF?|!VV_V@KG&Z^6UC^=>7IFU_O ML)Y5^7/#Y_ZB-OL3D>9IOOOUWYB'=O|2SX7:G<.-/@|&|WNC\:Q3]RP=^DFLW!>; 8A35-=Z+s$V*AM/4;-CK"\E3_R8.1&85 ^/IV5%YHB M@T^N37&=R3CXV M#-RV+|M*!3S :O[1ZG#{|}>WE^/_s'&G[!!3XLSQ,GR . M5)E9M$ +5,PO1L_B8'HY=)^?UG>77;!8]RRN;58/%+0-%++0N2W%/47?R&//=T>D.DXY=ANI3*(QY6OK.4L"(=O-Q4NWP*<B_M7L:D-2(3;38+E)1TA=6'SE4891W7_QV,D)?'=Y!P]%=K36P[&??.]?3>;/ M4)#"!O"62_ B!$@ ^<2[4SUEOI9'VK8:HJO'++U]\2*9'>M|\&DA7(8(ACL$ M0Y4)=R;4+3176'DH8&>I%Y""(ZG0\O*NWODKWSS8\K[@W2+HF ;==]:^RC+|M3=+'-)IC)/[@= LM4|LLD[_^*>>**1)$%K"8R"" ,(:FCZ|W+/ M^BS_/9A]>#Z?EOE,DY69^KQM(R5TG\AN;9.B:4=H/%)HO!W*DHV*FL2@@%B! M.A4<.),|, -2YY%I:=2DVIG4/;#XJ0*2]QC('P/|+K)6\(P^(-URI=%EB97 MC_I$7ZLUT_%P$'1KL1R$UFHUB9GX)^H,W1'LZ/"^U$D1+B$8*$-Q$,$08D"(D M:5,20]I=ZMD.I_\ZDW%G)SUU2Y\QG^_*%(X\%$7I=]>/A7MFDB,$ M3)(:&A&B.!4ZO\Y\ ^NI8B3NQJG8$;R/K4||/O2/>S=$A:?;L'D0?H@[Q* MU[3$6$ ^3;%6UQVO]*%7U^A'}$LZ[NL?:W!K3W' &&S6CH%4L=@U2HNU4DF" M=C%9+-E37&[#IRA] +QH\9O) ^,,@IOCSYU^+.E\S;B=7NKSUX@"V+Q26.1%4 M;+% $17;A8K1%H;/%05&LZV[H1:L#02EXTW _;8C[\>|B _;EGHX|I>]O)NWHY9P)X!V#, VU[@$CZF)8O) M]GLZ3O:O ^& Z:.CL/"Z)-,'|R M3/5,A:N?8(<7{A)>K-4Y#=#~9]=UC+.+1 M2I>WE.FE1++]D6'4"$0D7"2$B)$'$* 9M:]?M ^.GBOUX898++/JZ=E/[2>E2)X':#RS:XA#VA5N[G]PY_ M4- QO|UWM)OVTL#%'!83ZMRXKMI9]&^ULZACO%=(=_7(.YR5+WSIGE2F^;Z[M].MY-1BEWM.*GQ^FO=-1/;UUGBYGZ<*G28^3_@;KY"X!O3;.XNY;:"#L(.S\ ML(O.<<(.(TP@M]!H&KW$P M#VYV./Z]-Q-@MHD.#'0@-X75RD#BP0OL8+LL#'1C6XMY;?DGO MTA7+VQ7L6"%B]0IUN. ^Y_9,*QC.3CF*2 2GMT2ON- MM(*8A;%90&*FEBG4"DR4#I(RD5(]:-I&T<-SV86\4TQD: _2UJH4|NE.&]$> M#"YA7&)+^U+C$30!B,'H8UFEJZL?V(I10&\O:V.#PR7Y8$.#(.0^ZF"M;)B M:C]M!;$&T\OQU W1H3D(IH<,S5;ZVQ+EH _"'*TGO94GX(TAS+CU5B27&%L[M777Z?JE1N$F9/BZ(U!:5S5XLM6O++HW0NS@\V2ZX2(CN1T4<^BXST MKMG|9:U1&>8)3(]DFK@E@#&L]+FO^]6(+ZL>QAOVBGY32Z7|675N*3RX9M7U05,Y.I _R)/MJ[I222V9A'*T$|]T-E\L5%)$1\0K=R[AA]G[=&\UIRL]>2NC8+= "O(\3,Q. M-7!H+M69(_/*NFYZL*#X=;N>_PH[^<==+DOWD9^X/8]>U"|?F)8OF>3' R4Z; MRYFZ>HG? G2I+$YTX+B9QD5L?1*WQU^ ^!DS[U5]T+PZW$S>U/L!K3\,S:S6'2MG_$X_8%;!<[\V9^L/VYX?.Y"6BMV,)RM?N/.> ^]1, CI?#:=PR@6 M]EZ\5,M%]=/Z%["L\>.PS]&%I#$,[:6:?5%7S4|__*6GB(:)W2:V.?"P80,B MV-K.P^[9]Q>L#K!!.R!S<+ "=\6+[_E&K)7I57.N269SW/04H0@#>D9$3PS M2J>%L*G!][|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||2X12X%TU^EH=I6HSVZ0P4T:=$,$W5Q.0.E]D3Z?E%HP@2|H =#IP| MX!R?]>SQ:< 104MTT|"/R; MVHEO>-W!#5V'++*8NTD23&*TNXs$IS(5"E2Y"(3 M'66LS-U6T?7%F"XS0)"@!C.+59 *X$,2Y<6CI:;B3YV!:20Q 89=.[2D39M.?0DL MI!6E+7 /-[--H#=X7'0Q@|^ V"XK?&-D(;WA+2 QFZ.CO%(]SGC.B4V%)-RX MG'B:4V(SGFF=4|>5/3SEO>I9[""OI8DAW6BSYP16M.CIWBZ2! M>;>ZG]HDVQ+A9\4'*3'28\ 1T82&4UU?$ _<@4HJ.C19Y+;+44@! [3/@=C@PQ M]1 649XR9[G-Y38*RM(I)KO*=@KN#%C1%]1DERX.I,%83]W:[3X&RP^#$*= MN?2^G5O)5E)*^CSA>I(=23VB; 7*H:4!=)/VH\R\LJ4GZ4VO<'"4|*7M>\)/P.0"8##W MSHM. (NLQEA4GK"0ZIH-SSM9.Q2QOH3MM5.90(F1\7,'<2 MY$YQ(G.AT8X6A04X)M5R#BBW:\W _.K>+6MM@F F6I=./KY(B+=9/,SR_W8;%%5|L M69" 'ZK$M'[;_I626N\Q0XJNW$P.LL%SJK+-7QI7?P:)+II86RY\K;$6 MH> ,+N0M,T7_G.#_CZ@5 YKY'7SL)A$\71%*/#-R"5 K$!@COZG#H<$4]#=1.9 M!M+$]:6>W!.VO.=22%,#CPNDV9GONGLZ-M%*09>YAWM=X.3TRI0SV:")7#6 M2?QKO3?@XR$T O!\GO:I92WBD^0-?.8 G_<,?\/5 *MRS8M?[)61HMRR# MF46S(HQO)'7'!SN)RJB56IR?;& X;HH\!8$,:)XNU@UG?G2U Y>EES.@++B M^4HN"'U;MB6P _.J M^79M)>, _.JW"U5A/VRIF.P!\N7L ;5.6BFIM(V)&;5L\I43RYK.$O <NWF&FSQ4+DJ],S"'2(6S O&D%@TC%|;E%2O:)&21|:%W?^[.S MB<%J#U2.3MXY24Y;MO9%(U0[I=:?P;RM7FU6.-MNP<$,+4] ^F!^739N]R6 M,QN>VL%<1#D0-]MKL-)|=@T3/ #X/"&\YBZOB+9*ESBSCV]$3G99U>&6>/&TWHNZD25M,)1 74'E%>$4 MOY!,%,&5U33R^P!H0!5X61B@=W5KC%%'WFIT7N-(()(*Z?SR^6B91 3^"4F%4(>K]"SM\7A M99B?G:)WUR;Z"A9VT7^OE ;,M5)I T-N _4U6P2Q.PH2:XC0B[6H.34D3F:E MXH63I-=6(8@^!IU$25:7*7^D,*1DA6=91.I[:-90X#@#EUZH*$#M%9R"3\=A2?C?(%4@,AL]\3:P>HX>|Z: M/F9-!?-SK9<;'|"'3TU6%'OR0=!N[25MLU:KKSTY%Z*UMA2,,.* YC M[49*3B4IBD)GWCMN MMZN>F)JZ:UE!K,5$QK3(B2Z+ E0!HIE-I?%5MF!70'COP)T36?3O=6!+"-2 MG- CM(P$;>\2(Q* 15X]5XFILT]BT=VP&B(KK8C8?S24#C8H?UZ|%-@=>C>AT,+:CEOUAX9:9/3TLERFW%8R\44OQ/M9#U *4K5 M]>?(E|SK-?8H/FZ%4T.=9L.Lk94V[9B=4(C>D=WF;&JZV,Y3>22T7 M>.-K/O3K=* S3>5Q.@RF\X%*,/ 2 '5MT|===>;8:6)[YEK)P6 J8KIDB M7'#'LO)BF!&%13D,+47H0ND'*VJJSPIFEA43'K08R-%C/F#%+A,F<3'59>IO? M4;!:T!>(A)C%Z MK+J5V"L,KF"%DV6N"]EX8;3:7U;Q!OA5B5>>! M.:KDMW-T.-#$S*9SC.&%)5G;]YU(T4E3;RFW2DO@:FT9CCB2)41-%OA+JA' ^3 HQ1<[.=:HGI RYJ MVLR1 ,>Y+%'}>N#&7*667*=[U.X2'OG4#MB?EN6'=W?N-96@'[?&D$:081;& MWANJ1\4%K'E3NUC#=2NV4 /I.?!---=OG5AC,>0!4.<@%7QOZ#3=D,5W5+++ MPXUEb\>K6(1~9=Z5(BO.788 8 :GU*4LE4JG*C1;E5)ZYP-&,65%!7A*Y0 M"O10":":ED*0W5AL)S'2B6 #CURHV0LSVKGSNA*[=8[V$B2CA=T*W41E-98DQ)4 %UCA-E@/0REK&49H6Q=*M0 MUGU8Z?.3\ABI9KH>=KBI.VZ5YQ@<7EA@+=#R. ATT'2MT/.8*;> XA_N.5-5C MK3S'L['#A'C-:EDOSC?,K-D>T]8C\!=E9IXP2G!,G&'!1RQ31E#M2TCQCW%LN MZ98PYB1VC59VC3S&?:2 ?CM_[>|8SCX1L8M&]3GJ%$>#?S,(V+>DK=?WH M:-*S5*@\|.0 6!D';,P[BA;?P9V$*BTFNBJUJUCD%R1-;C94FQ:9CO0A9"D|$ M+5/+\0%]1NT_0P1L3V+:#P4.)?AQT'O>^HNW-DS!=#]O? M.!AC /,#)%S^+3@VMJ7.[^' 1E8_#:GBK0-[@L9*H).80(:9E&<8OF_1 I.]*

MF/X8(]0&#I=8CPLY R'|,I"6 0=6@RTG\"=TQ_[H@A[RGL,,Q^6F$^X^SGP MH.#E;$(^R W$E.%S8U2>:=,IKGHGV)V?C/F>]5OO5REX+Z:?P ,NZZE;]+I_M%\QG9C#C);QEPZ2,WJ2S"A;]{8 >[K/W?8QVCZ.(Z,^G'UZ?)O^`I96?+RZ= M+L\0!+Y;/S3DP=9N>]$!GE0O.SG:855"]$CVN], M-ODP]/L.U$P8W.*|D%,25[\$!{\PX]85133M#[?,3[SO?>8.-?^==I@?B;" MXD=.,%OZG%)'LM\T2&?!:=-ZZY,7IQ\|^ #C,,? [R<<3& D"::?T Z<#;(E# M _\E+"H\O75&O_C/__SX8U23 +_]+I+#3W*.(W"E\9K$!FYQU!!V:'BF"Z(MHU[GAEF:EGQ3ZO1,IJG-'&%=9=6 TF8 M17;"CE'$[*-A^?P/=E^M2K.LHB,Z,6Y5.G<@>MC\WW[,"K#0)>3KXCS[6DI*; M]2!#@=->]@66&RPCJP[IZ_8)@!A@S6OJ8L/NM1:5L"6[^7T87*(ZH6'4F1\T M9=HZ+-<-F96-6T=D,$U"7#)2Z)T)EBUR[E-EU1HP51&)=B=VU(28A MH_H<* BVR>&>BX=A=85\|USA 0M; RSRT#V,QAI5&E1K+@ 'MQ.8F_\5SN1;G#@11#R:.+ZX=[-*A8/=T#G^*#(!;UOSX7(.LKZ^$,0A\Z0OT>H!*_ 2+ MGH7|BV3]'@XM >.1!#&-]|@DK]QJX=)2$&|=5I;-<@*B$S T+7*ABQ3$L*V@ M')T*;G+-26;1!>GA'XF&0[.,|ZK,2IJKO9+7^^4B5(6 '314!!<]RG2 ;PFV MN6U(P*]3F>`Y3]592X)"+_!T\M(25&O=[:0A98I%6*K&6&AN;6R+(+4"1 ME9%ZN1((X863AN6%Y&0)>]_F!3 ^PS-**I32?\0$_ Y#__D/B8",@s9Vj$+5O MIMC+AP&G+S%615%€-Ä€*X6L';X-JO*:-MN6LV:VH!6$\CUW;MP#)K/0)H-USD)VU%PA Q'8H'1;MT|).CZ2UDKLIC@U#(MNE33:/;[_#2J?W((%3X'M@TOQM5X_)E2%P9G&>;0/']SX7(6 3\$'A[5# M9RB]1;3G4L:T@N:MO9G\W+GDK6SQ0!]D27[%12|U!DO|] E@K5I(A)6>G82@QP46F]IQ M&E0+5 "\"K2Q4+<2N8:*:3)MD9Q_38\LI*N3V%[<,\n+RZB"M=1=6VMK!>23 M|N6MF@A?54W+@-0.[M!R)8#QYXS71M7U5? 0#M\S=]_8\U)%9P''!8Q_ V%$< M=_ #AI;K]"X+!AR!0KHI%H9KS'V%#VZ)SJT(U_ X F|MT])\T73 RG+|F'),X M+K |ZK.N.;/E/T=Y=N.HA\Z;4K&=3K8@4B@4.)4DL ^0CDM*Q#" \(6=.^MFVL MD8FD-ZB.&K'@HI]|[^Y HQFAZ4[^%ZRX&U(B8|65UBO3,%$Y(+N=$. MY:=S-0]UR(T'B>]KUI4R3586*)09EYCJ08EA22E ;#A*.,F:UR,%YJ$:|&,&2E00C#'W,*QB0K(/%6%&,A^1ZTBF("+7W9'+H*)>BHRDK*"$ M\Y2#N,LRDG/O4UMP1FK4S26W5CSO6R!DI=CK+N,SI*(\=8DW6=S#@M2Y*7V N1 MYH)(55*B-)6>&\:RPFUR#$!%GO/"DL)0K%K"U(*R8@N:))D9:C75#\,Q1+|_ M .9(Y-N'Y+C\ZE3CSJN93:876&US MNP;#R">>]:$:^<1:N7GMC?"9(Z6A'L,0.E+:W!!9V-0966KAMMQ^BDG%7.&) M8R(EO-2&E#@D%P3C+A>3*E[E2&#[!)@4?Q=&<Y!]W[1 M0"M-"F'K"P+1)W=]D)9[U@FC20BM8!ZAXA5 [H#TMH2+ ^6>Y:4K[!HSEFM]ST;|X>)S\)E1K9?=& M.'VNQ5,GG1$O1KOBGBQI|.AHM0)D#!9Z@SA!1;1:!=48QNNIH"8KE6>;|FD M G1|5A!N:4YXFC(B#|L2E|$CCC)!5":QIW,I72||Y&RK8+=(*57,*>*M MQS UYXDR.B.IU#EC6M/"9 ,#.N@DX_L:XHOT/D+7DAQYA*Z[0Y?FGBEM+2ER M6F(.04E*8241IF!E 4*0B=M19)H)3\7&A#,/)T5E1%NC22],*3*5IU+9AXN M6H@1ND:S[(%"#YK0K7QYLB0-Z\#=[746A\CK6.+RJ8YK_"|R,+&8TOH_'E MJW3SXI9%I[\Q<<1R9ADFNO&%TQ H/ANBR<*3(=)9J1KFS^2$D|M,5.KP>@ /\ M/G/X"W"ZTP%&[.6"ATHQ22=E^9UE|R.U -RLN,"-:MR-*#VB](C2]X#2VK$R MHT5.M &5@^>E!;PV%E%:LTR5IDCE(92(/T-I.1$\'4'ZVT%ZM-/?|1Q>4QU[MY(R'/73LA.&IL|42"VP_(&|\F+)+-UF,I\|F=I,UEQKL7@|Z1\D"BP+EPW-@ M45O3FIHL*[8C'0 J#GCG#JA09/F\|JH-2GE\5N01+T>\|'/RFR+#&3>IRR5A MTA2$>XY1-%E)+-7'}M(KQ:8B:PI@S&@<7K0)9] 9_ '$\'(HU,/OV%_DWWAHNT8900BU/%&D[E7(&I|*3<'U+W3Q3)Q23A7CZ;=:1X=/3F M#,N92#E)79D1+1#)=,W"]M"V-"F'K"P+1)W=]D)9[U@FC20BM8!ZAXA5 MMN1(_/IW&$+T<5YDSB 89[\W#"W&Z],!GUQ9U<3'/$#KN+1G9=,2EH]:P!F M)2C13..DS+*<,&)-X5,F,['E)6,8)2UE1@I5];,0A(-*RW:=|D8SXHTXULU MD>\#G_=7T'B(\ )P[YX>,3YS3KDLN"&Y=|&;>:;)5GE&I/5>%=)#VFO74%PF0 M!5(I0&A@!2] @C*XIW!$, <4]ZD5V0/0S097U-UQ>,XG.VCL\GR;$53: M8!MHD-#A?4 @% .!'$[M1UEO|6I)YM4BNL#0|#&9@\3F-]S|/S7IG^H/V,DU% M5M@,Y0UO.!F&9>B9:O?^D3: ^[Y#*8X]B.|!LA\AOU+A\ _\RNX6=?3 M/T]@<@T!CC_U8XO&L<'1\?5H?#3':SP|W^/TC U.GTR#4UBJAW>X?|/B=IH1 MJM!NWGR/1)SC<+H _=*S&@Y/%V" [P3]9+E3HE"YT13F.,14 X2 M1(@)POYRC.4' [?/ JP1=%8* .GRM"12,$)46 MDDBC7'ZB$UH>G^+ 1VA\- MMB^8]AUQV^?"UZ3+&9;&RHFANO?$O"I*9Y$0)(QVE5):%G0H\0RF%=^ [ONFC MH?:1&'RG0 - V:]H+ERS4'\FENL+@D"<)*R/S&)G\O=20'S=|/-KC+C_XT=[: M*%GZ3#NB"UX0[A0#D5 7I"P=D[04C.FM"- ,:F$T_]3]<\UMDK8.@OZU.=CMAOBN69D4F1<@99F&9%*"B+2S F3E:E2 MZ0%GC'GPH)G-SY(9ME?=80W> ^>,.I >K(-D>V>9L4\-P:[6Q)F*&"<$,S(K42 M),L*E16,<>]W^G3?)H[B??="0__CWH!R6 Z:37@V=C%\ F0^@MESV.7#ZP L M9UJR J1X7A(NO"(* (S03*3:*VDSOM6WY#8ZP+V &9]DHZ-K- H?1"&83> Q/VU-X6*[!)FDV- #G.2L"RG2,2RZS,'/\J^2>)YZZ.AF!G5S4:L2*E=9 =K(I5&KQXG>0 MD+'+X-AE\-8A%]5P=)=TX2E1M,Q4LS"411*'7W++QPH-OTM_<3Z= M\)>KP_O>+Y8/%:TX^:/O"IX!$W_QC9*(U2.4/E)K-JT+TM-.,VSP'[O4"DG^?>V9J\|!SMW79%KHLJ2$9Y2G3]4Y(51<;@%\.W<|!O$S2]W4/@P/'2;)*5W]E M L2Z^XWX.>+GB)|W#;93'N1|G1+'%"><2HS83@UA5MK2T8(K>9 X|>^.GW0B MY;T:01X]?GY#=]2=G]*MQV$0V7CWM:`'Z(AKAY [:]|@H2RI5+@C+,2%"Y9R4 M-#.$2BY5D1DX, ^HP#1?UXO6T;.,]6=8WZ7&T?^>H?)B.IL /2! ?8VW?5PB7Y M28(K)XWJBXZZI5.\%) |<@IJYM3L78' D^CO]P#6!RNIG:]:IO)LEI M;1;+>MDD]WRV!.323Y.WG'}$@,H<':HDI48N{F M[&X3DB_3Q7DRW*:?U?SW!+CTZ64]G26,=DW@8E_CV}X.OOX R|E+6+'>6N3^ M5W!;*,P?STU=K<_@RG%C <]$SN'2B;0EE"L[PH:<&G]3'V*Q=I^KV6A< MX/Z]A=LL]?$,V%(RF@-06&(XUNT0U!#EA29YSK.B$K)*5&Z^NP2-PUO-$@XKO6V/OTXO;@$4/GX_LV' MI*]33ZZ^B'^|4 UP=X /6*Z+)1%@=.O\=!|!U^ P M|-%K&*4XJ^1 A^C$2FW ($WMD"|% B M0@I>& CP$L-WYK!.V% <5,SLCC#7.+)'EP^#.0]T";Q#S;%99+P/A]SL3 M; M;=81LO^^-PX. #P&_6$U3^Q* CXLO?I7U;`?2)&\]O" .YY3,>#2CBM?-I.5N$ M>6U,I#!]*R:5(@>$ T (?SO.%YPD!$Q:B7%USMOH']=T)LSZE1;)S>$<6'TP). MN,OT2K07!7>EREFZI4T9X-*!|:TK-ZA [LT4D64*VA16V4ESS?(RO0GW'IZS MU\L:|A,.V:2RASI[#@/&-)33R*1@"\O0>L(K'MZ<0%+!]_"P0.)%7LKQU.0 MR*Y&GMPUD]VDVX=DM|`^5WZ+V@ ^C7[OJNXSDU3VP/J=,C_X+75Y:+KF/YIZ"$WM'0^2T&OLB 0&0=,65= M:C#%6I 50BI7|+0008DW6B>%JF-.,JOI@NYZ+FATE<51S1Y XCHXV0+,*IX;" ME\'ZD+01H0>]/!"&NQL.!2Y 5]M1UEO|6I)YM4BNL#0|#&9@\3F-]S|/S7IG^H/V,DU% M5M@,Y0UO.!F&9>B9:O?^D3: ^[Y#*8X]B.|!LA\AOU+A\ _\RNX6=?3 M/T]@<@T!CC_U8XO&L<'1\?5H?#3':SP|W^/TC U.GTR#4UBJAW>X?|/B=IH1 MJM!NWGR/1)SC<+H _=*S&@Y/%V" [P3]9+E3HE"YT13F.,14 X2 M1(@)POYRC.4' [?/ JP1=%8* .GRM"12,$)46 MDDBC7'ZB$UH>G^+ 1VA\- MMB^8]AUQV^?"UZ3+&9;&RHFANO?$O"I*9Y$0)(QVE5):%G0H\0RF%=^ [ONFC MH?:1&'RG0 - V:]H+ERS4'\FENL+@D"<)*R/S&)G\O=20'S=|/-KC+C_XT=[: M*%GZ3#NB"UX0[A0#D5 7I"P=D[04C.FM"- ,:F$T_]3]<\UMDK8.@OZU.=CMAOBN69D4F1<@99F&9%*"B+2S F3E:E2 MZ0%GC'GPH)G-SY(9ME?=80W> ^>,.I >K(-D>V>9L4\-P:[6Q)F*&"<$,S(K42 M),L*E16,<>]W^G3?)H[B??="0__CWH!R6 Z:37@V=C%\ F0^@MESV.7#ZP L M9UJR J1X7A(NO"(* (S03*3:*VDSOM6WY#8ZP+V &9]DHZ-K- H?1"&83> Q/VU-X6*[!)FDV- #G.2L"RG2,2RZS,'/\J^2>)YZZ.AF!G5S4:L2*E=9 =K(I5&KQXG>0 MD+'+X-AE\-8A%]5P?=)=TX2E1M,Q4LS"411*'7W++QPH-OTM_<3Z= M\)>KP_O>+Y8/%:TX^:/O"IX!$W_QC9*(U2.4/E)K-JT+TM-.,VSP'[O4"DG^?>V9J\|!SMW79%KHLJ2$9Y2G3]4Y(51<;@%\.W<|!O$S2]W4/@P/'2;)*5W]E M L2Z^XWX.>+GB)|W#;93'N1|G1+'%"><2HS83@UA5MK2T8(K>9 X|>^.GW0B MY;T:01X]?GY#=]2=G]*MQV$0V7CWM:`'Z(AKAY [:]|@H2RI5+@C+,2%"Y9R4 M-#.$2BY5D1DX, ^HP#1?UXO6T;.,]6=8WZ7&T?^>H?)B.IL /2! ?8VW?5PB7Y M28(K)XWJBXZZI5.\%) |<@IJYM3L78' D^CO]P#6!RNIG:]:IO)LEI M;1;+>MDD]WRV!.323Y.WG'}$@,H<':HDI48N{F M[&X3DB_3Q7DRW*:?U?SW!+CTZ64]G26,=DW@8E_CV}X.OOX R|E+6+'>6N3^ M5W!;*,P?STU=K<_@RG%C <]$SN'2B;0EE"L[PH:<&G]3'V*Q=I^KV6A< MX/Z]A=LL]?$,V%(RF@-06&(XUNT0U!#EA29YSK.B$K)*5&Z^NP2-PUO-$@XKO6V/OTXO;@$4/GX_LV' MI*]33ZZ^B'^|4 UP=X /6*Z+)1%@=.O\=!|!U^ P M|-%K&*4XJ^1 A^C$2FW ($WMD"|% B M0@I>& CP$L-WYK!.V% <5,SLCC#7.+)'EP^#.0]T";Q#S;%99+P/A]SL3 M; M;=81LO^^-PX. #P&_6$U3^Q* CXLO?I7U;`?2)&\]O" .YY3,>#2CBM?-I.5N$ M>6U,I#!]*R:5(@>$ T (?SO.%YPD!$Q:B7%USMOH']=T)LSZE1;)S>$<6'TP). MN,OT2K07!7>EREFZI4T9X-*!|:TK-ZA [LT4D64*VA16V4ESS?(RO0GW'IZS MU\L:|A,.V:2RASI[#@/&-)33R*1@"\O0>L(K'MZ<0%+!]_"P0.)%7LKQU.0 MR*Y&GMPUD]VDVX=DM|`^5WZ+V@ ^C7[OJNXSDU3VP/J=,C_X+75Y:+KF/YIZ"$WM'0^2T&OLB 0&0=,65= M:C#%6I 50BI7|+0008DW6B>%JF-.,JOI@NYZ+FATE<51S1Y XCHXV0+,*IX;" ME\'ZD+01H0>]/!"&NQL.!2Y 5]M1UEO|6I)YM4BNL#0|#&9@\3F-]S|/S7IG^H/V,DU% M5M@,Y0UO.!F&9>B9:O?^D3: ^[Y#*8X]B.|!LA\AOU+A\ _\RNX6=?3 M/T]@<@T!CC_U8XO&L<'1\?5H?#3':SP|W^/TC U.GTR#4UBJAW>X?|/B=IH1 MJM!NWGR/1)SC<+H _=*S&@Y/%V" [P3]9+E3HE"YT13F.,14 X2 M1(@)POYRC.4' [?/ JP1=%8* .GRM"12,$)46 MDDBC7'ZB$UH>G^+ 1VA\- MMB^8]AUQV^?"UZ3+&9;&RHFANO?$O"I*9Y$0)(QVE5):%G0H\0RF%=^ [ONFC MH?:1&'RG0 - V:]H+ERS4'\FENL+@D"<)*R/S&)G\O=20'S=|/-KC+C_XT=[: M*%GZ3#NB"UX0[A0#D5 7I"P=D[04C.FM"- ,:F$T_]3]<\UMDK8.@OZU.=CMAOBN69D4F1<@99F&9%*"B+2S F3E:E2 MZ0%GC'GPH)G-SY(9ME?=80W> ^>,.I >K(-D>V>9L4\-P:[6Q)F*&"<$,S(K42 M),L*E16,<>]W^G3?)H[B??="0__CWH!R6 Z:37@V=C%\ F0^@MESV.7#ZP L M9UJR J1X7A(NO"(* (S03*3:*VDSOM6WY#8ZP+V &9]DHZ-K- H?1"&83> Q/VU-X6*[!)FDV- #G.2L"RG2,2RZS,'/\J^2>)YZZ.AF!G5S4:L2*E=9 =K(I5&KQXG>0 MD+'+X-AE\-8A%]5P?=)=TX2E1M,Q4LS"411*'7W++QPH-OTM_<3Z= M\)>KP_O>+Y8/%:TX^:/O"IX!$W_QC9*(U2.4/E)K-JT+TM-.,VSP'[O4"DG^?>V9J\|!SMW79%KHLJ2$9Y2G3]4Y(51<;@%\.W<|!O$S2]W4/@P/'2;)*5W]E M L2Z^XWX.>+GB)|W#;93'N1|G1+'%">&

M,)S0:..3)6Z^%D^\;9YXF]=R.&PW@/GMVR:Z2D8KT<\UU_H-=+!T)@S!],6> M6S<]C9+UHV$#ET<355OI@5A0> _')PT87HTH6+ ^$K 2%"?P(.5@%M6-7EWG M;6^B@:IZL]SW4I\1AW;;>:Z!*QOF,15GM;P'EXT3:=$ M/ZL^C4BZ'&N?9$\[!%K":EADO(*>]B4/[HC:&Y Y+9@\'^24;A^7KMU\ .:S/0 M88C42^DSQ/JP9H[O)8NTUT@>VKM>10%Y^61=@NQ:+8L.FK4DT[!T1E65W.6%/ MOIS_W'A4&U_I]*VYE2RNZ8A-R1FRP*[I-K4&I L@&FO:AR2#E04318XJ<#.*, MC)2+BA6@R3E>5BW:,L6M#{$)*>,)B7'UA3G9+4BB(YRKD3XC+<5ZY[C.1 U 6VQ* M-3H`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|-VFRV'9$$6T["SHC=.EXGK;-}B?XP M92W#6QR&(=.<9+(Q$%<^<3Z[C-&)&2=6V4, V2BTMB2 E"R %= YROC?8 $ 'PA5V M ^0E9*H%+71]/[L'+'WL.EXLFV+Z4B>Q'I'"S)F.[XOT^GF.GXA>80%'-A;7 MJ2@8%S9Q:],O,XY>6U]/(LMV, |:LG&>)OE>>+=>++L27]VDWS68,&%.4D0V MX2G;](G?I.AM/SAY?P.\]#%Z],; GF=Y45QRJNKEPW0=!']=PAM8 ^0+O6Z MJ2==*8G0-5INU/5!PUX*]"PE46?PMEDHO;;]DMXVPSV(;O):*4MM<3FY4L;"=!/OUT2ZAR=[" 1==/9N&@&@VE7*V$)A1LA/D M%7R<8P2UR'}+K*A6'+=32S/1/7..*(5(\X>=<,8 ^/ *X75>M.!3/H"HTMT0!Q MW#%'L59B#0MNO0UQTOF=!@=,KFQ(T M; Y PA5=914:(;#GJCFT;//=/SNEK#=^Y!9B*S?25@7$U:-#/SZ6CN:+!UE$S MU[7UXV&"AU9G.%.L:4B6<1X!X"[R/!(-S*@KLZRH$0E -$R[H)9F2=;U B-E M5[Z3FH,*K:.=1=P.F<9.E7+,WKP:]9NFMEIXKYDB<1NG 9\7!) (5/1D]A,LAI'# M*X8- ^8#4]F1>}$TA+NGGP-" CPVLTO.4%/P"R>XUJZB=\&CLS.,$ZG"PT#.] M 1E+T#__ /K\ :LOP"HLK>FV;Z]WMA(CV)CG*K)O0AH#!7*-E3PVI,&Q>\NU(_B{FC]383: <9GSS4 [0]DKY.=5 M+O03$F IKZ|KW:9/MP-H6RXV6-NI VUT8OKK70K9?A$6'](NRYNTL!MKLK*NO M;WQG_9>B9B5]/0XO8HZ!W%+XN4(V%^1<(@=7=`V"!9^,"4-I"P6F/ OEM]SR M\,\)'S6Y1K4G'/ !ATZT0F(RWU4X5Y\6ZC/LNX=;N/37+],C\CO/^`S\A.90 M+2*CE$<$ILD-%FC(`MS +H!XD):1YR6MKEMT,,U:F#;MU@-J9!VM=.L+BD?X M(LM#EW%,EJ[@3?)=)?*^65M!W32&R^4OZ+# ^Z=IR47+LBFIODS;9QM*W & M N4>*5>IP&1R[@MSOCV(-%-?VQS))B)8Y0/O FXEF.]*2#0Z^]#%O; *D.U* 6 M4> .5S]-BJ*X(U>Q#D.C". @L?3F[87M4?&;TX)F3W+$8E*N]QHK(E]$3E M POTRBLVX%XN= _XXIC14%5;$PL<#63%*FD8B5 .0HHB"HJ MPT&2]W3:QNB27M0K7F0B2(AY34G?42%G)FKU'+1 ;FMP0R\;-6-RL&A'",ZU MH=W^!D?KOQ;7Y)L98=L]CCG)O/Y#08 @DMUO>+J[C>@@80 MW&@?
>/)'HOT#Z)`2X% GXY'VOA*5W2C4XYV5#0[*^1FX36K<3:43%6O2$VM M,9]KQJ^C7D%<9NV3@^-X2W76.:&>$;5,H93C2\1QV6]E/$!MW@IU,<69 M7#D8X^5,Q+&#FP$ ^AGF)2B*UID:SDLNI!P('VO?-*4" RVG=XO>=F4] O8#(!<=5T6YX> LY*?$*$14-FH?CO[06_4P)1X> M3D)IV>[(^H84 ;@?U 1@Z_AU'73%O :=+_G&H[.V5W5L - \0%Z'>L<:F8QG=_OZRACK?3LJG/-.KGN<1>SPQ["=XU?_^L2H625D:%^CA M"ECX)S9#RR)=2LF8_K=:2O8RZH69@W!B4P0469+Q&K:L8ZPKF[3]_[^A|&"%5 MM.%AG_9P&PNF'OU<-$_^=MW[G>W!/U;AMOO!OT\4)!:8VZMO^W_A#!;:T+ ML>!<C^P _7Y;;$>O1HZRH+;/6'7, '2Y!8Z'(U[+R"IZ$? 1S^/HATIOP#Y :T;1 MR@8(M4<2_&YL?*ZRW29NGI#MG=K+$2R_:[_$ _?+M9ODMQQ2FC6VD-3$2)H[' [/ MB!)KQ?.6[WT30*SD!T)&@H6;Y%<''/D>G?: =M!GCL\,4^*/MLC'L4M%+/K?8#'WNC&PIMK%'QWTV"7#P5*YI MX^W1^-Y2[P^W>6G@7|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|'"WD$|MO3D6EOK[GZ#BY= MM4U7|'N\|#LQ1X9WT*V0%? TJ^CU> ^CTQS=`4N3,'\/O74TB.*0[59,(-IY$ M8-GC@:]:?$&*0)'O0=^1$\3],6.@>2>>\]BWKC1I<4>_M%'MX&'NPW>UE+2KVH-B#8@\OSUAX4\4:%&LX$&-1N04VO6MC;!WR13|K2H9] MCB# ^36O6*KXX7;$GS6V4/Y%>1VD?)?*TO-GIVX"B(-GL!-KY)C&\"/TIX4 MMU#N,G,E3.6$4MU#'<0G&+%\0M3DQK9#A'P"Y4ZH:RT1ROCT8W_;.M MHE'D]\2 *$OL+N=O3<`2;3O6/V2.OKZP$Q2X4NW@\NYB, ^>$+L0K$+Q2Y> Ms+LX<4;&9'NIXGO++91J0[[W5#>CB68(VW5_"UM1]I:^(',N "I&/[?;IM4D6 MP?.GSGABVS^",$]NM#!E9?FW[^;L@NM9'O%F33@H? BS/^6\" M\+=3W3Z+4 Y-CY*'AU62 _?(TWJ6G45).4 9S2E^>C9G491D%[T$R418NVXPON?LD2Y,,ME&QHCIE=96>?#3| N(H_TT6+M"\6 MP^%.67K-,L]S[WYL44*NW-PBL3ZZL1X6+-WF=B_MZ76(IV!+W?WL!3M^'CS] M>LFU.$ 3_!IN6B.)(.]Z7Q:GE=:!5FVVG%FH%$&I<,2@^7,27 ,: V0[.G.1>:2O' 02'&P=?RZ#CPY MKX&W)M)E>*9>91K6V/BA>0^0)&7SDI^6?,X*@\]# U+8Q-K?++:;97B5E$B1I M4MVC<L^ORA^EUUG6V%'Z',#>4[!#GY<|YCY+(^X8W=?MZ9.,S:]?=W; Q|Q MQI.7=)R7AFLOZS1[N[4'$8[]!. ^YI7K"0[5X8I7(W[2BXDY?3*-DK%"1_2WI M.;MMFB?PL]W'U;*MPSW;U%GWCJFS]RJHW-FM/\1[L=X.*#C'7.I#OEZ7V,ZCH MD?:%SRL ^WBAV<;H8>BR2:GE(D/12T8^BG\)21CV58-MC*&OQ[9T*LHI6C%*R* M>M9" [F.2*>&C"$H1E!)\.T*H/3(H'[K+YBFURW&WBYDF2:=5E7I:FF)12"135W%LE4%2C]$91S7VHYGLMO&39O9VCGO3E*.I1 ME#-(?E64HRA'48ZR;O35**11]LV>(9*B&D4URKY1E*,H1]DW^QA>:X:1;S^\ MMI?!LW40_?D;W$G&4FV>S#F6@]TLOCE|& X>28#LL(^ICG:(1U/(J8ZVMT=3 MR*F.MK=`VQ@Y- ^V\[JV#KVR!L@O#\@A,>R0H?-C'5$<[Q*,IY%'1V!NC*>14 M1]O:HRG-],6?]L%5(!MZI/L-D*BUT0/=_;[!]$Z_86-L^>AK4>XM=__^O'] ML_[ZTV_OWBQVMGN:+J>'PF-6+/F_UI?/=^O/T29X+OC,8QI@6R/#GASPE> ^X ML:FB746[ND=M2HHQTZ<>4:UH5]&NHMTG&4_H3YYZ67<|<38RG'M&C M:%?1KJ+=)5!W9%C;&] [[I>N3)\# ^=&E>&)[[>%K6>.73[[W3L: [=Y&8BKX_M/(K^Z>MK%7L_+-I23'3#F .GAKIF1:^[/IVBUTW#['"-#.1L4Q>[^M(IB- 8Q MCSSDE6N1@4[1X[]>]3R?B0\U%;%V1]&2KC>R#&7:*HK=^6D5Q6Y,L1-+ M4:RBV)V?5E'LIJ:M?= $]PQ;1;E'2KFZ,[ZS!? @>W _SALY5X?]#, RG\|[O MSA7K/!B24]QSPYV1[9SR/4VRDQ1%'M<#NUP]E*+2?Z)6XZ-4QE7Q5[+KS MTRIZW91>G;% ,P/>L@N2*9%%&Q6:M:D9,>]9'Y$& M!KNE7&POGV*5P?ZB"(Z/F? F+)@7%T 8+EQ^C;KJCB:/<@*5(EE%LD=&LB!EK4-N#*1(5MF(RD9\KJ"N*B%^$/Z]2:!4/ M+S-8Z"+A*JRKI,Q^%)4Z(]=5B1B*8G=^6D6QG&|[T MB36:3]9R*IV98IVCY1VL0_W(:=DI]Q:C1;I'2KE.R)FH>+2VBV)V25E'LYL$M MRSUD::M(5I'L<9'LB6F.?/.0O:PR:A?O'BGOZIYUK.;M@\NC5\%WT_#Z?L+M M?N7.WP#-,Y9[\Y15<5[,M(A?\32?S ^!SC7^:,)ZSDY>E=2+4OD'CBE)V7>$QU MM$,\FD)=.;2]/9I"3G6TO3W:OLBY%]; LUWJ<9WV2%#WXL(^!CG:(1U/(J8ZV MMT=3R*F.MK=4'QAZ'K?V+[PH\KSC]5;PE%4\:EW9*NYW.,$@%?2; M*9->`?IO@`^*9'=_6D6RFY.LXRF2522[\],IDMWPIBU'#7[5]+KSTRIZW53$ MJEF2BG#WZ+2*<#>]: <<>6::C:E]1[*Y]TAV4YU1I9QR*GGBF05R1X7R=HC MPSID!5E1K*+8XZ)8:WS(C8)W4=REHN;W0K'W+$S2I$K@]2R+-/Y7GOSKP'17 M22'Y[8!XO&BW.IL*ZW,TR32FHMZP7SWI[,?.F B^1#F38+QE= M%&=0G.'%< 9KY/G:L[(49U"<07&&E\$93LR1;7HOG#6H9CS*6W.DWAK=|<:' MW'-==)2 H:|$^\,=M:.IL3UW[7Y*=Z7X*\Z@.,.]-8_ >ZS^@^?N>K#7W. 1&/,UKQAV."@Y*)+RLE8 MU9UWI&6\4AQS*W+2&ELH**.\#E*^0ZUJ,VK[_LG4]]5P.'06;$]YA8K2VX% MF;*^"%*=0G.)0.<7$'!G>4T5G%:=0G$)QBA?"*7!BTM39WL2D?645RG.C/#?' MZKFQ[/$AUZ.K5 XE[I6XWU*I!U@&MO=4|=O]$?? *,E"U0KK+*!**R6BRO5?1 MBE4H5]%8Q8MD%2?.R+1?OKM1^1"4# ^%H?0CC[='WOE+NK=D?[]#'!D0_KM@] M-]7'P55SY-*GAIN!8D_ZEI?R[X X35]DO6CFD?2@- M@=0%O%*,)|:]P^*>#@4^Z2@[NSF? 1X/ME4E:-O$C@%*^<EL?PJ9Q4#>O7 M,0NKNDBR" AN694C#==YWE5SEW>)E54=-(Y,P33(D(]TJ$I:6VIP7..]:1UIP M@R^K"EBN>S0O+EB6)M5">QCU#V-2Q7]HDY9E1?T8%FG%#E!&L.FR@6;K[]] W0(@ D>45+!C6!9Y'K.RLV!:@ M3=[1+9WS]Z+7: ^6E+1*L10E2-4O3FQ>IY"WV^T6 M+T,0]F!S#.DF3:?'QQWU5[M(A?\32?S ^!SC7^:,)ZSDY>E=2+4OD'CBE)V7>$QU MM$,\FD)=.;2]/9I"3G6TO3W:OLBY%]; LUWJ<9WV2%#WXL(^!CG:(1U/(J8ZV MMT=3R*F.MK=4'AYKIBS^N*O

*S^E,;2;"KYG|^<@&T.IS=N^2213#'$R.]'C_1<'3KC?$|@C(J2TD-M!SXH9Y1C!^:9#AJO20M>1NH|8-Y'R_@>&+|2@>5O/7(%]B1YL{EB>[F(;S]·M,@PNV(8R"+|"WO,41T?PFN949W"K+0\<3(EYS,<6"OE72!/F:SQB)0,G:\N M%&%^=,O8B$@0VODD%0A52.G.V|^R]<0E"]2.?!)P/X_6D&7H'53 2C/%<{[G4*T ZCMM MA7$9ZO0L1AB=AUIE8,3(LQ]=.&H.":K!6[^^AI-VX6(S4I$=6'.>L^;(UA# M7IV!Z10+,LRW Y:SC2 #68R6'$(%@$(=#076XGS!ZTM<?A,0H1DV.EIP.Y><~MK+M7G<\@^!*1SU9Y[NDR4%,/QSUXOR5738E#OU]}*G6CBXDRD&CK7N7FNEMW[V?X:BD);*IY7)%)6!fZ^4*D2)-*$(K]VA$T:++|$;T+3 G#'US!L6O5Et:7P/K+4@Y7N<)XD)Y="< YX54MW2C1A@0!0>O8+R5:O.#<~MS)V;]=@!S7._/#^B9{E7Q[@<]@%P\R-9LR;SQ00/-EF(K8 #EX$%8=_FP#MQ M@@IKF=8/5'3D!*FN(-$7#M6N|>8$\?YPDX;ES8/?V.+M7Q\^#+!',"&\]3<3. MJ4L_"J,U\4L)"V>1%P?6=Y/#15$7B.O;#[.[^?VE?6_#/5X2,".&Z5"D8.ES M*·A:1PHV(0$=H_.[M6#K[Y_:I9&I"$4,>:.F!Q.U5[XA^24W0 MV;,4,-_BOO"7RW497<=#1RNCI0]IGW;-VM,6U1H&?Y(:.^7#]"-BJ4"EPH,V8 M.Z+6DA@"*1A7S,G.K@)Q]*N8\%Y1H6GGM:*^!&$D M*4!S(#]F+&]M_8(!#@ 'LV<<>TM\fX'N(+>=9)ZE2>!Q0%WV6A_B+%,7,4*2 M$Q*\1ATF01JW$\)3Y.3+K6ADY9,?UVM2B-NMYJN9_?G5P.R18'0Z.'F5 MHTFOYD&XK4P+ZA&[1#-VC]HGPY8'U6EO5!4J#G?<3LA=>2 MR\'|U5GG_@@^QX)46>,T,"EY9D)K$<{CDXQ?RXM-#)7=4)@0NBT4$!<`@ M/W[5IU.//W150KR 'W;'Q]+-&HO?]{<8RC&2X;B\9B*(+)1,:K$'I:M:;ER2!"#Y_*,M&H3T2>LBO+Y=LFHG6@X-WU.?L>4*B>TB58&KG+<,KH&OF2I3K6)9%SHF10%!$2<5*.K3%\.2NZ(ERZD)OEH!NP9 /&$[%@Q(T#@?I,!? $Q/C;AM6W+ M3'?%E3Q0P;3 +U'GT%3%K>Q#^\ZR];VI(6F?US6;^>Q(3(;C 39A%NB5MS$=@M%?.$GM-`/%)EK@=]WG;J8Z*TK:I8#\|C':E8E(B]]_9AIVF,;M*I)X\V^^\V,Y%,??_RK(2,NFN0) *@<RL2LM.W3*!8#>2N8+BG9L-2B\5FK.H8Y)21(#T5D>BBN74cS/B4-(M2#Q0O-6K=<>3+]+K.H\'+2IU8BRX?YPS08I+1=DK!\Y.6>RJ4C^"WX+2X!0/-*WS'90+7 ,202QW01ZCD23DU?CX 579.W73BL28D0ZJ$Y5.-@' M'"UC;[."-GA3@.=VB0Z3W2|;=TW-'K%A=2P"W24%MFF(XG29.]/'&|5Q"$ MCB6#R#P7=F29.A9E5&>"\7HNNM M"E6%/@"Q8TSY["21.'1T'T>0YQ1/4U0R7<4(A>HG*;#HMT23464|A8A:8(X M7-*>FI'V(PX4AD'E%&WHHPU9VH'5k!#RJEW]C=*_X/3.(X,N0W>,//P?A8(0M M]/HG,<0$^X"@92OQ%7M UN2*W.2A(#3Z2/% #UE*6(LT\;$+F_L_f<\B. M8NKF>10,fX,)@eH@A(#2\?:8NNSI0]CK!B33H#-FK^6Z,? &D9H@7MXQW2/%\4F>,K9P.73^\'HL0!MIFW.@D4>>U3(5SH2C MNEQ*WYDODs[0)D2R(\X<;E AZQ]UOM0>S M_DHZ:A)0AO:[=-HY[#R<>3<1N^C>&:+00+H)Y4X,0>,]Z$!JZK[+5UMZS7A M *VS_3' F7. 2@@<'9M05IQ&BC$'G:]:LV9*.?U@[NUT _=>=1%.7NC O+Z>SU$/,-+$H;3 MDU*.IK7)%)2@9DHF/4RLD(F]9<$ISZ3C5".VB*(E3T.3X5:4[323DAH\E5?72'-A0P8,KF64=>A10H;++*EL<<'M'&K&U*)!TH#)]NB$"PP4: {,41X(06V'..B1LDDUS>;E.-WH6CJC4(R$.5++R M\!UPXK.W,:-PGA=X07QB'SW$K#1R=A0QE&>1.T-.EK!QV@<FP% ,@7F&J)^*-M"ZM423ZH M1S4@4APU9MJBQ.4-C:8(LIMD!V"?DN7ZBX9C-M? O(F1*K%A9DH,2$!6051&>T]!$C]6$/5I>5#=&'+HXR2]MQP)H6KX@IP;G8d GXU*(X%1B+I0)8A3YUD9\0.4O1P,-5VWZ^0 J6$3X63%$MG+0#CX63 ML."OPU:/LB'@VU!20'6F6C#X17#L9&<792,\3$.$H #XR#6H,$< VH3D; MY+@^Z- ZED@6@4+G\G<04#M*$!.O9+CB(*9$<*5)yO=$$+1N=E.=1:H M0\N>FAW.7#0V'<#9]X$1OT$ZUCL/5.'H&5A@)E2?CV3)$*\(.OG^8^G M.AD+YQ^W\4BOES$$*:M.8LXWI-HA< =F'_LAI>XY=`L? Y'}TP0[E\.RC/ MK2Q^L[9G0XH1%-589^OA=C5)R+H1:G"GJ=O^UM2]-Q"\I5GI#U(4!-U(Y_/T.@_ <%>4R)1LM%XLXDXLKLR>90D)<9)H MOH YXH\1!;V/HQ0/U&45?5'&KW"NK 0+@5EL- _CNU\Q9#L^.*2[.)HEN6M.7**#F;P'G;"'"A+ _,V5*EERITV7(Z\0[R8HP M)DM9Q1V#R&0_UL FCLN$UW]-0A_*?>"T@.Y|C$ CNA-WV.!L^RG{!#@(3>5/%.M,2\(\'1%?V1%6-$<(%*K$= 8M?.85";*$0WUJM^*BS)IU0/ACK&#!.ViY9Z!8 M4AGZ6?[FA3-4I]#*3%GW[28SC=YH#1*01YKI>9({$#9DI\%8,!U*18U!@?'O2-MDY}(.2ATI(IF2)\HN+ G4&R]_70&0;)_O&KD4M'.N<\[V!(P@N)\B 6QA@! M9R18(\;46"]ZF&A [RS%@%'N3)P'V'IFDMK"M!84UW@)D.OF9!?EMX!1. M/-M62-RTK* *EO;/BRU42DT"G?S--6J5E6*=R#RNSI'#DC\=.%&!$ *85<1.;L;X$ M0X&6$=>Q6-T/3'$!=24>>Y3\$ >'CIF.;Y5\|U 8WX)W3'%RKDLU M0=]Y5T\CH">U;1/D)):44:XQ-V7"{8(P#):G5=?X)0"_]%VXZY&J.%4=>E.M.8V)0[\.22I;C"-1R_IBFM.0FP"3>98FJ<F)PTI;P&Y(B*-917<8BF>)<ASGN84-Z'/;P/H=V;2$M%X.MR*UP0FV1+? 8R#ZG2M2]ET+>]]P3IT8.CS!4> ^&G$&(T47'Y.?#7.Y4#$ OT= MV.47*L4P+/[#%X|&G/PA5I10&=@Q2#D2/$]U@1=N!FMU("_KR.A,DV43),'0! M1\N^&&[ME?1:)\NAEH'GWT:DP. _'%/$ MMJ;/:%@!;M[0^"@9",3] L8$83+5(:65$R0Q2@T1OD=8

*MEU[*NJHW" ^2)&G12Z{TZET:)2EU%K/HL26(A=CG,%PQ;*T.S.:0FZL"#E M0P@_EO 56<{7F'V.O'\K/D@B"RN+F+9BA/SUP7?? M$A# ,>H@\1PQ@&TL5YM GU632D,ET>#F= ,)8NP6'U;HB$S3'4PV,J0\)7": MF'<1\7V1Q'O,@'Y#]>YL_7V/OK;'V6WDN 1Y[ODEREVK]^'H^Q@L,Y[W8,4$ D3_X^,/+0M_B'8Q<<.,U%Y]#AQ.8* M24S,>#XNWY$2]7OY*G,1)RGUE6CB'C*F>A8R&U^G#8%WAZ,7G% :V)M6(.4& M4++AS;/[T.] X8525$7G8? #N3&VMV'V[L:MF<1/7T}:25:%&X)-&RC5,HXF* M:R.*R7K16VAV:43A9-RHN(W#ATA.:O0D)1=U:*T>3M5>Q)<6UH%Y8+M/OENS M3*I%2#3233R0&Y

*AE;IO/G2L/<;)D4%P*RN_C.9X6)P M=7WY_O+B_/KRXP?V\3W[=`7YX>+RT_F_V.#WP<6_KR__\#;*#&X>H"0CA]N_MIG44V=1(WV:3RQ;[I[90CMB@53[Q:0$MEH)Q,HLR-^(N7C$$.:.4<6O?[!%"*
M>;2D=1$HR(`6"V4]P>PU4Q#2EHI/XTS!]1U3 ;:^R-$[CBQ>*K,/&];Q1(NK? MQ@FW0&]QCOGF,SIM=T_,I[_+GO7H$_2G46* W\0W_"4]HGK_&7A;LWPV>F MO?>NTV[,O>#TPS"=HZ/|E0Z?"3%LQ,? #(PE3$ @2]1EOU4X 3!RJZ (O3 M:7NO3^ZVR67/!^:s. M;M@-PON"""(5\/4V4A)XP&$/4VI5X)>!,:>RTf8]2*RX+Q8LjPPID* M4%?N/%(B)SE>&4D5RSC*=XR3.<&UC^1>M.CBDHFA%0%*1;4>Z)M;AO09)\Q6[-^0,1uO)W0:!)%:,/2
LV-MD6Z$$[0EI%YiZA?!+K7 :8ZQF6#)=-$,,PH|!X5.MIE"P#)9(&@)[W-0MI __M*(Z/S<)S663HTSGM?#O5%^"3]=0*PA;21%_=0>4N4(RHJ->=4#6>[,C1[*M^OQFI442E4(|))\$7/KAK-!&BG&Z&?1&+5L+9+&-
M,G>TW?'E.?ARN@5\N5X"UT^VYD*=&I-SUEDF\?+ OO*8NV3<@$[=*VPG8TL-$]P+PT.@6!MRT[0%0+0)H$Z YN-MTQ$OAL#.,2!<50HE.B<\ZG0(&C1Z8IP%2XE[;Z*0"_]GU'46&!=8 'ILO% MV=)
&0Y$\USE(D]0EA@_!K[J2A#:"8(,`>B<7WZ_)V>G9 M1^:? 7[U\ OX^%@V.-/3HT>1F]),+N65W;P)50)(.5KD4*2IBN#*2 O0J+Z>(124/A^>$;\CV2+T3:4V)!=2+(2(5 M:2*9BVYT*KCI3T4&)40UVL5E)PUYO5-K122
M&TD3D*&7!(&YJD)YPNX3YG?<\UB>#/GKA=AT5M<3);OKP1($!<X.XE#BDXX^EC\S39.IYN'"#NT?54+4Q-V]Y!08RI(`MC-5[@E.,1BA7AK9DQ%!N1,,6Y*_DB53232FU7#Z^Y!AQ9]?LHC#IW2!NALOU6RK/1&R(,<^&C5NB
M*W? V)M$=CZ3!M]59EN\A+"DV>]ZYP+!!]GA>D>DEDDEL 9E^#6B]BWWH_M-]9,O)DA51?$=THQ]16AE"14)"M1?JKJW#,_3Z7#?NQ*?,Q1RC!LX,[PAE2 M$F/-BERM9HJ[\W51*D6U4R75T&>3$;>SC)>BE*SKT#IE2MZ
]HND M*_*M;S#(HQ'V++,QRO3=+ ,,HU ->R4:K?FD8("UR*OYD&#^)$5F)v=/2#] MQ7$'Z+2QLS32W\#,\EPZ!(V%'<:4U1Z(B3]Y)L?(.\0U98B* ZF'6CC(.,"M2]++*WB541>K+!]V%9@7&>NVH0)SKG!/@R:72" !ZE%Y,)6
<*!3P%DE9(+6 MH)PN[%=W9_[E6F" RH2U46+4%)=$V*XP(869A%F+*]W!P*(W=M5?1H>BA*CT%?#H9Z1 "_:<UB'1XC-R3 MAP\=+++3W>,>XXNSD!+EH#9'1*$>0
M/DA)NM*Y2E2=Q"!.$'N%[L?M;$+T9+-L(S+H!(E#QTD)L0SUIQF% F##T!0^ MH(=*F$9V[6\$QO4W6@BEQ#(+3KOMT?]BV<<ZWDVASX/G;BG;;=]=/[PEBD-U\0^S:I?ZW^O'7,+3FZ'152&BFN69_UG\=5GY/^/Z,8:FRX?
O3WI MR^3MU0U3@-VQPZ?I2=#E,,H.IVPW\'#WIG4(C3'{@,XB3||?2+78|='Q MZ=*IVC7+.^%>Rs/MV8^3]\$2OTSC1P&[$QZT+I]W"U117|,OAK=UEILS>R> MTH(//M1\GPT(>]*=OU-MTYOBV@=]"2K;XM(V
MMM?.OWT?E-X98ZN-I^.O3V2O3P.LI/*(KRE>C"1D;'.+.44OO-G'\;,b6-]J 7K;AR55XLEU:,MG,VV#-0-]V/0M<6%,$0NZ[E9U,+SLM_HUD#G'A M* +CT+|AU]R\T.8R3!0D-FD^A+;+.G5 M:?[IN5EL^:/A"G?W
3@>"9_AFTIXZ)`HH;*H.\C* MOVB\)+M,F AG,,OIUBZ0Z]*IB(B[^Y?K:.?#>#U_+>>>%5.?X5A;"LFLQ8C>Z MX&4KF&CG= %9)^Y=O)7LE[$2N;.O]`DJS&@@G8ALO5.15T9$(\.KWL+8GOT. M8XUDY@9O+FV40E*4-,@_?
^-R^W^:=]E';L.],"G\PGS?&C2I-TD-47YVAJ4W\ MX[[ ]/ZA2&C2-T-4O1YX>/@,/;fTS7[=,E^:OFZ GCU^>Z V>75]3E^XM>G2T4A&,`OXCA*BBB>NW\9>E=N#?#9Z;]==;= -M;V%#E)+FS AX(9,91B)#*@6\1%KV1XT)"%&
[$90#&,Z9)?:.M%*R[' W!=.[.3>]I4UMV.Q\01-1.I;]"I&V+'LJDQWIPZ:G//416@]Y*0 M.U@#R/^$Y(1(HQNROU2(FL#5_ED6<"WC*-GDKM&+7BLF2\'+,Z=*86T)4[MCQ8"(F<(%CHSDBN4\Q2G#=(' Z'20>R!0BE18R\V81
I^)S#N3)\6YS(H@R55 MA2N:#2;=M#2*<0=#(!ST7[F[B?"2.,3F@"A,0*B2)HP4,2#3!! M6AQ4*TC]-NQ29YCF5,$0NZ[E9U,+SLM_HUD#G'A M* +CT+|AU]R\T.8R3!0D-FD^A+;+.G5 M:?[IN5EL^:/A"G?W

MNAV7=^(EV+7+!)?2F92/!5)A5$UBHB.%3/@@@3QI&;S47I&A>H\6 GW2W%]7 M]C:->XH&Q[.2]$/0^{RM")RR<7,I4Z'Y=NM#5S$%V1+B2S9@22P#&[?L(/K M3Y+]8Q>QAOE]0=8QS/%V(;]9:?>%4)-$3?*

*014$EG"WHEQ9W"+V-TUUZ FGK M,GW1F%*]V-14#] .:<*7^:(N<#E; =[(81)T4UC&8!UZ2/-7]_6#]NTS!+,Z8T M^!EI.3,]\SL)B3]VP^(R:NG^T5:+CD" P"2K\;+TT8(,>Y-_T"P5%07C;K8O YUZDK<%+>B^.[N0GPV'N7^0"L$?%;!=P:9_E:\L%3(C(21*5L4HT X'OA,N%/E[UD 98X M:]+=_)=%0E:MVCGS*F-@IDWF""?$%H9B^%0MD78/29M,>/A/8T;KVR8NB&R/tU\"2DC_ L-MEH;$5%#$VSMKW]T-O-O(? 9B^G[FO0A>5;BCKXD]$O;&YO-(W//TDLY*ZP^2 M\9;XKQ&;VR0T+++<?B<1A\Y.'5<< G+**VF(*IC3.)N~W5EKI?\$>DN.!D MN^?)60\||\D^ E7'LV+)%-$V0ZAN_K&WT)LS[LD?C:SHWT=U1HGOG M*[J89#W&D=DB/P>VNJ=Y):SN-FDI*AP6E!A]ZCI:6O4W)?DN\ [3BM"@B@] M&?WAW9!#;95,__Q0:)&FGP@CC"Y]\8UG#6+ *'3X+;P+):)B'()%%TLUB+?!T]I.8F%?RA!R'EN/P(WE&55R2N6]2P)L2BH M3=U++>,#\\O@&P6 M,#VTGP?3=A&V>6,$'N9ZJ]FSOFMH164:XJTP_KU[0 5.BJW-YG;$.KM?MF3FCHCC%HU/#B[-%%t;@T=0A*0]<S3)(:MTL!W:78PD2C]V1..@RFK>99]$ZRKIUTDUPW0454I%/%(7SU"M@0R4#\5XQ"!

MG(LO'T4ZA!Z%$#CLWN3R:CM1;UB4)2^64ZV#!C?3[=-1HXR=2!^U[25ZKT'PI MW.^824RH'VXQP.0=OW73WMV!@!ZG"],\&>B'^P>.8VNH..!XC^ %;$OO)IC!GN7N2R9<+$-+ M=F?AJ/'F>B7SAP\W'HT-\19%$!5I W$*.MO9D>BGGC3*Y[,%^1&*+D,9]K=M3(4#.]G3PL14= 8q3{4#.]G>5 ELHY9),]:M0EA,<$!]0WN)DP.B ML]5]"-V3Z&ADKD^[Y$M7C;WD!<3M2+3;>ECK<D .-0$B;T?

*(B)X8U<+D+)W6M&7H MU8H$@^9~H,+03ZFCF4[Y1 1JGR,)€"CRX90IEV(!R9EKVH-^[GX[UQ\GU74% M!$[UM(4&2MLYEZ*0&[$4+)MT$[P)1B\'TMU?TONM^5%QW_F"&'B-!Q$$DZ[?*

M52(\9Q%'7'B601>6G+@8;-2^/E/G1$?O-]*VUG9]9O??" YOGK9,,: MW@"OM\:^.0X8FW5R0:!OH-0H"(TY7WY)?O- ^.EQ?MZ4'Y_C'$G.Z/87+PZS M=_IE;)$'>A4#P)GW'=0>)+N[%$[UG#:$YN6N>F.!3^F2R8)N77.

*(//6.ZX;: MRJ3Z4_\R ;.E*5BI<:#PA"0U UXOZ<^]:N{YWLYY5H@P>]0@R|Z@OA=8.XT[M"KDZ(!$13U<M6XTR'$,*\,Z%STS$LD/9.8%Y2IT_<;9SI@N24)*3$&8 @>95B<+E*VW;@:[>><<+:,AX2"USIGC#65Y(Y6&.*

MC&]0QOVTS^93O/$Y<9'?R%OR#'@^[O(EN0R0>+N# 9Y=>L]FX1@:KP!\G:. M7::Z[^.YTX)@4?.WB MD9RBKX.?P5N!N78<435(S!F1N"M@GP[E=P78.*== MOG-4C':)]W4V3O\NPD>42]0YMER:?

&F5O6;,:.H(9JZK<#B. M&A<>.QXY3<@R[S\Q^:,OD)YUK)1A#&8W'E+LLKJ#[IV4TE[@] F5K0+[S(49N-M$94.0)7=S01,%DV0#01]PCP!\@L'XKPUF*LB%0M<3):4#%3 EM:]D>6;9*

M$W:#93984N.Q1\,O8!Z/++>EIFEZAPS]A O.YJZ$-CH: .V791E\@!7KIW4P M-[8NRFLP]\8 LQ<#K8#H[9FDI_L[[*6C'S,[VX]"_*]IX4@87YSK0K$+[^G6 M8H9^A&%O/#4UX5'SZ/C*VBAJH*#,,/.] H(Q4LO97(O/.62)%-

>U%3N1 W9 M+C"_"ZBAYY6411BD"3?X>YC9$1V=.=_I,&Y+[+D,.# MKK[B=E(7&@-[-]"=N' &=[:^9#HTTJR0"[*1LI#K,@MD8(CO]7+%PNZ/E!9 M=.;0 @-.:!;.8ESGAW4%17.5V@-M2O3S<.;DZ?*

\?:I&J7BM=BZ,]1^!==#C$ 6!B)?7L6XVVF6V2+_Q9)=7O\\?TSN>>YN\ .$;EM&Y. OROE5 M)/Q%0;&2HY M-KJC#&I2X>&YA[CE42#+)"//4H,>)E]O1!GKS40/@5C)+5 Q:C<%YL0?##" M),T2*\Y*<^N6=/1(W7,SU2J8R<1?*

*V6X^,0:"8 ?_.Q?>62)-7P @OPICE(':"PR;;B!)F7&5G%"13B0EVSI>]0YK$ MM#45SI9I2'+2F?C$AY\MAN>R$!!3&*KSU]A:H69L")#FBM0HH]6'D$A5:ITL(M_E2N78.3PUP.6EK83G*UDK?UTD/F*F.X>)*

(2K/0;"H:B8A5*NIV/R)9^Q/#8 M6[!8-VX" /RK-/3WSM0)TK^WHQ+^.G6_NPY$D\W+#9.L X_&CVDODK;$<44)-M>M!,.YHW3O.L8X'SLXD#0[\A:4N^)OT!^Q2-]D1KA_CEMT7L4ILKZ'>8EF2*0I93;(.RHLCI K+$\|\P-

*J9ZV0\WJ$.3 M2'B6ZZ.0_-/"NO3)IX5X9[3/D)EPZI3O"ZB2-AL4D9]HY++2+\6[*SS3KH<9 M0L 5X$]:HX8JZ[U\)K-^-YEXN$*D]GI,F6;MPBEW.)@JOZI47=HD D:D(A! M\MO.T7R/8+62"VTGE.W?*

*4^*0OFKIMHR6RTLR5"W*MKB^<+:.^R=^)&,3KRR. M-J@3O.!$?R%3UM;#HI.X)!*39.K@?UR AC&0F=PU^.1Y7WZ?GM94XG1IY^ M)A:A[H]FMQ\WFAF;X8*9T X,^H.'818#@5#PI,9T=_I3 MZ:R[!U:X$B?\]2!59.69Z*

#>06L2P9+B.0BI2852)*IB-"+\;PF[B\LPRD] M+WFI+-=9 2SL,BW:-F4I?@5\43C2RHO(5,%)6I DW,ZR1-145]*\)?PRR/(M.3)0>G&%KO=9A&SFD89TP\331;<2\(C(+:)R[U0/&]+L+R%92A5)#1G^TNB

*M:M=2>).XUR;#'E5Q,D8]T*VMJ[G??RNME4]G)VMZ>K)'UZK".<$D3VH] M[(@(Y233D(0N)/2=O*QW]>/NH^M+FS>)]9K[P*C>V4;Z1:1L06JKW*1*G8. M9)TJMX@-=B'L%Y%M1T?B^,Q"$3@*BV\=V' G@KW[.3-*

*Z7,D2$*X,Q(6"[M 7+,O1?LM"UJB>MCO\=?&OP+8I7%V]Q)O?)&E>;(:(U)*

*[WC_7QJLR;*F+W7\SR|[C*^ P_R6>\W(2\U[_M#],50S\PJ)%YCK0+#0Y2)#=^GG#PTOPD3Y+YE\R?V;3)PPI;3V+ ^\N]3\SVR_M@MA:\"BORW1O&IS BXVB*N09-3]6PK*3+L]77?:+,P-^W,1YRWD#X>3O8Y;%-*

MRZ'NKJ%\?Q9[I,A-;%<;^RCOUWR+%GF4U!U6/6ZR.HDU[A0:?D>?>XJ#(,X1$)8>'//UY(OH!K &8W'E+LLKJ#[IV4TE[@] F5K0+[S(49N-M$94.0)7=S01,%DV0#01]PCP!\@L'XKPUF*LB%0M<3):4#%3 EM:]D>6;9*

M$W:#93984N.Q1\,O8!Z/++>EIFEZAPS]A O.YJZ$-CH: .V791E\@!7KIW4P M-[8NRFLP]\8 LQ<#K8#H[9FDI_L[[*6C'S,[VX]"_*]IX4@87YSK0K$+[^G6 M8H9^A&%O/#4UX5'SZ/C*VBAJH*#,,/.] H(Q4LO97(O/.62)%-

>U%3N1 W9 M+C"_"ZBAYY6411BD"3?X>YC9$1V=.=_I,&Y+[+D,.# MKK[B=E(7&@-[-]"=N' &=[:^9#HTTJR0"[*1LI#K,@MD8(CO]7+%PNZ/E!9 M=.;0 @-.:!;.8ESGAW4%17.5V@-M2O3S<.;DZ?*

\?:I&J7BM=BZ,]1^!==#C$ 6!B)?7L6XVVF6V2+_Q9)=7O\\?TSN\$3VH6=

MR9%N/,DG7TV>[8 M<5>#PRCGMQI:)SR#>^K .,6MNCQ>ZFQ^B =<4$#R07;E%@VB ';,: $89}_M?3 HB9O\\TF#D5VM@)?3 MR*?#$Q&2R/3AWMNO/\)= ?@_1*22Z(O 7SR/I>]R6PTU<6"1;R:)';EX .GC-E,[N15(4*Y!4 M:&ZMT5B)R4?%# .TMY: R5Z"*# 1; C(VPIY6K1_G4M^;XCWCS5Z/S6@O E MH/WJU=&8" !P*0*ZE!@KP0AW5LC;:N M&>(\+VYF$FR)1VW+)"\!P3-YL&$X>I=]X@?N=)$52\N =FFW8OX^S!<%K5& M#F+N@O%#XB7@:5UD* ;E)0"C|C>:O|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arct-20240930_htm.xml IDEA: XBRL DOCUMENT 0001768224 us-gaap:ConstructionInProgressMember 2023-12-31 0001768224 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001768224 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001768224 arct:SegirusIncMemberarct:Covid19VaccineMemberarct:ResearchCollaborationAndLicenseAgreementMember 2022-11-012022-11-01 0001768224 us-gaap:GrantMember 2023-01-012023-09-30 0001768224 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001768224 us-gaap:CommonStockMember 2023-03-31 0001768224 arct:CollaborationRevenueMember 2023-01-012023-09-30 0001768224 2023-03-31 0001768224 us-gaap:ComputerEquipmentMember 2023-12-31 0001768224 2024-01-012024-09-30 0001768224 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001768224 us-gaap:GrantMember 2024-01-012024-09-30 0001768224 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001768224 arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMemberus-gaap:GrantMember 2023-01-012023-09-30 0001768224 2023-06-30 0001768224 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001768224 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001768224 srt:MaximumMemberarct:WellsFargoCreditAgreementMember 2022-12-232022-12-23 0001768224 arct:TwoThousandNineteenOmnibusIncentivePlanMember 2024-09-30 0001768224 arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMemberus-gaap:GrantMember 2024-01-012024-09-30 0001768224 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001768224 arct:WellsFargoCreditAgreementMember 2024-06-26 0001768224 arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2024-01-012024-09-30 0001768224 2022-12-31 0001768224 us-gaap:CommonStockMember 2024-06-30 0001768224 us-gaap:GrantMember 2024-07-012024-09-30 0001768224 arct:SegirusIncMemberarct:ManufacturingAndSupplyOfArct154DrugProductMemberarct:ResearchCollaborationAndLicenseAgreementMember 2024-09-30 0001768224 us-gaap:CommonStockMember 2024-07-012024-09-30 0001768224 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001768224 us-gaap:CommonStockMember 2024-09-30 0001768224 2023-09-30 0001768224 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001768224 arct:WellsFargoCreditAgreementMember 2024-06-262024-06-26 0001768224 us-gaap:EmployeeStockOptionMemberarct:TwentyTwentyOneInducementEquityIncentivePlanMember 2024-09-30 0001768224 arct:CslCollaborationAgreementMember 2023-12-31 0001768224 arct:WellsFargoCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-06-26 0001768224 arct:SegirusIncMemberarct:ManufacturingAndSupplyOfArct154DrugProductMemberarct:ResearchCollaborationAndLicenseAgreementMember 2024-04-012024-06-30 0001768224 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001768224 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001768224 2024-07-012024-09-30 0001768224 arct:SegirusIncMemberarct:Covid19VaccineMember 2024-01-012024-09-30 0001768224 us-gaap:CommonStockMember 2024-03-31 0001768224 us-gaap:RetainedEarningsMember 2023-09-30 0001768224 us-gaap:RetainedEarningsMember 2024-09-30 0001768224 srt:MinimumMemberarct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember 2021-09-012021-09-30 0001768224 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001768224 arct:CysticFibrosisFoundationTherapeuticsIncMemberarct:UnderlyingAgreementMember 2023-01-012023-09-30 0001768224 us-gaap:EquipmentMember 2023-12-31 0001768224 arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember 2021-09-30 0001768224 arct:OtherMemberarct:CollaborationRevenueMember 2024-07-012024-09-30 0001768224 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001768224 2023-12-31 0001768224 2024-03-31 0001768224 2023-04-012023-06-30 0001768224 arct:SegirusIncMembersrt:MaximumMemberarct:ResearchCollaborationAndLicenseAgreementMember 2022-11-01 0001768224 arct:DirectorsOrOfficersMember 2024-07-012024-09-30 0001768224 arct:CollaborationRevenueMember 2023-07-012023-09-30 0001768224 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001768224 arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMemberus-gaap:GrantMember 2023-07-012023-09-30 0001768224 us-gaap:RetainedEarningsMember 2023-12-31 0001768224 arct:WellsFargoCreditAgreementMember 2024-09-30 0001768224 arct:PhaseICllinicalStudyMemberarct:CslCollaborationAgreementMember 2024-09-30 0001768224 arct:SegirusIncMemberarct:Covid19VaccineMemberarct:ResearchCollaborationAndLicenseAgreementMember 2023-12-31 0001768224 arct:CslSegirusMemberarct:CollaborationRevenueMember 2024-01-01